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Cystic Fibrosis (CF) is a degenerative disease, which causes thickening of the
airway surface liquid and reduced mucociliary clearance, which provides an ideal habitat
for bacterial infections. Early treatment of CF in children can prevent chronic infection,
improve quality of life, and increase life expectancy. The most predominant bacteria found
in CF-diseased lungs is Pseudomonas aeruginosa (Pa), which can be treated with inhaled
tobramycin. Excipient enhanced growth (EEG) powder formulations are well suited for
administering tobramycin to children, as the EEG approach provides minimal upper
airway loss and targeted drug delivery. This method uses an initially small aerosol for high
extrathroacic transmission, and includes hygroscopic excipients within the formulation
that absorb moisture from the humid airways and increase lung retention of the aerosol.
The overarching goal of this work was to develop delivery systems and strategies for
improving respiratory drug delivery to children with CF, which was based on insights from
computational fluid dynamics (CFD) simulations and in vitro models. The studies
presented in this dissertation have three distinct and sequential phases: (i) CFD methods
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development; (ii) respiratory device design and optimization; and (iii) complete-airway
modeling for aerosol delivery strategy development.
The methods development phase produced meshing and solution guidelines that
were computationally-efficient, accurate, and validated based on in vitro data. Results
showed that the two-equation k-ω model, with near-wall corrections, was capable of
matching experimental data across a range of Reynolds numbers and particle sizes that
are specific to respiratory drug delivery. The guidelines also provided comparable
accuracy to the more complex Large Eddy Simulation (LES) model, while providing
multiple order-of-magnitude savings in computational time. The device optimization
phase developed a highly efficient delivery system for tobramycin administration to
pediatric CF patients. Correlations were developed, based on flow field quantities, that
were predictive of aerosolization performance and depositional loss. Successful a priori
validation with experimental testing highlighted the predictive capabilities of the
correlations and CFD model accuracy. The best-case delivery system demonstrated an
aerosol size of approximately 1.5 µm and expected lung dose of greater than 75% of
loaded dose, which is a marked improvement compared to commercial devices. The
delivery strategy development phase identified optimal EEG aerosol properties that better
unify drug surface concentration. These studies present numerical models of a
tobramycin EEG powder formulation for the first time, and provide the first instance of a
complete-airway CFD model evaluating pediatric CF lungs. Results show that EEG
aerosols are capable of delivering the drug above the minimum inhibitory concentration
in all airway regions, reducing regional dose variability, and targeting the lower airways
where infection is more predominant. In conclusion, results from this dissertation
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demonstrate: (i) accurate and efficient CFD models of respiratory drug delivery; (ii)
optimized designs for respiratory delivery systems; and (iii) optimal delivery strategies for
inhaled tobramycin to pediatric patients with CF.
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Chapter 1: Specific Aims
Respiratory drug delivery with pharmaceutical aerosols offers a number of
advantages compared with other delivery routes and for many medications is the most
logical approach in the treatment of lung diseases and conditions. While potentially
beneficial, challenges associated with respiratory drug delivery include aerosolizing the
powder at a respirable size with limited flow energy, penetrating the extrathoracic airways,
which are intended to filter foreign objects, and depositing the aerosol at the intended
location within the lungs to achieve the desired biological effect. Additional challenges
after the medication is deposited in the lungs include dissolution within the limited airway
lining fluid, avoidance of clearance mechanisms, and absorption in the mucus and airway
tissue.
Of the various patient groups that may benefit from respiratory drug delivery,
administration of pharmaceutical aerosols to infants and children is especially difficult.
Their relatively small extrathoracic airways are an obstacle to delivering drugs to the
lungs. Furthermore, infants and children often do not comply with receiving inhaled or
other forms of medication. Even with good patient compliance, only approximately 1% to
10% of the initial aerosol is typically delivered to the lungs, and inter-subject variability is
expected to be high. Further reductions in lung delivery efficiency and increases in intersubject variability are expected with diseased lungs.
To improve respiratory drug delivery for infants and children, innovations are
needed in pharmaceutical delivery strategies, devices, and formulations. The overarching
goal of this work is to develop and optimize strategies and devices for improving
respiratory drug delivery to infants and children using computational fluid dynamics (CFD)
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and in vitro models. To accomplish this goal, objectives are targeted in three key areas:
(i) model development, (ii) device development, and (iii) delivery strategy development.
As described in more detail below, each of these key objectives is intended to move the
field of respiratory drug delivery forward. In particular, the primary application of this work
is to quantitatively analyze and optimize the delivery of inhaled antibiotics to children with
cystic fibrosis (CF).
The validation of a CFD model is often an iterative process of defining and
adjusting numerous meshing and solution parameters until good agreement is made with
experimental data. The first objective of this dissertation intends to streamline the model
development process by defining a set of meshing and solution guidelines that are
validated for the micro-particle size range and under flow conditions that are consistent
with respiratory airways. Naturally, each project is unique and requires its own
considerations, but these guidelines strive to reduce the effort taken to develop a CFD
model by providing a baseline set-up that is known to give accurate results.
With sound numerical methods, one can apply CFD to obtain detailed physical
insight into the performance and behavior of aerosol-delivery devices. The second
objective of this dissertation uses CFD to provide insight into dry powder inhaler (DPI)
and cannula device development, which improve aerosol delivery efficiency.
Specifically, delivery systems aim to provide a relatively small particle size, for increased
lung penetration, and a high emitted dose (ED), for reduced device losses.
The third objective of this work applies the developed nasal and lung models (with
validated CFD methods) and optimized aerosolization device in the development of a
delivery strategy for the administration of inhaled antibiotics to children with CF. The

23

delivery strategies employed, and developed by our group, include enhanced excipient
growth (EEG) and nose-to-lung (N2L) administration with correctly-sized aerosols. As a
first step, the delivery strategy will be assessed and optimized with regional CFD
simulations of the patient interface, nasal cavity, and upper tracheobronchial (TB)
airways. Thereafter, complete-airway CFD simulations will be used to optimize aerosol
delivery throughout the lungs with the goal of uniform antibiotic concentrations. There are
numerous CFD models of particle transport through the lungs in the literature and by our
group, but there has been little work to date specific to drug delivery in pediatric lungs as
well as in diseased lungs.
The objectives stated above build upon one another, and all focus on providing a
CFD-based analysis of the treatment of pediatric CF lung infections with inhaled
antibiotics. The most recent data from the Cystic Fibrosis Foundation Patient Registry
(2016) states approximately 30,000 people are living with the disease, with the median
age of diagnosis being 4 months old. CF is a debilitating disease, which greatly reduces
quality of life, with a mean survival of 48 years (Cystic Fibrosis Foundation Patient
Registry, 2016). The disease primarily affects lung function, but also affects the pancreas,
liver, sweat glands, and vas deferens (Elborn, 2016). In fact, the name of the disease
originates from the pancreatic fibrosis and cysts that were described when CF was first
identified (Andersen, 1938).
CF is caused by a genetic mutation in the Cystic Fibrosis transmembrane
conductance regulator (CTFR) gene (Cheng et al., 1990), which causes poor transport of
Na+ (increased absorption) and Cl- (reduced secretion) ions through the epithelial cells
(Matsui et al., 1998; Tarran et al., 2001), and effectively dehydrates the lungs. This
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dehydration leads to thicker mucus and decreased mucociliary clearance (Stoltz,
Meyerholz, & Welsh, 2015), which causes bacterial infections to reside in the lungs for
much of the patient’s life (Boucher, 2007). The most dominant bacterium found in CF
lungs is Pseudomonas aeruginosa (Pa) (Elborn, 2016), which typically forms a biofilm in
the thick mucus. Biofilms are colonies of cells encased in a sticky substance (Donlan,
2002) that attach to the lung surfaces, which makes it difficult for the patient’s mucociliary
clearance to remove the bacteria (Boucher, 2007). The combined effects of bacterial
infection and thick mucus leads to the three main types of lung damage in CF:
bronchiectasis (irreversible thickening of airway walls), mucus obstructions, and
inflammation, which all drastically reduce lung function. Key spirometry tests to evaluate
the extent of CF lung damage are the percent of predicted forced expiratory volume in
one second (%FEV1) and forced vital capacity (%FVC), with percentages compared to
the baseline given for the patient’s age. Reported functional performance for CF patients
from 11-13 years of age are a %FEV1 and %FVC of approximately 75% and 85%,
respectively (de Jong et al., 2004), which demonstrates how severely the lungs can be
damaged at a young age with early disease progression.
CF mortality rates have improved in recent years and are expected to continue to
improve (Burgel et al., 2015), with the increased survival attributed to advances in
treatment methods (Elborn, 2016). The low median age of CF diagnosis (4 months) is
due to the screening of newborns in many developed countries (Mayell et al., 2009), which
allows parents and clinicians to begin treating lung infections early in the patient’s life.
Approximately one-third of children have signs of lung damage in computed tomography
(CT) scans by the age of three (Elborn, 2016), so starting treatment methods early is of
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paramount importance. The methods known to improve quality of life and survival are the
use of techniques to aid mucus clearance in the lungs (physiotherapy, vibrating
respiratory devices, and breathing exercises), inhaled and oral antibiotics to treat infection
(Geller & Rubin, 2009), and improvements in nutrition (Elborn, 2016). Early treatment of
Pa can prevent patients developing a chronic lung infection during childhood (C. R.
Hansen, Pressler, & Hoiby, 2008; Hoiby, 2011), hence the need to improve the pediatric
administration of antibiotics.
Tobramycin was the first commercially available inhaled antibiotic, as it has high
activity, low toxicity, and is easily radiolabeled (A. L. Smith, 2002). A key trial that
demonstrated the efficacy of tobramycin for treating CF was conducted by Ramsey et al.
(1999) who demonstrated an average 12% increase in FEV1, 26% decrease in pulmonary
exacerbations, less hospitalization, and a 1.1 log10 CFU/g reduction in Pa infection.
Inhaled tobramycin is available in two forms: tobramycin inhaled solution (TIS), which is
loaded into a nebulizer, and tobramycin inhaled power (TIP), which is loaded into a DPI.
TIP is the focus of this work as DPIs require less cleaning and sterilization than nebulizers,
and can deliver antibiotics faster (Somayaji & Parkins, 2015). An important consideration
when treating any bacterial infection with antibiotics is to minimize the possibility of
resistant forms of the bacterium. If the concentration of tobramycin delivered to the airway
surface liquid (ASL) is below the minimum inhibitory concentration (MIC), then strains of
Pa develop that cannot be treated with the antibiotic (Dalhoff, 2014). Therefore, it is
imperative that the respiratory delivery of inhaled tobramycin is highly efficient and
provides consistent dosage in order to minimize the possibility of antibiotics resistance.
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Numerous studies from our group have demonstrated that the EEG method is a
very efficient approach for delivering pharmaceutical aerosols to the respiratory airways
(Hindle & Longest, 2012; Longest et al., 2015; Longest & Hindle, 2009b, 2012; Longest,
Tian, Li, Son, & Hindle, 2012; Tian, Hindle, & Longest, 2014; Tian, Longest, Li, & Hindle,
2013). EEG utilizes a spray-dried formulation of a drug that produces an aerosol with a
mass-median aerodynamic diameter (MMAD) of less than approximately 1.5 µm (Son,
Longest, & Hindle, 2012; Son, Longest, Tian, & Hindle, 2013), when sufficiently
aerosolized by a DPI. These small particles have low inertia, which leads to increased
penetration fractions, and reduced losses in the delivery system and extrathoracic region.
The formulation includes a hygroscopic excipient that causes particle or droplet growth,
once inside the lungs, by absorbing moisture from the humid airways. The aerosol size
can increase to an MMAD of 3-6 µm (Tian et al., 2014; Tian et al., 2013), which increases
its inertia and improves lung retention once it has penetrated deep in the conducting
airways. EEG is expected to be a viable method for delivering tobramycin to pediatric
patients with CF and diseased airways. The high delivery efficiency of the EEG method
offers a targeted approach of providing high dose concentrations in the ASL of the
conducting airways. Combined with N2L administration via a streamlined nasal cannula,
losses in the patient interface and extrathoracic region are expected to be low (Longest
et al., 2015). Using a nasal cannula also has the expected benefit of reducing patient
distress, especially for infants and young children, when compared to a facemask
(Amirav, 2011; Everard, 2003).
Previous work from our group has also demonstrated the importance of using a
concurrent experimental and CFD approach when developing aerosol delivery systems
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(Behara, Farkas, Hindle, & Longest, 2014; Behara, Longest, Farkas, & Hindle, 2014a,
2014b; Hindle & Longest, 2013; Longest, Azimi, Golshahi, & Hindle, 2014; Longest,
Azimi, & Hindle, 2014; Son, Longest, Tian, et al., 2013) and evaluating particle transport
through the lungs, with validation against in vitro (Longest & Hindle, 2009a; Longest,
Hindle, Das Choudhuri, & Byron, 2007; Longest, Tian, Delvadia, & Hindle, 2012; Longest,
Tian, Walenga, & Hindle, 2012; Longest & Vinchurkar, 2007b; Tian, Longest, Su,
Walenga, & Hindle, 2011) and in vivo (Longest et al., 2015; Walenga & Longest, 2016)
data. CFD models provide a high degree of engineering insight, such as localized
deposition patterns, flow field characteristics, and predictions of turbulence behavior. For
optimization of a system, changes to design parameters can be made and quickly
evaluated via CFD (once the baseline model is developed), without running a large
number of experiments. However, the numerical model must be validated against
experimental data to ensure the conclusions drawn from the CFD results are accurate.
Therefore, much of the work for this dissertation relies on collaboration with Dr. Michael
Hindle at the VCU School of Pharmacy, and this joint effort combines the numerical and
experimental sides of the investigation, in order to improve device design and evaluate
deposition in the airways.
The expected contributions to the field of respiratory drug delivery from this
dissertation are summarized as follows:
•

An experimental and CFD model of a 6-month-old infant for the evaluation of
N2L delivery methods

•

A set of CFD meshing and solution guidelines, which are validated against
suitable experimental data, and will form the basis of future numerical work
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•

An optimized DPI and nasal cannula interface, using CFD insight, which
provides highly efficient tobramycin delivery to children

•

Three characteristic experimental and CFD models of the diseased upper
airways from patients with CF aged from 2-3, 5-6, and 9-10 years old

•

A CFD-based proof of concept for the application of EEG formulation
tobramycin to treat pediatric CF lung infections

•

Preliminary delivery parameter recommendations for use with EEG and N2L
aerosol administration that maximize lung delivery of the aerosol and improved
dose uniformity across multiple lung levels based on an initial complete-airway
CFD model of a child with CF

Objective 1: Accurate CFD Simulations of Aerosol Delivery in Infants and
Children
Rationale
From the perspective of developing a skill set, Objective 1 provides a fundamental
understanding and working knowledge of modeling aerosol transport through pediatric
airways via CFD. The breathing infant lung (BIL) model has been used previously for in
vitro evaluation of surfactant administration in a representative complete-airway model
(Holbrook, 2015). However, questions remain related to how accurately the BIL model
approximates deposition in infant lungs, especially in terms of regional deposition. Insight
from CFD models can be used to investigate deposition patterns in the packed bed and
determine how that compares with an anatomically accurate model.
Flow and particle behavior in the nasal passage is very different compared to the
distal airways considered in the BIL model. Airflow conditions are usually transitional or
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turbulent, and impaction is the primary deposition mechanism in the extrathoracic
airways. As such, CFD models require different methods and considerations. There is
limited material available in the literature for a validated methodology for applying CFD to
nasal passage geometries. Such guidelines are available for the aerospace, oil and gas,
and automotive industries, but these recommendations may not be applicable to
extrathoracic airways. Therefore, Objective 1 also aims to define a set of validated
meshing and solution guidelines that can help guide CFD model set-up, and streamline
the development stage of an investigation. This also develops a broad set of CFD skills
and a foundation to aid in the completion of subsequent objectives.
Methods
For the BIL model evaluation, a stochastic individual path (SIP) model for infant
airways will be developed and validated against well-defined algebraic correlations. A SIP
model separates the airways into three distinct regions and models each of them
individually to account for changes in flow regimes through the distal airways (Longest,
Tian, Delvadia, et al., 2012; Tian et al., 2011). The model starts with an anatomically
accurate geometry of the extrathoracic airways to Bifurcation 3 (B3), which was
developed from CT scan data. In this region, flow is turbulent and highly transient, and as
such a turbulence model and transient formulation of the transport equations are applied.
The second region covers B4-B7 with physically realistic bifurcation geometries
(Heistracher & Hofmann, 1995), where the flow is laminar and can be modelled with a
steady-state formulation. The third region encompasses B8-B15, and has the same flow
conditions as B4-B7, but a new sample of particles are introduced into the domain to
account for possible particle convergence issues as larger particles deposit upstream.
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The infant SIP model will be based on the original adult version, but scaled to match infant
dimensions. The CFD model of the packed bed will be compared against various
bifurcation regions in the infant SIP model to evaluate regional and total deposition
characteristics.
To develop CFD meshing and solution guidelines for the airways, an initial
validation study of a simplified geometry will be conducted using the two-equation k-ω
model. A CFD model will be developed and validated against the experimental data from
Pui et al. (1987), who evaluated particle deposition in a 90° bend test geometry across a
range of Reynolds and Stokes numbers that are consistent with microparticle deposition
in the upper airways. Once the guidelines are validated for the representative 90° bend
geometry, they will be applied to an anatomically accurate model of an infant nasal
passage, and validated against in vitro data provided by the VCU School of Pharmacy.
This requires development of experimental and numerical infant N2L models, which are
obtained via the segmentation of CT scans. Segmentation is a process whereby one
selects pixels in the CT images that define the airways through the nasal passage.
Selecting pixels for each slice defines voxels, which build up the 3D model, and smoothing
algorithms in the software package provide a realistic representation of the nasal cavity.
The geometry can then be converted to CAD data and used to build the required
experimental and numerical models.
Tasks
Task 1.1: Evaluate Deposition Realism of In Vitro Packed-Bed Breathing Infant Lung
Model (BIL)
•

Status: Complete and published (Bass & Longest, 2018a)
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Task 1.2: Recommendations for Simulation of Microparticle Transport and Deposition
Using Two-Equation Turbulence Models
•

Status: Complete and published (Bass & Longest, 2018b)

Task 1.3: Validating CFD Predictions of N2L Aerosol Delivery in a 6-Month-Old Infant
Airway Model
•

Status: Complete and published (Bass, Boc, Hindle, Dodson, & Longest, 2019)

Outcomes
The work completed by Objective 1 provides a thorough evaluation of an in vitro
method for modelling whole-lung aerosol delivery using CFD insight, a set of meshing
and solution guidelines for the numerical modelling of microparticles in the upper airways,
and an experimental and CFD model of a 6-month-old nasal passage. The CFD-based
evaluation of packed bed lung models will determine whether such models are accurate
in their predictions of total and regional deposition. The solution guidelines provide a
foundation for future CFD work in all areas of respiratory drug delivery, and aim to
streamline the CFD model development process. The 6-month-old nasal model will be
used in future work by our group to assess N2L delivery methods to infants, both
numerically and experimentally. Objective 1 also provides the fundamental knowledge
and skill sets required to model aerosol transport, through delivery systems and the
airways, which are required for successfully completing Objective 2 and 3.
Objective 2: Quantitative Analysis and Design of High Efficiency Pediatric DPIs
Rationale
Commercial DPIs are generally inefficient due to high device and extrathoracic
losses, which typically arise from relatively large particle diameters (>2 µm) and high
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velocity flows used to disperse the powder. Delivery efficiency of devices can be improved
with highly dispersible powders and improvements in aerosolization performance.
Previous work from our group has shown how turbulence characteristics of the flow
deaggregates the powder and reduces particle size (Longest, Son, Holbrook, & Hindle,
2013). Recent work has also shown that non-dimensional turbulence parameters, derived
from CFD models, correlate well with the aerosol MMAD and ED for DPIs that utilize dose
aerosolization and containment (DAC) units (Longest & Farkas, 2018). The DAC unit
comprises a capsule that holds the powder, with inlet and outlet capillaries that introduce
an air jet to aerosolize the powder. These DPIs are designed to be used with a low volume
(LV) of actuation air, and are referred to as LV-DPIs. This objective uses DAC units with
a higher flow rate (HF), which are referred to as HF-DPIs. It is expected that numerous
changes to the HF-DPI design parameters can be explored via CFD, and predictive
correlations can be used to estimate device performance, with a focus on minimizing
MMAD and maximizing ED. Once the DAC unit is optimized, improvements will be sought
in the design of the cannula that delivers the aerosol to the nasal airways, which provides
a thorough and complete optimization of multiple elements of the delivery system.
Methods
Initial work will begin by applying the same non-dimensionalization and correlation
methods to the HF-DPIs as developed for the LV-DPIs presented by Longest and Farkas
(2018). Initial correlations will be developed using a number of prototype devices for which
the MMAD and ED have been experimentally determined. Other flow field and turbulence
characteristics will be explored via the CFD model, to determine what aspects of the
device design drives performance at high flow rates, which will lead to additional non-
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dimensional parameters and correlations. Once a predictive correlation is found,
numerous CFD models of DAC unit designs will be evaluated in terms of aerosolization
performance. The best designs will then be tested experimentally to verify the CFD
predictions and ensure the predicted performance of the DAC unit is achieved. A similar
quantitative approach to design evaluation will be applied to the nasal cannula in order to
reduce deposition losses in the patient interface. This method demonstrates the benefits
of leveraging the strengths of experimental and numerical models, and combining them
to drive the optimization of the delivery system.
Tasks
Task 2.1: CFD Optimization of an Inline DPI for EEG Tobramycin Formulations
•

Status: Complete and published (Bass, Farkas, & Longest, 2019)

Task 2.2: Develop DPI Patient Interfaces for Improved Aerosol Delivery to Children
•

Status: Complete and in press (Bass & Longest, 2020)

Outcomes
Meeting the requirements of Objective 2 provides CFD-driven optimization of a
delivery system for administering inhaled antibiotics to pediatric CF patients. The methods
used to determine design optimizations are also beneficial for future work that aims to
improve device performance. Once the performance of the delivery system meets a predetermined level of efficiency, the transport of aerosol through the airways and deposition
patterns will then be evaluated by Objective 3.
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Objective 3: CFD Predictions of EEG Aerosol Antibiotic Delivery to Children with
Cystic Fibrosis
Rationale
To date, few studies have developed CFD models for the diseased airways of
patients with CF. Damage to the lungs from CF is known to affect airway morphometry
with bronchiectasis (thickening of bronchi walls), general inflammation from infection, and
mucus obstructions. Therefore, the geometry of an airway CFD model for CF patients
would be very different to healthy lungs, which is expected to affect the flow field and
particle trajectories. The first such study in this field was conducted by Awadalla et al.
(2014) who developed a Large Eddy Simulation (LES) model of porcine lungs with CF
that replicate human CF lungs. Results showed that reduced airway diameters lead to
higher flow velocities, which in turn caused an increase in deposition due to impaction.
They also concluded that submicron particles may be critical in treating disease in the
narrow airways. The first CFD investigation into aerosol administration in human CF lungs
was conducted by Bos et al. (2015). They developed CFD models from CT scans of 40
adult patients and evaluated whether delivered concentrations of Aztreonam lysine (AZLI)
were sufficient in the ASL to treat infections. Results showed that concentrations were
adequate in the majority of cases considered, though there was a large amount of intersubject variability. Interestingly, they also showed that the lung lobes with the most
amount of disease had less ventilation, and hence less aerosol delivery. Primary
limitations to this study include a number of assumptions regarding particle size and the
ASL thickness, and CFD results were not directly validated against in vitro or in vivo data.
Bos et al. (2017) extended this work with a second study comparing two nebulizers and
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their efficiency at delivering TIP. Again, the CFD deposition results from this study were
not validated against an experimental model. Objective 3 aims to build upon these studies
by validating and evaluating EEG N2L administration of tobramycin to pediatric lungs with
CF lung damage.
Methods
Three CF diseased lung models will be developed that are representative of
patients aged 2-3, 5-6, and 9-10 years old from CT scans. This objective requires
collaboration with Dr. Harm Tiddens’ group at Erasmus Medical Centre (Rotterdam,
Netherlands), as they will be providing the CT scans, and conducted the human CFD
investigations into CF lung deposition mentioned previously (Bos et al., 2017; Bos et al.,
2015). If the CF lung scans do not include the extrathoracic region, nasal models will be
developed from our own in-house database of CT scans and combined with the diseased
airway model. Generating experimental and numerical models from CT data requires
segmentation of the scans as described in Objective 1. The fidelity of the scan resolution
limits how accurately distal regions of the lung can be extracted from the CT images, and
models of pediatric CF lungs typically terminate when the airway diameter is 1-2 mm
(which is approximately Bifurcation 6) (Bos et al., 2015). SIP geometries will be used to
determine deposition in each lung lobe, with dimensions that are consistent with CF lungs.
The SIP geometries will also be modified to account for the bronchiectasis and other
forms of lung damage associated with CF. Deposition data from the experimental and
numerical CF SIP lung models will be used to determine whether sufficient concentrations
of tobramycin are delivered to the ASL, via the optimized delivery devices.

36

Tasks
Task 3.1: Develop In Vitro Upper Airway Geometries of CF Patients in Age Ranges of 23, 5-6, And 9-10 Years
•

Status: Complete and in vitro testing complete

Task 3.2: Develop CFD Models of Upper Airway Geometries for Pediatric Patients and
Evaluate Delivery Efficiency and Aerosol Growth with Comparisons to In Vitro
Experiments
•

Status: Complete and manuscript in preparation

Task 3.3: Extend and Develop CFD Lung Models to Predict Regional Lung Deposition
and Tobramycin ASL Concentrations in Healthy and CF Complete-Airway Lung Models
•

Status: Complete and manuscript in preparation

Outcomes
Objective 3 provides a proof of concept for applying the EEG approach, via N2L
administration, for the treatment of bacterial infections in CF lungs with inhaled
tobramycin. Specifically, three upper airway geometries are developed from CT scans of
individuals with CF in the age ranges of 2-3, 5-6, and 9-10 years old. These geometries
enable experimental and numerical models of aerosol deposition after inhalation of
antibiotics from the optimized delivery system. The models will also be beneficial for future
studies, by our group and others, in the field of CF treatment. Extending the lung model
into distal regions provides insight into regional deposition patterns, and determines
whether tobramycin is delivered in sufficient quantities to provide an ASL concentration
that is high enough to eradicate the bacteria.
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Chapter 2: Evaluate Deposition Realism of In Vitro Packed-Bed
Breathing Infant Lung Model (BIL)
2.1

Objective
The objective of this study was to determine whether packed bed in vitro models,

which contain spheres as the primary repeating unit, provide a realistic representation of
aerosol deposition in the tracheobronchial region of infant lungs based on computational
fluid dynamics (CFD) predictions. To focus on impaction deposition in the
tracheobronchial airways, particles in the size range of 0.5 to 10 µm are evaluated.
Systems considered are the packed bed arrangement with an inlet jet generated by
outlets of the upper airway model and a realistic bifurcating airway anatomy. To
understand the deposition in each of these systems, CFD simulations are implemented.
Numerous studies from our group have validated the accuracy of CFD models for
predicting aerosol deposition in comparison with in vitro lung experiments (Longest &
Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian,
Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and in vivo data
(Longest et al., 2015; Walenga & Longest, 2016).
2.2

Introduction
In vitro airway models provide a convenient and scientifically useful testing

platform for determining aerosol delivery to and deposition within the lungs (Byron et al.,
2010; Carrigy, Ruzycki, Golshahi, & Finlay, 2014; R. Delvadia, Longest, & Byron, 2012;
Warren H. Finlay & Martin, 2008). These models can be used to determine inhaled dose
of airborne pollutants and bioaerosols arising from environmental exposures. In vitro
airway models are also useful in determining the lung delivery efficiency of inhaled
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medications and developing more efficient respiratory drug delivery systems. Specific
advantages of in vitro airway models include the avoidance of human subject testing with
the associated safety and ethical concerns, a reproducible and controllable platform with
well-defined physical attributes, and the ability to instrument the system as needed.
Disadvantages include limited establishment of in vivo-in vitro correlations (IV-IVC) and
difficulty in reproducing the highly complex and dynamic airway system (Byron et al.,
2010).
Considering infants, a number of studies have implemented in vitro models to
evaluate aerosol deposition in a portion of the airways. Widely used infant nasal models
based on a single subject scan have been reported for pre-term (Minocchieri et al., 2008)
and 9-month-old (Janssens et al., 2001) infants. Javaheri et al. (2013) developed a
characteristic infant nasal model based on 10 previously published geometries in the age
range of 3-18 months. Xi et al. (2012) developed a set of pediatric nasal models across
an age range from infant to 5-years-old. The studies of Storey-Bishoff et al. (2008) and
Golshahi et al. (2010) provide examples of implementing in vitro infant nasal models to
determine the lung delivery efficiency of inhaled aerosols. Carrigy et al. (2014) further
reviews the development of infant and pediatric extrathoracic models with applications to
determine lung delivered dose from inhaled pollutants and inhaled pharmaceutical
aerosols.
A hybrid-style in vitro lung model can be defined as containing a geometrically
realistic upper airway structure and an approximation of the remaining lung anatomy. As
reported by Carrigy et al. (2014), pediatric extrathoracic models typically connect to a filter
or aerosol impactor to evaluate total lung delivery and particle size distributions (PSD) of
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the lung delivered dose. More detailed hybrid-style in vitro lung models also contain some
of the upper tracheobronchial bifurcating airways. For example, Delvadia et al. (2012)
report small, medium, and large adult upper airway geometries through the third
respiratory bifurcation with the airway outlets contained in a lung Plexiglas chamber with
a filtered outlet. Pulmonary deposition was calculated as the dose deposited on the
chamber walls and filter at the chamber exit, which assumes that no dose is exhaled due
to the presence of a breath-hold period. A mixing inlet style system was used to reproduce
accurate inhalation profiles. Delvadia et al. (2012; 2013) report very good agreement
between in vitro predictions of lung deposition and in vivo studies across multiple
inhalation waveforms and devices, and the ability of in vitro models to capture intersubject
variability. Verbanck et al. (2016) developed an adult in vitro airway model extending to
approximately the fifth airway generation and connected each outlet to a separate
collection filter. Studies by Longest et al. (2015; 2012) have implemented a hybrid-style
in vitro model and sized the lung chamber prior to an impactor to reproduce realistic lung
aerosol residence times in order to study hygroscopic aerosol growth during a respiration
cycle. While providing additional information about respiratory aerosol transport, these
hybrid-style lung models have not attempted to capture the mechanisms of particle
deposition in the lower lung and, therefore, are not capable of capturing exhaled aerosol
dose and regional aerosol deposition.
Packed beds, also known as glass bead media or granular beds, are a form of
porous media composed of spheres or beads in a tightly packed arrangement (Nield &
Bejan, 1999). Fluids can move between the spheres and the spherical surfaces providing
a high surface-area to volume ratio. Packed beds are traditionally used for gas or liquid
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flows with surface reactions, as with component extraction or purification applications, but
have also been characterized for aerosol filtration. Gebhart et al. (1973) initially
characterized diffusional and sedimentation deposition in a packed bed structure.
Subsequent studies characterized aerosol deposition by interception (K. W. Lee &
Gieseke, 1979) and impaction (D'Ottavio & Goren, 1982) in packed beds.
Both packed beds and the alveolar region of the lung have a high surface-area to
volume ratio, which in the case of a packed bed can be tuned to equal that of the lung
(Gebhart & Heyder, 1985). As a result, several studies have used simple packed bed
models as an approximate surrogate of the human lung for deposition in the
sedimentation and diffusion regimes. Brand et al. (1994) used a packed bed model as a
test case to evaluate the sensitivity of the aerosol derived airway morphometry approach.
It was assumed that aerosol bolus dispersion was identical in the lung and packed bed
tube filled with 0.8 mm beads. Rosenthal et al. (1992) compared aerosol dispersion in a
packed bed tube and in human subject studies. Aerosol dispersion in the human lungs
was largely influenced by the larynx and breath-pause period, which were not captured
in the packed bed media. Hence, inclusion of the upper airways and laryngeal jet were
shown to be important. Rosati et al. (2003) used a packed bed model as an “approximate
surrogate to the human lung” to compare the difference in the deposition of polydisperse
and monodisperse aerosols.
Very few studies have previously generated a hybrid in vitro airway model by
combining a realistic extrathoracic airway model with a packed bed model of the lower
lungs. This interesting idea was originally suggested by Gebhart and Heyder (1985). As
shown in Figure 1 of their study, they approximated the mouth-throat as a 90-degree bend
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and reproduced the first several bronchi leading to a packed bed. Modifications to the
packed bed length and bead size allowed the model to capture deposition by diffusion
and sedimentation consistent with in vivo experiments. In a short conference paper by
Saini et al. (2002), a hybrid model is reported consisting of a larynx cast and glass bead
model in a triangular geometry containing three different glass bead sizes. This model
could

theoretically

capture

impaction,

sedimentation

and

diffusion

deposition

mechanisms similar to lung airways. However, comparisons to in vivo data of lung aerosol
deposition are not provided.
Similar to Gebhart and Heyder (1985), an appealing approach for creating a
complete airway in vitro model is to combine a realistic 3D printed upper airway geometry
with a packed bed structure. Realistic upper airway geometries have been shown to
predict delivery efficiency of aerosols to the lungs consistent with in vivo data (R. Delvadia
et al., 2012; R. R. Delvadia, Hindle, et al., 2013; Yu Zhang, Gilbertson, & Finlay, 2007).
Packed bed arrangements can capture correct surface area to volume ratios of the lung
as well as correct sedimentation and diffusion properties of submicrometer particles
(Gebhart & Heyder, 1985). However, it is not currently known if packed beds can capture
impaction similar to airway bifurcations in the mid- and lower-level bronchi. Introducing a
jet of airflow to a packed bed will spread through the bed in a manner that may be similar
to a bifurcating network. Furthermore, the intersections of packed spheres form flow
dividers that will serve as aerosol deposition points potentially similar to the branching
airways.
The envisioned hybrid-style complete-airway model for an infant consists of a
realistic upper airway geometry derived from a CT scan together with a shell of the plural
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region. The plural cavity is filled with monodisperse beads. Of interest is whether the
packed bed region can capture correct total deposition similar to the lung airways and if
the model can capture regional (spatial) deposition distributions. Matching both total and
regional deposition will require correctly capturing impaction, sedimentation and diffusion
mechanisms at the appropriate time scales and flow rates of respiration. More advanced
complete-airway models will implement multiple bead sizes, as with Saini et al. (2002).
However, the first challenge is to determine if a packed bed of spheres can capture
impaction similar to the bronchi and bronchioles of the respiratory airways.
2.3

Methods
An overview of the systems considered in this study is shown in Figure 2.1. The

infant complete-airway in vitro model integrates a CT-scan-based upper airway geometry
through B3 with a packed bed structure to represent the remainder of the lungs (Figure
2.1a). The realistic model is truncated at approximately B3 based on resolution of the CT
scan and structural integrity of the model. The TB airways extend beyond B3 through
bifurcation B15, which contains the terminal bronchioles and leads to the respiratory
bronchioles containing alveoli. A stochastic individual pathway model, as developed by
Longest et al. (Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012;
Tian et al., 2011), is shown in Figure 2.1b extended from B3 exits through B15. The
respiratory airways contain approximately 300,000 bronchi/bronchioles (including the
respiratory bronchioles) and 480 million alveoli (Ochs et al., 2004), which is not practical
to reproduce with current 3D printing technologies. To represent the conducting airways,
this study implements a packed bed (PB) model as shown in Figure 2.1c. The tube shown
in the PB model is the transition between the outlet of B3 to the sphere array. It is expected
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that this transition region will have an important impact on performance of the PB model.
This study focuses on deposition comparisons between the SIP and PB models, using
CFD simulations. These systems, as well as the complete-airway model, are described
in more detail in the following sections.
Infant Complete-Airway Model
The infant complete-airway in vitro model (Holbrook, 2015) was originally
developed to evaluate the improved compliance of the lung while administering
surfactants to infants. The upper airways (MT-B3) of the infant complete-airway model
were based on an adult model (Walenga, Tian, & Longest, 2013) referred to as Model D,
and scaled to match infant morphometric data (Phalen, Oldham, Beaucage, Crocker, &
Mortensen, 1985). The lower airways (B4 onwards) are represented by a pleural cavity
shell, constructed from an infant computed tomography (CT) scan that was completely
filled with 6 mm diameter spheres. The pleural cavity was scaled so that the Functional
Residual Capacity (FRC) was 150 mL of airspace after the spheres were added. The 6
mm spheres were initially selected for the infant complete-airway model because the
hydraulic diameter of the triangular void between three connected spheres (0.62 mm) is
a reasonable approximation of the number average diameter of the remaining infant
tracheobronchial airways from B4 to B15 (0.45 mm). However, this sphere diameter may
not be ideal, and the current study intends to determine whether alternative sphere sizes
may be more suitable for matching deposition in the infant lung. To represent the airway
surface liquid, 12 mL of water was added to the pleural cavity to form liquid bridges
between the connected spheres. Administration of surfactant to the model reduced the
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surface tension of these liquid bridges and improved lung compliance in a realistic way
(Holbrook, 2015).
CFD-Packed Bed (PB) Model
A CFD model was constructed to represent the PB region of the complete-airway
model with a focus on the junction between the B3 outlet and surrounding spheres (CFDPB model; Figure 2.1c). The sphere arrangement is a hexagonal close packed formation,
which gives the maximum packing density for equal diameter spheres. To account for the
water added to the infant complete-airway model, filleted surfaces represent the liquid
bridges between each connected sphere. The 0.29 mm radius of these fillets (see Figure
2.1) determines the added volume of the liquid bridges, which matches the 12 mL of water
used in the infant complete-airway model.
The inlet duct of the CFD-PB model is equivalent to the outlet of the upper airways
in the infant complete-airway model. That is, the CFD-PB inlet represents the transition
from the infant complete-airway upper airways to the pleural cavity filled with spheres.
The results evaluate two examples of CFD-PB models: one that replicates the infant
complete-airway model with the spheres representing the lung from B4 onwards (CFDPB B4+), and another where the spheres represent the lung from B7 onwards (CFD-PB
B7+). The intention of the CFD-PB B7+ case is to determine whether the spheres should
only model the smaller tracheobronchial airways, with inclusion of more of the bifurcating
lung geometry upstream of the packed bed.
The inlet duct points toward the center of what this study refers to as the first
sphere. The distance from the inlet duct to the first sphere is the same as the length from
the inlet to the carina for the first bifurcation that the CFD-PB model represents. For
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example, the CFD-PB B4+ case uses a distance from the inlet to the first sphere that
matches the carinal length of B4. Imposing this distance on the CFD-PB configuration
aims to capture impaction on the surface of the first sphere similar to the first bifurcation
that this sphere replaces. Other cases are evaluated that consider the packed bed after
the inlet duct, thereby looking at a cross-section (CS) of the sphere array, which are
referred to as CFD-PB CS models. These models do not use an inlet duct and instead
introduce flow into the domain through the entire CFD-PB model rear inlet surface (Figure
2.3a).
The CFD-PB models (Figure 2.3) extend three sphere diameters laterally both
above and below the tubular inlet, with respect to gravity, to capture spreading of the
airflow in the packed bed. Symmetry is present along the center of the inlet duct, so the
domain extends three sphere diameters away from this symmetry plane. In the axial
(downstream) direction, each case has an adjusted domain length so that particles do not
escape through the outlet during a realistic transport time. At most, the domain extends
16 sphere diameters.
ICEM CFD 14.5 meshing software (ANSYS, Inc., Canonsburg, PA, USA)
generated the tetrahedral, Delaunay mesh for the domain (Figure 2.3b). There is a
conformal mesh interface between the inlet mesh and remaining domain, with a one-toone match between vertices and cell faces (Figure 2.3c). This ensures there is no
interpolation of variables across the interface when solving the flow field. The mesh
accurately resolves the shape of the filleted surfaces between spheres with appropriately
aligned mesh lines (Figure 2.3c). The two near-wall prism layers included in the mesh are
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sufficient to resolve the boundary layer under low-speed, laminar flow conditions. The
volume mesh quality has a minimum value of 0.1.
To minimize the numerical error in the CFD results, a mesh dependency study was
performed to identify the most efficient and accurate cell size for the models. The
deposition profiles for a coarse (1.6 million cells), and fine (12.9 million cells) mesh for the
CFD-PB B4+ geometry were compared to determine if results converge to the same
solution as the cell size is decreased. The deposition fraction for the coarse and fine mesh
had an absolute difference of 0.2% for the 5.0 µm particles. Reducing the refinement level
lower than the course mesh made it difficult to resolve the curvature of the fillets between
sphere contacts. As these meshes give similar results, the coarse mesh was used for all
simulations. At most, the cell count for the largest evaluated domain (CFD-PB CS) is
approximately four million cells.
CFD-Stochastic Individual Path (SIP) Model
Previous studies by our group have documented the details and development of
the SIP approach for CFD modeling of the complete airways (Longest et al., 2015;
Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al.,
2011). Briefly, a SIP geometry is a randomly determined individual pathway through the
lung from B4 to B15, where at each bifurcation, one branch is continued and one is not.
Previous work by our group has shown that following a pathway through the lower left
lobe of the lung provides deposition characteristics that are representative of the average
of all lobes (Longest, Tian, Delvadia, et al., 2012). CFD simulations of the SIP geometry
begin with the B4 inlet and assume steady laminar flow. Velocity and particle profile inlet
conditions are generated from simulations in upstream airways. While it is known that
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turbulence is generated in the laryngeal jet and extends often past B4 based on CFD
simulations (Xi, Longest, & Martonen, 2008) our previous results indicate that the best
agreement with human in vivo data for pharmaceutical aerosols is achieved assuming
turbulence occurs above B4 and laminar flow occurs below B4 (Longest et al., 2015;
Walenga & Longest, 2016). To allow for the injection of additional particles to best resolve
deposition, the SIP model simulations were divided into B4-B7 and B8-B15 sections.
The bifurcations used in the previously developed adult SIP models are based on
a physically realistic geometry (Heistracher & Hofmann, 1995) and adult morphometric
data (Yeh & Schum, 1980), which provide anatomically accurate models. Simulating the
lung bifurcations with the SIP method greatly reduces computational processing times,
and studies have validated the results against experimental in vitro (Longest, Tian,
Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 2011) and in vivo
(Longest et al., 2015; Walenga & Longest, 2016) data.
To create the infant CFD-SIP model, available morphometric data must be scaled
to match infant dimensions. A review of the literature (Dunnill, 1962; Herring, Putney,
Wyatt, Finkbeiner, & Hyde, 2014; Hislop, Wigglesworth, & Desai, 1986; Langston, Kida,
Reed, & Thurlbeck, 1984; Thurlbeck, 1982) shows large variation in measurements of
infant FRC and volume fractions of the bronchial, bronchiolar, and alveolar-interstitial
regions, which are the morphometric data required to scale from adult to infant
dimensions. As an alternative approach, the scale factor used to convert from adult to
infant dimensions was taken as the ratio of the average B3 outlet diameter from the infant
complete-airway model and the adult morphometric data (Yeh & Schum, 1980), which
gives a value of approximately 0.29.
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Applying this dimensional scale factor to the adult morphometric lung data (Yeh &
Schum, 1980) results in an FRC of approximately 145 mL. This value is within the span
of lung volumes found in the literature for infants, which range from 127 mL (Hislop et al.,
1986) to 222 mL (Herring et al., 2014), and matches well with the 150 mL FRC used in
the infant complete-airway model. Furthermore, the World Health Organization (WHO)
Growth Charts (WHO, 2006) indicate that the 50th percentile female and male has a height
of 49 cm and 50 cm respectively at birth, which applied to infant airway dimension
correlations (Phalen et al., 1985) gives a B3 outlet diameter of approximately 2.55 mm
with a standard error of 0.37 mm. This compares favorably with the average B3 outlet
diameter from the infant complete-airway model, which is 2.30 mm.
Transport Equations and Numerical Methods
The ANSYS FLUENT 14.5 software package (ANSYS, Inc., Canonsburg, PA,
USA) was used to solve the flow field and particle trajectories through the domain. The
model settings use the best practices developed by our group in previous projects
(Longest et al., 2015; Longest, Tian, Walenga, et al., 2012). In brief, this includes double
precision accuracy, use of the SIMPLEC algorithm for pressure-velocity coupling, secondorder upwind spatial discretization for flow variables, and the Runge-Kutta scheme for
particle tracking.
The model simulates the infant lung under mechanical ventilation, which uses a
sinusoidal volumetric flow rate over a 0.5 s interval (further details are described below).
Therefore, the problem is time-dependent by nature, and the model requires transient
flow conditions with first-order implicit temporal discretization. The solver uses a relatively
small time-step size, and runs a suitable number of iterations between these time steps.
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For all cases, a time step size of 0.005 s is small enough that the change in inlet velocity
between time steps is minimized and 100 iterations per time step accurately resolves the
flow field.
The peak inlet velocity is 2.68 m/s for the CFD-PB B4+ case, which occurs halfway
through the sinusoidal ventilation inhalation profile and is the highest inlet velocity
considered. This gives an estimated maximum Reynolds number at the inlet of
approximately 400. This is far below the critical Reynolds number value for internal flow,
so the laminar viscous model is sufficient for the flow environment. Therefore, particles
are not subject to turbulent conditions, such as turbulent dispersion or the effects of
turbulent anisotropy near wall boundaries.
As the CFD-PB model represents the lung distal to at least B4, the gravity force is
included to capture the sedimentation deposition mechanism, which becomes more
important as the velocity slows. In the PB geometry, the effect of gravity acting in 3
separate orientations is considered. Because particle diameters are 0.5 µm and higher,
effects of Brownian motion are neglected.
Considering particle injection profiles, the CFD-PB models implement a parabolic
particle distribution (Longest & Vinchurkar, 2007b). This particle profile captures the fact
that particle flux into the geometry starting from a well-mixed upstream concentration is
proportional to the local fluid velocity flux. For the CFD-PB CS case, where particles enter
throughout the PB geometry, a random uniform concentration is assumed at each of the
multiple inlets.
The injected size distribution separates the particles into nine bins, with particle
diameters between 0.5 and 10 µm. The particle injection introduces 500 particles of each
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bin size per time step, which totals 450,000 particles tracked through the domain.
Previous work by our group has shown that this method gives suitable particle
convergence (Longest, Tian, Walenga, et al., 2012).
At birth, the 50th percentile weight for girls and boys is 3.2 and 3.4 kg respectively,
based on the WHO Child Growth Chart (WHO, 2006). The selected ventilation
parameters for an infant in this weight range are a tidal volume (𝑉𝑡 ) of 28.4 ml and
inspiration time (𝑡𝑖𝑛 ) of 0.5 s (Walsh & DiBlasi, 2010). For a sinusoidal flow profile, the
transient inlet velocity (𝑣𝑖 ) based on ventilator parameters and inlet area (𝐴𝑖 ) is:
𝑣𝑖 =

1 𝜋𝐶𝑉𝑡
𝜋
sin ( 𝑡)
2 𝑡𝑖𝑛 𝐴𝑖
𝑡𝑖𝑛

(2.3.1)

Equation (2.3.1) is found by using an arbitrary sinusoidal volumetric flow rate curve
(𝑄 = 𝐴 sin(𝜔𝑡)) and integrating to get the volume of air added to the lung at any given
time (𝑉 = ∫ 𝑄 𝑑𝑡). The known added volumes at zero time (𝑉 (0) = 0) and inspiration time
(𝑉 (𝑡𝑖𝑛 ) = 𝑉𝑡 ) are applied to determine the 𝐴 and 𝜔 parameters that defined the volumetric
flow rate. The volumetric flow rate is then divided by the inlet area to find the transient
inlet flow velocity. The scaling parameter (𝐶) is included to control the fraction of the tidal
volume that enters through the inlet of the CFD-PB models, as they represent a fraction
of the entire lung. For the CFD-PB models, the scaling parameter is the inverse of the
number of outlets at the upstream bifurcation level, so that the flow though the CFD-PB
model represents the fraction of the lung in question. For example, if the CFD-PB model
represents B4-B15, the scaling parameter is one eighth, as there are eight outlets at the
B3 level.
For the CFD-PB models, evaluating a sub-domain of a larger packed bed imposes
challenges when defining the boundaries between adjacent domains in a numerical
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model. Each CFD-PB case uses wall boundaries at the left, rear, top, and bottom sides
of the simulated domain (see Figure 2.3), and the results assume that these boundaries
have little influence, as they are sufficiently far away from the region of interest. To verify
this assumption, the velocity magnitude close to these wall boundaries is evaluated for
all cases and the geometry is deemed suitable if the magnitude is small relative to the
region of primary particle deposition. Furthermore, particle deposition on the domain
extremes are checked, and the geometry is considered sufficiently large if very few
(<0.1%) particles deposit on these wall boundaries.
As the sides of the CFD-PB sub-domain that connect to adjacent domains are
walls, the side opposite the inlet defines an outlet boundary to permit flow through the
sphere array. An outflow defines the boundary condition at this outlet, with a weighting of
one, such that all flow entering through the inlet leaves through this boundary. For the
CFD-SIP model, outlets also use outflow boundary conditions, except that each outlet
has half of the mass flow rate that enters the inlet at each bifurcation level.
Comparison Criteria
Deposition efficiency (DE) is the mass of particles that deposit in a pre-defined
region, over the mass of particles that enter that region, expressed as a percentage:
𝐷𝐸𝑖 =

Mass Deposited in Region i
× 100
Mass Entering Region i

(2.3.2)

The advantage of the DE is that results can compare individual regions of interest
directly by excluding upstream particle deposition.
Deposition fraction (DF) is the mass of particles that deposit in the entire
computational domain, over the mass of particles that enter the domain through the inlet,
expressed as a percentage:
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𝐷𝐹 =

Mass Deposited
× 100
Mass Injected

(2.3.3)

The DF can be calculated from the DE by:
𝑛

𝐷𝐹 = 1 − ∏
𝑖=1

(1 − 𝐷𝐸𝑖 )

(2.3.4)

where 𝑛 is the number of bifurcations or sphere layers in a given range. DF provides an
estimate of total deposition in a region by considering all upstream losses.
Residence time (𝑡𝑟𝑒𝑠 ) is the amount of time that a particle spends within a predefined region of the domain. For the entire domain, the residence time is the difference
between the time the particle escapes through the outlet boundary and the time the
particle entered the domain. Similarly, for a given range of sphere layers, the residence
time is the difference between the times that the particle crosses the first and last layer of
spheres in the range.
2.4

Results

Comparison of CFD Predictions and Algebraic Correlations for Deposition
To verify that the CFD predictions of infant aerosol deposition are reasonable,
comparisons were made across a particle size range of 0.5 to 10 µm to established
algebraic correlations. The CFD model included the infant mouth-throat (MT), upper
tracheobronchial region through B3, and remaining TB region as a SIP geometry through
B15, resulting in an Infant MT-B15 model. The algebraic correlations for comparison
capture particle deposition due to sedimentation and impaction. Three correlation models
were considered, which implement different approximations for deposition. Specifically,
the Finlay model (W. H. Finlay, 2001) combines an analytical approximation for
sedimentation (Heyder & Gebhart, 1977) and an empirical impaction probability (Chan &
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Lippmann, 1980). The ICRP (ICRP, 1994) and Rudolf (Rudolf, Kobrich, & Stahlhofen,
1990) models both use the same empirical expressions, but use different parameters to
predict DE in the MT, upper tracheobronchial, and lower tracheobronchial regions.
Figure 2.4 shows that the CFD results from the Infant MT-B15 model compare
reasonably well with the range of established algebraic correlations. The Infant MT-B15
model deposition data also exhibits the expected S-shape profile, where smaller particles
with lower Stokes numbers are able to follow the flow streamlines, and larger particles
deviate from the streamlines and deposit due to impaction. As predictions from the Infant
MT-B15 CFD model compare well with these established algebraic correlations for
impaction and sedimentation in the airways, it is acceptable to use it as a benchmark for
comparison when evaluating the suitability of packed bed in vitro lung models. Hence, the
deposition characteristics for a range of bifurcations in the CFD-SIP model can be
compared with the CFD-PB model to determine whether the latter accurately represents
drug deposition in an infant lung.
Influence of CFD-PB Walls on Velocity Field
To ensure the CFD-PB domain is sufficiently large, the velocity magnitude near
the top, bottom, left and rear of the model is evaluated for all cases before analyzing
particle deposition. Figure 2.5 shows an example of such a velocity field, and that applying
wall boundaries conditions at all locations, except the inlet and outlet, does not influence
results. The velocity field in Figure 2.5 is for the CFD-PB B4+ case at the peak of the
sinusoidal inhalation, which gives the highest inlet velocity for all cases considered. The
nodal value at Point A is 1.2e-5 m/s and is considerably smaller than the maximum value
in the domain (3.8 m/s). Figure 2.5 also shows that the air entering the domain is a
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relatively high velocity jet directed at the first sphere opposite the inlet duct, which is
immediately diffused. The implications of this phenomenon on particle deposition are
discussed further below.
Effect of Inlet Style on Particle Deposition in CFD-PB Models
The outlet from the prototyped upper airways can be located in the CFD-PB model
in a number of different configurations, which are presented in Figure 2.6b-d. The naming
convention for CFD-PB inlet configurations refers to the direction of the duct with respect
to the sphere array. As randomly filling the pleural cavity makes it difficult to determine
the sphere arrangement around the prototyped bifurcation, the sensitivity of the model to
each inlet configuration is evaluated.
Figure 2.6a compares the three inlet configurations and the possible gravity
orientations for each case based on transport during the infant inhalation period. The X
and Y inlet configurations both show very similar deposition profiles, whereas the Z inlet
configuration resulted in less deposition than the other cases. The Z inlet requires the
removal of one sphere from the array to include the inlet duct, which means there is a
greater distance between the inlet and the nearest wall where particles may deposit. This
is the likely cause of differences in results and demonstrates the importance of the inlet
configuration. Note that the distance from the inlet to the first sphere opposite the duct
matches the carinal length for B4 for the X, Y, and Z inlet configurations.
Changing the gravity orientation for each inlet configuration has little influence on
the DF for all particle sizes. As expected, there is a very small amount of deposition due
to sedimentation in the upper tracheobronchial airways. Subsequent subsections
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investigate the total and regional deposition characteristics of the CFD-PB model in more
detail.
Figure 2.6 demonstrates that the model is not sensitive to the inlet direction with
respect to gravity, but it is sensitive to how close the spheres are to the inlet duct. To
minimize the influence of the inlet position on deposition results, the sphere arrangement
around the bifurcation outlet can be included in a prototyped model. Using the Z inlet
configuration, the first sphere in the packed bed can be located at a given distance from
the inlet duct. To ease the transition from realistic airway bifurcations to the packed bed,
the first sphere can be located at a distance from the inlet that matches the distance to
the carina for the next bifurcation. Therefore, subsequent cases that require an inlet duct
use this type of inlet configuration, with carinal lengths of 3.92 mm for the CFD-PB B4+
case and 2.25 mm for the CFD-PB B7+ case.
Effect of Sphere Size on Particle Deposition in CFD-PB Model
Figure 2.7 compares the deposition profiles over inhalation for three CFD-PB B4+
cases that each use a different sphere diameter; as the sphere size increases, the DF
decreases. This demonstrates that total deposition in a packed bed experimental model
can be potentially tuned to match the behavior of an infant lung by varying the sphere
size. However, the results show that deposition is very sensitive to small changes in
sphere size for larger particles (>3 µm). For example, the DF for 5 µm particles drops by
approximately 50% and 80% (relative difference) as the sphere size increases from 1.0
mm to 1.5 mm and 2.5 mm respectively. Therefore, selecting an appropriate single sphere
size, or even several sphere sizes, to represent the infant lung for a wide range of particle
diameters would be difficult.
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Comparison of Particle Deposition in CFD-SIP and CFD-PB Models
Figure 2.8 compares deposition in the CFD-SIP results with the CFD-PB B4+ and
B7+. In Figure 2.8a, the CFD-PB B4+ model uses 6 mm spheres and represents the infant
lung distal and inclusive of B4, and the CFD-SIP results show DF from B4 to B15. The
total DF compares quite well between the CFD-SIP and CFD-PB B4+ models, with the
absolute error decreasing from 5.22% for the 0.5 µm particles to -7.55% for the 7 µm
particles. Note that particles larger than 7 µm are neglected here as it is expected that
most would deposit in the MT-B3 region.
In Figure 2.8b, the CFD-PB B7+ model again uses 6 mm spheres, but this time
uses the inlet from B7 to introduce flow into the domain. The CFD-SIP results show DF
data from B7 to B15. In this case, the CFD-PB B7+ model matches the DF of the CFDSIP model better for the sub-micrometer particles than CFD-PB B4+, with absolute errors
that are less the 1%. However, the results do not compare well for the larger (>4 µm)
particles.
The deposition profiles in Figure 2.8 show how the models behave with regard to
total deposition, but do not describe the spatial deposition through the lung. Figure 2.9
shows the particle deposition in three regions for the CFD-PB B4+ case. The three
regions are the sphere directly opposite the inlet duct, the spheres that surround the inlet
duct, and then the remaining spheres in the domain. The inset image shows the 3D
particle deposition on the first sphere. From Figure 2.9, it is clear that the majority of
deposition occurs on the first sphere that the particles encounter as they enter the packed
bed. This goes against the intended behavior of the model, as the packed bed should
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replicate the lung bifurcations by allowing particles to penetrate into downstream regions
of the domain matching both total and regional deposition.
If a packed bed model can be designed to overcome the impaction issue at the
inlet that is apparent in Figure 2.9, it is important to evaluate how the particles travel
through the rest of the packed bed domain. Figure 2.10 compares the deposition profile
from a CFD-PB CS case through a number of layers with the results from B5 to B15 of
the CFD-SIP. Up to 16 layers of spheres are included in the CFD-PB CS model, as this
covers the maximum distance that the particles travel through the domain during the
transient inhalation profile. Note that consistent residence time between the CFD-PB CS
and CFD-SIP models is not considered at this stage, but is explored below. These results
show that the total DF is much higher across all 16 sphere layers than the CFD-SIP
model. The only way to match particle deposition between the two models is to consider
just one layer of spheres in the CFD-PB CS model. Again, this shows that regional
deposition in a packed bed model does not compare well with what is expected in the
infant lung.
Comparison of Particle Residence Time in CFD-SIP and CFD-PB Models
Figure 2.11a and b show frequency plots of particle residence time through the B4B7 and B8-B15 regions of the CFD-SIP model respectively. Table 2.1 shows the mean
and range of particle residence times for the full CFD-SIP model. The results for CFD-PB
B4+ through two sphere layers are presented in Figure 2.11c and Table 2.2. Two sphere
layers were selected so that the mean residence time for all particle sizes compares well
with the CFD-SIP data (0.089 s for CFD-PB vs. 0.097 s for CFD-SIP). However, the
standard deviation (SD) and spread of data in the plots shows that there is considerably

58

more variability in residence time in the CFD-PB model (SD = 0.080 for CFD-PB vs. 0.023
for CFD-SIP). This is likely due to the number of different pathways that particles can take
when they reach a sphere junction compared to a bifurcation. Similar behavior is seen
when looking at the results for the CFD-PB CS case in Figure 2.11d and Table 2.3. Here
the CFD-PB CS model covers nine sphere layers to match the mean residence time
(0.099 s for CFD-PB vs. 0.097 s for CFD-SIP), but again there is more variability in the
particle residence times (SD = 0.053 for CFD-PB vs. 0.023 for CFD-SIP).
Comparative Dimensions of CFD-PB and CFD-SIP Models
These results have so far focused on quantitative values for DF and the residence
time of particles travelling through the CFD-PB domains. A qualitative comparison
between the size of the CFD-PB and CFD-SIP models can also be made. The bounding
box around the B4-B7 and B8-B15 sections of CFD-SIP have a diagonal length of
approximately 18 mm and 13 mm respectively. This means roughly five sphere layers of
the 6 mm spheres are required in the CFD-PB model to match the length of the CFD-SIP
model. The results from Figure 2.11 show that two layers of 6 mm spheres after the inlet
duct are required to match residence times between the CFD-PB B4+ and CFD-SIP
models, and nine layers of 6 mm spheres are required for the CFD-PB CS case.
Therefore, the overall dimensions of either version of the PB model that would be capable
of representing residence time are considerably different from the SIP model. This finding
is further complicated by the other fundamental issue highlighted by the results of this
study, which is the majority of particles impact on the first sphere of the CFD-PB model.
As such, regional deposition results for an optimized packed bed model, in terms of both
deposition and dimensions, would not be representative of human lungs.
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2.5

Discussion
This study concludes that packed bed models do not provide a realistic

representation of aerosol deposition in an infant lung. Although total deposition compares
well between the CFD-PB and CFD-SIP models, regional deposition via impaction
behaves very differently in a packed bed than it does in lung bifurcations. The positive
outcomes from this investigation are that the Infant MT-B15 model matches the deposition
profile predicted by well-known algebraic correlations, and that the application of packed
bed models for a complete-airway in vitro model have been more completely evaluated
with a clear conclusion.
The lung deposition data from the Infant MT-B15 model were benchmarked
against three well-known algebraic correlations (W. H. Finlay, 2001; ICRP, 1994; Rudolf
et al., 1990), but ideally this study would compare with in vivo results. Unfortunately, in
the literature to date, little in vivo aerosol deposition data are available due to ethical
concerns associated with studies on infants. One study (Salmon, Wilson, & Silverman,
1990) evaluated aerosol delivery in 9 to 36 month old boys via a face mask and nebulizer
system. However, the deposition was assessed by collecting urine samples and
estimating lung absorption of the delivered dose, which only provides total lung deposition
results. Several other studies (Amirav et al., 2002; Chua et al., 1994; Fok et al., 1996;
Mallol, Rattray, Walker, Cook, & Robertson, 1996) used gamma scintigraphy to obtain
regional deposition data, but were all performed on diseased lungs (cystic fibrosis,
bronchiolitis, or bronchopulmonary dysplasia), which makes it difficult to compare the
results with healthy infant lungs.
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The geometry of the packed bed results in a flow field that is considerably different
from airway bifurcations. This in turn gives particle deposition characteristics that are not
comparable to the lung. The images in Figure 2.12 show the two possible ways that
spheres may contact each other in a close-packed array, and the resulting voids available
for airflow. Note that each of the voids shown in Figure 2.12b is connected to one of the
orifices on the voids in Figure 2.12d, and so on in the sphere array.
The geometry in Figure 2.12b can be described as a trifurcation with triangular
inlets and outlets. The walls of the trifurcation are very close to any potential outlets, which
may explain the amount of impaction deposition seen in the results. The general shape
of the geometry also contrasts greatly with lung pathways, which are typically bifurcations
with circular or elliptical cross sections and have longer straight sections approaching
each bifurcation. The geometry in Figure 2.12d is further removed from observations of
human lung anatomy. Here, multiple flow pathways converge in a relatively large cavity,
which suggests a chaotic flow field and particle motion. In summary, the shape and
characteristics of the voids between packed bed spheres do not resemble lung
bifurcations, which explains why the aerosol deposition results do not compare well in this
study.
It is important to recall that the focus of this study was on impaction deposition in
a packed bed that is dimensionally similar to airway bifurcations. The major finding is that
spatial and temporal deposition of aerosols in packed beds is very different from lung
bifurcations. Hence, the packed bed model as constructed in this study cannot be used
to form a complete-airway deposition model for particles in all size ranges that can
correctly capture regional particle deposition. It does appear that a correctly configured
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PB model can capture total lung deposition from impaction provided that multiple sizes of
spheres are used.
These results have limited impact on previous studies that employed packed beds
as lung models. For example, the study of Gebhart and Heyder (1985) focused on
diffusion and sedimentation deposition of particles less than or equal to 1.5 µm in
diameter. The study of Rosenthal et al. (1992) has already established that particles in
PB models are dispersed differently over time than in human lungs, as we observed in
Figure 2.11. However, this finding should not preclude the use of PB geometries as a
uniform testing standard for comparison studies that require a model with fine scale
structures or large surface-area to volume ratios as in the lungs. For example, the PB
geometry remains an excellent model for evaluating the sensitivity of the Aerosol-Derived
Airway Morphometry (ADAM) technique as with Brand et al. (1994).
One difference between an in vitro packed bed model and the CFD implementation
in this study is the sphere arrangement. The geometry in the CFD model uses closely
packed spheres, whereas an experimental model would typically lead to random packing.
However, it is expected that the conclusions would be the same with a random fill sphere
arrangement, as the key issue with packed beds is that the geometry is very different
from lung bifurcations. A random fill sphere arrangement would only exacerbate the
difference between a packed bed and the human lung, and lead to more variability in the
flow field and particle deposition.
Based on the results of this study, we view the use of a PB in a complete-airway
in vitro model as limited. One potential solution may be to 3D print airway bifurcations
through the impaction zone of the TB airways and implement a PB for sedimentation and
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diffusion deposition in the alveolar region. However, 3D printing all conducting airway
pathways down to approximately B15 is currently not practical and may result in a very
fragile structure. A PB alveolar region can accurately reproduce the deposition surfacearea to air-volume ratio of the lungs. However, the overall volume of the model will be
significantly larger than in vivo conditions due to the large volume occupied by the
spherical solids. Hence, spatial resolution of regional deposition cannot be reproduced
for direct comparisons with gamma scintigraphy radiolabeled aerosol deposition results.
Provided that it is not important to match spatial resolution of deposition, the hybrid-style
model of Saini et al. (2002) may be capable of capturing regional aerosol deposition. This
model was composed of a laryngeal structure attached to a triangular geometry
containing multiple levels of different sizes of spheres. Based on the illustration of the
model, there are only 2 or 3 layers of spheres on each level, consistent with CFD
predictions that large regions of bifurcating airways can be reproduced with several layers
of spheres. Furthermore, the triangular structure of the container will allow for different
uniform cross-sectional velocities in different zones of the model, enabling multiple
deposition mechanisms to be captured. Provided that the lung is viewed as a series of
concentric shells that are opened, laid flat, and stacked, the Saini et al. model may be
worth further exploration as a complete-airway alternative. In contrast, truly resolving
spatial and temporal deposition with an in vitro complete-airway model, which was the
focus of this study may require the consideration of 3D printed in vitro upper airways
together with tissue engineering or excised (ex vivo) animal lung models.
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2.6

Figures

Figure 2.1:

Overview of models described throughout the study: (a) In Vitro Complete

Airway Model, (b) CFD-SIP (B4-B15), and (c) CFD-PB (with B4 inlet duct).
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Figure 2.2:

Geometry of (a) 6 mm packed bed with fillets between connected spheres

and (b) close-up view of Triangle 1.
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Figure 2.3:

CFD-PB mesh and geometry showing (a) isometric view of full sphere array,

(b) close-up view of inlet duct mesh (with length to carina included), and (c) close-up view
of first sphere that shows the conformal interface between unit cells, aligned mesh lines
to capture fillets accurately, and near-wall prism layer mesh.
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Figure 2.4:

Comparison of deposition profile for the Infant MT-B15 model predicted by

CFD with three well-known algebraic deposition correlations.
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Figure 2.5:

Reduction of velocity magnitude close to the wall boundaries on the top,

bottom, rear, and side of the domain, with a nodal value of 1.2e-5 m/s at Point A.
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Figure 2.6:

Evaluation of inlet configurations with (a) showing the deposition profile for

each case, and (b), (c), and (d) showing the X, Y, and Z inlet configurations, respectively.
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Figure 2.7:

Comparison of deposition profiles when varying the sphere diameter in the

CFD-PB B7+ model. Only the 0.5 to 7 µm particles are shown as the majority of larger
particles deposit in the upstream airways.
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Figure 2.8:

Comparison of CFD-SIP results with (a) CFD-PB B4+ and (b) CFD-PB B7+.

Error (%) is presented as the absolute difference between the deposition fraction in the
CFD-SIP and CFD-PB models.
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Figure 2.9:

Comparison of deposition fraction in multiple sphere zones of CFD-PB B4+.
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Figure 2.10: Number of sphere layers required in CFD-PB CS to match CFD-SIP
deposition fractions.
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Figure 2.11: Particle number frequency distribution vs. residence time for (a) CFD-SIP
B4-B7 and (b) CFD-SIP B8-B15, (c) CFD-PB B4+ through two sphere layers, and (d)
CFD-PB CS through nine sphere layers. Number of spheres layers in each CFD-PB case
was selected to match the mean residence time in the equivalent CFD-SIP model.
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Figure 2.12: Basic geometry showing (a) trifurcation spheres, (b) trifurcation void (fluid),
(c) large cavity spheres, and (d) large cavity void.
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2.7

Tables

Table 2.1:
Particle
Diameter
[µm]
0.5
1
2
3
4
5
7
0.5-7

Residence time for the CFD-SIP model.
Count
[-]
7073
7024
7228
5355
4225
2151
408
33464

Mean (SD)
Residence Time
[s]
0.102 (0.033)
0.100 (0.029)
0.098 (0.023)
0.093 (0.018)
0.095 (0.019)
0.093 (0.014)
0.099 (0.014)
0.097 (0.023)

Minimum
Residence Time
[s]
0.076
0.076
0.077
0.078
0.078
0.080
0.084
0.076
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Maximum
Residence Time
[s]
0.427
0.394
0.413
0.250
0.251
0.186
0.141
0.427

Table 2.2:
Particle
Diameter
[µm]
0.5
1
2
3
4
5
7
0.5-7

Residence time for the CFD-PB B4+ model through two sphere layers.
Count
[-]
24630
23925
24886
25796
26031
26478
12570
164316

Mean (SD)
Residence Time
[s]
0.090 (0.081)
0.093 (0.081)
0.089 (0.078)
0.086 (0.079)
0.086 (0.078)
0.082 (0.076)
0.099 (0.085)
0.089 (0.080)

Minimum
Residence Time
[s]
0.011
0.011
0.010
0.011
0.012
0.011
0.012
0.010
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Maximum
Residence Time
[s]
0.489
0.482
0.471
0.494
0.477
0.485
0.490
0.494

Table 2.3:
Particle
Diameter
[µm]
0.5
1
2
3
4
5
7
0.5-7

Residence time for the CFD-PB CS model through 12 sphere layers.
Count
[-]
26354
23697
23744
22847
16105
6847
126
119720

Mean (SD)
Residence Time
[s]
0.091 (0.048)
0.091 (0.046)
0.096 (0.046)
0.094 (0.044)
0.099 (0.046)
0.099 (0.045)
0.124 (0.086)
0.099 (0.053)

Minimum
Residence Time
[s]
0.025
0.026
0.026
0.027
0.027
0.031
0.046
0.025
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Maximum
Residence Time
[s]
0.448
0.466
0.452
0.448
0.435
0.455
0.421
0.466

Chapter 3: Recommendations for Simulation of Microparticle
Transport and Deposition Using Two-Equation Turbulence Models
3.1

Objective
The objective of this study is to determine both mesh and CFD solution parameters

that enable the accurate simulation of microparticle deposition under flow conditions
consistent with the upper respiratory airways including turbulent flow. To represent
conditions similar to the upper respiratory airways, a simple 90 o curved tube is selected
as a characteristic geometry. This geometry provides a different test scenario than the
constricted tube model that is typically used to represent turbulence in the upper airways.
Both the nasal and MT airways contain curved tube features that are associated with high
particle deposition. Furthermore, deposition in bifurcations is often approximated with
correlations for deposition in curved tubes (Martonen et al., 2000). The comparison metric
considered will be total microparticle deposition, based on the well documented
experimental results of Pui et al. (1987) with Re = 6,000 and Re = 10,000. For
comparison, Breuer et al. (2006) previously published LES in curved tubes with excellent
agreement when compared with Pui et al. (1987). In addition to an evaluation of mesh
and solution parameters, a key question to be addressed is whether the LES agreement
with experiments (Breuer et al., 2006) can be matched with the correct use of a much
simpler and computationally efficient two-equation turbulence approach.
3.2

Introduction
Laminar, transitional and fully turbulent flows are all expected to occur in the upper

respiratory airways. Transitional and turbulent flow as well as the process of flow regime
change from laminar to turbulent flow is notoriously difficult to predict and can be
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influenced by upstream conditions, wall surface roughness and even environmental noise
(Schlichting, 1987; Tennekes & Lumley, 1972; Wilcox, 1998). Transitional and turbulent
flows are known to have a significant impact on particle deposition through the interaction
of turbulent eddies and discrete elements, which typically increases deposition compared
with the laminar flow case (Crowe, Troutt, & Chung, 1996). Therefore, accurate
predictions of lung doses arising from either inhaled pollutant particulate matter or
pharmaceutical aerosols requires reasonable approximations of both the turbulent flow
field and the interaction of turbulent eddies with particles.
The upper airways consist of the oral and/or nasal geometry, trachea and
approximately the first six airway bifurcations. Jets of airflow with flow detachment and
recirculation are formed in the nasal valve and larynx (Xi et al., 2008; J. X. Xi et al., 2012).
As described in previous experimental and numerical results (Ahmed & Giddens, 1983a,
1983b; Ghalichi et al., 1998), transition to turbulence in flow constrictions of 50 and 75%
area reductions occurs at Reynolds numbers of approximately 1,100 and 400,
respectively, which are significantly lower than the typical value of 2,300 for a straight
cylindrical conduit. Considering a mean inhalation flow rate of 60 L/min (LPM), upperairway Reynolds number values for an adult range from approximately 10,620 (larynx) to
553 (bifurcation B6). Peak inhalation flow rate with a dry powder inhaler (DPI) can reach
160 LPM (R. R. Delvadia, Wei, Longest, Venitz, & Byron, 2016), significantly multiplying
these Reynolds number estimates at the point in time when the largest concentration of
an inhaled pharmaceutical aerosol is entering the lungs. Furthermore, inhalers introduce
air jets or sprays in the mouth-throat (MT) geometry, which are frequently turbulent and
significantly impact MT depositional loss of the aerosol (DeHaan & Finlay, 2004; Longest,
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Hindle, Das Choudhuri, & Xi, 2008). In a previous study of the laryngeal jet, Xi et al. (2008)
showed that the turbulent viscosity ratio maintained a value of at least 2 through
bifurcation B6 at an inhalation flow rate of 30 LPM. The study of Lin et al. (2007) also
showed turbulence intensity values of 20% extending from the laryngeal jet into the lungs.
A number of studies have demonstrated the importance of turbulence on deposition
throughout the upper airways (Ball, Uddin, & Pollard, 2008; Jayaraju, Brouns, Lacor,
Belkassem, & Verbanck, 2008; Lambert, O'Shaughnessy, Tawhai, Hoffman, & Lin, 2011;
Longest, Tian, Delvadia, et al., 2012; Matida, Finlay, Breuer, & Lange, 2006; Xi et al.,
2008; J. Xi & Longest, 2007; Z. Zhang & Kleinstreuer, 2011). Surprisingly, some of these
studies have shown that turbulence can increase or decrease depositional loss (Longest
& Vinchurkar, 2007b; Xi et al., 2008). While eddy interaction serves to increase
depositional particle losses, the blunt turbulent velocity profiles can actually reduce
impaction at carinal ridges. Furthermore, increased eddy viscosity can reduce secondary
flows and associated particle impaction on bifurcation sidewalls.
Turbulence has been captured in respiratory airway geometries with models that
range in complexity from the one-equation Spalart-Allmaras model (Wilcox, 1998) to full
resolution of all turbulence scales with direct numerical simulation (DNS) (C. L. Lin et al.,
2007). Specific examples include two-equation turbulence models such as the k-ε
(Stapleton, Guentsch, Hoskinson, & Finlay, 2000) and k-ω (Xi et al., 2008; Z. Zhang &
Kleinstreuer, 2011), detached eddy simulation (Jayaraju et al., 2008), large eddy
simulation (LES) (Jayaraju et al., 2008; Jin, Fan, Zeng, & Cen, 2007; Matida et al., 2006)
and DNS (C. L. Lin et al., 2007). In general, studies that compare results from multiple
models typically find that the simpler model is inadequate compared with the more
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complex model. This move to more complex turbulence models makes the simulation of
large airway regions including the influence of transient inhalation over a 5 s period
impractical due to the time and computational power that is required to run the
simulations. Critical questions that are often overlooked in turbulence model comparison
studies include: (i) what impact will discrepancies in velocity and turbulence parameters
have on particle deposition, (ii) are the simpler models being properly applied, and (iii) is
the most developed version of each simpler model being applied. For example, Ball et al.
(2008) compared experimental results with predictions of two-equation turbulence models
and found discrepancies in the velocity and turbulent kinetic energy (TKE) results.
However, particle deposition was not considered and the more recent Low Reynolds
Number (LRN) k-ω model was not included. Matida et al. (2006) compared aerosol
deposition between LES and shear stress transport (SST) k-ω turbulence models and
found significantly better predictions with the LES model compared to in vitro
experiments. While these results were based on particle deposition, they did not include
LRN k-ω predictions and neglected near-wall (NW) corrections, which were previously
shown to be important (Matida, Finlay, & Grgic, 2004). Similar findings of superior
performance with a LES model compared with a standard k-ω model without NW
corrections were reported by Jayaraju et al. (2007). Furthermore, while LES has been
found to be more accurate than two-equations models based on the predictions of
turbulence properties, the increase in computational cost is very large. In a simple
representative geometry of a curved pipe at Re = 10,000, Breuer et al. (2006) reported
that grid convergent results required approximately 2.3 million control volumes. In a
constricted pipe test geometry, Zhang and Kleinstreuer (2011) reported that LES
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simulations required approximately 100-fold more computer power than using a twoequation turbulence model.
Two-equation turbulence models implement the Reynolds Averaged Navier
Stokes (RANS) equations and simulate turbulent effects typically with a kinetic energy (k)
and dissipation (ε or ω) term. Transport equations are formed for the two turbulence
terms, which are then combined into a turbulent viscosity scalar that is present in the
RANS equation and functions as an added viscosity on the flow field (Wilcox, 1998). The
effect of turbulence on particle dispersion is then approximated through the use of an
eddy interaction model, which implements the turbulence terms to stochastically recreate
eddy structures and predict associated chaotic motion of particles as a random walk
(Crowe et al., 1996). A primary shortcoming of all two-equation turbulence models is the
assumption of isotropic (direction independent) turbulent fluctuations near wall
boundaries (Wilcox, 1998). Matida et al. (2004) provided a NW correction for anisotropic
turbulence effects, which has frequently been applied (Longest & Hindle, 2009a; Longest
et al., 2007; Longest et al., 2008). Longest and Xi (2007) reported that improved NW
interpolation of the velocity field was also needed in turbulent simulations using twoequation models. Of the available two-equation models, the LRN k-ω model has been
most successful in predicting transitional and turbulent flows including reasonable
predictions of particle deposition (Kleinstreuer & Zhang, 2003; Longest & Hindle, 2009a;
Longest et al., 2007; Longest et al., 2008; Longest, Tian, Delvadia, et al., 2012; Longest,
Tian, Walenga, et al., 2012; Longest & Xi, 2007; Tian et al., 2011; Z. Zhang & Kleinstreuer,
2003, 2011). Low Reynolds number refers to the fact that the model simulates the flow
field all the way through the viscous sub-layer, i.e., the low Reynolds number region, and
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can be successfully applied to both low and high Reynolds number flows (Wilcox, 1998).
The primary advantage of two-equation models is high efficiency approximation of very
complex transitional and turbulent flow phenomena. However, questions remain if these
models can successfully be applied to predict particle deposition in the upper respiratory
airways (Ball et al., 2008; Matida et al., 2006).
Studies that have used the LRN k-ω model with NW anisotropic and sometimes
velocity interpolations have reported reasonable agreement with experimental results of
turbulence metrics and particle deposition. Zhang and Kleinstreuer (2003) compared the
performance of two-equation turbulence models in a constricted flow geometry and
showed that the LRN k-ω model reproduced laminar, transitional and turbulent flow
characteristics comparable with the experimental measurements of Ahmed and Giddens
(1983a, 1983b, 1984). Other studies also using the constricted tube geometry have
reached similar conclusions (Ryval, Straatman, & Steinman, 2004; Varghese & Frankel,
2003). The more recent study of Zhang and Kleinstreuer (2011) considered a series of
two-equation turbulence models compared with LES in constricted tube and MT
geometries. The LRN k-ω model was again shown to perform well and predictions of
nanoparticle deposition in the MT were similar to LES. Our group has successfully applied
the LRN k-ω model to predict particle deposition in the upper respiratory airways with
good agreement to in vitro (Longest & Hindle, 2009a; Longest, Tian, Walenga, et al.,
2012; Longest & Vinchurkar, 2007b; Longest & Xi, 2007) and in vivo (Longest et al., 2015;
Walenga & Longest, 2016) studies. These simulations have considered pharmaceutical
aerosols including jet and spray effects from DPIs (Longest, Tian, Delvadia, et al., 2012;
Longest, Tian, Walenga, et al., 2012; Tian et al., 2011), metered dose inhalers (MDI)
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(Longest, Tian, Walenga, et al., 2012; Walenga & Longest, 2016; Walenga et al., 2013),
and soft mist inhalers (R. R. Delvadia, Longest, Hindle, & Byron, 2013; Longest & Hindle,
2009a; Longest, Hindle, & Das Choudhuri, 2009). For example, Longest et al. (2012)
showed that the MT deposition predicted by the LRN k-ω model with NW corrections was
within 10% of in vitro experimental data for complex pharmaceutical aerosols including
the effect of polydisperse aerosol size, transient inhalation over an approximately 5 s
period and turbulence for MDI and DPI devices.
Based on successful applications of the LRN k-ω model with NW corrections in
predicting aerosol deposition in upper airway geometries, it appears that this model
provides a good compromise between accuracy and efficiency. However, in other studies
we have shown that computational mesh structure and type can have a dramatic effect
on solution accuracy (Longest & Vinchurkar, 2007a; Vinchurkar & Longest, 2008).
Guidelines for the use of the LRN k-ω model and for two-equation models in general are
not well defined for applications to the respiratory airways. The current specification of 20
layers of computational cells through the turbulent wall region including the buffer layer
(ANSYS, 2012) may be computational prohibitive for large complete-airway simulations
(Longest, Tian, Delvadia, et al., 2012), and not necessary. Current recommendations may
also be difficult to implement in complex geometries such as the nasal valve and larynx
where flow passages are very narrow (Subramaniam, Richardson, Morgan, Kimbell, &
Guilmette, 1998). For example, Walenga et al. (2014) reported excellent agreement with
experimental results of particle deposition in the nose with a nasal cannula interface using
only 5 NW cell layers. Furthermore, no recommendations are currently available for
overall layer-to-layer (L2L) thickness of the NW mesh, or recommendations on the
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method used to calculate gradients within control volumes, which interact with mesh type
and resolution to influence the solution accuracy. Finally, mesh style in conjunction with
turbulence modeling has previously not been considered in respiratory airway
geometries.
3.3

Methods

Experimental Model and Results
This numerical study aims to evaluate mesh and CFD solution parameters based
on comparisons with the experimental data from Pui et al. (1987) in a 90° curved tube
geometry. The Pui et al. data was collected by measuring the deposition of monodisperse
aerosols with Stokes numbers from 0.1 to 1.4 through glass and stainless steel 90° bends
with internal diameters (ID) of 0.93, 3.95, 5.03, and 8.51 mm and Reynolds numbers (Re)
of 100, 1,000, 6,000, and 10,000.
In this study, CFD-predicted aerosol deposition results are compared with the
following Pui et al. (1987) experimental data sets: Re = 6,000 with ID = 5.03 mm; and Re
= 10,000 with ID = 8.51 mm, which were both evaluated with stainless steel tubes. This
covers a range of turbulent conditions and changes in the geometry by increasing the
tube diameter. The correlation from the experimental study gives aerosol deposition
efficiency (𝜂) as a function of particle Stokes number (St), as:
𝜂 = 1 − 10−0.963St

(3.3.1)

The deposition efficiency and correlation results for the selected experimental models are
given in Table 3.1.
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Numerical Geometry and Meshes
The inset in Figure 3.1a shows the full computational domain that matches the
experimental setup of the Pui et al. (1987) geometry. The straight entry and exit sections
of the tube were included to ensure that the flow is fully developed at the 90° bend inlet
and smoothly exits the geometry, as was the case with the experiemental model. The
curvature ratio (bend radius over tube radius) also matches the original setup, with ratios
of 5.7 and 5.6 for the Re = 6,000 and 10,000 cases, respectfully.
Mesh Dependency
Preliminary results compared five meshes to evaluate the dependency of results
on mesh resolution. The 90° bend section for each case had approximately 1,400,000,
672,000, 368,000, 208,000, and 83,000 hexahedral cells, inclusive of the NW layers.
Initially, only the three finer meshes were compared, but results were almost identical, so
the two coarser meshes were also evaluated. Consistency between deposition profiles
(deposition fraction vs. particle diameter), velocity profiles at the inlet and outlets, and
pressure drop across the tube were considered. Sensitivity of the turbulent flow to mesh
resolution was also assessed by comparing u+ vs. y+ plots between the five meshes and
to Spalding’s equation (1961). These u+ vs. y+ plots were generated from data in the
region of fully developed flow within the turbulent buffer and sub-layer near the wall.
The mesh dependency evaluation concluded that the coarse case (368,000 cells)
gave the best compromise of small numerical error and reduced cell count. In several of
the meshes that are evaluated in subsequent sections of this study, the resolution of the
mesh in the NW region is adjusted to determine the influence on results. In all cases, the
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core mesh (covering the bulk flow) for the grid independent case was retained, and
different NW mesh resolution parameters are then applied.
Near-wall Mesh Resolution
Traditionally, there are two approaches to modelling the NW region when using
two-equation RANS turbulence models. The wall function method uses an empirical
formulation to model the flow in the inner and outer layer with a relatively large NW cell
height. Wall y+ values should ideally be greater than 30, with 15 as an acceptable
minimum. For low to medium Reynolds number flow, such as the respiratory airways, the
ANSYS FLUENT Theory Manual (2012) advises against using the wall function approach
as the assumptions that the method uses are not applicable to this flow regime. The other
approach is to use the enhanced wall treatment (EWT) method where the mesh aims to
fully resolve the NW turbulent layers. This method is considered to be y+ independent,
but wall values of one are recommended. The main concern when using the EWT method
is that there are an adequate number of cell layers to resolve the flow in the NW region.
When using the k-ω turbulence model in ANSYS FLUENT, the EWT method is
implemented by default.
Initially four meshes are compared that each have varying degrees of NW mesh
resolution and are suitable for the EWT method. These meshes are referred to as the
Recommended, Intermediate, Targeted, and Poor Ratio cases, and are presented in
Figure 3.2a. The Recommended mesh follows the NW mesh resolution guidelines in the
ANSYS FLUENT Theory Guide (2012), with 20 cell layers that cover the region from the
wall up to a y+ value of approximately 60 and a first layer thickness that gives a wall y + of
approximately one. These recommended guidelines aim to model the flow in the sub-
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layer and buffer region accurately when using the EWT option by using a high-fidelity
mesh in the NW region. However, there are several close proximity surfaces in the nasal
cavity, especially the meatuses, where such a high level of mesh resolution is not feasible.
Ideally, the NW mesh in an upper airway model would be similar to the Targeted mesh,
with five equally spaced NW cell layers and a first layer height that gives a wall y + of
approximately one. Here the resolution is fine enough to capture the large flow field
gradients near the wall, but the overall cell layer height is thin enough to be included
between close proximity surfaces. Fewer cell layers also drastically reduces the total cell
count, so accurate results from the Targeted mesh would provide a more computationally
efficient model. The Intermediate model uses 10 equally spaced NW cell layers with a
wall y+ of approximately one. This provides a level of mesh resolution that falls within the
Recommended and Target models. Finally, the Poor Ratio mesh is similar to the Targeted
case, with the exception that the L2L ratio from Layer 1 to 2 is 1.8, and the layers are then
equally spaced from Layer 2 to 5. This mesh is included in the evaluation to determine
how poorly defined L2L thicknesses can influence the results. In complex geometries, the
meshing software can stretch and shrink cell layers in order to conform to the surface.
Therefore, it is possible to have large increases in the L2L ratio such as the Poor Ratio
case, which may not accurately capture high gradients in the flow field.
After evaluating the four NW mesh conditions described above, both first cell layer
height and L2L ratio are considered. The effect of increasing the thickness of the first NW
layer is evaluated using the meshes shown in Figure 3.2b. The definition of these Wall y+
meshes uses only one NW layer to neglect the influence of L2L ratio on results.
Consistency in deposition profiles between cases will indicate that first layer thickness
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does not influence results within the range considered. The effect of L2L ratio between
Layer 1 and 2 is explored further with the meshes in Figure 3.2c. The Ratio meshes
determine at what point the ratio between Layer 1 and 2 becomes excessive and begins
to influence results. The NW layer thickness in Figure 3.2c is consistent between each of
the Ratio meshes and gives a wall y+ of approximately one.
The NW meshing parameters require known values of wall y + in order to be
defined. These values can be estimated before running the CFD simulation using the
following equations. The skin friction (𝐶𝑓 ) is approximated from the Reynolds number (Re)
by using Blasius’ equation for turbulent flow in a circular pipe (Blasius, 1913), which is
given by
𝐶𝑓 ≈ 0.0791Re−1⁄4

(3.3.2)

The wall shear stress (𝜏𝑤 ) is defined with the skin friction, fluid density (𝜌), and average
flow velocity (𝑢) as
1
𝜏𝑤 = 𝐶𝑓 𝜌𝑢2
2

(3.3.3)

The wall friction velocity (𝑢∗ ) is given by
𝜏𝑤
𝑢∗ = √
𝜌

(3.3.4)

Finally, the distance from the wall to the center of the first NW cell (Δ𝑦𝑤 ) is determined
from the desired wall y+ (𝑦𝑤+ ), fluid dynamic viscosity (𝜇), fluid density, and wall friction
velocity as
𝑦𝑤+ 𝜇
Δ𝑦𝑤 =
𝜌𝑢∗
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(3.3.5)

Note that Equations (3.3.2) to (3.3.5) do not give exact mesh definitions, but serve as
good estimations to get sensible NW layer thicknesses. Table 3.2 summarizes each of
the meshes described here and includes the meshing parameters that are used to
generate the required NW cell layers.
Mesh Construction and Cell Types
The meshes shown in Figure 3.2 were generated by the ICEM CFD 14.5 meshing
package (ANSYS, Inc., Canonsburg, PA, USA). The effects of the NW cell layer
parameters were initially explored using hexahedral cells, as shown in Figure 3.2d for the
Targeted case. This mesh type was constructed using the block mesh approach available
in ICEM CFD 14.5, which allows the user to create a regular, mapped, hexahedral mesh.
Regular hexahedral meshes are ideal for CFD analysis in airway type systems, as
they generally give the best accuracy when applied to the finite volume method
(Vinchurkar & Longest, 2008). However, this type of mesh construction is not possible
when developing models of nasal anatomy and potentially the MT, as the geometry is
often too complex. Irregular tetrahedral meshes are employed in such cases, as they are
able to conform to intricate surfaces, but numerical accuracy and robustness is sacrificed
to some degree (Vinchurkar & Longest, 2008). Therefore, this study will compare the
results of hexahedral and tetrahedral meshes directly to determine if there are substantial
drawbacks associated with using tetrahedral meshes when modelling aerosol deposition.
The mesh on the right side of Figure 3.2d is an example of the tetrahedral meshes used
in the evaluation, specifically the Targeted NW cell layer case. These meshes were also
generated with ICEM CFD 14.5 using the Tetra meshing capabilities. First, a CAD model
of the 90° bend was supplied to the meshing software, and a patch-dependent, triangular
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shell mesh was generated for each of the surfaces. A Delaunay algorithm was then
utilized to fill the 3D volume with tetrahedral cells based on the triangular shells. Next, cell
layers were inflated from the tube walls into the fluid volume to generate a prismatic NW
mesh. After this inflation stage, the mesh is smoothed to ensure that the quality metric for
all cells is greater than 0.1. Finally, the entry and exit sections of the model were extruded
normal to the inlet and outlet of the 90° bend. This extrusion process generates prismatic
cells that are aligned with the flow direction, which helps model the fully developed
behavior in this region. The tetrahedral meshing method outlined here ensures good
mesh quality, but is surprisingly more involved that hexahedral mesh construction. That
said, tetrahedral meshing of complex geometries is much simpler than trying to apply the
blocking method to irregular surfaces.
Physics Model and Solver Settings
The ANSYS FLUENT 14.5 CFD software package (ANSYS, Inc., Canonsburg, PA,
USA) solves the transport equations that describe the flow field and particle trajectories
through the numerical models. Initially, existing best practices developed by our group for
modelling aerosol deposition in the extrathroacic region were applied to the
Recommended, Intermediate, Targeted, and Poor Ratio meshes. The k-ω model solves
the TKE and specific dissipation rate (SDR) fields, as is generally recommended for
internal flows. The LRN correction uses a coefficient to dampen the turbulent viscosity
that is determined when the TKE and SDR transport equations are combined. This
coefficient is calculated from the material properties, turbulent field quantities, and model
constants; the details of which are given by Wilcox (1998). The LRN correction should be
applied when flow is close to the transition regime. Currently, the solver uses the
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SIMPLEC scheme for Pressure-Velocity coupling, with Least Squares Cell Based (LSQ)
gradient discretization, and second-order upwind schemes for flow variables. Particle
trajectories through the domain are modeled using Lagrangian tracking with the RungeKutta scheme (Longest et al., 2015; Longest & Hindle, 2009a; Longest et al., 2007;
Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Longest &
Vinchurkar, 2007b; Tian et al., 2011; Walenga & Longest, 2016). The particle drag,
turbulent dispersion, and eddy interaction model are modified with NW correction userdefined functions (UDFs), which correct for turbulent anisotropy near wall boundaries
(Longest et al., 2008; Matida et al., 2004) and perform NW velocity interpolation (Longest
& Xi, 2007). The NW correction may mask the behavior of the underlying physics models
and solver settings, so they are neglected when comparing the variability between the
four meshes. Once mesh and CFD solution parameters are defined that reduce the
inconsistency in flow and particle deposition results, the UDFs will be applied to compare
with the Pui et al. (1987) experimental data.
Turbulence
To date, LRN k-ω turbulence has been the two-equation model of choice for CFD
particle deposition studies from our group. It has been extensively validated against in
vitro (Longest & Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012;
Longest, Tian, Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and
in vivo (Longest et al., 2015; Walenga & Longest, 2016) experimental data, and provided
accurate results in these studies. Advanced models, specifically the k-ω SST and
Reynolds Stress Model (RSM), are available that aim to model turbulence with greater
accuracy and detail. The SST k-ω model combines the free-stream advantages of the k-
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ε model with the NW benefits of k-ω. It is the recommended RANS turbulence model in
the ANSYS FLUENT User Guide (2012), and includes a LRN option for modeling flow
that is close to transition. Chen et al. (2009) used the SST k-ω model for a CFD
assessment of flow through the nasal cavity in patients with septal deviations, although
their study did not include particle deposition. The RSM has both ε and ω formulations,
and solves seven additional transport equations for each of the Reynolds stresses. Rygg
and Longest (2016) applied RSM to model pharmaceutical aerosol deposition in the adult
nasal cavity, as its formulation includes turbulence anisotropy near walls without
additional UDFs.
Despite the advanced formulation of SST and RSM k-ω, preliminary work for this
study showed that these models increased processing times by approximately 30% and
did not show substantially different results in terms of NW mesh sensitivity compared with
the LRN k-ω model. In addition, RSM gave a very unusual velocity profile at the inlet and
outlet of the 90° bend when compared to the other turbulence formulations. Therefore,
the remainder of this investigation will use the LRN k-ω model, based on its previous
successful use. Preliminary results also show that particle deposition appears to be
dependent on the NW mesh only when the turbulent dispersion model is activated. This
suggests that results are sensitive to resolution of the NW TKE field, as this quantity drives
the turbulent dispersion model and its influence on particle deposition. Therefore,
consistency in the NW TKE field between meshes is the primary initial focus of this study,
which in turn is shown to give consistency between deposition profiles.
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Gradient and Spatial Discretization Schemes
The default gradient discretization scheme available in ANSYS FLUENT is the
LSQ scheme developed by Anderson and Bonhaus (1994). This method computes the
cell gradient by using a weighting that is based on the distance from the cell centroid to
its adjacent cells. The two other options available for gradient discretization are the
Green-Gauss Node-based (GGN) and Green-Gauss Cell-based (GGC) methods.
Equation (3.3.6) describes the Green-Gauss Theorem , which defines the gradient of any
field variable at the cell centroid (∇𝜙) by using the cell volume (𝑉), number of cell faces
⃗⃗⃗⃗𝑓 ).
(𝑁𝑓 ), field variable value at the face centroid (𝜙𝑓 ), and the face area vector (𝐴
𝑁𝑓

1
∇𝜙 = ∑(𝜙𝑓 ⃗⃗⃗⃗
𝐴𝑓 )
𝑉

(3.3.6)

𝑓=0

In the CFD solution, everything in Equation (3.3.6) is known except for 𝜙𝑓 , which is where
the GGN and GGC methods are applied. The GGN method approximates 𝜙𝑓 by taking it
as the average of the face node values, as given by Equation (3.3.7):
𝜙𝑓 =

𝜙0 + 𝜙1 + ⋯ + 𝜙𝑛
𝑁𝑛

(3.3.7)

As the GGN method requires calculation of nodal values, it is generally more
computationally expensive than other methods. Note that, 𝑁𝑛 is eight for a hexahedral
cell, four for a tetrahedral cell, and six for a prismatic cell. The GGC method approximates
the field variable value at the cell face by taking it as the average of the current cell (𝜙0 )
and the other cell that is attached to the face (𝜙1 ), as given by Equation (3.3.8):
𝜙𝑓 =

𝜙0 + 𝜙1
2
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(3.3.8)

Preliminary results showed that switching from the LSQ to GGC method had little
influence on the flow field and deposition results. Therefore, the Results section will only
focus on how the model behaves when the LSQ vs. GGN methods are applied. The
disadvantage of the GGN method being more computationally expensive will be
acceptable if it is capable of providing consistent results between the different NW
meshes.
It is noted that preliminary work also evaluated spatial discretization methods that
are alternatives to second-order upwind in ANSYS FLUENT, including the third-order
MUSCL scheme. These schemes were all excluded from further evaluation as they either
did not apply to tetrahedral meshes, or did not have a positive effect on results at the
Reynolds numbers considered in this study.
Wall Roughness
Preliminary work showed that activating the wall roughness model, with
parameters that are consistent with the tube materials used in the Pui et al. (1987)
experiments, had a negligible effect on the CFD deposition profiles (changed by <1%).
This is most likely because the tubes were made from stainless steel and glass, which
are relatively smooth materials, hence the associated wall roughness height was very
small (<2 µm). However, the layered additive manufacturing process of common 3D
printers often leads to rough surfaces and should be considered when evaluating regional
and highly localized deposition (Holbrook & Longest, 2013).
Near-wall Correction
The NW correction UDFs developed by Longest and Xi (2007) have been used
extensively by our group when validating numerical results against in vitro (Longest &
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Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian,
Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and in vivo data
(Longest et al., 2015; Walenga & Longest, 2016). These UDFs perform two corrections:
(i) anisotropic velocity fluctuations are introduced, and (ii) the wall-normal velocity is
damped in the NW region, which is consistent with particle-wall hydrodynamic
interactions. Furthermore, whenever velocity and turbulence field quantities are required
for a calculation, they are interpolated at the particle location instead of using cell centroid
values. Including anisotropic turbulence and damping velocity fluctuations in the NW
region for pharmaceutical aerosols was originally implemented by our group in a study by
Longest et al. (2008). This method built upon work reported by Matida et al. (2004), which
in turn was based on DNS data from Wang and James (1999). The NW correction UDF
also redefines the drag force (𝐹𝐷 ) for all particles as a function of the particle Reynolds
number (Re𝑝 ):
)
𝐹𝐷 = 18(1 + 0.15Re0.687
𝑝

(3.3.9)

Two control parameters are used to determine at what point each correction is
applied to the particle. If the normal distance from the particle to the wall is less than the
NW limit parameter, the UDFs use linear interpolation (based on the particle distance to
the wall) to approximate the velocity and TKE values at the particle’s current location, and
the wall-normal velocity component of the continuous phase is damped. The NW limit
parameter is typically mesh, flow, and particle size dependent, and as such, is modified
during the model development stage to match experimental data.
If the non-dimensional particle y+ is below the y+ limit, the eddy lifetime is calculated
based on the interpolated TKE value, and an anisotropic fluctuating velocity is defined
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with the new TKE value and random numbers from a Gaussian distribution. The eddy
lifetime and fluctuating velocity are then updated each time the particle enters a new eddy.
Unlike the NW limit, the y+ limit parameter is not case dependent and set to a value of 60,
as this has given good results in a numerous previous studies (Longest et al., 2015;
Longest & Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012;
Longest, Tian, Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Matida et al., 2004;
Tian et al., 2011; Walenga & Longest, 2016).
In previous work, the linear method for NW interpolation that the NW correction
UDFs use is best described by Walenga and Longest (2016). For this project,
interpolation of the velocity and TKE fields was modified in an effort to make the NW
correction less mesh dependent, as the objective is to improve consistency in results for
different NW meshes. The modified approach first uses an inverse-distance weighted
method to calculate all nodal velocity and TKE values in the domain, based on the cell
centroid values to which each node is connected. Next, the cell in which the particle is
currently located is identified, and the same inverse-distance weighted method is used to
interpolate the velocity and TKE values at the particle location from the nodes that define
the cell. In order to minimize computational effort, Shephard’s method for interpolating
irregularly-spaced data is employed (1968), and extended for use in 3D space.
Computation time is also reduced by storing all nodal values in memory, and retrieving
the data as needed when interpolating to the particle location. In all, processing times for
this modified method are negligible when compared to the time taken to reach a
converged solution for the flow and turbulence transport equations.
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Boundary Conditions
Due to the simplified model geometry, the boundary conditions for this study are
relatively straightforward. At the inlet, a uniform velocity magnitude of 17.42 m/s was
specified for the Re = 6,000 case and 17.16 m/s was specified for Re = 10,000 (as the
tube diameter is larger). Despite applying a uniform inlet velocity, the flow reaches a fully
developed state before it enters the 90° bend section. Default values for Turbulence
Intensity (5%) and Turbulent Viscosity Ratio (10) are applied, as the length of the straight
section should minimize the effects of inlet conditions on the turbulence field in the 90°
bend. The outlet from the domain simply uses the outflow condition, whereby all mass
that enters though the inlet also leaves through the outlet. All walls on the straight and
90° bend sections use a no-slip condition, and particles are trapped upon wall contact
with the particle center of mass.
Particle Injection
Particles are introduced into the domain with a blunt, random spatial distribution,
as recommended by Longest and Vinchurkar (2007b). The blunt profile defines a uniform
proportion of particles throughout the bulk flow, and then rapidly decreases the proportion
as the particles near the wall. This realistic distribution is used as more particles enter
along higher flux rings of flow. For the circular tube, a center point, normal vector, and
radius define the random inject coordinates. The center point is selected so that particles
are injected into the tube where the straight entry section of the tube ends and the 90°
bend starts.
For the Re = 6,000 case, the injected particle size distribution uses seven bins with
particle diameters that match the Pui et al. experimental data as described in Table 3.1.
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The size distribution for the Re = 10,000 CFD case also uses seven bins, with the 4.567.66 µm particles matching the sizes in the Re = 10,000 experimental data, and the 1.503.80 µm selected to match the Stokes numbers in the Re = 6,000 case. No experimental
data is available for these three smaller bin sizes, and these particles are included to
compare against the correlation at the lower end of the size range. The CFD model injects
5,000 particles for each bin size, as previous validation of steady-state models by our
group have shown that tracking this number of particles per bin gives good particle
convergence (Longest, Tian, Walenga, et al., 2012).
Comparison Criteria
Deposition Fraction
The deposition fraction (DF) is defined as the ratio of the deposited particle mass
to the injected particle mass and is expressed as a percentage:
DF =

Particle Mass Deposited
× 100
Particle Mass Injected

(3.3.10)

Continuous Phase Velocity
As mentioned previously, preliminary results showed that the differences in the
NW mesh layers are most sensitive to the effects of the turbulent dispersion model. This
model uses the combination of the mean (𝑢̅) and fluctuating (𝑢′ ) parts of the flow velocity,
which is hereafter referred to as the continuous phase velocity (𝑢) where:
𝑢 = 𝑢 + 𝑢′

(3.3.11)

The fluctuating velocity used by the turbulent dispersion model is defined by a random
number from a Gaussian distribution (𝜁) and the TKE (𝑘), given by:
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2
𝑢′ = 𝜁 √ 𝑘
3
3.4

(3.3.12)

Results

Sensitivity Study
Application of Current Best Practices
Figure 3.3 shows the TKE profile at 20°, 40°, 60°, and 80° around the 90° bend for
the Recommended, Intermediate, Targeted, and Poor Ratio meshes. The plot shows a
steep gradient near the wall, with a profile shape that is consistent with the DNS results
from Wang and James (1999). In Figure 3.3a, the results for each mesh are all similar,
as the flow is relatively uniform as it leaves the straight entry section of the tube. However,
as the flow becomes more disturbed moving through the bend from Figure 3.3a to d, the
profiles show more variability between the four meshes. Variability between each of the
TKE profiles in Figure 3.3 can be evaluated by applying a 6th-order polynomial line of best
fit (R2 > 0.999) and taking 30 equally-spaced sample points throughout the NW region.
Moving from a location of 20° to 80° in the bend, the average and maximum standard
deviation increases from 0.20 to 0.46 m2/s2 and 0.41 to 0.90 m2/s2 respectively.
Qualitatively, both the peak TKE value near the wall and incline of the NW gradient vary
considerably in each case. In order to achieve accurate and consistent results from the
turbulent dispersion model, the TKE field in this NW region must be well resolved.
The continuous phase velocity, which the particles experience near the wall in
each of the four meshes, is shown graphically in Figure 3.4. The continuous phase
velocity is calculated from Equations (3.3.11) and (3.3.12), with the random number
assumed to have a value of one for the purpose of comparison between different CFD
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models. This assumption is necessary, as the random number that the commercial code
uses is not known.
The values are sampled at the outlet of the 90° bend on the outer edge of the
curved tube radius, as this location has the most variability and clearly deomonstrates the
difference between each NW mesh. The mean velocity profiles for each case are very
similar (not shown), but Figure 3.4 demonstrates how different the flow field can be when
the fluctuating velocity is included. From Figure 3.4a to c, a sample particle moves through
the NW cell layers of each mesh at a wall-normal distance of 60, 50, and 40 µm,
respectively. The y+ values are included to indicate the non-dimensional wall distance for
reference, with the average value for all four cases used, as the flow field varies for each
mesh. From this figure it is clear that the particles are exposed to very different continuous
phase velocities between each mesh. As the continuous phase velocity varies for each
mesh, the particle trajectories through each computational domain are also different.
The variability in the TKE field close to the wall in turn affects the particle deposition
profile between each of the four meshes, as seen in Figure 3.5. At the smaller end of the
microparticle size range, particles are more susceptible to turbulent dispersion (Hjelmfelt
& Mockros, 1966; S. L. Lee & Durst, 1982; Sommerfeld, 1990) and as such, show more
variation in DF for each mesh. As diameters move towards the nanoparticle size range,
the particle momentum becomes too low to be influenced by dispersion or pass though
the viscous sublayer. Between the Targeted and Poor Ratio mesh, the DF decreases by
about 25% for 2.89 µm particles (40.32% vs. 30.10%), 50% for 2.38 µm particles (30.30%
vs. 15.28%), and 73% for 1.10 µm particles (2.28% vs. 8.58%). Note that meshes in
Figure 3.3 that gave lower peak TKE values and a shallower gradient also gave less
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particle deposition. That is, lower TKE provides less turbulent dispersion, which results in
lower DFs for particles less than 4 µm, as expected.
Including the Green-Gauss Node-based Discretization Scheme
Using the GGN method for gradient discretization greatly reduces the sensitivity of
the TKE field to the NW mesh resolution, as shown in Figure 3.6. As before, the
differences between the four meshes become more varied as the flow progresses through
the 90° bend. However, there is less overall variability between each case. Using the
same method as before, GGN decreases the average and maximum standard deviation
by 40% and 45% respectively for the 20° profile (0.20 vs. 0.12 m2/s2 and 0.41 vs. 0.23
m2/s2), 33% and 40% for the 40° profile (0.29 vs. 0.20 m2/s2 and 0.60 vs. 0.36 m2/s2),
22% and 32% for the 60° profile (0.38 vs. 0.29 m2/s2 and 0.75 vs. 0.51 m2/s2), and 13%
and 25% for the 80° profile (0.46 vs. 0.40 m2/s2 and 0.89 vs. 0.67 m2/s2). Furthermore,
the peak TKE values compare closely with one another, and the incline of the gradient
near the wall is similar for all four meshes. Removal of the Poor Ratio mesh from this
comparison would further improve agreement in the TKE field.
As a result of less variability in the TKE values, there is much better consistency
in the deposition profiles for each mesh, as shown by Figure 3.7, especially for particles
less than 4 µm in diameter. Now, between the Targeted and Poor Ratio mesh, the DF
decreases by about 5% for 2.89 µm particles (42.46% vs. 40.06%), 18% for 2.38 µm
particles (31.06% vs. 25.58%), and increased by 6% for 1.10 µm particles (4.30% vs.
4.54%). Table 3.3 summarizes the mean and standard deviation for the DF across all four
meshes and compares the LSQ and GGN methods. This confirms that less variability in
the TKE field gives less variability in particle deposition results. More importantly, these
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results show that application of the GGN method greatly reduces the sensitivity of the
flow field and particle trajectories to the NW mesh resolution.
Near-wall Mesh Resolution
Figure 3.8a shows that increasing the L2L ratio for Layer 1 to 2 from a value of 1.0
(i.e. the same mesh as the Targeted case) to 1.1, 1.2, and 1.5 (as shown in Figure 3.2c)
does not appreciably influence the particle deposition profile when using the GGN
method. This is consistent with the reduced variability between results, especially the
Poor Ratio case, which was presented in Figure 3.7. This means the variable L2L ratio
capabilities that are available in meshing software can be employed without negatively
affecting the aerosol deposition results. These meshing features allow the thickness of
NW cell layers to be reduced when the surface-to-surface proximity decreases, which
maintains the required mesh resolution near the wall.
Figure 3.8b demonstrates how increasing the thickness of the first NW layer from
an approximate wall y+ of 0.5, 1.0, 2.0, and 5.0 affects the deposition profile. Note that
these meshes use only one NW layer so the L2L ratio does not mask the sensitivity of
results to the target wall y+. For comparison, the Targeted mesh, with a wall y + of one and
five equally-spaced layers, is also included in this figure. From this plot it is clear that
increasing the thickness of the first NW cell layer, and associated wall y+ value, rapidly
increases the DF for small (<4 µm) particles. Convergence of the deposition profiles
occurs when using a first layer height that gives an approximate wall y+ of 1.0.
In summary, the results show that the Targeted NW mesh, which is desirable for
infant nasal models, is capable of producing deposition results that are comparable with
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the Recommended NW mesh in a simplified model, when suitable best practices are
applied.
Tetrahedral Mesh Type
Using a tetrahedral mesh, as depicted in Figure 3.2d, and the GGN method gives
a very consistent deposition profile across the four NW meshes considered, as shown in
Figure 3.9. This draws parallels to the behavior seen when activating the GGN method in
Figure 3.7. Table 3.4 summarizes the mean and standard deviation across all four
meshes, and shows that the variability between each case is much less than the
hexahedral meshes (see Table 3.3). Therefore, highly mesh independent results can be
produced with tetrahedral meshes and the GGN method, which are desirable for the
complex surfaces.
Figure 3.9 also includes the deposition profile for the hexahedral mesh that uses
the Targeted NW mesh parameters from Figure 3.7. Interestingly, the DF of the 1.10 µm
particles for the tetrahedral meshes is much greater than the hexahedral results (14.26%
vs. 4.30%). The fact that smaller particles are more influenced by subtle changes in the
velocity and TKE field is the likely cause of this discrepancy between results. Recall that
the NW correction UDFs also influence DFs for the smaller particles, and have not been
applied at this stage in the study.
Near-Wall Correction
Figure 3.10a and b present the effects of applying the NW correction UDFs to the
hexahedral and tetrahedral mesh with targeted NW cell layers respectively. For reference,
the No UDF lines in each plot are the deposition profiles for the Targeted hexahedral and
tetrahedral meshes from Figure 3.7 and Figure 3.9 respectively. As expected, increasing
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the NW limit parameter decreases the DF for particles less than 4 µm, as the UDF begins
damping the wall-normal flow velocity further away from the wall. The plots also show that
setting the NW limit to zero, effectively disabling the damping of wall-normal velocity, still
influences the results as the particle drag force and turbulence anisotropy correction are
applied outside of this limit.
Adjusting the NW limit parameter allows the computational results to be tuned to
match experimental data. The results from the tetrahedral mesh in Figure 3.10b show
that increasing the NW limit leads to a gradual decrease in DF for small particles, which
makes it easier to fine-tune the results. Figure 3.10a shows that the hexahedral mesh
gives a very abrupt change in DF when adjusting the NW limit parameter beyond 2 µm.
This is most apparent when looking at the results when changing from a NW limit of 2 to
5 µm for the 2.38 µm particles, as the DF drops from 14.28% to 2.24%. Generally, setting
the NW limit parameter to a value of approximately 1 to 2 µm gave consistent results
between mesh types, and compares well with experimental data (as detailed in the
following section).
Comparisons with Experimental Data
Figure 3.11a and b compares the CFD deposition profile for the 90° bend
hexahedral and tetrahedral models, with the Re = 6,000 experimental data and correlation
from Pui et al. (1987). From this comparison, it is clear that applying the best-case mesh
and solver parameters, with the NW correction UDFs, gives a very good match between
experimental and numerical results. To provide the best match to the Pui et al. data, the
hexahedral case uses a NW limit value of 1.0 µm, and the tetrahedral case uses 2.0 µm.
Note that the CFD results also exhibit the characteristic S-curve that is common for
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deposition profiles in the pharmaceutical aerosol size range. This profile shape is not
represented by the correlation, but is apparent in the experimental data points. It is noted
that the CFD predictions match the experimental data points better than the algebraic
correlation at a majority of the points considered.
Figure 3.11c and d show the comparison between a hexahedral and tetrahedral
CFD model that also adheres to the recommended guidelines developed by this study,
and the Re = 10,000 experimental model. The experimental and numerical data also
match well, which suggests that the CFD meshing and solver guidelines that are
recommended by this work are applicable to a range of flow characteristics. Interestingly,
both of these cases gave the best match to the Pui et al. data with NW limit values of
zero; hence, the wall-normal fluctuating velocity does not need to be damp for these
models. This may be a specific characteristic of high Reynolds number cases. Recall that
the Re = 10,000 case uses both a larger diameter tube and higher inlet flow rate, so the
recommended CFD guidelines are independent of model geometry and inlet conditions.
3.5

Discussion
This study determines a set of meshing and solver guidelines that provide

consistent results across several different NW meshes, and have been validated against
experiments of aerosol deposition. The selected meshes have evaluated the effects of
the number of cell layers, wall y+, L2L ratio, and cell type (hexahedral or tetrahedral) on
the flow field and particle trajectories, in order to determine the most efficient use of NW
cell layers for aerosol deposition models. The investigation explored different
discretization schemes and control parameters for anisotropic turbulence correction, with
final results showing a reliable match with the Pui et al. data. The guidelines are applicable
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across a range of flow Reynolds numbers and particle sizes. Table 3.5 summarizes the
recommended guidelines at the conclusion of this study.
As expected, the DF of particles less than 4 µm is most sensitive to the NW TKE
field, because particles in this size range are largely influenced by eddy motion and have
sufficient momentum to maintain an eddy dispersion velocity. Lower TKE in the NW
region leads to less deposition of these smaller particles, and as such, one should strive
for CFD models that give a reliable TKE field before having confidence in deposition
results. Application of the GGN discretization scheme greatly reduced the variability of
the TKE and particle deposition results across all the evaluated NW meshes with the
small expense of an 11% increase in computational time (over 5,000 iterations).
Therefore, the reasonable upper airway meshes, with five equally-spaced layers, can be
applied to future work in contrast with the previously recommended NW mesh with 10-20
layers. Further exploration of the NW mesh parameters with the GGN scheme showed
that it is important to aim for a wall y+ of approximately 1.0, and that varying the L2L ratio
did not drastically influence the variability of results between cases. This means that
should the meshing software increase or decrease layer thickness to confirm to the model
geometry, the results should not be significantly affected.
Use of the NW correction UDFs allows the numerical results to be tuned to match
experimental data. As with previous studies (Longest et al., 2015; Longest & Hindle,
2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian,
Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Matida et al., 2004; Tian et al., 2011;
Walenga & Longest, 2016), a y+ limit of 60 was suitable for the anisotropic turbulence
correction. For the Re = 6,000 case, a NW limit of 1-2 µm was required to match
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experimental data for the hexahedral and tetrahedral cases, below which the wall-normal
velocity is damped. For the Re = 10,000, a NW limit of zero was used, which means that
the velocity damping correction was not required in the more turbulent case.
Generally, CFD results tend to over-predict deposition, especially for smaller
particle diameters. The UDFs correct this over-prediction by introducing anisotropic
fluctuating velocity components with random numbers from a Gaussian distribution, and
damps the wall-normal velocity component as the particle approaches the wall. The
current study improved the UDFs by introducing an inverse-distance weighted
interpolation method to approximate velocity and TKE values at the particle location,
based on cell centroid values. This modification aims to make the correction less mesh
dependent. Results show how the NW limit parameter adjusts the deposition profile for
hexahedral and tetrahedral meshes. Based on the results of this study with the
recommended meshing guidelines, we recommend NW limit values of 1-2 µm for
transitional flows with Reynolds number below 10,000, and removing the NW limit
correction when the Reynolds number exceeds 10,000. In summary, use of the
aforementioned guidelines and anisotropic turbulence correction leads to a very good
match between the numerical and experimental data for this 90° bend model.
The findings from this study are consistent with previous work that has evaluated
the LRN k-ω model in simplified models of biological internal flow. Studies by Varghese
and Frankel (2003) and Ryval et al. (2004) both concluded that the LRN k-ω model gave
a good match to experimental data when modeling flow through a stenosed tube, which
is similar to constrictions in blood vessels or the respiratory airways. These models have
similar flow conditions to the 90° bend model presented in this article, as they all
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experience laminar, transitional, and turbulent flow. Matida et al. (2004) demonstrated
realistic NW corrections are required in order to match deposition results from the k-ω
model to experiments. The same conclusions are drawn from the current study, as
application of the NW correction UDFs, which were in part (anisotropy but not NW
interpolation) based upon the findings of Matida et al. (2004), allows the deposition profile
to be tuned to match the Pui et al. data (1987). Specific to modelling pharmaceutical
aerosol deposition in the lungs with LRN k-ω, Xi and Longest (2007) reported good
comparisons between numerical models, of both realistic and simplified geometries, and
experimental data. The meshing and solution parameter recommendations presented in
this paper add to the research field by providing clear guidelines for using the LRN k-ω
model. This will streamline the CFD model development process for future work that plans
to take advantage of the efficiency and accuracy that the LRN k-ω turbulence model
provides for microparticle deposition.
Recently in the literature, there has been a shift towards using more complex
turbulence models in CFD studies. The LES model resolves the turbulence field in greater
detail than two-equation RANS models. Its formulation is also capable of overcoming
some of the inherent NW issues with the k-ω model, which are outlined by this study,
without the need for corrections. However, LES models demand much longer meshing
and solver processing times, as very small cell sizes are necessary to resolve the required
length scales, which in turn gives high cell counts. Zhang and Kleinstreuer (2011)
compared the LRN k-ω, SST transition, and LES models for nanoparticle deposition in a
constricted tube and idealized human airway model. They observed negligible differences
between the three turbulence models for predicting laminar, transition and turbulent flow.
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They also report that the more complex LES model required 100-fold more computational
resources than the two-equation RANS model. Conversely, Jayaraju et al. (2008)
concluded that LES/DES provided a better agreement with experimental data for a MT
model than k-ω. However, their study used the standard implementation of the k-ω model,
which does not include the LRN correction. It is noted that the two-equation RANS CFD
models that are discussed here and have successfully matched experimental data (Ryval
et al., 2004; Varghese & Frankel, 2003; J. Xi & Longest, 2007; Z. Zhang & Kleinstreuer,
2011), including the present study, have used the k-ω model with LRN correction.
Similar to how this study compared the LRN k-ω CFD results to the Pui et al. model
(1987), Breuer et al. (2006) provided a comparison between LES results and the same
experimental data set. They showed a good match between the DF from their
computational model and the curve fitted correlation. Figure 3.12 reproduces the
deposition profile for the Re = 10,000 model from Breuer et al. (2006), and includes the
results from this study for the Re = 6,000 and 10,000 cases, and both hexahedral and
tetrahedral meshes. This comparison across different Reynolds numbers is reasonable
as the Pui et al. correlation is only a function of Stokes number, and hence is independent
of Reynolds number. Figure 3.12 shows that the LRN k-ω models gives similar deposition
results to the LES model across a range of particle diameters (Stokes number).
Therefore, we believe that the LRN k-ω model, with the guidelines and NW corrections
defined by this study, is capable of modeling aerosol deposition under conditions
consistent with the upper respiratory airways. Advanced turbulence models are invaluable
for modeling complex phenomena and aiding the development and validation of twoequation RANS models. For example, the NW correction UDFs utilized by this work rely
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on findings from the DNS data from Wang and James (1999). However, the LRN k-ω
model provides a more computationally efficient method that can resolve the flow field in
sufficient detail to capture microparticle deposition with the same degree of accuracy as
LES models.
Future work will apply these guidelines to upper airway geometries and aim to
provide the same reliable and validated results that are presented here. This investigation
showed that both hexahedral and tetrahedral meshes can be used with little drawbacks
for either cell type. Using tetrahedral meshing capabilities makes the modelling of
complex airways like the nasal cavity much easier, where using a regular hexahedral
mesh on complex geometries is not possible. Cut-cell meshing technologies should be
explored, where a Cartesian grid is fitted to the geometry by excluding and cutting cells
outside of the domain. This method results in a mesh that is mostly regular and
hexahedral in the core, with some tetrahedral, pyramid, and other polyhedra near the
surface. The core mesh would provide the robust and computationally efficient benefits
that are common with regular hexahedra, but it is unclear at this stage how the cut cells
near the surface affect turbulence properties and aerosol deposition in airway CFD
models.
In conclusion, this study has provided a set of recommendations for mesh and
solver settings that give consistent and validated results for a characteristic geometry. It
is expected that application of these guidelines to more complex geometries will improve
the model development process and provide more reliable aerosol deposition results in
the upper respiratory airways.
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3.6

Figures

Figure 3.1:

Overview of geometry and particle deposition locations on the 90-degree

bend at deposition times of (a) 0.003 s, (b) 0.006 s, (c) 0.009 s, and (d) 0.012 s. Results
shown are for the Re = 6,000 case that follows the CFD guidelines recommended at the
conclusion of this study.
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Figure 3.2:

Summary of meshes used to evaluate the sensitivity of the TKE field and

particle deposition related to near-wall resolution and cell type.
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Figure 3.3:

Initial near-wall TKE profiles for each of the four meshes at angles around

the 90-degree bend of (a) 20 degrees, (b) 40 degrees, (c) 60 degrees, and (d) 80 degrees.
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Figure 3.4:

Continuous phase velocity (combined mean and fluctuating parts) to which

the particle is exposed at wall-normal distances of (a) 60 µm, (b) 50 µm, and (c) 40 µm,
for several mesh configurations.
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Figure 3.5:

Comparison of particle deposition profiles between the four meshes.
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Figure 3.6:

Reduced sensitivity of TKE to the mesh when using Green-Gauss Node-

based discretization scheme at angles around the 90-degree bend of (a) 20 degrees, (b)
40 degrees, (c) 60 degrees, and (d) 80 degrees.
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Figure 3.7:

Reduced sensitivity of deposition when using Green-Gauss Node-based

method.
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Figure 3.8:

Comparison of results when varying the (a) layer-to-layer ratio and (b) target

wall y+ value.
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Figure 3.9:

Deposition comparison when using a mesh with a triangular surface,

prismatic near-wall layers, and tetrahedral core. Each of the near-wall mesh resolutions
presented use the same parameters as the hexahedral cases.
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Figure 3.10: Adjustment of near-wall UDF parameters to tune deposition results and
match experimental data for the (a) hexahedral and (b) tetrahedral mesh with targeted
NW parameters.
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Figure 3.11: Comparison to Pui et al. (1987) data when all CFD recommendations are
applied for (a) Re = 6,000 with the hexahedral mesh, (b) Re = 6,000 with the tetrahedral
mesh, (c) Re = 10,000 with the hexahedral mesh, and (d) Re = 10,000 with the tetrahedral
mesh.
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Figure 3.12: Comparison of LRN k-ω results using the best practices from this study with
LES data from Breuer et al. (2006). Particle diameters converted to Stokes number to be
consistent with the LES study and across different tube diameters.
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3.7

Tables

Table 3.1:

Experimental results and correlation predictions for selected Pui et al.

(1987) models.
Reynolds
Number
[-]
6,000

Tube
ID
[mm]
5.03

10,000

8.51

Stokes
Number
[-]
0.03
0.13
0.19
0.36
0.60
0.72
1.00
0.03
0.13
0.19
0.27
0.29
0.46
0.75

Particle
Diameter
[µm]
1.10
2.38
2.89
4.01
5.20
5.70
6.74
1.50
3.10
3.80
4.56
4.73
5.98
7.66
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Experimental
DE
[%]
6.1
13.4
29.6
55.0
76.0
80.6
88.4
N/A
N/A
N/A
48.4
50.3
65.6
82.7

Correlation
Prediction
[%]
6.4
25.0
34.4
55.0
73.6
79.7
89.1
6.4
18.5
28.3
45.0
47.4
63.9
81.0

Table 3.2:

Summary of near-wall meshes and parameters.
# NW
Layers
20

First Layer
Thickness (y+)
0.02 (≈1.0)

Intermediate
Targeted
Poor Ratio

10
5
5

0.02 (≈1.0)
0.02 (≈1.0)
0.02 (≈1.0)

Wall y+ ≈ 0.5
Wall y+ ≈ 1.0
Wall y+ ≈ 2.0
Wall y+ ≈ 5.0
Ratio = 1.0
Ratio = 1.1

1
1
1
1
5
5

0.01 (≈0.5)
0.02 (≈1.0)
0.04 (≈2.0)
0.10 (≈5.0)
0.02 (≈1.0)
0.02 (≈1.0)

Ratio = 1.2

5

0.02 (≈1.0)

Ratio = 1.5

5

0.02 (≈1.0)

Name
Recommended

Layer-to-Layer
Ratio
Layers 1-8: 1.1
Layers 8-20: 1.0
1.0
1.0
Layer 1-2: 1.8
Layers 2-5: 1.0
N/A
N/A
N/A
N/A
1.0
Layer 1-2: 1.1
Layers 2-5: 1.0
Layer 1-2: 1.2
Layers 2-5: 1.0
Layer 1-2: 1.5
Layers 2-5: 1.0
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Total NW
Thickness
0.70
0.20
0.10
0.20
0.01
0.02
0.04
0.10
0.10
0.12
0.15
0.26

Table 3.3:

Mean and standard deviations of the deposition fraction for the

Recommended, Intermediate, Targeted, and Poor Ratio meshes when using the Least
Squares Cell-based (LSQ) and Green-Gauss Node-based (GGN) gradient discretization
methods.
Particle
Diameter
[µm]
1.10
2.38
2.89
4.01
5.20
5.70
6.74

LSQ
GGN
Mean (SD) DF Mean (SD) DF
[%]
[%]
5.77 (2.37)
3.91 (0.59)
24.82 (5.88)
28.12 (2.47)
36.57 (3.94)
41.11 (0.95)
58.58 (0.60)
60.29 (0.80)
75.67 (0.85)
77.24 (1.77)
82.83 (0.32)
83.81 (1.52)
91.87 (0.10)
92.05 (1.06)
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Table 3.4:

Mean and standard deviations of the deposition fraction for the

Recommended, Intermediate, Targeted, and Poor Ratio meshes when using a tetrahedral
volume mesh, prismatic near-wall cell layers, and the Green-Gauss Node-based (GGN)
gradient discretization method.
Particle
Diameter
[µm]
1.10
2.38
2.89
4.01
5.20
5.70
6.74

Tetrahedral Mesh
Mean (SD) DF
[%]
13.35 (0.55)
32.58 (0.50)
42.78 (0.32)
61.76 (0.51)
79.38 (0.31)
85.78 (0.34)
94.02 (0.15)
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Table 3.5:

Mesh

Flow

Particles

Summary of recommended mesh and solver parameters.
Model/Parameter
Target Wall y+
Number of NW Layers
L2L Ratio
Turbulence
P-V Coupling
Mom. & Turb. Schemes
Gradient Discretization
Numerical Accuracy
Tracking Scheme
Turbulent Dispersion
Eddy Interaction Model
NW Correction

Setting/Method
0.5-1
5
1.0 (may be increased with no negative effects)
LRN k-ω
SIMPLEC
Second-order Upwind
Green-Gauss Node-based
Double Precision
Lagrangian with Runge-Kutta
Interpolate TKE at particle location from nodes
Modified via UDF
NW Limit = 1.0-2.0 µm

129

Chapter 4: Validating CFD Predictions of N2L Aerosol Delivery in a 6Month-Old Infant Airway Model
4.1

Objective
The primary objective of this study is to validate mesh and CFD parameters against

experimental data for accurate modelling of microparticle deposition in an infant nasal
airway for the assessment of N2L aerosol administration. Previously developed meshing
and solution parameters will be applied to the CFD model, with other considerations
specific to infant nasal models observed. Specifically, the commonly used tetrahedral and
new polyhedral mesh types are compared, as well as laminar and turbulent flow
conditions, and monodisperse versus polydisperse aerosol approximations. To validate
the CFD predictions, in vitro experiments are reported in an identical nasal airway
geometry with a nasal cannula interface. As a secondary objective, high efficiency N2L
aerosol delivery is demonstrated in an infant airway model using both CFD and in vitro
approaches, which is enabled by the use of micrometer-size particles as with the EEG
strategy.
4.2

Introduction
The enhanced excipient growth (EEG) method of pharmaceutical aerosol delivery

(Hindle & Longest, 2012), with nose-to-lung (N2L) administration via a streamlined nasal
cannula, can vastly reduce deposition loses in the patient interface and extrathoracic
airways (Longest et al., 2015) leading to high efficiency lung delivery. The EEG approach
employs a spray-dried formulation of the drug, which when aerosolized, generally has a
micrometer or sub-micrometer mass-median aerodynamic diameter (MMAD) (Son,
Longest, & Hindle, 2013; Son, Longest, Tian, et al., 2013). The low inertia of these small
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particles allows them to follow flow streamlines and penetrate deep into the conducting
airways with little depositional loss. The aerosol formulation includes a hygroscopic
excipient, which absorbs moisture from the humid airways, thereby causing the particles
or droplets to grow and reach conventional sizes for respiratory aerosols (3-6 µm) as they
reach the distal regions of the lungs. This aerosol size increase is associated with an
increase in inertial deposition and sedimentation, which minimizes exhalation of the
aerosol and may allow for targeted aerosol delivery. The EEG method therefore reduces
device and extra-thoracic depositional losses, while allowing targeted delivery and greater
retention in the conducting airways (Longest et al., 2015; Tian et al., 2014; Tian et al.,
2013).
Using N2L aerosol administration via a streamline nasal cannula provides several
benefits over alternative methods of aerosol delivery, which make it well suited for efficient
aerosol administration to infants. Infants are generally nose breathers (ICRP, 1994), so
delivery through the nasal passage can occur simultaneously while the patient is on noninvasive ventilation. For aerosol delivery to infants, facemasks are often used instead of
cannulas, but present several drawbacks. Two notable review papers on aerosol delivery
to infants report that patient distress (Everard, 2003) and crying infants (Amirav, 2011)
lead to reduced lung drug dose during aerosol administration via a facemask. Studies
also report that an airtight seal is required between the facemask and patient face for
optimal delivery (Amirav & Newhouse, 2001; El Taoum, Xi, Kim, & Berlinski, 2015), which
is difficult to achieve. Furthermore, there is evidence in the literature that nasal cannula
systems may provide improved lung delivery efficiency compared to facemasks in infants
and children (Amirav, Borojeni, Halamish, Newhouse, & Golshahi, 2015; Reminiac et al.,
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2017). It is expected that using small diameter particles (MMAD < 2 µm) for N2L aerosol
delivery leads to high efficiency lung doses, as the likelihood of impaction deposition is
reduced as particles travel through the nasal cavity and nasopharynx (Storey-Bishoff et
al., 2008; Tavernini et al., 2018).
Multiple studies from our group have demonstrated that a concurrent experimental
and computational fluid dynamics (CFD) approach can successfully develop and evaluate
aerosol delivery systems, with successful validations compared with both in vitro (Longest
& Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest,
Tian, Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and in vivo
data (Longest et al., 2015; Walenga & Longest, 2016). Deposition results from CFD
models can provide valuable insight into the behavior of the aerosol transport through the
delivery system and the nasal cavity, in terms of both the flow field and deposition sites.
For example, a high concentration of deposition in a localized region of the CFD model
may indicate the potential for design improvements, which may not be apparent in
experimental data. However, one can only have confidence in results from a numerical
model after it has been validated against experimental data based on the parameters of
interest. Based on this approach, both numerical and experimental aspects of an analysis
can be used simultaneously to facilitate improvements in a targeted drug delivery strategy
or device.
To achieve validation of CFD results with experimental data, it is imperative that
sound methodology is used in the numerical model in the areas of geometry development,
mesh generation, sub-model selection, and solution parameters. Bass and Longest
(2018b) recently developed a set of meshing and solution guidelines for application of the
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low-Reynolds Number (LRN) k-ω turbulence model when simulating microparticle
deposition under conditions similar to the upper-airways. This previous study presented
an excellent match to both experimental and Large Eddy Simulation (LES) deposition
data across a range of particle sizes and flow conditions in a representative 90°-bend
geometry. However, it is important to confirm the same meshing and solution guidelines
are applicable to a more complex model of the infant nasal cavity. For example, it is
currently an open research question if turbulence should be included in simulations of
nasal particle deposition. This is further complicated by the presence of the nasal cannula
interface, which forms two jets of airflow entering the nasal vestibule and progressing
through the narrow nasal valve.
4.3

Methods

Nasal Model Development from Computed Tomography Scans
Pre-existing medically necessary computed tomography (CT) scans of nasal
airways from 3-6-month-old infants were reviewed for scan quality and completeness
under an institutional review board (IRB) approved protocol. To develop an infant model
with a targeted age of approximately 6 months, the selected scan was of a 68.2 cm and
7.7 kg male that was approximately 20 weeks (5 months) old. The patient height and
weight both fell within the 25th and 75th percentiles for a 6-month-old (6mo) infant (WHO,
2006). Therefore, it was expected that the model was representative of the target age
(Tavernini et al., 2018), despite being approximately one month younger. Of the available
scans, the selected scan was chosen because the infant’s mouth was closed, it was
complete from the nostrils through the larynx, and the slice resolution was sufficiently
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small at 1 mm. The scan was reviewed by a pediatric otolaryngologist and found to be
free of nasal abnormalities.
The CT scan was segmented by the Mimics software suite (Materialise, Leuven,
Belgium) to generate a 3D model of the infant nasal cavity from the 2D image slices. The
process of segmentation involves selecting pixels in the CT scan, which combined with
the slice thickness become voxels for each slice. The tools and capabilities provided by
Mimics allow users to speed up the process by selecting threshold regions of pixels that
fall within a greyscale range that are considered internal airways (i.e. not bone or soft
tissue). Mimics also automatically smooths the block-shaped voxels to provide a realistic
representation of physical anatomy. Once image segmentation is complete, the 3D model
is transferred to 3matic (Materialise, Leuven, Belgium) where additional post-processing
steps are performed such as wrapping, STL mesh quality improvements, and surface
triangle reduction. Surface wrapping covers the initial surface with a second STL surface
that removes any non-manifold faces (where three or more faces share a single edge),
free edges (holes), or sliver faces, thereby removing any erroneous triangles from the
surface. The STL surface is then converted to CAD data using the skin surface
capabilities available in SpaceClaim (ANSYS, Inc., Canonsburg, PA, USA). This process
involves manually creating polygonal patches (approximately 50) that are wrapped to
conform to the faceted surface. Therefore, instead of the nasal cavity being defined by
thousands of STL triangles, it is represented by approximately 50 CAD format surfaces.
This step makes it possible to import the model into third-party CAD software.
In SolidWorks (Dassault Systèmes, Paris, France), the nasal cavity was further
modified to generate a suitable experimental model that can be produced with 3D printing.
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This included supports for locating the streamlined nasal cannula and connections to an
outlet filter to measure recovered lung dose. Design considerations were also made to
simplify the 3D printing of the model. The model was separated into three regions that
approximate the anterior nose, middle passage, and nasopharynx, as this makes it easier
to clean support material from inside the nasal cavity and provides insight into the regional
deposition within the model. The nasopharynx part of the model was also split in half to
remove support material from around the glottis, and then sealed with locating pins and
epoxy.
Figure 4.1a shows the CAD surfaces of the 6mo airway experimental model with
cannula support, outlet filter connection, and connections between the three regions.
Figure 4.1b shows the air interface of the cannula, nasal cavity, and filter connection that
form the CFD model surfaces. Figure 4.1b also clearly illustrates the complexity of the
infant nasal airway, especially in the region of the turbinates and larynx.
Experimental Set-up
Micrometer-sized aerosols were generated using a novel mixer-heater in
combination with a commercial nebulizer operating with reduced aerosol output. The
mixer-heater delivery system is shown in Figure 4.2. The mixer-heater (61.6 mL internal
volume) was designed to efficiently mix nebulized aerosol with incoming ventilation gas
and then heat the aerosol to reduce it to micrometer or sub-micrometer size for inhalation.
Consistent with infant high flow nasal cannula ventilation, air at a flow rate of 6 L/min was
introduced into the mixer-heater with the heating element set to 60 °C, which resulted in
an exit aerosol temperature from the streamlined cannula of 35 °C. Aerosol was
generated from a 0.5% w/v albuterol sulfate solution prepared by dissolving albuterol
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sulfate USP (Letco Medical, LLC, Decatur, AL) in water. The particle size of the emitted
aerosol was similar to previous EEG studies, however an EEG excipient was not included,
as hygroscopic growth in the airway model was not investigated in this study. An Aerogen
Pro nebulizer (Aerogen, Galway, Republic of Ireland) was used in the mixer-heater,
however the mean (SD) output of the nebulizer was reduced to 70 (7) µL/min compared
to typical values of 300-400 µL/min when operated using the Aerogen Controller.
Reducing the output of the nebulizer was required to ensure drying of the aerosol to
micrometer-size at the infant gas flow rate. This was achieved by reducing the sinusoidal
operating voltage amplitude of the controller to 14.1 Vrms compared to the normal
operating value of 50 Vrms for the commercial nebulizer. The nebulizer was filled with 3.5
mL of the nebulizer formulation and weighed prior to and following nebulization for each
run (duration of 20 minutes). The mass of nebulized formulation and the concentration of
the formulation was used to calculate the nominal dose of nebulized drug. Standard infant
ventilator tubing with a diameter of 10 mm was used to connect the mixer-heater device
to the streamlined infant cannula.
Aerodynamic particle sizing experiments were performed using the Andersen
Cascade Impactor (ACI, Copley Scientific, Nottingham, UK) placed in an environmental
chamber (Espec, Hudsonville, MI) set to 35 °C and 99% relative humidity (RH) to minimize
effects of evaporative size changes during measurements. The aerosol output at the exit
of the nasal cannula was positioned at the entrance to the ACI. The ACI inlet entrained
the aerosol exiting the nasal cannula plus additional makeup air from the environmental
cabinet for a total ACI flow rate of 28.3 L/min. Drug was collected from the impactor stages
and filter to determine the emitted dose, the MMAD and particle mass fraction less than
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1 μm and less than 5 μm. MMAD and particle fractions were determined by linear
interpolation. MMAD values were directly calculated as the size associated with a
cumulative count of 50% based on mass percentages calculated relative to the impactor
dose. Particle mass fractions were calculated as the cumulative mass fraction frequency
associated with sizes of 1 μm and 5 μm, respectively. A minimum of three measurements
were performed.
Studies were also performed to determine the regional deposition of the mixerheater generated micrometer drug aerosol in the infant model as shown in Figure 4.2.
Aerosols were continuously generated in these steady-state flow experiments as
described above, with the outlet of the streamlined infant nasal cannula inserted into the
nostrils of the airway model. Aerosol delivered through the infant nasal model was
captured on a low resistance respiratory filter positioned at the exit of the trachea and
was considered as the delivered in vitro N2L dose. A constant flow of 7 L/min was drawn
through the airway model. As described previously, the physical model was identical to
the CFD model and included the nostrils, turbinates, nasopharynx, larynx and a portion
of the trachea. The model was segmented into three portions: 1) the anterior nose, 2) the
middle passage, and 3) the nasopharynx, larynx and trachea. Drug deposited on the
model components and respiratory filter was recovered and analyzed using a validated
isocratic HPLC method. AS quantification was performed with a validated HPLC method
using a Waters 2695 separations module with a 2475 fluorescence detector (Waters Co.,
Milford, MA). Chromatography was performed using a Restek Allure PFP 150 mm × 2.1
mm column (Bellefonte, PA). The mobile phase, consisting of methanol and ammonium
formate buffer (20 mM, pH 3.4) in a ratio of 70:30, respectively, was eluted at a flow rate
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of 0.4 mL/min and the detector was set to an excitation wavelength of 276 nm and
emission at 609 nm. The column temperature was maintained at 25 °C, and the volume
of each sample injected was 100 μL. The limit of quantification was 0.5 µg/ml (Behara,
Longest, et al., 2014b; Son, Longest, & Hindle, 2013). The recovered emitted dose from
the mixer heater was calculated as the mass of drug deposited on the ventilator tubing,
cannula, nasal airway model and respiratory filter. Regional drug deposition was
expressed as a percentage of the recovered emitted dose from the mixer heater.
Numerical Model
As with all CFD to experimental comparisons, the numerical model aims to
replicate the experimental set-up as closely as possible. The following sections detail
aspects of the CFD model set-up and the steps taken to ensure accurate and reliable
deposition results.
Meshing and Solution Guidelines
Bass and Longest (2018b) recently provided a set of CFD meshing and solution
guidelines for modelling aerosol deposition in the respiratory airways, under transitional
and turbulent flow conditions, using the LRN k-ω turbulence model. These guidelines
detailed near-wall (NW) mesh parameters and solver settings that provided a good match
to experimental and LES data of micrometer (from approximately 1.0 to 7.5 µm) particle
deposition in a characteristic 90° bend geometry. Table 4.1 summarizes the
recommendations from that study, which will be applied to the current numerical model,
with the intention of validating the mesh and solver settings against experimental data of
micrometer particle deposition in an infant nasal cavity during N2L aerosol administration.
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In addition to validating the CFD meshing and solution guidelines, this study
explores the assumption of laminar flow versus a turbulence approximation modeled with
the LRN k-ω turbulence model for infant nasal airways. Results evaluate the turbulent
nature of the flow and its influence on both monodisperse and polydisperse aerosols.
Flow through the infant nasal cavity is generally in the laminar or transitional regime when
considering the Reynolds number at the connection tubing inlet (approximately 900).
However, the complexity of the nasal passages and transition from the patient interface
to nostrils may induce turbulence in the flow. Specifically, the nasal cannula interface
creates air jets that enter the most constricted portion of the nose, i.e. the nasal valve.
CFD models with the LRN k-ω turbulence approximation generally tend to overpredict microparticle deposition, due to the assumption of isotropic NW turbulence.
Longest and Xi (2007) developed a method of NW correction by utilizing FLUENT userdefined functions (UDFs), which built upon previous work by Matida et al. (2004) and
Wang and James (1999). The NW correction UDFs include anisotropic velocity
fluctuations in the continuous phase and damp the wall-normal velocity in the NW region
to represent particle-wall hydrodynamic interactions (Longest, Kleinstreuer, & Buchanan,
2004). Further details on these corrections have been reported in previous studies from
our group (Longest & Xi, 2007; Walenga & Longest, 2016), and recent improvements to
interpolation methods were reported by Bass and Longest (2018b). The key control
parameter used by the NW correction UDFs is the NW limit, as it determines the particleto-wall distance below which wall-normal velocity is damped. This parameter is adjusted
to match numerical and experimental deposition data, with Bass and Longest (2018b)
reporting values of 1-2 µm provided good comparisons in their 90° bend study. The
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present work will compare results using the NW corrections versus the standard turbulent
particle dispersion model, and a case that includes the LRN k-ω turbulence approximation
of the flow field, but without the particle dispersion model activated. This investigation will
also determine whether the NW limit control established in the simple 90° bend study can
be applied to the highly complex infant nasal cavity model.
Meshing Approaches
This study compares two types of unstructured meshes for modeling aerosol
deposition in the patient interface and nasal cavity. Ideally, numerical models use
structured hexahedral meshes, as they generally give the best solution accuracy, stability,
and computational efficiency. However, the complex geometry of the infant nasal cavity
makes it prohibitively difficult to apply a structured mesh. Unstructured tetrahedral
meshes are often used when a hexahedral mesh is not possible, as they are able to
conform to complex surfaces and efficiently fill the domain volume with good-quality cells.
Bass and Longest (2018b) concluded that a tetrahedral mesh with five prismatic NW cell
layers provides similar microparticle deposition to a hexahedral mesh in a simplified
geometry under flow conditions similar to the infant airways. However, differences in the
deposition predictions were observed for 1 µm particles between meshes with tetrahedral
and prismatic NW cells, which required more correction. In the current study, the
tetrahedral and prismatic NW cell mesh is explored and applied to the infant nasal
geometry, with mesh parameters that were established in the much simpler 90°-bend
considered by Bass and Longest (2018b), as shown in Table 4.1. Figure 4.3a shows the
meshing structure of the tetrahedral cells with prismatic NW cell layers at the tube inlet,
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and Figure 4.3c shows a cut through the middle meatus that exposes the interior nasal
mesh.
The tetrahedral and prism mesh shown in Figure 4.3a and c was generated using
the FLUENT meshing capabilities (ANSYS, Inc., Canonsburg, PA, USA). The process
begins by producing a triangular surface mesh that conforms to the complex geometry.
Curvature, proximity, and locally defined size controls are used to adjust the mesh sizing
in order to obtain an accurate representation of the geometry surface and increase fidelity
in regions of interest and importance. To generate the volume mesh, the software uses a
Delaunay algorithm to fill the domain with tetrahedral cells, and the five-sided prismatic
NW cells are added by inflating the surface mesh towards the cell interior. Definition of
the NW cell layers follows the recommendations provided by Bass and Longest (2018b)
of five equally spaced layers with an approximate wall y + of one (see Table 4.1.) Once
the meshing process is complete, the cell nodes are smoothed using the capabilities in
FLUENT meshing to ensure that all cells have an orthogonal quality greater than 0.25,
which provides a high-quality discretization of the domain.
In addition to tetrahedral meshes, FLUENT meshing is capable of producing
polyhedral meshes, which are composed of cells with any number of faces, edges, and
vertices. Polyhedral cells generally have more faces than hexahedral or tetrahedral cells,
which results in more cell neighbors, and hence better resolution of gradients in and out
of the control volume (Sosnowski, Krzywanski, & Gnatowska, 2017). The various
orientations of each cell face (see Figure 4.3d) also increases the likelihood of having
flow aligned with a cell face, which can reduce numerical diffusion, as it does for flowaligned hexahedral meshes. There is much anecdotal evidence in the CFD community
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that polyhedra provide faster convergence with lower cell counts than tetrahedra.
However, a review of the literature shows there has been no direct evaluation of these
two unstructured meshing approaches in the field of respiratory drug delivery research.
The closest comparison comes from Lotfi et al. (2016) who concluded that polyhedra
provided superior results to tetrahedra when modelling flow through a stented artery.
However, their study did not provide details on convergence or computational efficiency.
A study from van Ertbruggen et al. (2008) developed a CFD model representation of
alveolar structures in the lungs, which used a polyhedral mesh, and made good
comparisons with experimental data for laminar, very low speed flow. However, a direct
comparison of results from tetrahedra and polyhedra was not made. Furthermore, both
of these previous studies did not include particle transport and deposition. Peric (2004)
provided a complete comparison of polyhedral and tetrahedral meshes for a simple 3D
lid-driven cavity flow model under laminar conditions, and showed that polyhedra required
50% less memory and less than 20% of the computation time.
The advantages described here make polyhedral meshes a promising approach
for developing computationally efficient airway models. Figure 4.3b shows the polyhedral
mesh at the tube inlet and Figure 4.3d shows the interior mesh in the middle meatus.
These images show that the polyhedral cell faces are generally 5- or 6-sided polygons,
and as such, the NW cell layers have a varying number of sides. The process of
generating a polyhedral mesh is similar to tetrahedral meshing, including the generation
of a tetrahedral volume mesh. Once the volume mesh is complete, the software uses
dualization and agglomeration algorithms to convert the tetrahedral cells to polyhedral.
The details of this conversion are covered in more detail in the ANSYS User Guide (2017)
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and other resources. As with the tetrahedral mesh, the final step is to smooth the mesh
and ensure all cells are high quality with orthogonal quality greater than 0.25.
In the preliminary stages of this project, other meshing approaches were
considered. In particular, we initially evaluated the cut-cell meshing capabilities of
FLUENT meshing. A cut-cell mesh is generated by starting with a Cartesian grid that
encloses the geometry. Cells outside the domain are then excluded or cut to conform to
the complex surfaces, which results in hexahedral cells in the bulk of the domain and
irregular polyhedral cells near boundaries. This approach is appealing as it provides the
numerical accuracy and stability of hexahedral cells with the ability to conform to complex
geometry. However, cutting the cells near close-proximity surfaces, such as the thinwalled cannula prongs, generated poor quality cells and an inaccurate representation of
the geometry. This issue could be overcome by locally refining the mesh near these closeproximity surfaces, but the cell count for the coarsest cut-cell mesh exceeded that of the
finest tetrahedral mesh. Furthermore, the core hexahedral cells are Cartesian, but not
flow aligned, so there may be no numerical benefit to using this mesh technology in the
airways. Therefore, we decided not to pursue the cut-cell meshing approach further for
respiratory aerosol simulations.
Mesh Dependency Study
A mesh dependency study was performed on both the tetrahedral and polyhedral
meshes to determine the optimum grid resolution. In Figure 4.4, the volume-average
velocity magnitude, turbulent kinetic energy (TKE), and nasal cavity deposition efficiency
(DE) are compared for a coarse (2.76 million cells), medium (5.71 million cells), and fine
(11.50 million cells) tetrahedral mesh, and also a coarse (0.88 million cells), medium (1.80
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million cells), fine (3.56 million cells), and extra fine (7.42 million cells) polyhedral mesh.
The DE is calculated from particles that are exposed to the turbulent dispersion model,
but no NW corrections are applied. The comparison shows that the 5.71 million cell
tetrahedral mesh and 3.56 million cell polyhedral mesh each give the best compromise
between grid convergence and solution processing times. Between the medium and fine
tetrahedral mesh, the volume-average velocity magnitude, TKE, and nasal cavity DE
differ by only 0.008 m/s, 0.004 m2/s2, and 0.2% respectively. Similarly, the fine and extra
fine polyhedral mesh differ by 0.003 m/s, 0.004 m2/s2, and 0.2%. Therefore, the remainder
of this study uses the 5.71 million cell tetrahedral mesh and 3.56 million cell polyhedral
mesh to compare each cell type and validate the CFD solution parameters. These cell
counts are similar to grid convergence established in other nasal studies including the 36 million cells used by Walenga et al. (2014) and the 4 million cells used by Frank-Ito et
al. (2016).
Boundary Conditions
Boundary conditions in the CFD model were set to replicate the flow in and out of
the experimental model. Mass flow inlet and outlet boundary types were applied at the
tube inlet and filter connection outlet, with mass flow rates that gave 6 and 7 LPM
respectively. The inlet conditions in the delivery tube, with a 10 mm inner diameter (ID),
gave an inlet Reynolds number of approximately 900, which suggests the flow in the tube
will be laminar. However, it is known that changes in cross-section, obstructions, and
changes in flow path can induce transitional and turbulent flow regardless of inlet flow
conditions (Wilcox, 1998). As mentioned previously, the effect of laminar and LRN k-ω
models on flow and particle deposition are evaluated in the Results section. Pressure
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inlet boundaries were applied to both the left and right nostrils in the gap between the
cannula surface and airway walls, which were exposed to ambient pressure (gauge
pressure of 0 Pa). The additional 1 LPM flow from the difference between the delivery
tube inlet and filter connection outlet flow rates enters the domain through the nostrils,
and using pressure inlets enables this inflow to vary in local velocity.
For the LRN k-ω model cases, turbulence boundary conditions are required at
each of the inlet boundaries, which were defined with hydraulic diameter and turbulence
intensity. For the tube inlet, the hydraulic diameter is simply the 10 mm tube ID, as the
cross section is circular. Turbulence intensity at the tube inlet is estimated to be
approximately 6% based on the approximation:
−

𝐼 = 0.16Re𝐷

1
8

(4.3.1)

where: 𝐼 is turbulence intensity and 𝑅𝑒𝐷 the Reynolds number using the inlet hydraulic
diameter (ANSYS, 2017). For the nostril inlets, the hydraulic diameter is calculated by
considering each boundary as an annulus and estimating the inner and outer diameters
by measuring the perimeters in the CAD software, which resulted in approximately 8.1
mm for both boundaries. As inlet velocity and Reynolds number at the nostrils is not
known a priori, the turbulence intensity at the nostril inlets is assumed to be 1%.
Preliminary work tested the effect of this assumption on particle deposition by changing
turbulence intensity to 5% at the nostril inlets, and negligible influence was seen in
deposition fractions (DFs) throughout the domain. Therefore, the turbulence intensity
estimates made here will not largely affect the particle deposition results.
An additional geometry extension was applied to the inlet, which was 30 mm long
(3 times the inlet diameter), to better match the experimental conditions. Similarly, a
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numerical extrusion was also added to the filter connection outlet, but due to recirculation
in the filter connection, its length was increased until there was no reverse flow at the
mass flow outlet. Particle deposition was checked on the inlet extrusion wall in the unlikely
event there was reverse flow in this region, but this did not occur in any of the considered
cases. Particles did deposit on the outlet extrusion wall, but these particles were not
included in evaluations of deposition in the nasopharynx region. That is, it is assumed
that any particles that deposit on the outlet extrusion are collected by the outlet filter.
Solution Strategy
As is typical for CFD simulations, the first convergence check was that the
residuals for all transport equations fall below at least 1e-4. Flow rates through the
pressure inlet nostrils were also checked to ensure that mass was conserved through the
domain. Due to the difference in flow rates between the filter connection outlet and tube
inlet, flow through both nostrils should be 1 LPM. Therefore, we were confident that mass
through the domain was conserved if the flow rate through the pressure inlet boundaries
is within plus or minus 0.01% of this expected value. Volume-average velocity magnitude
and TKE were also monitored for the entire domain, and the solution was deemed
converged when these quantities converge to a stable value with negligible fluctuation.
During the CFD model development, we were unable to reach a converged
solution using the steady-state formulations due to mass imbalance in a number of cells
in the filter connection region. Further investigation of the flow field in this region showed
an area of recirculation where the flow leaves the nasopharynx and enters the filter
connection. Physically, this recirculating region is unstable, with the re-attachment point
oscillating in time, making the problem fundamentally transient (time-dependent). To
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correct this issue, we switched from the partially converged steady-state solution to a
time-dependent formulation. This solution strategy, with an appropriately small time-step,
allows the model to capture the physically correct oscillatory flow and reach a high degree
of convergence, which was less than 1e-5 on all residuals. To confirm this method is valid,
flow quantities are compared at the end of each time step to ensure there is little change
in the flow field outside of the oscillating region. Particle DFs are also compared at the
10th and 20th time step to make sure particle trajectories do not change with respect to
time. For all cases considered, switching from the partially converged steady-state
solution to transient provided excellent convergence and showed negligible change in the
flow field and deposition characteristics. Furthermore, evaluation of the flow field revealed
the flow recirculation was in a region outside of the infant nasal cavity and nasopharynx
(in the filter connection), and therefore does not contribute to extrathoracic loses.
However, the effect of flow recirculation on the in vitro deposition results is discussed in
later sections of this study.
Particle Injections
In the experimental model, the tube that connects the mixer-heater device to the
streamlined nasal cannula has a 10 mm ID, but the outlet from the mixer-heater used for
aerosol generation is 6 mm ID. That is, the 10 mm tubing fits around the outside of the 6
mm mixer-heater outlet, which has a 2 mm wall thickness. Therefore, particles are
injected into the CFD model at the inlet to the tube, with a 6 mm circular diameter and a
blunt profile distribution in space.
Both monodisperse and polydisperse particle size distributions were evaluated in
this study. The polydisperse size distribution used in the CFD model neglects the three
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larger particle size bins (5.8 µm, 9.0 µm, and 10.0 µm) of the ACI analysis, as these bins
combined account for less than 1% of the total particle mass delivered to the experimental
model (0.28%, 0.19%, and 0.15% respectively). To ensure good particle deposition
convergence Tian et al. (2015) recommended 10,000 particles be injected for each size
bin, which in this case results in 60,000 total particles. To compare the total DF in each
region of the CFD model to the experimental data, the DF for each size bin is multiplied
by the mass of particles for that bin and divided by the total injected mass, which is then
summed over all bins. This is described as
𝑛𝑖
𝑁𝑖

(4.3.2)

𝐷𝐹𝑖 × 𝑚𝑖
𝑀

(4.3.3)

DF𝑖 =

𝜑𝑖 =

6

(4.3.4)

DFRegion = ∑ 𝜑𝑖
𝑖=1

where 𝑛𝑖 is the number of particles deposited for size bin 𝑖, 𝑁𝑖 is the number of particles
that enter the CFD domain for bin 𝑖, 𝐷𝐹𝑖 is the deposition fraction for size bin 𝑖, 𝑚𝑖 is the
mass of particles from the experimental size distribution for size bin 𝑖, 𝑀 is the total
injected aerosol mass, and 𝜑𝑖 is the deposited mass fraction for size bin 𝑖. The regionbased DFs presented in the Results section use the above equations, with 𝑛𝑖 given as
the number particles that deposit in a given region.
A monodisperse aerosol is also evaluated by the CFD model to determine whether
it gives comparable results to a polydisperse size distribution. The monodisperse particle
size is 25% larger than the MMAD of the polydisperse aerosol, which results in 1.78 µm
(where the measured MMAD is 1.4 µm). This approach has previously given comparable
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results for both in vitro (Longest, Tian, Delvadia, et al., 2012) and in vivo (Longest et al.,
2015) deposition in the upper airways. Theoretically, the multiplication factor is needed
because the particle deposition increases at a non-linear rate for an increasing particle
diameter. For particle deposition convergence, 90,000 particles are injected into the
domain for the monodisperse aerosol (Longest et al., 2015). The monodisperse aerosol
also uses the same diameter and spatial distribution at the tube inlet as the polydisperse
injection.
4.4

Results

Experimental
The droplet size of the albuterol sulfate aerosol exiting the infant cannula was
determined to have a mean (SD) MMAD of 1.4 (0.1) m and GSD of 1.4 (0.0) with 99.5%
and 25.5% of the particles less than 5 m and 1 m, respectively.
For the aerosol deposition experiments, the overall mean (SD) drug recovery was
84.3 (3.4) % of the nominal dose. Deposition in the mixer heater was low (2.1% of the
nominal dose) demonstrating the efficiency of the delivery system. Table 4.2 shows the
mean (SD) experimentally determined deposition fractions expressed as a percentage of
the recovered emitted dose from the mixer heater. Deposition on the patient interface
(tubing and cannula) was low with only 2.23% of the dose being found in this region.
Similarly, deposition in the infant nasal airway model was also low, with less than 5% of
the recovered emitted dose being deposited in the combined nasal passages. For this
micrometer-sized aerosol generated using the mixer heater, the mean drug deposition
fraction on the respiratory filter was 92.96 %, indicating highly efficient N2L delivery under
these steady-state inhalation flow conditions.
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Comparison of Polyhedral and Tetrahedral Meshes
As discussed in the Methods section, it is expected that polyhedral meshes may
provide faster convergence than tetrahedra. Figure 4.5a and b respectively plot the
volume-average velocity magnitude and TKE in the CFD domain against solution
iterations for the steady-state solution of the flow field. These plots show that the
polyhedral mesh reaches a converged solution in approximately 2,000 iterations
compared to approximately 3,500 iterations for the tetrahedral mesh. Recall that the
steady-state model is switched to a transient formulation, with constant boundary
conditions, to capture flow oscillations in the filter connection and thereby enable
convergence. Also note that the mesh-independent polyhedral case uses 3.56 million
cells and the tetrahedral cases required 5.71 million cells. Therefore, the polyhedral mesh
is capable of reaching a converged solution faster, and with less computational expense.
These combined benefits of polyhedral cells result in CFD models that provide a flow field
solution almost 3 times faster than tetrahedra, making them extremely computationally
efficient, which is very beneficial for time-consuming transient simulations.
In addition to improvements in processing time, polyhedral cells provide the
benefits described in the Methods section, specifically better cell-face gradient resolution
and reduced numerical diffusion. The accuracy of polyhedral cells is evaluated by
comparing CFD particle deposition results with experimental data, as shown below.
Comparison of Laminar and Turbulence Models
A Reynolds number of approximately 900 at the 10 mm ID inlet suggests laminar
conditions. However, changes in cross-section and flow obstructions can induce
turbulence in the flow field, especially in regions of air jets and shear layers. Figure 4.6
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shows iso-surfaces of turbulent viscosity ratio (TVR) in the CFD model, which is the ratio
of turbulent viscosity to laminar viscosity. That is, a TVR of two means the turbulence in
the flow makes the fluid twice as viscous as the laminar case. From Figure 4.6 it is clear
that that the TVR is at least two in a large portion of the nasal cavity, and reaches a ratio
of at least five where the flow transitions from the patient interface to nasal cavity and
around the glottis, as it is a flow obstruction. Therefore, a turbulence model is required, in
this case the LRN k-ω model, in order to capture the flow conditions in the CFD domain.
The inclusion of turbulence in the model also has an influence on particle trajectories and
deposition, as the particles interact with both the mean flow and turbulent eddies. It is
also interesting to note that the filter connection region exhibits a large amount of turbulent
flow, which may reduce the number of particles that reach the outlet filter and overestimate deposition in the nasopharynx region.
Figure 4.7 shows the DF as a function of particle aerodynamic diameter (ρp = 1000
kg/m3) for the laminar flow field and turbulent flow field with turbulent particle deposition,
over a span of aerosol sizes. The MMAD of the test aerosol (1.4 µm) is labelled within
this span. Interestingly, at this small aerodynamic diameter there is practically no
difference between the laminar and turbulent model DFs. This is because particles less
than approximately 1.5 µm lack sufficient inertia to remain on the random paths induced
by turbulent fluctuations at the low level of turbulence in this flow field. They also lack
sufficient inertia to traverse the viscous sublayer that is formed in turbulent flow. Note that
the LRN k-ω model captures the viscous sublayer, which in this application has off-wall
height dimension of approximately 0.25 mm, or approximately 175 times greater than the
MMAD. In contrast, as the particle aerodynamic diameter increases beyond 1.5 µm,
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particles are able to follow dispersion paths and reach the NW region by crossing the
viscous sublayer. Therefore, for CFD models of aerosol deposition in the nasal airways
to be applicable to the widest range of particle sizes, turbulence models should be
included. In this instance, the small size of the test aerosol means that total DFs between
laminar and turbulent models are similar. However, for an accurate and realistic
representation of the flow field deposition across a relevant particle size distribution (i.e.
1-7 µm), CFD models should include turbulent flow conditions and dispersion.
Comparisons between CFD and Experimental Data
Comparisons of the CFD monodisperse and polydisperse deposition predictions
to experimental data are provided in Table 4.2 to Table 4.5. Table 4.2 presents the DFs
for the laminar CFD case, Table 4.3 is the LRN k-ω case with turbulent particle dispersion
deactivated, Table 4.4 is the LRN k-ω case with turbulent particle dispersion activated,
and Table 4.5 is the LRN k-ω case with turbulent dispersion and NW correction UDFs.
The difference parameter (Diff.) is defined as the absolute value of absolute difference
between the CFD and experimental data (i.e. |DFCFD − DFExp |). All four cases show good
agreement with the experimental data, with the highest average difference across all
model regions being 1.75% for the polydisperse case with turbulent dispersion activated
and without NW corrections (see Table 4.4).
The polydisperse laminar case gives the closest match to the experimental data
with an average difference of 0.29% across all regions and a maximum difference of
0.68% in the anterior nose. However, from Figure 4.6 and Figure 4.7 we conclude that
turbulence should be included in the CFD model to provide a physically realistic
representation of flow through the domain, and be applicable to a relevant range of
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microparticle sizes. Of the turbulent cases considered, both the monodisperse and
polydisperse case that used NW correction UDFs gave very close matches to the
experimental data, with average differences of 0.52% and 0.63%, respectively. It is noted
that the NW correction UDFs used a NW limit control parameter of 2 µm on all wall
surfaces and for both the monodisperse and polydisperse cases. This NW limit value
corresponds well with the 1-2 µm values used by Bass and Longest (2018b) in their
previous validation work.
In general, the monodisperse aerosol, which has a particle size 25% larger than
the polydisperse MMAD, under-predicts deposition in the proximal regions (nearest the
inlet) of the nasal cavity compared to the experimental data and polydisperse deposition.
For example, in the patient interface for the NW correction UDF case, the monodisperse
aerosol predicts 1.21% less deposition (absolute difference) than the polydisperse case.
In downstream regions, the monodisperse and polydisperse cases compare closely to
one another. This is due to the larger particles in the polydisperse aerosol being filtered
by the patient interfaces and to some extent the anterior nose, so the size distribution in
the later stages is closer to the monodisperse aerosol. However, using a monodisperse
aerosol with a particle aerodynamic diameter that matches the MMAD of the polydisperse
aerosol would under-predict both regional and overall deposition in the CFD model.
Therefore, using a representative monodisperse aerosol that is 25% larger than the
MMAD gives a better approximation of overall deposition.
The close comparison between each aerosol type is apparent in Table 4.2 through
Table 4.5 and Figure 4.8, which shows particle deposition sites in the model for the
monodisperse (Figure 4.8a) and polydisperse (Figure 4.8b) aerosols for the laminar flow
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case. The key difference between Figure 4.8a and b is the polydisperse case highlights
deposition hot spots that are not apparent in the monodisperse case, in particular the
cannula bifurcation and in the nasal cavity close to the left prong. Both cases show a
region of deposition at the rear of the nasopharynx, which is expected as this is the region
where the bulk flow undergoes its most abrupt change in direction. Therefore, the
polydisperse aerosol gives better physical insight, but the monodisperse aerosol gives
good overall deposition results, and reduced computational expense. As such, there are
benefits and drawbacks to both approaches that make them desirable for either high
fidelity or high efficiency models.
Figure 4.9 compares the deposition in the turbulent flow field with the standard
dispersion model (Figure 4.9a) and with NW correction UDFs (Figure 4.9b). Figure 4.9b
shows that applying the NW correction UDFs, with a NW limit value of 2 µm, gives a better
overall match to the experimental DFs, and validates the CFD mesh and solution
parameters for infant N2L aerosol administration. The standard dispersion model in
Figure 4.9a tends to over-predict deposition in regions where there is the most change in
flow direction, specifically the patient interface and nasopharynx. Both of these figures
also show a large amount of deposition on the filter connection, which may suggest higher
deposition in the in vitro nasopharynx than would occur in vivo. Based on this observation,
future in vitro studies should consider a smaller diameter filter size to avoid unnecessary
deposition in the filter connection and housing that would not occur in vivo. This region
also showed a large amount of flow recirculation, which is not desirable for either a CFD
or in vitro model.
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4.5

Discussion
This study demonstrates the N2L EEG approach is a viable method for aerosol

delivery to infant lungs. The small aerodynamic diameters and low inertia allows a large
amount of the aerosol to penetrate the nasal cavity, which results in a high lung dose with
greater than 90% of the aerosol delivered through the connection tube. The previously
developed CFD mesh and solution guidelines from Bass and Longest (2018b) were found
to be appropriate for simulating microparticle deposition in the infant nasal airway based
on good matches to experimental DFs. The best practice set-up, which includes the LRN
k-ω turbulence model with NW corrections and follows the other recommendations in
Table 4.1, resulted in an average absolute difference of 0.63% across all regions
considered compared to the experimental results. The physical insight provided by the
CFD model highlights deposition hot spots, specifically the cannula bifurcation and close
to the prong outlets, which can be optimized in future studies to further reduce drug
delivery loses in the patient interface and nasal cavity. The particle deposition patterns
also show inadequacies in the in vitro model, where deposition on the filter connection
suggests higher loses in the nasopharynx than would likely occur in a patient.
A close match between numerical and experimental results is only possible when
the numerical model has been appropriately developed and applied. In addition to the
fundamental recommendations in Table 4.1, this nasal cavity simulation required
additional key aspects to be considered. The transient nature of the flow recirculation in
the filter connection required a time-dependent formulation and solution of the transport
equations, despite the experimental model being run under steady-state flow conditions.
While not surprising in hindsight, it is notable that the CFD solution would not converge
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until the correct physics of the transient oscillatory flow were added to the solution. Correct
prediction of particle deposition in the patient interface required an accurate spatial
distribution for particle injection into the domain, which matched the outlet diameter of the
mixer-heater device. In addition to previous work from our group and others (Vaish,
Kleinstreuer, Kolanjiyil, Saini, & Pillalamarri, 2016; Y. Zhang, Finlay, & Matida, 2004)
Table 4.3 to Table 4.5 show how the NW corrections address the over-prediction of
microparticle deposition that is present with the standard two-equation turbulent
dispersion model, and gives the closest match to experimental data for all turbulent cases
considered.
Beyond the meshing and CFD solution parameters, several other approaches to
CFD model set-up were compared and evaluated; specifically, the mesh cell type,
whether turbulence is required, and monodisperse and polydisperse particle size
distributions. This study evaluated the capabilities of polyhedral cells compared to
traditional tetrahedral cells for CFD simulations with complex geometry. The topology of
polyhedral cells provides several numerical advantages, and results show that polyhedra
provide a converged solution in less iterations with a lower cell count than tetrahedra,
while also comparing well to experimental deposition data.
With regard to flow conditions, flow and microparticle deposition in the nasal cavity
were evaluated for both the laminar and LRN k-ω model. The laminar flow case provided
a good match with experimental DFs, but using the LRN k-ω model gives a more
physically realistic flow field and is suitable for a broader range of N2L applications across
the relevant microparticle size range. Furthermore, evaluation of TVR showed regions of
relatively high turbulence around abrupt changes in cross section and flow obstructions,
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which must be accounted for in the CFD model. Viewed another way, running the nasal
simulation as a laminar flow would be equivalent to conducting a physical experiment with
a gas that had a viscosity two to five times below that of air (which does not exist), and
assuming the fluid was air.
The results compared both monodisperse and polydisperse aerosol deposition,
where the monodisperse aerosol was represented with a particle size that is 25% larger
than the MMAD of the polydisperse aerosol. The CFD model showed that the
monodisperse aerosol can be comparable to polydisperse and experimental data for total
and regional deposition. However, the polydisperse aerosol highlights deposition hot
spots that are not apparent in the monodisperse case. Therefore, monodisperse aerosols
are useful in the model development phase, as they required less computation time, but
more accurate results require a polydisperse size distribution, which enables additional
useful insights.
As a secondary objective, this study demonstrates high efficiency N2L delivery
using an aerosol with a small initial size (MMAD of 1.4 µm). The aerosol was produced
with a mixer-heater similar to the study of Longest et al. (2013), but with a lower device
volume and using a reduced nebulizer output. The primary advantage of this mixer heater
system is that it employs a commercial mesh nebulizer, but uses heating elements to dry
the droplets into smaller particles while maintaining a temperature and relative humidity
that are safe for direct inhalation. Using this approach, lung delivery efficiencies greater
than 90% of the aerosol that enters the connection tube were demonstrated in a 6mo
airway model under steady state flow conditions.
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In comparison to similar studies with infants, Lin et al. (2015) used a commercially
available vibrating mesh nebulizer and humidifier, and evaluated delivery flow rates of 3,
6, and 12 LPM across two different face masks for a 2-year-old nasal model. They
reported MMADs of 2.8 µm to 3.3 µm exiting the facemask, and an inhaled mass of 2.8%
to 6.4% (expressed as a percentage of dose loaded in the nebulizer). El Taoum et al.
(2015) compared numerous scenarios for a 7-month-old model, including seven different
patient interfaces, jet and vibrating mesh nebulizers, and three breathing patterns. In their
study, lung doses (as a percent of nominal dose) range from <0.001% to 2.97%, but
aerosol MMADs were not reported. Regarding nasal cannula systems, Sunbul et al.
(2015) evaluated HFNC, Bubble CPAP, and SiPAP systems on a 26-week-old model
(approximately 6 months) with different nebulizer positions, and found optimized lung
doses (as a percent of nominal dose) of 0.79% to 1.30%. Reminiac et al. (2017) studied
nasal high flow nebulization both in vitro and in vivo using the SAINT infant airway model
(Janssens et al., 2001) and a non-human primate (macaque) for jet and vibrating mesh
nebulizers, which were also placed in different locations within the system and with
varying flow rates. They reported low aerosol MMADs at the cannula outlet, similar to the
present study, from 1.05 µm to 1.43 µm. However, they also reported low lung doses
ranging from 0.03% to 0.85% in vivo and 0.46% to 4.15% in vitro, due to high system
loses in the humidifier, tubing, and cannula.
The aerosol size considered in the current study is similar to that recommended
by Longest et al. (2014), who demonstrated 45% to 60% lung deposition in an infant
model of invasive mechanical ventilation. A recent correlation from Tavernini et al. (2018),
which built upon work from Storey-Bishoff et al. (2008), estimates that for the

158

monodisperse case presented in the current study, approximately 1.23% of particles that
enter the nostril will deposit in the cavity and nasopharynx. Furthermore, Clark et al.
(2018) demonstrated the need for using smaller aerosol sizes to maximize lung aerosol
delivery to pre-term infants. However, it is noted that only EEG aerosol delivery offers a
method to retain small particles or droplets, once they are inhaled and enter the lung
airspace.
A primary limitation of the current study is the use of steady state inlet and outlet
boundary conditions in both the experimental and numerical models. Infants have very
short inhalation times. Therefore, efficient aerosol delivery will require synchronizing
aerosol generation from the nebulizer with a portion of the inhalation period. The effective
synchronization of the aerosol delivered to an infant was recently demonstrated by
Dhapare et al. (2018). An additional limitation is the absence of a hygroscopic excipient
in the test aerosol. As mentioned previously, the aerosol delivered to the experimental
model had similar particle aerodynamic diameter to EEG aerosols, but used 0.5% w/v
albuterol sulfate instead of an EEG formulation. Previous studies have shown that particle
size increase has an influence on upper airway deposition (Schroeter et al., 2001;
Walenga et al., 2014).
This study has expanded recommendations for the accurate simulation of particle
deposition during N2L aerosol delivery. Using these recommendations, close agreement
between the CFD predictions and in vitro experimental results of regional drug deposition
was attained. This study has also further demonstrated how a concurrent CFD and in vitro
approach (Hindle & Longest, 2013; Longest & Hindle, 2009c) can lead to valuable insights
regarding drug delivery strategies. Finally, the validated CFD model now provides a useful
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tool to further understand and improve the N2L approach for administering
pharmaceutical aerosols to infants.
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4.6

Figures

Figure 4.1:

Overview of geometry showing (a) experimental CAD model and (b) air

interface of the CFD model. Images show the streamlined nasal cannula, three sections
of the experimental model, complex surfaces of the nasal cavity, and outlet filter
connection.
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Figure 4.2:

Experimental

set-up

schematic showing the mixer-heater aerosol

generation device, patient interface, and nose-to-lung model.
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Figure 4.3:

Examples of polyhedral and tetrahedral volume meshes of the domain

showing the (a) 5.7 million cell tetrahedral mesh, (b) 3.6 million cell polyhedral mesh at
the inlet boundary, (c) 5.7 million cell tetrahedral mesh, and (d) 3.6 million cell polyhedral
mesh in the middle meatus.
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Figure 4.4:

Summary of mesh convergence for both polyhedral and tetrahedral mesh

types for key flow and turbulence field quantities and particle deposition characteristics;
specifically (a) velocity magnitude, (b) turbulent kinetic energy, and (c) deposition
efficiency on nasal cavity wall surfaces.
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Figure 4.5:

Progression of volume-averaged (a) velocity magnitude and (b) turbulent

kinetic energy during solver iterations, which shows faster convergence for the 3.6 million
cell polyhedral mesh compared to the 5.7 million cell tetrahedral mesh.
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Figure 4.6:

Iso-surface plots showing turbulent viscosity ratio values of 2 and 5 in (a)

isometric, (b) side, (c) front, and (d) top views, which demonstrates large regions of the
domain experience noticeable turbulence, especially at the interface from the cannula
prongs to nasal cavity and around the glottis. Slices aim to show the model geometry
without obscuring the iso-surfaces.
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Figure 4.7:

Comparison of deposition profiles for laminar and turbulent with near-wall

correction cases. Deposition fractions are similar between the two cases for small (<2µm)
particles, but as the particle aerodynamic diameter increases (ρp = 1000 kg/m³) the
laminar flow field predicts less deposition.
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Figure 4.8:

3D particle deposition sites, with comparisons to experimental (exp) data,

for laminar flow with (a) monodisperse aerosol and (b) polydisperse aerosol.
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Figure 4.9:

3D particle deposition sites, with comparisons to experimental data, for the

polydisperse aerosol with (a) the standard turbulent dispersion model and (b) turbulent
dispersion with NW corrections.
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4.7

Tables

Table 4.1:

Mesh

Flow

Particles

Summary of recommended mesh and solver parameters.
Model/Parameter
Target Wall y+
Number of NW Layers
L2L Ratio
Turbulence
P-V Coupling
Mom. & Turb. Schemes
Gradient Discretization
Numerical Accuracy
Tracking Scheme
Turbulent Dispersion
Eddy Interaction Model
NW Correction

Setting/Method
0.5-1
5
1.0 (may be increased with no negative effects)
LRN k-ω
SIMPLEC
Second-order Upwind
Green-Gauss Node-based
Double Precision
Lagrangian with Runge-Kutta
Interpolate TKE at particle location from nodes
Modified via UDF
NW Limit = 1.0-2.0 µm
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Table 4.2:

Summary of deposition fractions for the monodisperse (Mono.) and

polydisperse (Poly.) laminar cases.

Region
Patient Interface
Anterior Nose
Middle Passage
Nasopharynx
Filter

Exp.
Mean DF (SD)
2.23% (0.16%)
1.11% (0.15%)
1.51% (0.26%)
2.18% (0.87%)
92.96% (2.93%)

Mono.
DF
Diff.
1.06%
1.17%
1.21%
0.10%
1.53%
0.02%
1.83%
0.35%
94.37% 1.41%

Poly.
DF
2.28%
1.79%
1.50%
1.79%
92.64%

Diff.
0.05%
0.68%
0.02%
0.39%
0.32%

Average
0.61%
0.29%
Diff. is defined as the absolute value of absolute difference between the CFD
and Experimental (Exp.) data.
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Table 4.3:

Summary of deposition fractions for the monodisperse (Mono.) and

polydisperse (Poly.) turbulent cases with dispersion deactivated.

Region
Patient Interface
Anterior Nose
Middle Passage
Nasopharynx
Filter

Exp.
Mean DF (SD)
2.23% (0.16%)
1.11% (0.15%)
1.51% (0.26%)
2.18% (0.87%)
92.96% (2.93%)

Mono.
DF
Diff.
1.62%
0.61%
1.71%
0.60%
1.43%
0.08%
3.07%
0.89%
92.17% 0.80%

Poly.
DF
3.44%
2.43%
1.60%
2.73%
89.81%

Diff.
1.21%
1.32%
0.08%
0.55%
3.16%

Average
0.60%
1.26%
Diff. is defined as the absolute value of absolute difference between the CFD
and Experimental (Exp.) data.
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Table 4.4:

Summary of deposition fractions for the monodisperse (Mono.) and

polydisperse (Poly.) turbulent cases with dispersion activated.

Region
Patient Interface
Anterior Nose
Middle Passage
Nasopharynx
Filter

Exp.
Mean DF (SD)
2.23% (0.16%)
1.11% (0.15%)
1.51% (0.26%)
2.18% (0.87%)
92.96% (2.93%)

Mono.
DF
Diff.
2.73%
0.50%
1.27%
0.16%
1.42%
0.10%
3.00%
0.82%
91.58% 1.39%

Poly.
DF
4.99%
1.76%
1.54%
3.14%
88.58%

Diff.
2.76%
0.65%
0.02%
0.96%
4.39%

Average
0.59%
1.75%
Diff. is defined as the absolute value of absolute difference between the CFD
and Experimental (Exp.) data.

173

Table 4.5:

Summary of deposition fractions for the monodisperse (Mono.) and

polydisperse (Poly.) turbulent cases with near-wall correction UDFs.

Region
Patient Interface
Anterior Nose
Middle Passage
Nasopharynx
Filter

Exp.
Mean DF (SD)
2.23% (0.16%)
1.11% (0.15%)
1.51% (0.26%)
2.18% (0.87%)
92.96% (2.93%)

Mono.
DF
Diff.
1.42%
0.82%
0.99%
0.13%
1.15%
0.37%
2.42%
0.25%
94.03% 1.06%

Poly.
DF
2.62%
1.78%
1.08%
2.38%
91.52%

Diff.
0.39%
0.67%
0.44%
0.20%
1.45%

Average
0.52%
0.63%
Diff. is defined as the absolute value of absolute difference between the CFD
and Experimental (Exp.) data.
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Chapter 5: CFD-based Optimization of an Inline DPI for EEG
Tobramycin Formulations
5.1

Objective
The objective of this study was to implement CFD simulations to develop

quantitative correlations that predict the aerosolization behavior of an inline air-jet DPI for
children and then use these correlations to optimize aerosolization performance. In order
to develop the flow-field based correlations for aerosolization performance, CFD
simulations of four initial devices were conducted and compared with the previous
experimentally determined aerosolization metrics reported by Farkas et al. (2019). Based
on these findings, a second iteration of designs was developed and tested both
experimentally and with the evolving CFD model. The complete set of ten devices was
then used to identify the best CFD-based dispersion parameters for predicting MMAD and
ED in the pediatric air-jet DPIs. These dispersion parameters were then used to develop
a CFD optimized design for improved performance with increased ED and reduced
MMAD compared with previous studies. As a final step, the best-case designs were
produced and tested experimentally to validate the CFD predictions and optimization
method.
5.2

Introduction
In the field of respiratory drug delivery, computational fluid dynamics (CFD) is

proving to be an increasingly useful tool for the development and optimization of dry
powder inhalers (DPIs). For example, in a series of papers, Coates et al. used CFD to
investigate the effects of mouthpiece length and grid design (2004), capsule size (2005),
flow rate (2005), air inlet size (2006), and mouthpiece geometry (2007) on DPI
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performance in terms of capsule, device, and extrathoracic losses. More recently Shur et
al. (2012) modified the air inlets of a Cyclohaler, guided by CFD analysis, to match the
aerosolization performance of the HandiHaler.
Our group has developed a series of high efficiency air-jet DPIs that are operated
with 10 ml of air (via a syringe) (Farkas, Hindle, & Longest, 2018b; Longest & Farkas,
2018; Longest, Farkas, Bass, & Hindle, 2019). These air-jet DPIs use small-gauge hollow
capillaries that pierce a powder-containing capsule as part of loading the device, and
serve as the air inlet and aerosol outlet. The inlet capillary supplies a high-velocity,
compressible, turbulent jet that initially fluidizes the powder bed. It is expected that
significant turbulence and high shear forces further break up the initially formed
aggregates, which reduces the particle size while in the capsule chamber (Longest &
Farkas, 2018; Longest et al., 2019). Once the size of an aerosolized aggregate is
sufficiently reduced, it is able to escape the powder chamber through the outlet capillary
and enter the patient interface.
A detailed approach to modeling DPI aerosolization and transport in CFD could
utilize Lagrangian particle tracking (Longest & Farkas, 2018; Longest et al., 2019) or
discrete element modeling (DEM) (X. Chen, Zhong, Zhou, Jin, & Sun, 2012; Tong, Zhong,
Yu, Chan, & Yang, 2016; Yang, Wu, & Adams, 2014) as a representation of the powder.
However, CFD with DEM becomes computationally expensive when a complete device
and powder dose need to be simulated in order to make design improvement predictions.
For example, current DEM simulations that attempt to capture powder structural
properties with particle-particle and particle-wall interactions are currently limited to one
or two particle agglomerates (Ariane, Sommerfeld, & Alexiadis, 2018; Wong, Fletcher,
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Traini, Chan, & Young, 2012). In contrast, an effective approach for predicting the
aerosolization behavior of a DPI is to develop predictive correlations that relate dispersion
parameters, which use CFD-predicted flow and turbulence quantities, to aerosolization
performance metrics (Coates, Chan, et al., 2005; Longest & Farkas, 2018; Longest et al.,
2019; Shur et al., 2012).
Specific to the air-jet DPI development in the current study, Longest and Farkas
(2018) developed quantitative flow-field-based and tracer-particle-based correlations that
related device aerosolization to flow and turbulence dispersion parameters for a very low
volume of actuation air (i.e. 10 mL). The tracer-particle method used a relatively small
number of Lagrangian particles, compared to modelling the entire powder bed, to sample
turbulence and flow quantities throughout the domain. To quantify device performance,
the aerosolization metrics of mass-median aerodynamic diameter (MMAD) and emitted
dose (ED) (also often referred to as emitted fraction) were used. Their study showed that
MMAD had a strong direct correlation (R 2 > 0.8) with two flow-field-based dispersion
parameters, which were a non-dimensional form of turbulent kinetic energy (k), denoted
∗
by 𝑘𝑓𝑖𝑒𝑙𝑑
, and the product of non-dimensional k and non-dimensional specific dissipation
∗
∗
∗
rate (ω), denoted by 𝑘𝑓𝑖𝑒𝑙𝑑
× 𝜔𝑓𝑖𝑒𝑙𝑑
. The ED also showed a strong correlation with 𝑘𝑓𝑖𝑒𝑙𝑑
∗
∗
∗
∗
and 𝑘𝑓𝑖𝑒𝑙𝑑
× 𝜔𝑓𝑖𝑒𝑙𝑑
, as well as 𝑘𝑓𝑖𝑒𝑙𝑑
/𝜔𝑓𝑖𝑒𝑙𝑑
and wall shear stress (WSS). The predictive

capabilities of these correlations were evaluated by Longest et al. (2019) by comparing
the predicted MMAD and ED from CFD models to experimental results a priori, with
results showing a low root-mean-square (RMS) error (again, for a 10 mL actuation air
volume). The findings from these two studies demonstrated that dispersion parameters
can be correlated to be predictive of MMAD and ED performance for air-jet DPIs. They
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also suggested that the powder goes through a two-stage aerosolization process, where
the first stage involves the initial dispersion from the stationary powder bed to the flow
field, followed by secondary breakup in the high-velocity, highly-turbulent air jet.
The present study builds upon the previous development of a high-efficiency inline
air-jet DPI, and applies this platform to the delivery of tobramycin to children with cystic
fibrosis (CF). A primary symptom of CF is dehydration of the airway surface liquid in the
lungs, due to poor ion transport through epithelial cells (Matsui et al., 1998; Tarran et al.,
2001), which produces thickened mucus and poor mucociliary clearance (Stoltz et al.,
2015). Poor lung clearance and abnormal ion concentrations lead to frequent bacterial
infections, the most predominant of which is Pseudomonas aeruginosa (Pa) (Elborn,
2016), which can be treated by inhaled antibiotics. tobramycin was the first commercial
inhaled antibiotic (A. L. Smith, 2002), and is available as either a solution or powder for
nebulizers or DPIs, respectively. The efficacy of treating Pa infections with tobramycin
was demonstrated in a clinical trial by Ramsey et al. (1999) who reported an average
12% increase in FEV1 (forced expiratory volume over 1 second), 26% decrease in
pulmonary exacerbations, less hospitalization, and a 1.1 log 10 CFU/g reduction in Pa
infection.
Our group is developing a pediatric DPI for the administration of spray-dried
excipient enhanced growth (EEG) powder formulation to children with CF as young as 2
years old. As described by Farkas et al. (2019), the delivery system is intended to provide
the aerosol and a full inhalation through either a sealed nasal cannula or mouthpiece
interface. By delivering a full inhalation from a positive pressure gas source, the device
has multiple advantages compared with typical passive DPIs including consistent
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actuation, the flexibility of oral or nasal lung delivery, potential expansion of the upper
airways, and resistance to exhalation through the device. The study of Farkas et al. (2019)
previously established that improved aerosolization was achieved when all of the
available gas flow was passed through the powder chamber. To achieve the much higher
flow rates (~15 LPM) compared with the previous studies of Longest and Farkas (2018)
and Longest et al. (2019) (~3 LPM), capillary diameters were increased, which alters the
turbulence and shear stress profiles within the device. As a result, aerosolization
characteristics and dispersion parameters are expected to be considerably different for
the current pediatric devices compared with the previous devices that were operated with
10 mL of actuation air.
The proposed pediatric device for tobramycin uses an inline, positive-pressure
actuation and air-jet aerosolization. Specifically, a standard ventilation bag is connected
to the inlet, which provides the actuation air volume (~750 mL) and a pressure drop (~6
kPa) across the device. The inlet capillary then supplies a high-velocity, highly-turbulent
air jet to the capsule chamber to aerosolize the powder. Initial devices are developed for
patients in the age ranges of 2-3, 5-6, and 9-10 years old, and aim to provide the
inhalation volume for one breath as part of the actuation process. The present study
focuses on the 5-6-year-old group, with a target inhalation volume of 750 mL and total
device air flow rate of 15 LPM.
Experimental aerosolization performance from four prototyped versions of the
proposed pediatric air-jet DPI are presented by Farkas et al. (2019) which forms the basis
of correlation development for the current study. The minimum device aerosolization
performance goals of the experimental study were an ED > 85% (of loaded dose), MMAD
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< 1.75 µm, fine particle fraction of ED < 5 µm (FPF <5µm/ED) > 90%, and FPF<1µm/ED > 20%,
all of which were achieved by the Case 4 device (FPF <1µm/ED was 19.5%). Considering
aerosol administration through in vitro airway models of a five-year-old child, the Case 4
device delivered 60.7% to the tracheal filter, with 8.3% nose-throat losses, when coupled
to the best-case nasal cannula design; and 63.8% to the tracheal filter, with 6.6% mouththroat losses, when coupled with the best-case mouthpiece design. This is a marked
improvement over the typical DPI performance for aerosol administration to children that
is reported in the literature. Specifically, for oral aerosol delivery to a 4-5 year-old in vitro
model, Below et al. (2013) reported 5% and 22% of nominal dose deposited on the
tracheal filter with the Novolizer and Easyhaler; and Lindert et al. (2014) reported 9% to
11% lung delivery efficiency with the Cyclohaler, HandiHaler, and Spinhaler. For transnasal aerosol delivery to children in the age ranges considered, little data is available in
the literature. The closest available study is Laube et al. (2012) who reported <4% of
loaded dose delivered to the tracheal filter in the 9-month-old in vitro SAINT model
(Janssens et al., 2001).
5.3

Methods
The current study builds upon the initial experimental work with pediatric air-jet

DPIs presented by Farkas et al. (2019), and the devices and results from that study are
referred to as Experimental Iteration 1. In the current study, CFD models are developed
for the devices in Experimental Iteration 1 and initial CFD dispersion parameters are
calculated based on our previous work with low (~10 mL) actuation volumes (Longest &
Farkas, 2018; Longest et al., 2019). A second round of pediatric air-jet devices is then
prototyped and tested experimentally, which is referred to as Experimental Iteration 2.
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New dispersion parameters, which are appropriate for the higher flow volumes of the
pediatric air-jet DPIs (~750 mL), are then developed for both device sets (Experimental
Iteration 1 and 2) and compared with the experimental data to determine their ability to
predict ED and MMAD. Device optimization then begins by evaluating numerous design
configurations with CFD and using the refined dispersion parameters to estimate
performance. The entire experimental, CFD, and optimization approach is described in
detail in the following sections.
Optimization Process
To meet the objective, the device optimization process is outlined by the block
diagram in Figure 5.1. This process utilizes concurrent experimental and CFD models to
provide physical insight into aerosolization performance, and iterations through the
process aim to refine the dispersion parameters and optimize the device performance.
The overarching aims of the process are to (i) provide an a priori validation of CFD-based
dispersion parameter predictions of aerosolization performance and (ii) determine the
best performing device parameters within the design space.
The Initial Device Development stage (Figure 5.1) is largely covered by the work
presented in our previous publications on pediatric air-jet DPI development (Farkas et al.,
2019; Longest & Farkas, 2018; Longest et al., 2019). Here the initial air-jet DPI concept
was developed with a combination of analytical, experimental, and numerical methods.
Fabrication of prototype air-jet DPIs uses computer aided design (CAD) models and 3D
printing for the plastic components, with small gauge stainless steel hollow tubes used
for the inlet and outlet capillaries. Once prototype devices are built, the Aerosolization
Experiments stage tests the aerosolization performance (MMAD and ED) of the DPI. The
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experimental setup uses a next-generation impactor (NGI) and high-performance liquid
chromatography (HPLC) to determine the particle size distribution and capsule retention,
both of which are used to establish performance metrics. In parallel to the Aerosolization
Experiments stage, the CFD Evaluation stage uses numerical models to provide insight
into the flow and turbulence conditions within the devices. It is expected that numerous
CFD simulations will be conducted during the optimization process (over 100 design
configurations), so the geometry, meshing, model set-up, and post-processing steps are
automated as much as possible. In the Correlation Development stage, the flow and
turbulence quantities from the CFD simulations are used to identify and develop
dispersion parameters that are predictive of the aerosolization performance metrics.
After predictive correlations are developed, the process loops back through the
Aerosolization Experiments and CFD Evaluation stages to test the correlations for
accuracy and develop insights into newly defined dispersion parameters (see Iteration 2
in Figure 5.1). Following correlation development and testing, it is important to evaluate
how changes to the device design influence the dispersion parameters and associated
aerosolization performance predictions. The flow and turbulence quantities from CFD
models of numerous design configurations are evaluated to determine trends between
design factors and device flow characteristics. These quantities are then used in the
dispersion parameters and correlations to provide predictions of aerosolization
performance. Finally, the predictions of aerosolization performance from the previous
stage are used to identify optimized device designs. The optimized device should both
provide good aerosolization performance and be an improvement over the devices from
Experimental Iteration 1. A priori validation of the CFD predictions was conducted by
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producing and experimentally testing the optimized devices to determine whether the
aerosolization performance predictions are accurate, without adjusting the models or
correlations after the simulations are conducted.
Experimental Materials and Powder Formulation
Albuterol sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena,
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France).
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ).
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis,
MO). Quali-V, Hydroxypropyl methylcellulose (HPMC) capsules (size 0) were donated
from Qualicaps (Whitsett, NC).
Multiple batches of a spray-dried AS EEG powder formulation were produced
based on the optimized method described by Son et al. (Son, Longest, & Hindle, 2013;
Son, Longest, Tian, et al., 2013) using a Büchi Nano spray dryer B-90 (Büchi LaboratoryTechniques, Flawil, Switzerland). The EEG powder formulation contained a 30:48:20:2%
w/w ratio of AS, mannitol, L-leucine, and Poloxamer 188.
Device Design and Experimental Methods
The devices that were tested in Experimental Iterations 1 and 2, along with their
inlet and outlet diameter configurations and operating conditions are summarized in Table
5.1. The naming convention for cases in Experimental Iteration 2 gives the inlet capillary
diameter followed by the outlet capillary diameter, as that is the primary design factor that
was evaluated. For example, a case called 1.83/2.90 uses a 1.83 mm inlet diameter and
a 2.90 mm outlet diameter, and all other design factors and operating conditions are the
same as Cases 3 and 4 in Experimental Iteration 1. This includes an operating inlet
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pressure of 6 kPa, which is easily generated with one hand operation of a pediatric size
ventilation bag (Farkas et al., 2019). The Half Q case is the exception to this naming
convention as it is the same device as Case 4, but implements a pressure drop of 1.5 kPa
to reduce the flow rate through the device by a factor of two. The 1.32/2.39 case used the
same outlet capillary diameter and pressure drop as Case 4, but included a 1.32 mm inlet
capillary to increase flow resistance and give a similar flow rate to the Half Q case.
Likewise, the 1.60/2.39 case used a 1.60 mm inlet capillary to give a flow rate that was
approximately 75% of Case 4. The 2.08/2.69 case has a similar outlet to inlet diameter
ratio (𝑑𝑜 ⁄𝑑𝑖 ) as Case 4 (i.e. ~1.30). The 1.32/2.90 case has the same average capillary
diameter (0.5 × (𝑑𝑖 + 𝑑𝑜 )) as Case 4 (i.e. 2.11 mm) and tests an example where the outlet
diameter is much larger than the inlet. Finally, the 3.00/2.08 case tests the influence of
having a larger inlet compared to the outlet diameter, and maximizes the flow rate (and
hence available flow energy) through the device.
Details on the device design and experimental methods for Experimental Iteration
1 are discussed in depth by Farkas et al. (2019). The additional experimental work carried
out for Experimental Iteration 2 in the present study followed the same device design,
operation, and methods as Experimental Iteration 1. In brief, a size 0 HPMC capsule was
loaded with 10 mg of AS EEG powder formulation, and the device used hollow capillaries
to pierce the capsule when the device was closed with a single twisting action. Actuation
of the device passes a high velocity air jet through the inlet capillary, which aerosolizes
the power, and the particles leave the capsule via the outlet capillary leading to the patient
interface. In the present study, the only design factors that were manipulated were the
inlet and outlet capillary diameters. Design factors that were kept constant included the
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insertion length of the capillary in the capsule, capsule size, piecing angle, piercing
location (along the long axis of the capsule), and a horizontal orientation of the device.
Preliminary experimental work considered angling the inlet capillary relative to the outlet
capillary, similar to Case 7 in the Longest et al. study (2019), in an effort to increase
secondary flow, but there was little improvement in aerosolization performance. Similarly,
preliminary work extended the outlet capillary length in an effort to expose the aerosol to
high shear flow for a longer duration, but again there was no improvement in MMAD or
ED compared with Experimental Iteration 1. Figure 5.2a shows a rendering of the Case
4 device in transparent plastic, with the capsule and capillaries clearly visible. Figure 5.2b
shows the internal flow path, which represents the computational domain for CFD models,
and the height to which the 10 mg powder bed fills the capsule.
All devices were actuated with a 6 kPa pressure drop via a compressed air line
and solenoid valve. Previous results indicated very similar device performance with either
a hand-operated ventilation bag or compressed air and solenoid valve setup (Farkas et
al., 2019). Inlet flow rate thorough each device was recorded before loading a capsule,
and the time of actuation (controlled by the solenoid valve) was adjusted to ensure that
750 ml passed through the device, which is consistent with a deep inhalation volume for
a 5-6 year old child (75% of total lung capacity) (ICRP, 1994). The aerosol
characterization was performed using an NGI and AS drug mass was quantified using
HPLC, with the device actuated into the NGI using a custom adaptor. After actuation,
HPLC was used to determine recovered drug masses in the capsule and device, and the
amount of powder that deposited on each stage of the NGI. As minimal size change is
expected in the aerosol under ambient temperature and relative humidity (RH) conditions,
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experiments were conducted with ambient air (T = 22°C ± 3°C and RH= 50% ± 5%) with
the NGI at room temperature. AS quantification was performed with a validated HPLC
method using a Waters 2695 separations module with a 2475 fluorescence detector
(Waters Co., Milford, MA). Chromatography was performed using a Restek Allure PFP
150 mm × 2.1 mm column (Bellefonte, PA). The mobile phase, consisting of methanol
and ammonium formate buffer (20 mM, pH 3.4) in a ratio of 70:30, respectively, was
eluted at a flow rate of 0.4 mL/min and the detector was set to an excitation wavelength
of 276 nm and emission at 609 nm. The column temperature was maintained at 25 °C,
and the volume of each sample injected was 100 μL. The limit of quantification was 0.5
µg/ml (Behara, Longest, et al., 2014b; Son, Longest, & Hindle, 2013). The recovered dose
from HPLC analysis for all experimental data presented in this study was greater than
90%.
The ED was defined as the difference between the loaded AS dose and the mass
of AS retained in the capsule and device after one actuation, divided by the loaded dose,
and expressed as a percentage. The MMAD was identified with linear interpolation of a
cumulative percentage drug mass vs. cut-off diameter plot from the NGI. The cut-off
diameters of each NGI stage were calculated using the formula specified in USP 35
(Chapter 601, Apparatus 5) for the operating flow rate of 45 LPM. The exception in the
present study is that the higher flow rate of some devices required the NGI to be operated
at a flow rate of 60 LPM. To account for this when determining the MMAD for these
devices, the cut-off diameters were recalculated using the formula from USP 35 for a flow
rate of 60 LPM.
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CFD Models
The computational domains and meshes were generated according to our
previously established best practices (Bass & Longest, 2018b; Longest & Holbrook, 2012;
Longest & Vinchurkar, 2007a). Meshes were composed of very high quality hexahedral
cells, with orthogonality greater than 0.25, and followed a similar construction style as our
previous air-jet DPI studies (Longest & Farkas, 2018; Longest et al., 2019). To reduce the
time required for CFD model development, geometry and mesh generation were
automated as much as possible using an input file with design parameters and
automation scripts, as it was expected that numerous design configurations would be
explored during the optimization process. This automation reduced the time to create
each mesh from approximately an hour of repetitive manual work to less than two
minutes, and minimized the possibility of human error. To confirm mesh independent
results, CFD quantities specific to flow, turbulence, and compressibility were evaluated
for a coarse (230,208 cells), medium (496,128 cells), fine (976,000 cells), and extra fine
(2,044,588 cells) mesh that represented the Case 4 device configuration, with mesh
independence established between the fine and extra fine mesh. Between these two
meshes, the volume-averaged velocity magnitude had an absolute difference of -0.05 m/s
(-0.30% relative difference), the volume-averaged turbulence kinetic energy had an
absolute difference of -0.02 m2/s2 (-0.19% relative difference), and the inlet and outlet
volumetric flow rates had an absolute difference of -0.102 LPM and -0.103 LPM
respectively (-0.54% and -0.53% respectively). This mesh resolution is also consistent
with the cell counts used in our previous air-jet DPI CFD work (Longest & Farkas, 2018;
Longest et al., 2019).
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For Experimental Iteration 1, cases have inlet boundary Mach and Reynolds
numbers ranging from 0.18-0.27 and 6,300-13,200 respectively. These cases are below
the recommended Mach number threshold of 0.3 for compressible flow, but the ideal gas
law for density modelling was implemented to be consistent with previous DPI studies
(Longest & Farkas, 2018; Longest et al., 2019) and to ensure CFD models are capable
of handling higher inlet velocity if the flow rate is increased during optimization. Based on
inlet Reynolds numbers, some cases exhibit highly turbulent behavior, and at the very
least flow is beyond the transitional regime. As such, the low-Reynolds number (LRN) kω turbulence model was implemented, which has been extensively validated for drug
delivery applications by our group (Bass & Longest, 2018b; Longest, Son, et al., 2013;
Longest & Vinchurkar, 2007b), and was shown give a good compromise between
computational accuracy and efficiency. Despite very high inlet Reynolds numbers, the
LRN correction was applied to account for the possibility of low turbulence regions within
the domain, particularly at locations far from the inlet capillary jet. The form of the LRN
corrections makes the model applicable to both high and low turbulence regions, as the
eddy viscosity damping coefficient approaches unity in regions of high turbulence and
hence has little effect. Based on the presence of a high velocity inlet jet and compressible
flow, shear flow corrections and compressibility effects were also implemented (Wilcox,
1998).
Consistent with our previous air-jet DPI CFD studies (Longest & Farkas, 2018;
Longest et al., 2019), a steady-state approach for transport equation discretization would
not provide a converged solution due to the presence of relatively high frequency (~1000
Hz) flow oscillations. As such, the CFD model used a partially converged steady-state
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solution as the initial condition, then switched to a transient approach, with a time step of
1e-4 s that provided good convergence and accurately resolved the flow oscillations.
Differences between volume-average flow and turbulence quantities were observed to be
negligible after approximately 100 time-steps, suggesting that start-up effects had
dissipated. As dispersion metrics are based on volume-average quantities, it is expected
that this solution strategy will be capable of providing predictive correlations, as was the
case when a similar approach was implemented by Longest and Farkas (2018).
Both flow-based and particle-based dispersion parameters were originally
presented by Longest and Farkas (2018), which demonstrated the predictive capabilities
of CFD models for DPI aerosolization performance. The former used volume-averaged
flow and turbulence quantities as the basis of the dispersion parameters, and the latter
used tracer particles to sample flow and turbulence quantities as their trajectories moved
from the powder bed and through the domain. As both flow-based and particle-based
dispersion parameters performed well in previous studies, the current study will analyze
an extended set of flow-based parameters, which reduces overall processing time.
All flow and turbulence transport equations were solved using ANSYS Fluent
v19.0, including the necessary sub-models and corrections described previously. CFD
models adhered to the recommended guidelines presented by Bass and Longest (2018b),
in particular the implementation of the Green-Gauss Node-based method for gradient
discretization. Spatial discretization of transport equations, including k and ω, were
second-order accurate. Convective terms used a second-order upwind scheme and
diffusion terms used central difference. Further details on the mass, momentum, and
turbulence transport equations are available in other publications (Longest et al., 2007;
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Longest, Vinchurkar, & Martonen, 2006). As with the meshing stage of CFD model
development, the setup in ANSYS Fluent that was required for each case was automated
as much as possible by utilizing the scripting capabilities of the Fluent text user interface.
In all experimental runs, the DPI was activated by applying a 6 kPa pressure drop
across the device. The CFD models implement this pressure gradient with a pressure
inlet boundary condition set to 6 kPa and a pressure outlet boundary condition set to 0
kPa, with all pressures given as gauge pressure. The pressure difference between the
inlet and outlet boundary drives flow through the computational model, and the device
geometry determines flow resistance and hence the volumetric flow rate. As an initial
validation check of both the model selection and boundary conditions, the inlet flow rate
between CFD models and available experimental flow rate data was compared to ensure
the numerical results were similar to the actual devices. On average, the absolute
difference between CFD and experimental flow rate differed by approximately 1 LPM, or
a relative difference of 6%. Generally, the CFD over-predicted flow rate compared to the
experimental results, which can be attributed to the surface roughness of plastic
components increasing flow resistance and minor simplifications of the geometry in the
CFD model.
Dispersion Parameters
The CFD-predicted dispersion parameters used in the current study and previous
work by our group (Longest & Farkas, 2018; Longest et al., 2019) use flow and turbulence
quantities to characterize the conditions that drive powder aerosolization within in the
pediatric air-jet DPI. Flow quantities are generally ubiquitous and well understood across
all scientific fields, such as inlet flow velocity, but turbulence quantities are less common
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in fields outside of CFD, such as turbulent kinetic energy (k) and specific dissipation rate
(ω). In turbulence modeling, the flow velocity is typically decomposed into time-averaged
and fluctuating components. The time-averaged component is the mean flow through the
domain and is represented by 𝑢̅, 𝑣̅ , and 𝑧̅ in the x-, y-, and z-directions, respectively. The
fluctuating velocity component represents the random and chaotic instabilities that the
turbulent eddies contribute to the flow, and is represented by 𝑢′ , 𝑣 ′ , and 𝑤 ′ in the x-, y-,
and z-directions, respectively. The combination of mean (time-averaged) and fluctuating
velocity components provides the instantaneous flow field velocity, i.e. 𝑢 = 𝑢̅ + 𝑢′ .
Turbulent kinetic energy (k) is the specific energy (per unit mass) that turbulence
contributes to the total flow field energy, and is defined as (Wilcox, 1998):
𝑘=

1 ̅̅̅̅
(𝑢′ 2 + ̅̅̅̅
𝑣 ′ 2 + ̅̅̅̅̅
𝑤 ′ 2)
2

(5.3.1)

with units [m2/s2]. A common analogy to describe the mean and fluctuating velocity
components is to consider a probe that samples instantaneous velocity at a single point
in a turbulent flow. The resultant sampling trace would show erratic oscillations in velocity
against time. In this case, the mean velocity (𝑢̅, 𝑣̅ , and 𝑧̅) would be the time-averaged
value of the oscillations, and the fluctuating component is the difference between the
instantaneous and mean velocity across any given time integration (White, 1991).
The second modeling quantity used in the two-equation k-ω model is the specific
dissipation rate (ω), which defines the rate at which turbulent eddies dissipate, and is
defined as:
𝜔=

𝑘1/2
1/4

𝐶𝜇 𝑙
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(5.3.2)

with units [1/s], where 𝑙 is the turbulence length scale and 𝐶𝜇 is an empirical model
constant (typically set to 0.09 as default). Physically, the specific dissipation rate
represents the rate at which turbulent energy (per unit mass) is converted to internal flow
energy. The presence of turbulence in the flow field contributes to the diffusive behavior
of the fluid with an effect similar to kinematic viscosity ( 𝜈). To model this additional
turbulence diffusion, the 𝑘 and 𝜔 quantities are used to define a turbulent kinematic
viscosity:
𝜈𝑇 =

𝑘
𝜔

(5.3.3)

with units of [m2/s].
In the dispersion parameters, flow and turbulence quantities are calculated as
volume-averaged values within the region of the capsule and outlet capillary. With
turbulence kinetic energy as an example, the volume-averaged quantities within the
discretized computational domain are defined as:
𝑛

1
𝑘 = ∑ 𝑘𝑖 × 𝑉𝑖
𝑉𝑇
𝑖=1

(5.3.4)

where 𝑉𝑇 is the volume of the capsule and outlet capillary, 𝑘𝑖 is the turbulent kinetic
energy in Cell 𝑖, 𝑉𝑖 is the volume of Cell 𝑖, and the summation is across all cells in the
capsule and outlet capillary region.
Evaluation of preliminary dispersion parameters began by identifying the
correlation strength between experimental aerosolization metrics and the CFD-based
parameters presented by Longest and Farkas (2018), which were developed for lowvolume devices (10 mL of actuation air) operated at higher pressures. In that study, the
∗
MMAD correlated well with 𝑘𝑓𝑖𝑒𝑙𝑑
(ratio of volume-averaged k to inlet velocity squared)
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∗
∗
∗
giving an R2 value of 0.87, and with 𝑘𝑓𝑖𝑒𝑙𝑑
× 𝜔𝑓𝑖𝑒𝑙𝑑
(where 𝜔𝑓𝑖𝑒𝑙𝑑
is ω non-dimensionalized

with a characteristic time scale) giving an R2 value of 0.94. However, correlations of these
dispersion parameters to MMAD for Experimental Iteration 1 devices in this study were
not as strong, with R2 values less than 0.6. Other dispersion parameters from the previous
paper were also considered for MMAD correlation, but did not achieve an R 2 value greater
∗
than 0.8. For ED, the previous Longest and Farkas study (2018) showed that 𝑘𝑓𝑖𝑒𝑙𝑑
and
∗
∗
𝑘𝑓𝑖𝑒𝑙𝑑
× 𝜔𝑓𝑖𝑒𝑙𝑑
had a strong correlation with R2 values of 0.96 and 0.98 respectively, again

for different low-volume high pressure devices. Though similar to MMAD in the present
study, these dispersion parameters did not show the same correlation strength to ED with
Experimental Iteration 1, with R2 values again below 0.6. Therefore, new dispersion
parameters were required that were developed specifically for this pediatric air-jet DPI
and its operating conditions.
In parameter development for the pediatric air-jet DPI, approximately 40 dispersion
parameters were correlated with both MMAD and ED. These dispersion parameters used
various combinations of variables for flow quantities, turbulence characteristics, design
parameters, and operating conditions. The strongest correlations (R 2 > 0.8) from this new
batch of dispersion parameters for Experimental Iteration 1 were identified and the
variables used in their development were tested for accuracy and robustness in
Experimental Iteration 2. The strength of correlation for the new dispersion parameters
developed in the present study are given in the Results section. They are summarized
here to discuss the variables from which they are constructed and how they aim to
describe the device flow conditions.
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For MMAD, the dispersion parameters that gave to the strongest correlation with
Experimental Iterations 1 and 2 (R2 > 0.8) are summarized in Table 5.2. To improve
correlation agreement with the MMAD experimental data, a common theme in all of the
dispersion parameters was the inclusion of the actuation pressure, or Δ𝑃 , which
represents the input flow energy per unit volume (J/m 3). The dispersion parameter that
gave the strongest correlations with MMAD was:
𝑘𝑑 ∗
Δ𝑃𝑣𝑖

(5.3.5)

where 𝑑 ∗ is the ratio of outlet to inlet capillary diameters and 𝑣𝑖 is the inlet capillary
velocity. The physical basis for this dispersion parameter is the input turbulent kinetic
energy (𝑘 in J/kg) per input flow energy (Δ𝑃 in J/m3). Division by air density can be used
to eliminate the differing basis of the energy terms, but it is not necessary considering
that all cases are actuated with room air. Based on trial and error experimentation, the
correlation with MMAD was significantly improved by multiplying the dispersion parameter
by 𝑑 ∗ /𝑣𝑖 , similar to the result of Longest et al. (2018).
The Δ𝑃/𝑘 ∗ 𝑑 ∗ parameter in Table 5.2 is similar to Equation (5.3.5), but the ratio of
k to inlet velocity is non-dimensionalized as it was by Longest and Farkas (2018). The
numerators and denominators are also reversed as this gave a better R2 value. The
𝑘𝜇/𝑣𝑖 Δ𝑃𝑑𝑜 parameter again includes similar variables as the previous two parameters,
but uses inspiration from the Bejan number (Bhattacharjee & Grosshandler, 1988) (Be =
Δ𝑃𝐿2 /𝜇𝑣, which represents a non-dimensional pressure drop) to non-dimensionalize the
parameter. The 𝑘 ∗ 𝜔∗ 𝑑 ∗ parameter applies the ratio of outlet to inlet diameter to the
𝑘 ∗ × 𝜔 ∗ parameter from Longest and Farkas (2018), which had a positive influence on the
R2 value for all cases considered. Finally, the 𝑣𝑖′ 𝑑 ∗ /𝑣𝑖 Δ𝑃 parameter is again similar to the
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first dispersion parameter discussed here, but the ratio of k to inlet velocity is nondimensionalized by using the fluctuating velocity component (𝑣 ′ = √2/3𝑘) instead of k.
For ED, the dispersion parameters that gave to the strongest correlation with
Experimental Iteration 1 and 2 (R2 > 0.8) are summarized in Table 5.3. In contrast to
Longest and Farkas (2018), none of the dispersion parameters that utilize a combination
of flow and turbulence quantities (such as 𝑣𝑖 and 𝑘) had a strong correlation with ED in
the current study, which evaluates a pediatric air-jet DPI as opposed to a low actuation
volume DPI. All dispersion parameters for ED presented in this study use inlet volumetric
flow rate (𝑄𝑖 ) with a scale factor as a prediction of aerosolization performance. The scale
factors that were most effective were 𝑑 ∗ , 𝑘, and 𝑑𝑜 , which all improved the correlation
from an R2 value of 0.74 to over the threshold of 0.8 for a strong correlation in this study.
Evaluation and Comparison Criteria
This study uses the following metrics to quantify device performance
improvements, compare the match between experimental and CFD results, and
determine the accuracy of dispersion parameter predictions.
The Relative Δ metric compares the predicted aerosolization performance of
design configurations with Experimental Iteration 1, in order to quantify performance
improvements over the initial designs. It is defined as the difference between the CFDpredicted MMAD ( MMADCFD ) and the estimated MMAD ( MMADEst ), based on the
estimated MMAD from Experimental Iteration 1, relative to the estimated MMAD:
Relative Δ =

MMADCFD − MMADEst
× 100%
MMADEst

(5.3.6)

Specifically, estimated MMAD (MMADEst ) is determined from the experimental data by the
linear line of best fit between MMAD and ED for Experimental Iteration 1, which is
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hereafter referred to as Experimental Iteration 1 Best Fit. That is, if a device configuration
has a predicted MMAD and ED that lies on Experimental Iteration 1 Best Fit, its Relative
Δ is zero and there is no improvement over the initial devices. If the Relative Δ is negative,
its MMAD is smaller than would be predicted by ED alone, based on the results from
Experimental Iteration 1, and vice versa for a positive Relative Δ. Therefore, a negative
Relative Δ shows an improvement in aerosolization performance over Experimental
Iteration 1 for a given ED.
Relative difference (Rel. Diff.) is a standard statistical measure, but has different
definitions given the application. In this instance, the difference is between the CFDpredicted and experimental (Exp) MMAD or ED, relative to the experimental value:
Rel. Diff. =

MMADCFD − MMADExp
EDCFD − EDExp
× 100 or
× 100
MMADExp
EDExp

(5.3.7)

This provides a basis for comparison between the CFD-predicted and experimentally
determined aerosolization performance.
RMS error is also commonly used in statistical methods. It is the square-root of the
sum-square of the difference between CFD-predicted and experimental results divided
by the number of data points:
RMS Error
2

2

∑𝑛𝑖=1(MMADCFD,i − MMADExp,i )
∑𝑛𝑖=1(EDCFD,i − EDExp,i )
=√
or √
𝑛
𝑛

(5.3.8)

This quantifies the error between the CFD-predicted and experimentally observed
aerosolization performance across all cases considered by the study.
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5.4

Results

First and Second Experimental Iterations
Figure 5.3 plots the MMAD against ED for Cases 1-4 from Experimental Iteration
1, and the dashed line is Experimental Iteration 1 Best Fit (R 2 = 0.98). The numerical
annotations in the plot correspond to the markers for each device in Table 5.4. This plot
shows that for these cases, increasing ED also increases MMAD. This is undesirable for
DPI aerosolization performance, as we want both a small MMAD and large ED to deliver
as much drug to the target area of the lungs as possible. Therefore, for improvement in
aerosolization performance we intend to develop devices that perform below this dashed
line. That is, for a given ED, the MMAD should be smaller than estimated from the linear
fit performance of Experimental Iteration 1.
Experimental Iteration 2 intended to test the accuracy and robustness of initial
dispersion parameter development, identify additional dispersion parameters, and
evaluate what aspects of device design and operation would plot MMAD and ED above
or below the Experimental Iteration 1 Best Fit. Figure 5.4 adds the MMAD and ED data
from Experimental Iteration 2 (Table 5.4) to Figure 5.3. The numeral annotations in the
plot correspond to the markers for each device in Table 5.4. From this figure it is clear
that the majority of cases exhibited similar or worse performance than Experimental
Iteration 1, as they plot close to or above the dashed line. The exception is Case 3.00/2.08
(VI), which has an MMAD that is approximately 0.5 µm smaller than what is expected
from its ED and performance estimations from Experimental Iteration 1.
The experimental results from Experimental Iteration 1 and 2, with CFD predictions
of the flow and turbulence fields for each device, were used to develop the dispersion
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parameters for MMAD and ED that were summarized by Table 5.2 and Table 5.3,
respectively. The strength of MMAD and ED correlations that use these parameters is
presented in subsequent sections. In line with the study objective, CFD-predictions of
aerosolization performance use the dispersion parameters, and their associated
correlations, to drive optimization of the device design.
Flow and Turbulence Characteristics
Before

presenting details on

the

dispersion

parameters,

aerosolization

performance, and device optimization, it is important to understand the flow field behavior
and characteristics within the device. As mentioned in the Methods, the flow is highly
turbulent and moderately compressible, with inlet Reynolds numbers over 10,000 and
Mach numbers up to 0.27 for the cases in Experimental Iterations 1 and 2. Figure 5.5
shows contours of k and velocity streamlines within the capsule of Case 4. The highest
level of turbulence, represented with k, occurs in the shear layer where the inlet jet meets
the relatively quiescent flow in the capsule, which propagates through the outlet capillary.
There is also a large velocity gradient between the center of the inlet jet and the dose
chamber. Points A (center of the jet) and B (top of powder bed) in Figure 5.5 have velocity
magnitudes of 110.36 and 4.39 m/s respectively (or Mach numbers of 0.32 and 0.01) with
only 1.88 mm between them. The velocity streamlines in Figure 5.5 demonstrate very
dynamic and chaotic behavior in the secondary flow patterns within the capsule.
As mentioned previously, preliminary experimental work tested whether angled
inlets or a longer outlet capillary would improve aerosolization performance with
increased secondary flow or more exposure to highly turbulent flow, respectively. It is
reasonable to expect that increased secondary flow patterns would entrain more particles
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from the powder bed and provide an improvement in ED. However, the preliminary work
showed little aerosolization improvement for devices with an inlet capillary angled at 30°,
60°, and 90° relative to the long axis of the capsule. CFD-predictions of secondary flow,
with the stream-wise flow considered to be aligned with long axis, also did not correlate
well with ED. It is also reasonable to expect that exposing particle agglomerates to highly
turbulent flow for a longer duration would aid secondary breakup and reduce MMAD.
However, extending the length of the outlet capillary from 18 mm to 30 mm and 60 mm
also showed negligible improvement in aerosolization performance.
This raises questions over the mechanisms within the device that are responsible
for the most effective forms of powder aerosolization. The large velocity gradient between
the inlet jet and remainder of the capsule region creates the correct amount of secondary
flow in order to maintain a high ED and not fluidize the powder bed too quickly. Also, the
maximum k to which particle agglomerates are exposed may drive secondary breakup
and determine particle size, as opposed to time of exposure. That is, if agglomerates pass
through the region of highest energy eddies and break up as small as that energy permits,
additional exposure time to smaller energy eddies may not reduce the particle size further.
This observation would explain why a longer outlet capillary length did not further reduce
MMAD.
Particle Size and Emitted Dose Dispersion Parameters
Figure 5.6 plots MMAD as a function of the dispersion parameter from Table 5.2
with the strongest correlation. For the 𝑘𝑑 ∗ /𝑣𝑖 Δ𝑃 dispersion parameter, the R2 value is
0.96 and standard error (SE) is 0.06 µm when correlated with MMAD. The dashed line on
the plot is the linear line of best fit between cases considered, and represents the
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correlation used to predict MMAD from the dispersion parameter. Considering the 95%
interval on a normal distribution, we can assume the correlation is accurate between plus
or minus double the SE, which is 0.12 µm and represented by the solid lines on Figure
5.6. For context, the coefficient of variation (CoV) is defined as the ratio of SE to the mean
MMAD, which in this case is 3.3%.
The high R2 value, small SE, and small CoV demonstrates a very strong correlation
between MMAD and the 𝑘𝑑 ∗ /𝑣𝑖 Δ𝑃 dispersion parameter. Beyond the statistical
measures, the plot of data points for each case relative to the linear correlation line also
suggests the 𝑘𝑑 ∗ /𝑣𝑖 Δ𝑃 dispersion parameter will accurately predict MMAD from CFD
results. The correlation closely matches the full range of data points, from devices with a
relatively small (1.6 µm) to larger (2.4 µm) MMAD, and also captures the effect of
operating Case 4 with a lower pressure drop with the Half Q case. Furthermore, the
correlation provides an accurate prediction for Case 1.32/2.90, with its MMAD in the
middle ground between the 1.6-1.8 µm cases and the 2.4 µm Half Q case, which further
demonstrates the correlation is accurate across a range of dispersion parameters and
MMAD values. Finally, CFD results for Case 1.32/2.39 and 2.08/2.69 both show these
devices had very similar dispersion parameter values, and the correlation is able to
accurately predict they have the same MMAD. That is, if these cases had the same
dispersion parameter value, but very different experimentally determined MMADs, the
correlation would clearly be inaccurate.
Similar to the MMAD dispersion parameters, Figure 5.7 plots ED as a function of
the dispersion parameter from Table 5.3 with the strongest correlation. As before, the
dashed line is the linear correlation (or line of best fit) and the solid lines represent plus
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or minus double the SE (or the 95% interval on a normal distribution). For the 𝑄𝑑 ∗
dispersion parameter, the R2 value is 0.86, the SE is 3.0%, and CoV is 3.8% when
correlated with ED. As mentioned previously, out of all the dispersion parameters
considered, the device ED consistently showed the best correlations with parameters that
used the flow rate (𝑄) through the device. Correlating ED with 𝑄 alone showed an R2
value of 0.74, and scaling by the variables summarized in Table 5.3 improved the
correlations.
Influence of Design Factors on Dispersion
To be predictive of device aerosolization performance, it is necessary to
understand how the CFD-predicted flow and turbulence variables in the MMAD and ED
dispersion parameters behave in response to design factor changes. These variables are
volume-averaged turbulent kinetic energy (𝑘) and inlet capillary velocity (𝑣𝑖 ) in the MMAD
dispersion parameter, and inlet volumetric flow rate (𝑄𝑖 ) in the ED dispersion parameter,
with 𝑣𝑖 directly calculated from 𝑄𝑖 . Figure 5.8 is a 3D surface plot of the CFD-predicted k
vs. inlet and outlet capillary diameters on the independent axes; and Figure 5.9 shows
CFD-predicted Q vs. inlet and outlet capillary diameters. These data points are the result
of running an array of 144 CFD models for every possible combination of 12 different inlet
and outlet capillary diameters ranging from 0.41 to 3.00 mm. An effort was made to
combine the inlet and outlet diameters into a single function that could describe the device
behavior, with respect to the dispersion parameter variables, in a standard x-y plot.
However, the clearest representation of how the flow and turbulence quantities vary in
response to design factor changes is with a 3D surface plot, as both 𝑘 and 𝑄𝑖 are
dependent on 𝑑𝑖 and 𝑑𝑜 by different relations. To estimate variable values in between the
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CFD-predicted data points, one could define a high-order bivariate polynomial to establish
a surface of best fit. However, in this case, the large number of CFD simulations was
sufficient to identify design factor configurations that were possible candidates for an
optimized device.
Considering both Figure 5.8 and Figure 5.9 together, there is a region where 𝑑𝑖
and 𝑑𝑜 are greater than 2.5 mm that shows k decreases (reducing MMAD) while Q
continues to increase (improving ED). This region of high Q and decreasing k is labeled
with ✱ in Figure 8 and Figure 9. Combining this with the MMAD and ED dispersion
parameters (𝑘𝑑 ∗ /Δ𝑃𝑣𝑖 and 𝑄𝑖 𝑑 ∗ respectively), Figure 5.8 and Figure 5.9 suggest that
device configurations in this region would give a small MMAD and high ED, which is the
desirable aerosolization performance. For a constant Δ𝑃 and 𝑑 ∗ , reducing 𝑘 and
increasing 𝑣𝑖 would give a smaller MMAD dispersion parameter and predicts a smaller
particle size. Likewise, for a constant 𝑑 ∗ , increasing 𝑄𝑖 would give a larger ED dispersion
parameter and predict less device losses. However, the predicted aerosolization
performance from design factors is not quite as simple as what has been described here,
as changing the inlet and outlet capillary diameters also changes the 𝑑 ∗ variable, which
has an effect on both the MMAD and ED dispersion parameters. Furthermore, the Q
through the devices in the region where 𝑑𝑖 and 𝑑𝑜 is greater than 2.5 mm is over 20 LPM,
which for an inhalation volume of 750 mL gives an actuation time of less than 2 seconds.
Therefore, the Q for these devices might be too high for the target age of a 5-6-year-old
subject. That said, it is valuable insight for developing devices that may target older
patients that inhale at higher flow rates. One final consideration regarding actuating DPIs
with higher flow rates is the resultant impaction parameter (typically given as 𝑑𝑎2 𝑄, where
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𝑑𝑎 is aerodynamic particle diameter) may be higher, which would suggest the possibility
of increased extrathoracic losses (Golshahi, Noga, Thompson, & Finlay, 2011; Javaheri
et al., 2013; Storey-Bishoff et al., 2008; Tavernini et al., 2018).
Aerosolization Performance and Device Optimization
As described above, possible device design configurations from 12 inlet and outlet
capillary diameters were considered, ranging from 0.41 to 3.00 mm, which required the
evaluation of 144 CFD models. The majority of these models, especially those with
relatively small capillary diameters, showed little improvement over Case 4, which has
exhibited the best aerosolization performance from Experimental Iteration 1 and 2. Table
5.5 summarizes the CFD-predicted aerosolization performance, from flow and turbulence
quantities and dispersion parameter correlations, of 25 cases that had inlet and outlet
diameters greater than 1.83 mm (as this is the inlet capillary diameter for Case 4). The
naming convention for the markers, which are used in subsequent plots to identify each
case, uses the first letter to identify the inlet capillary diameter and the second letter for
the outlet, where A is 1.83 mm, B is 2.08 mm, C is 2.39 mm, D is 2.69 mm, and E is 3.00
mm. The cases with markers highlighted in light grey are those where CFD-based
predictions suggest that both the MMAD and ED will be better than the aerosolization
performance of Case 4, and makers highlighted in dark grey are predicted to be worse
than Case 4. Here, better means the CFD-predicted MMAD and ED plot below
Experimental Iteration 1 Best Fit. What is most interesting from this data set is the CFDbased predictions show that ED can increase as MMAD decreases (as Figure 5.8 and
Figure 5.9 suggested), which was not apparent from Experimental Iteration 1. For
example, for Case AD and CD, the inlet diameter changes from 1.83 mm to 2.39 mm and
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outlet diameter is constant at 2.69 mm, with the CFD-predicted MMAD improving from
1.92 to 1.75 µm and ED improving from 87.7% to 92.7%. Conversely, in Experimental
Iteration 1, Case 3 and 4 had the same outlet diameter, but inlet diameters of 2.39 mm
and 1.83 mm respectively, and they showed little difference in aerosolization, with Case
4 having a marginally better ED.
Figure 5.10 adds the MMAD and ED data for the cases that CFD-based predictions
suggest are better than Case 4 (i.e. the light grey cases in Table 5.5) to Figure 5.4. The
additional annotations in the plot correspond to the markers for each case in Table 5.5.
As mentioned previously, cases that plot below the dashed line exhibit an improvement
in aerosolization performance compared to Experimental Iteration 1. The Evaluation and
Comparison Criteria section defined the Relative Δ metric that compares the estimated
MMAD (for a given ED) with the performance of devices from Experimental Iteration 1.
This provides a quantitative value to measure the difference between the CFD-based
predictions and the dashed line in Figure 5.10. Table 5.6 summarizes the Relative Δ
metric for each of the cases added to Figure 5.10, with a negative value indicating the
performance is an improvement over Experimental Iteration 1 and the value quantifying
the percentage improvement in aerosolization performance. From all the design
configurations considered here, Case 2.69/2.69 and 3.00/2.69 (DD and ED) are selected
for device optimization evaluation as they are predicted to have a smaller MMAD than
Case 4, a negative Relative Δ, and an ED greater than 90%. These two cases are
highlighted with the dotted ellipse in Figure 5.10.
Figure 5.10 also provides a comparison between the CFD-based predictions and
experimentally measured MMAD and ED for Cases 3 and 4. These data points lie within
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the SE of the MMAD and ED correlation and the standard deviation (SD) of the
experimental data. The accuracy of CFD-based predictions, with statistical observations,
is discussed in greater detail in the following section.
Experimental Validation
Table 5.7 summarizes the comparison between CFD-based predictions and
experimentally measured MMAD and ED for all experimentally tested devices. The
comparison to Experimental Iteration 1 and 2 serves as the typical validation of CFD
methods and the dispersion parameter correlations with experimental data. The
comparison with the two optimized devices provides an a priori validation of the
optimization process. That is, the CFD-based predictions of the MMAD and ED for those
two design configurations were established before validating their accuracy with
experimental testing, and no adjustments to either the CFD models or dispersion
parameter correlations were made after obtaining the experimental data. The relative
difference (Rel. Diff.) in Table 5.7 uses the standard definition for observed and predicted
data. The average Rel. Diff. between CFD-based predictions and experimental
measurements for MMAD is 2.9%, and the range of absolute error is from -0.07 to 0.13
µm (Case 1 and Case 2.69/2.69 respectively). Similarly, for ED the average Rel. Diff. is
3.5% and the range of absolute error is from -7.9% to 5.6% (Case 3.00/2.08 and 1.32/2.90
respectively). The RMS Error for MMAD and ED is 0.06 µm and 3.4% respectively, which
compares well with the SE from each of the MMAD and ED dispersion parameter
correlations. Based on these statistical measures, the CFD flow and turbulence fields with
𝑘𝑑 ∗ /Δ𝑃𝑣𝑖 and 𝑄𝑑 ∗ dispersion parameters provide a very good prediction of device
aerosolization performance, verified with a priori validation.
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Finally, the design configurations that were selected as candidates for optimized
devices provided improved aerosolization performance compared to Case 4. The MMAD
decreased from 1.69 µm to 1.55 µm and 1.59 µm, which is an absolute difference of 0.14
µm and 0.10 µm, for Cases 2.69/2.69 and 2.69/3.00, respectively. Similarly, the ED
increased from 86.0% to 90.4% and 92.3%, which is an absolute difference of 4.4% and
6.3%. This device optimization would not be possible without the insight into the
relationship between aerosolization performance and design factors that was possible
with a concurrent CFD and experimental approach.
5.5

Discussion
This study meets the objective by establishing dispersion parameter correlations

(𝑘𝑑 ∗ /Δ𝑃𝑣𝑖 and 𝑄𝑑 ∗ ) that accurately predict the aerosolization performance (MMAD and
ED) of a pediatric air-jet DPI. Using these dispersion parameters, a full sweep of 144 CFD
models, covering every configuration of 12 different inlet and outlet diameter capillaries,
was evaluated for optimized predicted performance. Two candidate optimized design
configurations were validated a priori, and found to have improved aerosolization
performance compared to Case 4. Throughout the study, valuable insights into the flow
and turbulence conditions within the capsule were obtained, and relationships between
CFD flow and turbulence fields and design factors were established.
The flow within the capsule during actuation of the DPI is surprisingly complex
given the relatively simple geometry. Inlet Mach and Reynolds numbers suggest
moderately compressible and highly turbulent flow, especially for cases with larger
capillary diameters and high flow rates, and high frequency flow oscillations require a
transient solution strategy. Analysis of the CFD velocity field shows a large velocity
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gradient between the center of the inlet jet and quiescent capsule (from 110.4 m/s to 4.4
m/s across a distance of 1.88 mm). The velocity gradient has an equally large negative
pressure gradient that generates the correct amount of secondary flow to aerosolize the
powder bed at an adequate rate. This premise is supported by the fact that ED correlated
well with device flow rate, meaning higher flow and velocities through the device lead to
greater entrainment of particles from the powder bed. Furthermore, Experimental Iteration
1 showed that MMAD increased with ED, which suggests that a larger negative pressure
gradient is capable of lifting the larger particles from the powder bed, hence the
simultaneous increase in both aerosolization performance metrics for Experimental
Iteration 1.
Beyond meeting the primary objective, this study also demonstrated how the flow
and turbulence fields, which are used in the definition of the dispersion parameters,
behave in response to changes in design factors. 3D surface plots show that k and Q vary
relative to inlet and outlet capillary diameters as independent variables. Results showed
that capillary diameters larger than approximately 2.5 mm lead to a relative decrease in
k and increase in Q, which according to the dispersion parameters gives the desired
decrease in MMAD and increase in ED. However, given the administration of the air-jet
DPI to children, there is a relatively low upper limit on the available flow rate through the
device to maintain low extrathoracic depositional losses, with the target being
approximately 15 LPM for a 5-6-year-old subject.
The dispersion parameter correlations established in previous work by our group
(Longest & Farkas, 2018; Longest et al., 2019) did not correlate well with Experimental
Iteration 1 in the present study, and were further weakened when applied to Experimental

207

Iteration 2. This is because of differences in the device and operation, including a larger
air volume, higher flow rates, and larger capillary sizes in the current study. As such, new
dispersion parameters were established that gave strong correlations, for both MMAD
and ED, when applied to the current data set of ten experimental runs (see Table 5.4).
What is consistent between the dispersion parameters used in the present study and
previous work is that the MMAD is at least partially dependent on the ratio between
volume-averaged k and inlet flow velocity. As 𝑘 is specific turbulence kinetic energy and
velocity is akin to specific flow kinetic energy, this ratio can be thought of as the ratio of
turbulence to flow energy. That is, when aiming for a small particle size, one should strive
to minimize this ratio and not necessarily minimize k alone. The addition of pressure drop
across the device to the MMAD dispersion parameter accounts for the energy used to
actuate the air-jet DPI.
This study also demonstrated the strength of the CFD methods and dispersion
parameters used in predictions of aerosolization performance with a priori validation.
Typically, CFD models are validated against experimental data after the devices have
been tested, and the CFD model parameters are adjusted until numerical and
experimental results match. In a priori validation, the devices are tested after the CFD
models are run, and results between the numerical and experimental data are compared
and reported with no changes to the CFD model setup. The results showed that the CFD
models and aerosolization performance predictions for the two optimized devices were
very close to the experimentally tested MMAD and ED, with small relative, absolute, and
RMS errors. This demonstrates that the CFD methods for air-jet DPIs established by our
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previous work (Longest & Farkas, 2018; Longest et al., 2019) and the newly defined
dispersion parameters are accurate predictors of device performance.
The two candidate optimized designs decreased the experimentally measured
MMAD by 0.10 µm and 0.14 µm (relative difference of 5.9% to 8.3%) and increased ED
by 4.4% and 6.3% (relative difference of 5.1% to 7.4%) compared to Case 4. Therefore,
these two devices demonstrated improved aerosolization performance compared to
previous air-jet DPI designs. However, there is more to consider when administering
pharmaceutical aerosols to children with air-jet DPIs than only the device aerosolization
performance. As mentioned previously, the flow rate through the optimized devices is
approximately 25 LPM, which, for a 750 mL inhalation volume, gives an actuation time of
less than 2 seconds. For the target age of a 5-6-year-old child, the inhalation flow rate
should be about 15 LPM and an actuation time of 3 seconds, meaning the optimized
devices may increase extrathoracic losses for the age of patients selected as the focus
of this study. That said, these devices may be suitable for older children with slightly larger
extrathoracic airways. The impaction parameter (𝑑𝑎2 𝑄) is often used when evaluating
extrathoracic aerosol deposition (Golshahi et al., 2011; Javaheri et al., 2013; StoreyBishoff et al., 2008; Tavernini et al., 2018). There is a large amount of inter-patient
variability when using this parameter, but the general trend is that particle deposition in
the nasal (or oral) passage typically increases as the impaction parameter increases. This
parameter shows that if the particle size (𝑑𝑎 ) decreases, the extrathoracic losses may be
the same or even increase if the flow rate (𝑄) increases. Comparing Case 2.69/2.69 and
3.00/2.69 to Case 4, the impaction parameter increases to 59.6 µm2-LPM and 68.3 µm2LPM from 38.0 µm2-LPM, which indicates extrathoracic losses will be higher for the
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optimized devices. However, the deposition vs. impaction parameter plots vary
considerably for different age groups (and even from patient to patient within age groups)
and typically have a non-linear S-shape profile, so the actual increase in extrathoracic
losses may be negligible for the optimized devices.
On the experimental side, limitations in the present study are consistent with those
reported by Farkas et al. (2019). One additional limitation is the variability in actuating the
device with a ventilation bag, which is the intended actuation method. Experiments used
compressed air and a solenoid valve to actuate the devices with a pressure drop of 6
kPa. This provided consistency from device to device and provided a clear definition of
boundary conditions for CFD models. However, variability in the operation of a ventilation
bag to actuate the device between caregivers could influence aerosolization performance.
Results from the Half Q case showed that actuating Case 4 with a pressure drop of 1.5
kPa gave an MMAD of 2.46 µm and ED of 72.0%, which was much worse than actuating
Case 4 with 6 kPa. This is perhaps at the extreme end of a low pressure drop, but
demonstrates the variability in device performance relative to actuation pressure. As
such, this should be taken into consideration when establishing caregiver operation
guidelines for actuation of the device.
Another limitation is the large number of design options that are available for the
air-jet DPI approach. Despite the large number of inlet and outlet capillary configurations
that were considered, many of the design factors available for air-jet DPIs have not been
evaluated. Preliminary work showed that angled inlet capillaries relative to the outlet and
longer outlet capillaries did not improve aerosolization performance. However, many
more aspects of the device design can be explored such as different size and shape
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aerosolization chambers (instead of a size 0 capsule), capillary piercing locations and
orientation (instead of along the long axis of the capsule), and actuating the device with
several smaller volumes of air (instead of 750 mL in one actuation). The negative pressure
gradient between the inlet jet and powder bed and its effect on secondary velocities within
the capsule has been discussed previously. Changing the aerosolization chamber (or
capsule) shape and size could leverage this phenomenon to improve ED, and would also
need to be considered when loading the device with larger or smaller drug masses.
Future work on improving the aerosolization performance of air-jet DPIs should
focus on expanding the exploration of the many available design factors and their
influence on MMAD and ED. Future iterations of air-jet DPIs design can use the physical
insight and dispersion parameters identified in the present study to drive the design and
optimize performance further. It would also be interesting to test how robust the newly
defined MMAD and ED dispersion parameters are when applied to the changes in design
that were discussed here. The secondary breakup mechanism that reduces the particle
size, after they are entrained in the flow, is also little understood at this stage. The MMAD
dispersion parameter shows that the ratio of k to inlet velocity should be minimized to
reduce particle size, but the exact characteristics of the flow and turbulence field that are
responsible for secondary breakup are unclear. The original concept used in the
development of air-jet DPIs by our group aimed to use highly turbulent eddies to break
up agglomerates, but this expectation has consistently been shown to be incorrect for the
air-jet DPIs. High-resolution, high-speed imaging of the particles within the device may
provide some experimental insight into particle break up within the flow. Similarly, utilizing
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DEM in numerical models could provide CFD insight into break up mechanisms for air-jet
DPIs, but such a model would be difficult to validate and very computationally expensive.
In conclusion, newly developed dispersion parameters with CFD predictions of flow
and turbulence quantities were capable of accurately predicting air-jet DPI aerosol
performance in terms of MMAD and ED with a priori validation. Greater insight in to the
flow and turbulence characteristics within the capsule was obtained, and the effect of
design factors on these quantities was identified. Optimized devices reduced the MMAD
by approximately 0.1 µm and increased ED by approximately 5%. However, these
devices may be better suited to children older than 5-6 years old due to increased device
flow rates.
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5.6

Figures

Figure 5.1:

Block diagram of device development and optimization process.
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a

Figure 5.2:

Overview of device geometry showing (a) CAD rendering with inlet and

outlet connections, stainless steel capillaries, size 0 capsule, and rubber O-ring, and (b)
internal flow pathway used for the CFD domain.
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Figure 5.3:

Plot of particle mass-median aerodynamic diameter (MMAD) against

emitted dose (ED) for Experimental Iteration 1 (Cases 1-4). Annotations correspond with
the Markers in Table 5.4. A small MMAD and large ED is desirable for aerosolization
performance. The dashed line is Experimental Iteration 1 Best Fit (R 2 = 0.98), where
particle size generally worsens with an improvement in emitted dose.
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Figure 5.4:

Addition of Experimental Iteration 2 to the MMAD vs. ED plot shown in

Figure 5.3. Annotations correspond with the Markers in Table 5.4. Generally, these
additional devices perform poorly compared to Cases 1-4, except Case 3.00/2.08 (VI),
which has better MMAD for a given ED.
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Figure 5.5:

Overlay plot on the mid-plane slice of turbulent kinetic energy field and flow

streamlines between the inlet and outlet capillaries in the capsule. Velocity magnitudes
at Point A and B are 110.36 m/s and 4.39 m/s, respectively.
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Figure 5.6:

Particle mass-median aerodynamic diameter (MMAD) vs. dispersion

parameter kd*/viΔP. The dashed line is the linear best fit and the solid lines show +/- 0.12
µm, which is double the standard error (or the 95% interval on a normal distribution). Note
that the Half Q (Δ), 1.32/2.39 (◊), 1.60/2.39 (∇), 2.08/2.69 (+), 1.32/2.90 (×), and 3.00/2.08
(✱) cases are from Experimental Iteration 2 (□ in Figure 5.4).
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Figure 5.7:

Emitted dose (ED) vs. dispersion parameter Qd*. The dashed line is the

linear best fit and the solid lines show +/- 6.17%, which is double the standard error (or
the 95% interval on a normal distribution). Note that the Half Q (Δ), 1.32/2.39 (◊), 1.60/2.39
(∇), 2.08/2.69 (+), 1.32/2.90 (×), and 3.00/2.08 (✱) cases are from Experimental Iteration
2 (□ in Figure 5.4).
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Figure 5.8:

3D plot of CFD-predicted data points for turbulent kinetic energy (k) vs. inlet

and outlet capillary diameter (di and do respectively). The MMAD dispersion parameter
(shown in Figure 5.6) suggests smaller particles sizes are produced when k is small and
inlet velocity (vi) is high.
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Figure 5.9:

3D plot of CFD-predicted data points for flow rate (Q) vs. inlet and outlet

capillary diameter (di and do respectively). The ED dispersion parameter (shown in Figure
5.7) suggests emitted dose is improved when the flow rate is increased, but there is a
limit given the administration of the devices to children.
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Figure 5.10: Addition of CFD predicted aerosolization performance to the MMAD vs. ED
plot shown in Figure 5.4. Annotations correspond with the Markers in Table 5.4 and Table
5.6. The devices annotated with ED and DD are selected as the optimized devices as
they have an ED prediction greater than 90%, better predicted MMAD than Case 4, and
show improved device performance compared to Experimental Iteration 1.
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5.7

Tables

Table 5.1:

Summary of experimentally tested device configurations and operating

conditions.
Name

di
do
[mm] [mm]
Experimental Iteration 1

Bypass

ΔP
[kPa]

Q
[LPM]

a

1.52

1.52

Yes

6.0

11.4

Case 2a

1.40

1.80

Yes

6.0

11.6

Case 3a

2.39

2.39

No

6.0

17.4

Case 4a

1.83

2.39

No

6.0

13.3

Case 1

Notes

Bypass flow with same
diameter inlet and outlet
capillaries
Bypass flow with smaller
inlet than outlet capillary
No bypass flow with same
diameter inlet and outlet
capillaries
No bypass flow with
smaller inlet than outlet
capillary, but same outlet
as Case 3 (best performing
case of Experimental
Iteration 1)

Experimental Iteration 2
Half Q

1.83

2.39

No

1.5

6.7

1.32/2.39

1.32

2.39

No

6.0

5.9

1.60/2.39

1.60

2.39

No

6.0

9.9

2.08/2.69

2.08

2.69

No

6.0

16.9

1.32/2.90

1.32

2.90

No

6.0

6.8

3.00/2.08

3.00

2.08

No

6.0

15.5

a: Results presented by Farkas et al. (2019)
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Pressure drop selected to
give 50% of Case 4 flow
rate
Inlet diameter selected to
give 50% of Case 4 flow
rate
Inlet diameter selected to
give 75% of Case 4 flow
rate
Similar outlet to inlet
diameter ratio as Case 4
Same average capillary
diameter as Case 4
Explores the effect of larger
inlet compared to the outlet
diameter

Table 5.2:

Summary of evaluated MMAD correlation parameters ranked in order of

preference based on R2 value.
Parameter
𝑘𝑑 ∗
Δ𝑃𝑣𝑖

Units
m
[
]
Pa-s

Variables
𝑑𝑜
𝑑∗ =
𝑑𝑖

Definitions
𝑘:
Turbulent kinetic energy
∗
𝑑 :
Non-dimensional length scale
𝑣𝑖 :
Inlet capillary velocity
Δ𝑃: Pressure drop across device
𝑘∗:
Non-dimensional ka

Δ𝑃
𝑘
[Pa]
𝑘∗ = 2
∗
∗
𝑘 𝑑
𝑣𝑖
𝑘𝜇
[−]
𝜇:
Fluid velocity
𝑣𝑖 Δ𝑃𝑑𝑜
[−]
𝑘 ∗ 𝜔∗ 𝑑 ∗
𝜔∗ :
Non-dimensional ωa
∗
1
𝑣′𝑑
𝑣′:
Fluctuating velocity due to
[ ]
𝑣′ = √2⁄3 𝑘
turbulence
Pa
𝑣𝑖 Δ𝑃
a: Non-dimensional turbulence parameters presented by Longest and Farkas
(2018)
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Table 5.3:

Summary of evaluated ED correlation parameters ranked in order of

preference based on R2 value.
Parameter
𝑄𝑖 𝑑 ∗

Units
[LPM]

𝑄𝑖 𝑘

m5
[ 3]
s
𝑚4
[ ]
𝑠

𝑄𝑖 𝑑𝑜

Variables
𝑑𝑜
𝑑∗ =
𝑑𝑖

Definitions
𝑄𝑖 :
Volumetric flow rate through the inlet
capillary
𝑘:
Turbulent kinetic energy
𝑑𝑜 :

Outlet capillary diameter

Note: The R2 value for correlation between emitted dose and 𝑄𝑖 alone is 0.7427,
hence scaling by 𝑑 ∗ , 𝑘, or 𝑑𝑜 improves the strength of correlation to R2>0.8
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Table 5.4:

Summary of aerosolization performance for Experimental Iterations 1 and

2. Experimental values are given as means with standard deviations shown in parenthesis
[n=3].
Name

di
do
MMAD
ED
[mm] [mm]
[µm]
[%]
Experimental Iteration 1
Case 1a
1.52
1.52
1.60 (0.16) 66.3 (3.1)
a
Case 2
1.40
1.80
1.63 (0.06) 70.2 (1.7)
Case 3a
2.39
2.39
1.70 (0.18) 85.1 (8.8)
Case 4a
1.83
2.39
1.69 (0.01) 86.0 (1.4)
Experimental Iteration 2
Half Q
1.83
2.39
2.46 (0.21) 72.0 (5.6)
1.32/2.39
1.32
2.39
1.85 (0.10) 77.9 (1.8)
1.60/2.39
1.60
2.39
1.71 (0.03) 83.5 (1.5)
2.08/2.69
2.08
2.69
1.84 (0.09) 88.7 (1.2)
1.32/2.90
1.32
2.90
2.11 (0.09) 73.3 (1.2)
3.00/2.08
3.00
2.08
1.61 (0.08) 80.7 (5.9)
a: Results presented by Farkas et al. (2019)

226

Marker

1
2
3
4
I
II
III
IV
V
VI

Table 5.5:

Summary of cases with inlet and outlet diameters greater than 1.83 mm,

which are in the range of design configurations that are similar to Case 4. Cases shown
are a sub-set of a full array of 144 CFD runs (all possible configurations of 12 different
capillary sizes).
di
[mm]
1.83

do
CFD MMAD
CFD ED
Marker
[mm]
[µm]
[%]
1.83
1.58
72.8
AA
2.08
1.65
77.6
AB
2.39
1.77
83.4
4a
2.69
1.92
87.7
AD
3.00
2.10
91.5
AE
2.08
1.83
1.55
71.9
BA
2.08
1.61
77.5
BB
2.39
1.71
84.9
BC
2.69
1.82
91.0
BD
3.00
2.03
96.5
BE
2.39
1.83
1.55
70.5
CA
2.08
1.58
76.1
CB
2.39
1.64
84.6
3b
2.69
1.75
92.7
CD
d
3.00
1.88
100.0
CE
2.69
1.83
1.56
69.2
DA
2.08
1.59
74.4
DB
2.39
1.62
82.9
DC
2.69
1.68
92.0
DDc
d
3.00
1.79
100.0
DE
3.00
1.83
1.58
68.1
EA
2.08
1.62
72.7
EB
2.39
1.63
80.8
EC
2.69
1.66
89.9
EDc
d
3.00
1.72
100.0
EE
Markers highlighted with light grey have CFD-predicted MMAD and ED
that plot below Experimental Iteration 1 Best Fit, and vice versa for the
dark grey markers.
a:
b:
c:
d:

Same inlet and outlet configuration as Case 4
Same inlet and outlet configuration as Case 3
Candidate configurations selected for optimized design
experimental evaluation
Cases where the correlations predicted greater than 100% ED
were capped at 100%
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Table 5.6:

Summary of CFD-predicted ED and MMAD compared to the estimated

MMAD based on Experimental Iteration 1 Best Fit. Cases shown are those that the CFD
predicts will perform better than Case 4 based on the data in Table 5.5.
do
CFD ED CFD MMAD Estimated MMAD Relative Δ Markers
[mm]
[%]
[µm]
[µm]
[%]
2.39
82.9
1.62
1.68
-3.89
DD
2.69
92.0
1.68
1.73
-2.72a
DE
3.00
2.39
80.8
1.63
1.67
-2.65
EC
2.69
89.9
1.66
1.72
-3.36a
ED
3.00
100.0
1.72
1.76
-2.51
EE
Relative Δ is the relative difference between the CFD-predicted MMAD and the
Estimated MMAD based on Experimental Iteration 1 Best Fit.
di
[mm]
2.69

a:

Candidate configurations selected for optimized design experimental
evaluation
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Table 5.7:

Summary of relative difference (RD) between the CFD-predicted (CFD) and

experimental (Exp.) MMAD and ED. The data shows how accurately the CFD and
dispersion parameter correlations predicted experimental aerosolization performance.
Experimental values are given as means with standard deviations shown in parenthesis
[n=3].

Name

di
do
[mm] [mm]
Experimental Iteration 1
Case 1
1.52
1.52
Case 2
1.40
1.80
Case 3
2.39
2.39
Case 4
1.83
2.39
Experimental Iteration 2
Half Q
1.83
2.39
1.32/2.39
1.32
2.39
1.60/2.39
1.60
2.39
2.08/2.69
2.08
2.69
1.32/2.90
1.32
2.90
3.00/2.08
3.00
2.08
Optimized Devices
2.69/2.69
2.69
2.69
3.00/2.69
3.00
2.69

CFD
[µm]

MMAD
Exp.
[µm]

RD
[%]

CFD
[%]

ED
Exp.
[%]

RD
[%]

Marker

1.53
1.63
1.65
1.77

1.60 (0.16)
1.63 (0.06)
1.70 (0.18)
1.69 (0.01)

4.2
0.2
2.9
4.8

67.9
71.3
84.3
83.1

66.3 (3.1)
70.2 (1.7)
85.1 (8.8)
86.0 (1.4)

2.3
1.6
0.9
3.4

1
2
3
4

2.44
1.83
1.82
1.84
2.08
1.62

2.46 (0.21)
1.85 (0.10)
1.71 (0.03)
1.84 (0.09)
2.11 (0.09)
1.61 (0.08)

1.0
0.9
6.5
0.0
1.6
0.5

70.5
75.7
80.3
90.9
78.9
72.8

72.0 (5.6)
77.9 (1.8)
83.5 (1.5)
88.7 (1.2)
73.3 (1.2)
80.7 (5.9)

2.1
2.9
3.8
2.5
7.7
9.8

I
II
III
IV
V
VI

1.68
1.66

1.55 (0.13)
1.59 (0.05)

8.4
4.4

92.0
89.9

90.4 (2.8)
92.3 (0.2)

1.8
2.6

DD
ED
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Chapter 6: Develop Dry Powder Inhaler Patient Interfaces for
Improved Aerosol Delivery to Children
6.1

Objective
The objective of this study was to explore different internal flow pathways for a

pediatric air-jet DPI interface that minimize device and ET depositional loss using
validated CFD methods. The design space was constrained to an internal flow pathway
less than 75 mm in length to provide a compact and portable device, and preference was
given to design concepts that are easy to manufacture and construct. The performance
target was total CFD-predicted losses in the flow pathway and ET region of less than 15%
for a pediatric subject. Combining this target with approximately 10% device loss from
Farkas et al. (2019) results in an expected lung dose of greater than approximately 75%
of loaded dose. Validated CFD models were used to evaluate several design iterations
that aimed to screen candidate design concepts until the performance targets were met.
A leading design concept explored in this study was the use of a 3D rod array, previously
designed to maximize aerosol deaggregation (Behara, Longest, et al., 2014a, 2014b;
Longest et al., 2015; Longest, Son, et al., 2013), to attenuate the high-velocity air jet that
leaves the DPI and thereby reduce depositional losses in the interface and ET regions.
6.2

Introduction
Delivery of pharmaceutical aerosols to the lungs typically requires a nebulizer,

metered dose inhaler (MDI), or dry powder inhaler (DPI). For the treatment of lung
infections in pediatric patients with cystic fibrosis (CF), tobramycin inhaled powder via a
DPI can be administered to potentially eradicate bacterial colonies. DPIs provide several
advantages, compared with using tobramycin inhaled solution in a nebulizer, as higher
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doses of the antibiotic can be delivered faster and the devices are easier to load and
clean (Somayaji & Parkins, 2015). However, DPIs are associated with several
disadvantages including poor lung delivery efficiencies, especially in children, as well as
requiring inhalation maneuvers that may be difficult for children to achieve. For DPI use
in children with oral inhalation, Below et al. (2013) reported 5% and 22% of nominal dose
was deposited on a tracheal filter in in vitro experiments when testing the Novolizer and
Easyhaler, respectively. Similarly, Lindert et al. (2014) reported 9% to 11% lung delivery
efficiency when testing the Cyclohaler, HandiHaler, and Spinhaler with pediatric in vitro
conditions. These devices were developed for use by adults, not the pediatric patients
that are the focus of this study, and the poor delivery performance may be attributed to
insufficient inhalation flow rates to correctly empty the inhaler and deaggregate the
powder. Inhalation flow rate and other device design considerations were considered in
two studies by Lexmond et al. (2017; 2014), who concluded that it is of paramount
importance to design devices specifically for children when developing DPIs and pediatric
delivery systems.
Our group has recently published several studies related to the ongoing
development of a pediatric DPI for the delivery of tobramycin, as a spray-dried excipient
enhanced growth (EEG) formulation, to children with CF (Bass, Farkas, et al., 2019; Bass
& Longest, 2018b; Farkas et al., 2019; Longest et al., 2019). The full delivery system
includes a ventilation bag, inline air-jet DPI, and patient interface, which is described in
detail by Farkas et al. (2019), and is designed to be as compact and portable as possible.
The ventilation bag provides a positive pressure gas source to actuate the device with
approximately 750 mL of air for a five-year-old child, which allows for oral or nasal
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administration and inhibits exhalation by the patient in the reverse direction through the
device. The air-jet DPI is composed of small diameter inlet and outlet capillaries that
penetrate a capsule-shaped powder chamber. The inlet capillary provides a high-velocity,
compressible, and turbulent air jet to the chamber that aerosolizes the powder and
delivers the aerosol to the patient interface via the outlet capillary. Bass et al. (2019)
presented an optimized inlet and outlet capillary configuration that maximized
aerosolization performance in terms of high emitted dose (ED) and low particle size,
which was quantified by the mass-median aerodynamic diameter (MMAD) of the aerosol.
The present study builds upon the experimental work by Farkas et al. (2019), which
presented an evaluation of losses in the mouthpiece (MP) and mouth-throat (MT) for oral
administration, and nasal cannula (NC) and nose-throat (NT) for nasal administration.
The Farkas et al. study (2019) actuated the high-efficiency pediatric air-jet DPI with a
inhalation volume for 750 mL, for a 5-6 year old subject, and with a 6 kPa pressure drop,
which is consistent with hand actuation of a small ventilation bag. The device was loaded
with 10 mg of EEG albuterol sulfate (AS) as a surrogate test formulation (in place of
tobramycin powder) and was actuated in connection with either in vitro 5-year-old MT or
NT models to test MP or NC patient interfaces, respectively. The best-case DPI and MP
combination for oral administration resulted in 21.8% device loss, 4.6% interface loss,
and 6.6% MT loss, which produced an estimated lung dose of 63.8% on the tracheal filter
(96.8% recovery). The best-case DPI and NC combination for nose-to-lung (N2L) delivery
resulted in 21.9% device loss, 6.1% interface loss, and 8.3% NT loss, which resulted in
an estimated lung dose of 60.7% on the tracheal filter (97.1% recovery). The current study
aims to develop the MP and NC further to reduce interface and extrathoracic (ET) losses
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for oral and nasal administration by utilizing computational fluid dynamics (CFD) based
analysis of various design concepts.
The primary disadvantage of the air-jet DPI is that the high-velocity turbulent jet
(which efficiently aerosolizes the powder) leads to losses when it leaves the device and
enters the patient interface and ET regions (MT or NT). The high velocity of the jet from
the outlet capillary imparts a large amount of momentum to the particles, which in turn
causes a large amount of impaction deposition downstream of the device. This was
clearly apparent from the impaction of the aerosol on the back of the MT model that was
observed by Farkas et al. (2019). The jet also tends to attach to the walls of the patient
interface, due to the Coanda effect, which directs the aerosol towards deposition surfaces
instead of traversing the MP or NC. As such, the flow pathway of the patient interface
(MP or NC) should be engineered to dissipate the intensity of the jet to minimize system
losses. Previous examples of this type of patient interface optimization include
improvements in mouthpiece performance of a capillary aerosol generator (Hindle &
Longest, 2013), the use of co-flow spacers with low actuation-air-volume DPIs (Farkas,
Hindle, & Longest, 2018a; Farkas et al., 2018b), and multiple design improvements to a
mouthpiece coupled to the Aerolizer DPI (Coates et al., 2007; Coates et al., 2004).
6.3

Methods

Overview and System Setup
An overview of the flow passages for the pediatric air-jet DPI system is shown in
Figure 6.1 for both oral and nasal aerosol administration. The air-jet DPI consists of an
inlet orifice flow passage, aerosolization chamber, outlet orifice flow passage, and smooth
expansion. The inlet and outlet orifice flow passages are frequently constructed with
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hollow metal capillaries and are therefore often referred to as inlet and outlet capillaries.
As described by Farkas et al. (2019) the air-jet DPI orients the inlet and outlet capillaries
along the long axis of the aerosolization chamber and does not include bypass flow
(straight through design). The air-jet DPI is connected to the ET model (MT or NT) through
the patient interface. For pediatric aerosol delivery conditions and the straight-through airjet DPI design, Bass et al. (2019) previously optmized the air-jet DPI design parameters
to maximize aerosolization performance. In the current study, the patient interface region
is evaluated and optmized to reduce both interface and ET depositional losses. As
desribed, a major source of this aerosol loss arises from the high-speed turbulent air jet
that enters the patient and ET region from the air-jet DPI outlet capillary. For this reason,
the outlet capillary and expansion region are in the pediatric interface models. The
fundamental question of this study is then how to design the patient interface for oral or
N2L aerosol adminstration that can attenuate a high-speed turbulent air jet while also
reducing deposition losses. Considering the interface, potential designs are illustrated in
Figure 6.2 based on an axial cross-section and plane of symmetry. Potential design ideas
include internal geometry control, wall surface characteristics, and internal flow
structures, such as the 3D rod array. Wall geoemtries are intended to either avoid
boundray layer separation (gradual expansion) or rapidly move the wall away from the
expanding jet (rapid expansion). A rough wall surface is included to improve boundary
layer attachment (via boundary layer “tripping”). Internal flow structures are intended to
quickly dissipate the turbulent jet with minimal particle depositional loss. Further details
of each patient interface design concept are presented later in this study.
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Farkas et al. (2019) presented the initial experimental evaluation of two MP
designs and three different NCs, as part of the development of an air-jet DPI for pediatric
administration of tobramycin. The regional losses for the best-case MP and NC, given as
ratios of deposited mass to the emitted dose from the device, are given in Table 6.1. The
present study aims to evaluate multiple MP and NC design concepts for use with the
same air-jet DPI via CFD predictions of patient interface and ET losses. The CFD models
were first validated against the experimental data for the best-case MP and NC from the
Farkas et al. study (2019) to ensure the applied methods produce accurate results. The
validated CFD models were then used to establish correlations for predicting downstream
losses using the outlet flow conditions of the patient interface. Using CFD models and the
deposition correlations, numerous design concepts of the MP were evaluated with a focus
on minimizing losses in the patient interface and MT model. Best performing design
concepts were then assessed in a full model consisting of the chosen MP design and the
pediatric MT geometry as a final evaluation of performance improvements. Finally, the
same lead design concepts were applied to the NC for N2L delivery, and these designs
were also tested in full CFD models of the interface and pediatric NT geometry.
Evaluation Process
To achieve the study objective, the process outlined by the flow diagram in Figure
6.3 was employed to evaluate numerous design concepts and assess the performance
improvements of candidate patient interfaces. The primary aims of the evaluation process
were to establish CFD-based predictive metrics for estimating the interface and ET
depositional losses associated with each design concept and to improve device
performance in terms of reducing these losses.

235

As with all numerical models, the computational results must be validated against
experimental data to ensure accuracy (Figure 6.3). In the present study, the CFD models
for oral and nasal administration were validated against the experimental data presented
by Farkas et al. (2019) for their best case patient interfaces. Regional deposition
efficiency (DE) in the patient interface (MP or NC) and extrathoracic regions (MT or NT)
were compared between the CFD models and experimental data. Initially, meshing and
solver parameters adhered to the recommendations from our previous work (Bass, Boc,
et al., 2019; Bass & Longest, 2018b; Longest et al., 2007) and adjustments were made
due to the specific requirements of this investigation, which are described in detail in
subsequent sections. Validation focused on maximizing model accuracy with the MP-MT
model, as it was used to screen the design concepts. Once model settings were
established for the validated MP-MT model, they were not adjusted for subsequent
models to ensure consistency between all cases considered.
With the model validation complete, the metrics to predict losses up to the first
impaction point from CFD flow field quantities were developed (Figure 6.3). This required
correlation of the chosen metrics with CFD-predicted DEs in the region of interest to
determine the strength of the metric for estimating interface performance. The intention
of this approach is to model the patient interface flow pathway independently from the
rest of the geometry to reduce processing times and increase the turnaround on
screening design concepts. That is, evaluation of flow field quantities from a CFD model
of only the MP or NC pathway can be used to predict depositional losses in the remainder
of the geometry, which combined with CFD predictions of deposition in the patient
interface can be used to efficiently determine performance improvements. Next, models
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of design concepts were developed and screened using CFD predictions of interface
losses and the aforementioned deposition metrics (Figure 6.3). Three design screen
iterations were required to minimize system losses, with each iteration using insight from
the last to improve performance and optimize the design (Figure 6.3).
Finally, four MP designs from the screening stage were selected for testing in a full
CFD model of the chosen interface coupled with the MT airway (Figure 6.3). Here the
performance of each design is evaluated with CFD-predictions of losses in both the MP
and MT regions. Therefore, any inaccuracies that the deposition metrics may have in
estimating losses in the MT are removed. The selected design concepts are then applied
to the NC, and the combined NC-NT models are tested with full CFD models to assess
the performance improvement for nasal administration. From the final four selected
design concepts, the best performing patient interfaces for oral and nasal administration
were identified based on CFD predictions of patient interface and ET losses. These bestcase designs will be experimentally tested to verify the performance improvements in a
future study.
CFD Models
Computational Domains and Spatial Discretization
The MT and NT models used in the original experimental work (Farkas et al., 2019)
were the scaled 5-6 year old VCU MT geometry (R. Delvadia et al., 2012; Wei et al.,
2018), and the realistic pediatric NT geometry from the RDD Online website
(www.rddonline.com), respectively. These models were selected for the experimental
study as their geometric characteristics were consistent with the 5-6-year-old age group
(Farkas et al., 2019) considered by the device design process. The computational
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geometry was created by importing these ET airways into SolidWorks 2018 (Dassault
Systèmes, Paris, France), and using its 3D modelling capabilities to combine the MT or
NT models with either the MP or NC patient interface, respectively. To maintain
consistency between the experimental and computational models, the NC prongs were
inserted 5 mm into the NT model and surfaces near the prong outlets were modified to
provide an airtight seal between the NC and nostrils. As such, there is no flow through
the nostrils around the prongs, as the device is designed to provide the full inhalation
volume to the subject during actuation. Similarly, the MP is centrally located within the
inlet to the MT model with an airtight seal, which is consistent with the patient’s lips
surrounding the MP during actuation. 3D models were transferred to SpaceClaim v19.0
(ANSYS Inc., Canonsburg, PA) where surface preparation and minor geometry
simplifications were made to facilitate the CFD meshing process, such as the removal of
small area faces, filleting sharp edges, and the addition of numerical extensions.
Mesh generation (i.e. the volume discretization of the computational domain) was
performed by using the meshing capabilities available in FLUENT v19.0 (ANSYS Inc.,
Canonsburg, PA). Due to the complexity of the geometries that include rod arrays, an
unstructured meshing approach was taken to accurately resolve the complex model
surfaces. Polyhedral cell topology, with prismatic near-wall (NW) cell layers, were utilized
throughout the patient interface and ET region in all models, as we have previously shown
that these types of cells are more computationally efficient than traditional tetrahedral
cells and provide accurate deposition results (Bass, Boc, et al., 2019). The NW mesh
resolution, which is critical to obtaining accurate CFD predictions of particle deposition,
was consistent with our previously established best practices (Bass & Longest, 2018b),
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which includes a wall y+ value of approximately one, five prismatic NW layers, and layerto-layer growth ratio of 1.2. Final evaluation of all meshes ensured the orthogonal quality
metric was greater than 0.25, with cell nodes smoothed until this threshold was achieved,
which ensures a high-quality volume discretization.
Mesh independence was established for the MT and NT validation cases using the
Roache method for grid refinement studies (Roache, 1994) by evaluating volumeaveraged velocity magnitude ( 𝑣𝑚𝑎𝑔 ) and turbulent kinetic energy ( 𝑘 ) between
successively higher resolution meshes. Throughout the mesh independence study,
solutions were checked to ensure they were within the asymptotic range of convergence
for which the Roache method is valid. For the MT model, three meshes with approximately
0.5-, 1.0-, and 2.0-million cells were evaluated, which gave normalized grid spacing ratios
of 1.60, 1.32, and 1.00, respectively. Between the 2.0- and 1.0-million cell cases, the grid
convergence index (GCI) for 𝑣𝑚𝑎𝑔 and 𝑘 was 0.07% and 1.54% respectively, which
suggests the estimated error from the 1.0-million cell case was low and acceptable for
use with this study. For the NT model, higher resolution meshes compared to the MT
model were required due to the increased model complexity, with meshes using
approximately 1.0-, 2.0-, and 4.0-million cells, which gave normalized grid spacing ratios
of 1.58, 1.25, and 1.00, respectively. Between the 4.0- and 2.0-million cell cases, the GCI
for 𝑣𝑚𝑎𝑔 and 𝑘 was <0.001% and 8.75%, respectively. Ideally, the GCI for 𝑘 in the NT
model would be less than 5%, but given that 𝑣𝑚𝑎𝑔 shows a very low estimated error and
particle trajectories in the micro-meter size range are more heavily influenced by the
velocity field than the turbulence field, the 2.0-million cell case was deemed acceptable.
A lower cell count is also preferred, as the transient solver was required (discussed in
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subsequent sections), which drastically increased computational expense. As a final
check of the selected mesh resolutions, Richardson Extrapolation (Richardson & Gaunt,
1927) was used to estimate the exact solution of each field quantity. The absolute
differences between the selected meshes and the estimated exact solution was negligible
in all cases, with values of -0.01 m/s and -0.09 m2/s2 for 𝑣𝑚𝑎𝑔 and 𝑘 in the MT model, 0.001 m/s and -0.22 m2/s2 for 𝑣𝑚𝑎𝑔 and 𝑘 in the NT model. Subsequent meshes used in
the evaluation of new patient interface designs use similar cell sizes to these validation
cases, as opposed to similar cell counts, to ensure the spatial resolution is consistent
between models.
Numerical Modeling and Solver Settings
The Mach and Reynolds numbers at the inlet to the patient interface, given a flow
rate of 13.3 LPM and inlet capillary diameter of 2.39 mm (Farkas et al., 2019), are 0.14
and 5,200 respectively, which suggest incompressible and transitional-to-turbulent flow
conditions. As such, a constant density for the fluid phase was implemented, in contrast
to the ideal gas law in previous studies (Bass, Farkas, et al., 2019; Bass & Longest,
2018b; Longest et al., 2019), which had a much smaller inlet jet diameter, as the Mach
number is far below the critical value of 0.3 for compressible flow. To model the
transitional-to-turbulent flow regime, the low-Reynolds number (LRN) k-ω turbulence
model was used, which has been validated by our group for both the evaluation of DPI
performance (Longest, Son, et al., 2013) and particle transport through ET airways (Bass,
Boc, et al., 2019; Bass & Longest, 2018b; Longest et al., 2007) for adults and children.
The formulation of the LRN correction to the k-ω model includes an eddy viscosity
damping coefficient that scales from zero to one in regions of low or high turbulence,
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which improves solution accuracy outside and inside the highly turbulent jet. Considering
the inlet jet, shear flow corrections were applied to model the shear layer between the
high-velocity jet and relatively quiescent flow in the patient interface.
Using a steady-state solution approach, preliminary work on the validation cases
showed the inlet jet would attach to the wall of the patient interface and move around the
domain with erratic behavior, which prevented convergence of the transport equations.
Therefore, a transient formulation of the transport equations was implemented to model
the transient nature of the inlet jet development. The flow was initialized with quiescent
conditions and the boundary conditions at the inlet caused the jet to propagate into the
patient interface. As with the preliminary work, the jet attaches to the walls and wanders
unpredictably in all cases considered, due to the Coanda effect. The transient solution
approach used a time step of 1e-3 seconds, which gave good flow field convergence
within 100 iterations per time step, and sufficiently resolved the inlet jet behavior. Also,
during preliminary work, observation of regional DE vs. time plots showed that the total
and regional deposition converged to a single value within 0.45 seconds, which
determined the maximum required simulation time, as an alternative to modeling the full
actuation time of 3 seconds. These transient solver settings and the mesh independent
spatial discretization resulted in processing times of between 24 and 72 hours (on 10
CPUs) depending on the cell count. This demonstrates the advantage of using the
computationally efficient and accurate LRN k-ω model, as more detailed turbulence
models with transient flow would drastically increase processing times.
FLUENT v19.0 (ANSYS Inc., Canonsburg, PA) was used to obtain solutions for all
flow and turbulence equations, including the aforementioned sub-models and corrections.
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As with the mesh generation step, all solver settings followed our recommendations for
modeling particle transport in DPIs and the respiratory airways (Bass, Boc, et al., 2019;
Bass & Longest, 2018b). Specifically, the Green-Gauss Node-based method for gradient
discretization, which combined with the NW mesh resolution requirements mentioned
previously, provide an improvement in grid independence in the NW region, and improved
consistency and accuracy in particle deposition data. The spatial discretization of flow
and turbulence equations were second-order accurate, while the standard pressure
interpolation scheme was used. Convective terms used a second-order upwind scheme
and diffusion terms used central difference. Further details on the mass, momentum, and
turbulence transport equations are available in other publications (Longest et al., 2007;
Longest et al., 2006).
A mass flow inlet condition was utilized at the inlet flow boundary to the patient
interface, with a mass flow rate that gave a volumetric flow rate of 13.3 LPM, which is
consistent with the volumetric flow rate through the Case 4 DPI presented by Farkas et
al. (2019). A 10 mm length of the device outlet capillary (inlet to the patient interface) was
included in the model to allow the flow to reach a fully-developed state before entering
the MP or NC. A pressure outlet condition was used at the outlet of the ET airway model,
with gauge pressure (relative to ambient pressure) set to 0 kPa. To minimize the influence
of the pressure outlet on the flow field in the ET models, a 60 mm numerical extension
was added to the outlet in the CFD domain. All wall boundaries in the CFD model use the
no slip shear condition and the effects of surface roughness on the flow field and particle
trajectories were neglected. Wall boundaries of the 3D-printed components used the trap
discrete phase model (DPM) boundary condition such that any particle that contacts these
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walls is assumed to deposit on the boundary. Wall boundaries of stainless-steel
components used the reflect DPM boundary condition, with default coefficients of
restitution, which assumes particles bounce off of these surfaces. This is a necessary
assumption about particle behavior when the aerosol interacts with the rod array to keep
processing times manageable, which has previously been shown to be acceptable
(Longest et al., 2015; Longest, Son, et al., 2013).
Particle Trajectories and Deposition Calculations
Particle trajectories were calculated with the DPM available in FLUENT v19.0
(ANSYS Inc., Canonsburg, PA), with the Runge-Kutta scheme used to integrate the
particle equations of motion, which is dependent on the underlying flow and turbulence
field quantities. Settings for the DPM follow our best practices (Bass, Boc, et al., 2019;
Bass & Longest, 2018b; Longest & Xi, 2007; Walenga & Longest, 2016), which have been
successfully validated against experimental deposition data. Microparticle trajectory
calculations with the DPM and LRN k-ω turbulence approximation generally over-predict
deposition when compared to experimental data, due to the assumption of isotropic NW
turbulence and the associated fluctuating velocity components. As such, Longest and Xi
(2007) proposed corrections to the NW flow and turbulence fields extending work by
Matida et al. (2004) and Wang and James (1999), which are implemented in FLUENT via
user-defined functions (UDFs). In summary, the NW corrections interpolate the velocity
field from the cell centroid to the particle location, implement anisotropic fluctuating
velocity components, and damp the wall-normal velocity to approximate particle-wall
hydrodynamic interactions. These NW corrections use a NW limit control parameter that
determines the wall-normal distance, below which, the wall-normal velocity is damped.
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Previous validation work (Bass, Boc, et al., 2019; Bass & Longest, 2018b) showed that a
NW limit of 1-2 µm was suitable for modeling microparticle deposition in the upper
airways, with a value of 2 µm used in the present study.
Particles were introduced into the model at the inlet to the air-jet DPI outlet capillary
(i.e. the inlet to the CFD domain) with a blunt spatial distribution, as the inlet Reynolds
number suggests the flow is in the transitional to turbulent regime. Initial particle velocities
also followed a blunt profile based on each particle’s radial location relative to the circular
boundary. A polydisperse aerosol was used in the CFD models, with the particle size
distribution determined by next-generation impactor (NGI) characterization at the Case 4
device outlet presented by Farkas et al. (2019). Particle deposition convergence was
ensured by following the recommendations from Tian et al. (2015) with 100 particles per
bin per time step, which resulted in 360,000 total particles (considering eight NGI bins
and 450 time steps).
Regional particle deposition in the device, interfaces, and ET models are
compared via DE, which is the ratio of particles that deposit in a given region to number
of particles that enter that region. To convert the DE from the CFD models (with a constant
number of particles per bin) to a DE that is consistent with the experimentally determined
particle size distribution, the CFD-predicted DE for each NGI bin is multiplied by the mass
fraction of particles for each bin, and then summed over all bins. This is defined as:
𝑛𝑖
𝑁𝑖

(6.3.1)

𝑚𝑖
𝑀

(6.3.2)

DE𝑖 =
𝜑𝑖 =
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8

DE𝑟 = ∑ 𝐷𝐸𝑖 × 𝜑𝑖
𝑖=1

(6.3.3)

where 𝑛𝑖 is the number of particles that deposit in the region for bin 𝑖, 𝑁𝑖 is the number of
particles the enter the region for bin 𝑖, DE𝑖 is the DE for bin 𝑖, 𝑚𝑖 is the mass of particles
from the NGI characterization for bin 𝑖, 𝑀 is the total aerosol mass, 𝜑𝑖 is the mass fraction
for bin 𝑖, and DE𝑟 is the DE for a given region. To determine the mass or number of
particles that enter the region, the mass or number of particles that deposit in upstream
regions is subtracted from the injected aerosol conditions. Finally, the total deposition
fraction (DF) for the entire domain, which is the ratio of particles that deposit in the domain
to the particles that enter the domain, can be calculated from the regional DE as follows:
DF 𝑇𝑜𝑡 = 1 − ∏(1 − 𝐷𝐹𝑟 )

(6.3.4)

Deposition Metrics
In an effort to reduce the computational cost associated with evaluating numerous
patient interfaces, CFD-based deposition metrics that are capable of predicting deposition
losses were sought. The intention being that only the interface flow pathway would have
to be modeled with CFD, and the flow field at its outlet could be evaluated to predict
downstream losses. For both the MP-MT and NC-NT models, the patient interface
accounted for approximately 25% of the total cell count, thus reducing processing times
by a factor of four-fold, which vastly improved the turn-around time on design candidate
evaluations. Candidate designs that exhibit reductions in interface and ET losses with this
approach were then fully evaluated via CFD models of the improved interface coupled to
the ET model in the final stage of this study. That is, numerous design concepts can be
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screened in a reduced amount of time before testing candidate interfaces via a full CFD
model and evaluating performance improvements.
Figure 6.4a and b show the separation of the MP flow pathway from the MT, and
Figure 6.4c and d show the separation of the NC flow pathway from the cannula
bifurcation and NT. The NC was split just upstream of the bifurcation as the objective of
the study was to evaluate interface designs that reduce the losses associated with the
high-velocity jet from the device outlet, and preliminary work showed that losses in the
NT region were not affected by changes to the jet intensity. That is, reducing the intensity
of the inlet jet to the NC did not reduce ET losses, but deposition on the bifurcation was
reduced, which suggests the potential for improvements in interface losses. Put another
way, the inlet jet causes impaction deposition on the first surface that it encounters when
it leaves the device outlet capillary. In the MP-MT model, this impaction surface is the
back of the mouth-throat and the model is split between the MP and MT regions. In the
NC-NT model, this impaction surface is the NC bifurcation and the model is split between
these two regions.
ET deposition metrics were evaluated by applying four different velocity profiles to
the MT and NT models at the inlets labeled in Figure 6.4b and d, respectively. These four
velocity profiles were named the Jet ( 𝑢Jet ), Turbulent ( 𝑢Turb ), Laminar ( 𝑢Lam ), and
Intermediate (𝑢Int ) profiles, and are plotted graphically in Figure 6.5a. The functions that
define each profile are:
𝑢Jet = 𝑢max × exp [−

(𝑟/𝑅)2
]
2𝜎 2

𝑟 1/7
𝑢Turb = 𝑢max × (1 − )
𝑅
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(6.3.5)

(6.3.6)

𝑟 2
𝑢Lam = 𝑢max × (1 − ( ) )
𝑅
𝑢Int =

𝑢Jet + 𝑢Turb
2

(6.3.7)
(6.3.8)

where 𝑢max is the peak velocity, 𝑟 is the radial location on the inlet boundary, and 𝑅 is the
maximum radius of the inlet boundary. Using the 𝑟/𝑅 definition for the radial location on
the inlet boundary simplified the conversion from circular to elliptical coordinates for the
inlet to the MT model. The 𝑢Jet profile uses a Gaussian function to define the jet-type
profile seen in Figure 6.5a, with 𝑢max determined from time-averaged peak velocity from
the oral and nasal validation cases and 𝜎 selected to provide a volumetric flow rate of
13.3 LPM consistent with the Case 4 DPI (Farkas et al., 2019). The 𝑢Turb profile uses the
1/7th power law for a turbulent profile (White, 2006); the 𝑢Lam profile uses the analytical
solution for laminar flow; and the 𝑢Int profile is simply the average of the 𝑢Jet and 𝑢Turb
profiles. The purpose of these velocity profiles is to evaluate how the ET losses are
affected as the jet intensity is reduced from a profile such as 𝑢Jet through an intermediate
range (𝑢Int ) to a full reduction of jet intensity with the 𝑢Turb and 𝑢Lam profiles for turbulent
and laminar flow regimes.
As the velocity profile changes, the spatial distribution of the particles that are
introduced to the computational domain must reflect the inlet conditions, as higher
velocities will carry in more particles. For example, a velocity profile such as 𝑢Jet would
give a particle distribution that is more concentrated towards the middle of the inlet,
whereas a profile such as 𝑢Turb would give a more even distribution of particles. To
determine the spatial distribution, each profile was treated as a probability density function
(PDF) and split into 32 equally spaced rings, with particles randomly assigned to each
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ring based on the PDF. This method of defining particle spatial distributions is similar to
that described by Longest and Vinchurkar (2007a), but applied to the four profiles used
to evaluate ET deposition metrics. The resulting spatial particle distribution for each MT
of NC inlet velocity profile is shown in Figure 6.5b.
Observations from the experimental work presented by Farkas et al. (2019)
demonstrated a large amount of deposition on the back of the throat in the pediatric MT
model. Therefore, initial work on predicting ET loss aimed to describe the intensity of the
jet as it enters the MT or NT model. Specifically, these metrics were the peak velocity,
velocity spread, and uniformity index, which were all evaluated on the plane between the
patient interface and ET region. Peak velocity is simply the time-averaged maximum
velocity on the sampling plane, velocity spread is the standard deviation of velocity on the
plane, and uniformity index (UI) is given as:
∑𝑁
̅ | × 𝐴𝑖 )
𝑖=1(|𝑢𝑖 − 𝑢
UI = 1 − (
)
2 × 𝑢̅ × 𝐴

(6.3.9)

where 𝑢𝑖 is the velocity on face 𝑖, 𝑢̅ is the area-average velocity, 𝐴𝑖 is the area of face 𝑖,
and 𝐴 is the total plane area. A UI with a value close to one describes a uniform flow
velocity, such as the 𝑢Turb profile, whereas a value closer to zero describes non-uniform
flow velocity, such as the 𝑢Jet profile.
6.4

Results

CFD Model Validation
Deposition patterns presented in this study generally split the domain into three
regions: the device outlet (outlet capillary and expansion), patient interface (MP or NC),
and the ET region (MT or NT). For the purposes of model validation, regional DEs are
compared between the CFD and experimental results in the patient interface and ET
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regions, with DEs on the device outlet provided for completeness. Figure 6.6a shows that
CFD predictions of aerosol DE were in close agreement with the experimental (Exp)
results in the MP and MT regions, with a maximum absolute error in regional DE of -0.6%
in the MT region. Total DF in the entire model also matched well between the CFD and
experimental data with an absolute error of 0.2%.
The validation of the NC-NT model, presented in Figure 6.6b, did not match as
closely to the experimental data as the oral model, but was still considered acceptable.
Maximum absolute error in regional DE was 5.1% in the NT region, and the CFD model
over-predicted total DFs in the entire domain by 8.3%. Note that adjustment of the NW
limit control parameter in the NW correction UDFs would reduce this over-prediction, but
we elected to apply the same CFD model settings to all models to ensure consistency
between cases. This lower degree of model validation relative to the MP-MT model was
deemed acceptable as the screening iterations focused on the MP design and general
trends in improving performance. However, the slight over-prediction of deposition in the
NC-NT model must be taken into consideration when interpreting and evaluating results
from those patient interfaces.
Deposition Metrics
Of the three deposition metrics described in the Methods section, correlating the
time-averaged maximum velocity on the plane at the outlet of the flow pathway with MT
(Figure 6.7a) and NC (Figure 6.7b) DE gave the best prediction of losses, with R2 values
greater than 0.95 and standard error ranging from approximately 0.5% to 0.6%. It is noted
that the different velocity profiles considered all had the same volumetric flow rate.
Therefore, deposition in the MT correlates with not only volumetric flow rate, but also the
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peak value of the velocity profile that enters the region. With such a strong correlation,
further development of deposition metrics was not required. Figure 6.7a plots the DE in
the MT region (Figure 6.4b) against the maximum velocity at the MT inlet for the four
imposed velocity profiles (Figure 6.5a). Similarly, Figure 6.7b plots the DE in the NC
bifurcation region (Figure 6.4d) against the maximum velocity at the inlet for the jet,
turbulent, laminar, and intermediate velocity profiles. As mentioned previously, the NCNT model was split into the domains shown in Figure 6.4c and d as preliminary work
showed that imposing velocity profiles at the inlets of the NT region (outlet of the NC
prongs) had little influence on reducing ET losses. However, the deposition metrics show
that reducing the intensity of the jet entering the NC bifurcations (as quantified by peak
velocity) can reduce interface losses at the first impaction point, just as in the MT with
oral aerosol delivery.
Figure 6.8a and b show the deposition patterns in the MP-MT model when the jet
(Figure 6.8a) and turbulent (Figure 6.8b) velocity profiles were imposed at the inlet. Figure
6.8a shows a large amount of impaction deposition on the back of the MT, due to the high
velocity jet entering the region, which was also observed experimentally by Farkas et al.
(2019). In Figure 6.8b, this impaction region was minimized as the intensity of the inlet jet
is vastly reduced with the turbulent velocity profile, which leads to a reduction in MT losses
from 8.8% to 3.8% at the same volumetric flow rate. In the laryngeal region of the pediatric
MT model, deposition patterns were similar between the jet and turbulent profile cases as
inlet effects are less apparent downstream in the domain. Similarly, Figure 6.8c and d
show the deposition patterns in the NC-NT model for the jet and turbulent velocity profiles,
respectively. As with the MT model, minimizing the inlet jet intensity reduces the losses
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at the first impaction point, which in the NC-NT model is the cannula bifurcation, from
7.2% to 0.9%. However, there is little difference in NT losses when imposing different
velocity profiles, with DEs ranging from 19.2% to 19.7%. This supports the insight from
the preliminary work and deposition metrics that NT losses are difficult to minimize with
changes to the design of the NC flow pathway, but NC interfaces losses can be improved.
Design Concept Screen 1
Diagrams that illustrate the MP design concepts in the first iteration were presented
in Figure 6.2a. These diagrams provide an axial, mid-plane slice of the interface aligned
with the top-down view and show the MP geometry along with any internal components.
The first iteration implemented four design concepts, with two variations of each concept.
The gradual expansion (GE) concept steadily increased the MP diameter from the circular
outlet capillary to the elliptical MP outlet. The variations of the GE concept used a smooth
(a) and an undulating (b) surface, with the intention being that the undulating surface
would increase turbulence through tripping the boundary layer, thereby keeping the flow
attached and preventing recirculation. The rapid expansion (RE) concept quickly
transitions from the outlet capillary diameter to the elliptical MP cross-section with a dome
shape that extends 6.5 mm from the capillary. The variations of the RE concept used a
one-step (a) and two-step (b) expansion, where the two-step expansion initially
transitioned to an elliptical cross-section that had half the radii lengths of the outlet over
the first half of the MP length. The intent of the two-stage RE variation was to determine
whether the MP cross-section should be increased incrementally to dissipate the intensity
of the inlet air jet. The rod array (RA) concept used 0.5 mm diameter rods arranged in a
3-4-3 configuration and placed in the flow pathway to break up the high-velocity inlet jet
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and reduce its intensity. The variations of this design concept placed the rod array close
to the outlet capillary (a) or close to the MP outlet (b) to provide insight on the optimal
positioning of the rod array. Finally, the tear drop (TD) concept placed a streamlined
obstacle in the flow pathway to both break up the inlet jet and minimize recirculation by
keeping the flow attached to the outer wall of the MP. The tear drop was suspended in
the flow pathway with six supports that were placed in a triangular arrangement and
followed a NACA 0012 profile to reduce their influence on the flow field as much as
possible. The variations of this design concept used a tear drop shape that extended into
the transition region between the outlet capillary and MP, and another design that moved
the leading edge of the tear drop away from the outlet capillary. The intent of these two
variations was to determine the effects on impaction deposition by moving the blunt edge
of the tear drop away from the jet source.
Table 6.2, used in conjunction with Figure 6.2a, presents the CFD-predicted losses
on the device outlet (DEDev) and patient interface (DEMP), and the correlation-predicted
MT losses (DEMT) for the eight MP designs described above. The GE cases both reduced
peak velocity at the MP outlet, which suggests an improvement in MT losses based on
the deposition correlation. However, the interface losses for both variations of the GE
concept were high (34.4% and 17.0%) compared to the original MP design (6.4%). It is
interesting to note that the undulating surface (GE-b) reduced the CFD-predicted MP
losses by approximately half compared to the smooth surface (GE-a). The RE design
concept also reduced peak velocity and the associated MT losses, with the added benefit
of a reduction in CFD-predicted interface losses compared to the original MP design of
6.4% to 1.8%. The RE-a design gave the best performance improvement of all eight cases
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considered in the first iteration, with the total domain DF reduced from 16.7% to 11.8%.
The RA-a case gave the best reduction in peak velocity and estimated MT losses of all
cases evaluated in the first iteration, from 8.8% to a predicted 4.9% comparing the original
MP and RA-a respectively. The two TD cases performed well in terms of minimizing flow
recirculation, reducing device outlet losses, and predicted MT losses, but a large amount
of impaction deposition on the leading-edge caused very high MP losses (57.0% and
54.7%). Based on the results from Design Screen 1, a combination of the benefits
observed for the RE and RA type designs may be utilized to improve patient interface
performance further. That is, the 3D rod array can be added to the RE geometry to both
give an improved reduction in jet intensity, interface deposition loss, and predicted MT
loss.
Design Concept Screen 2
The second iteration of design screening combined aspects of the RE and RA
designs from the first iteration, and also introduced the cylindrical expansion (CE)
geometry as an alternative to RE, as illustrated by Figure 6.2b. The RE-a+RA-a design
combines the geometry from the one-step variation of the RE concept with the rod
placement and configuration from the first RA variation in an attempt to leverage the
benefits of both designs from the first design screen iteration. RE-a+RA-c is similar to REa+RA-a with the rod array moved 6.5 mm downstream of the outlet capillary to gain insight
in the placement of the rod array and its effect on losses. RE-c+RA-a uses a two-step
expansion with a shorter first section than RE-b, and the first rod array variation, to
evaluate the effect of keeping the flow constrained as it passes through the rods. CE+RAa is similar to RE-a+RA-a except it uses the cylindrical type geometry to provide a direct
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comparison between the combined RE+RA with the CE+RA design concepts. The final
three designs in the second screening iteration (CE+RA-d/e/f) use the cylindrical
geometry with rod arrays that span the full width of the MP with the intention of preventing
the jet from reaching and attaching to the walls, as well as reducing the intensity of the
jet. The three rod arrays are located at 1.5, 10, and 20 mm from the outlet capillary to
evaluate the deposition losses as the rod array is moved away from the source of the inlet
jet.
Based on the deposition results in Table 6.3, adding the RA to the RE geometry
had the desired effect of improving MT losses by reducing the peak velocity of the inlet
jet, which brings the total DF below the target of 15% (see bold DF Tot values). However,
the deflection of the jet due to the rod array causes higher interface losses, when
compared to the RE-a case, as the flow is directed towards the side walls of the MP.
Moving the RA further away from the capillary outlet in the RE-a+RA-c case leads to
relatively high MP losses as the inlet jet flowed around the rods and attached to the walls
instead of passing through the rod array and diffusing. Of all the design concepts
considered in the second iteration, RE-c+RA-a had the worst performance in terms of
flow pathway losses due to the close proximity of the interface walls to the rod array. That
said, this case provides valuable insight as it shows that positioning the MP walls further
away from the rod array reduces patient interface losses, which is explored further in the
third design screen iteration. The CE+RA-a case had very similar performance to REa+RA-a, which shows that the slight change in the MP geometry has little effect on
reducing deposition losses. The final three CE design concepts with rod arrays that span
the full width of the interface also all had a similar level of performance (13.1-14.4% total
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DF). They show that moving the rod array away from the outlet capillary reduces the
losses on the device outlet, but increases interface losses, so that total losses remain
relatively constant. Despite the cases with rods spanning the full width of the interface
having the best performance in the second design screen iteration, it is desirable to find
design concepts that use fewer rods to simplify the construction of these patient
interfaces.
Design Concept Screen 3
Using insight from the RE-c+RA-a case, the third design screening iteration
introduces a forth RE geometry (RE-d), as illustrated by Figure 6.2c. Here, the MP walls
are initially twice as far away from the outlet capillary (maximum width of 36 mm) and
gradually taper towards the original elliptical cross-section. The intention of this design
concept is to keep the patient interface walls away from the flow when it is dispersed by
the rod array to reduce device outlet and MP losses. The RE-d+RA-a case was evaluated
as this rod array has provided good performance in the previous iterations and for direct
comparison with the RE-a+RA-a case. RE-d+RA-e used the best performing rod array
from the second design screen iteration and tested whether the large number of rods was
necessary to reduce interface losses despite the drawbacks in terms of MP construction.
RE-d+RA-g is similar to RE-d+RA-e, but the rods span half the width of the patient, with
this design included as an intermediate step. The RE-d+RA-a-434 case is the same as
RE-d+RA-a with the rods placed in a 4-3-4 configuration (as opposed to 3-4-3) and was
evaluated to determine whether this configuration provided performance improvements
over the other design concepts. Finally, the RE-d+RA-c-EC design concept uses the rod
array positioning seen in the RA-c case with an extended capillary (EC) that protrudes
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6.5 mm into the patient interface. The intention of this design is to keep the inlet jet away
from the device outlet and interface walls while forcing the flow through the rod array to
disperse the jet and reduce its intensity.
The results in Table 6.4 show all design concepts from the third screening iteration
provided CFD-predicted total losses of less than 10% in the device outlet, patient
interface, and MT regions. Widening the MP geometry had the expected effect of
preventing the dispersed jet from depositing particles on the interface walls, which is
clearly apparent when comparing the RE-d+RA-a case with RE-a+RA-a, as the wider
geometry reduced total losses by 5.9% absolute difference. There was little difference in
performance between the RE-d+RA-e and RE-d+RA-g cases, with the latter preferred as
it required less rods and is hence easier to build. Switching the rod array configuration
from 3-4-3 to 4-3-4 (RE-d+RA-a-434) gave a marginal improvement in reducing MP
losses, but gave a higher peak jet velocity and therefore larger predicted MT losses, with
total losses 0.9% higher (absolute difference) compared to the original configuration.
Finally, extending the outlet capillary into the MP (RE-d+RA-c-EC) provided the expected
improvement of reducing device outlet losses, and had total deposition losses that are
comparable with the other design concepts in the third iteration.
Figure 6.9 demonstrates how effective the 3D rod array is at diffusing the air jet in
the patient interface. Figure 6.9a shows the highly turbulent, high-velocity jet, which is
generated by the DPI outlet capillary, entering the RE-a MP design candidate. This jet
extends beyond the outlet of the patient interface and imparts a large amount of
momentum on the aerosol, which leads to increased deposition on the first impaction
point that the jet encounters, as described previously. The jet diffusion by the 3-4-3
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configuration rod array is clearly apparent in Figure 6.9b, with the jet almost fully
dissipated by approximately 30 mm into the 75 mm length of the RE-d+RA-a MP design.
The vast reduction in peak velocity of the flow leaving the patient interface is expected to
both reduce delivery system and ET losses, based on the previously presented deposition
correlations. The 3D rod array has the added benefit of providing a secondary breakup
mechanism to reduce aerosol size (Behara, Longest, et al., 2014b), which may lead to
further improvements in system performance.
Candidate Mouthpiece Designs
Four design concepts from the screening iterations were selected for evaluation
with full MP and MT CFD models: RE-a, RE-d+RA-a, RE-d+RA-g, and RE-d+RA-a-EC.
Figure 6.10 shows the CFD-predicted deposition patterns and regional DEs for the four
candidate design concepts. Only bin sizes from 1.09 to 3.26 µm are included in Figure
6.10 as they account for 84% of the initial particle size distribution and provide a clearer
representation of deposition patterns in the CFD domain. Comparing losses in Figure
6.10b-d with Figure 6.10a clearly shows that widening the MP geometry and including a
rod array to disperse the inlet jet provides a substantial reduction in CFD-predicted patient
interface and ET deposition losses, with an absolute difference in total DF of 10.3%. The
best performing case of the four candidate designs was RE-d+RA-a-EC with CFDpredicted total losses of 5.1% on the device outlet, MP, and MT region, which is a threefold reduction compared with the original MP (see Figure 6.6a). Comparing regional
deposition between RE-d+RA-a-EC and the original MP, CFD-predicted losses were
reduced from 2.4% to 0.6% on the device outlet, 6.4% to 2.2% on the MP, and 8.8% to
2.4% in the MT region.
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Candidate Nasal Cannula Designs
The top four MP design concepts were applied to the NC flow pathway, which
consists of the region between the outlet capillary and cannula bifurcation. Figure 6.11
shows the deposition patterns and regional DEs for the four NC designs. As with the MP
flow pathway, widening the NC geometry and including a rod array (Figure 6.11b-d)
reduces total deposition losses compared to RE-a by a two-fold reduction (Figure 6.11a).
Also consistent with the MP designs, the best performing NC case was the RE-d+RA-aEC design in Figure 6.11d. Comparing the RE-d+RA-a-EC MP and NC directly, device
outlet losses were similar (0.6% vs. 0.8%) and interface losses were a little higher in the
NC with an absolute difference of 1.1%. The downside to all NC designs is that losses in
the NT region are much higher than MT losses in all cases considered, with absolute
differences of approximately 18%, which leads to higher total DF losses. That said, recall
that the validation cases showed that CFD models over-predicted total deposition in the
NT model by 8.3%, so we could optimistically expect total losses to be 15-20% with
experimental testing of these NC design concepts.
Optimal Flow Rate for Nasal Administration
The results in Figure 6.11 are consistent with previous findings from this study that
changes to the flow pathway in the NC, and the subsequent changes to the flow profile
entering the nasal cavity, has little effect on reducing NT losses. Figure 6.8c and Figure
6.6d showed that imposing a jet or turbulent velocity profile resulted in negligible
difference in NT losses, and similarly Figure 6.11b-d show little change in NT losses
despite the same design concepts reducing MT losses by 6.4% (absolute difference)
when applied to the MP interface. One method to reduce impaction deposition in the NT
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region is to reduce the size of the aerosol that enters the nasal cavity, but exploratory
work of this approach yielded little performance improvement as the 1.69 µm MMAD from
the DPI as at the lower end of the characteristic S-curve deposition profile.
The alternative approach to reduce impaction deposition is to lower the flow rate
through the patient interface and NT to reduce particle momentum. Figure 6.12 compares
the CFD-predicted particle deposition for the best performing NC design concept (REd+RA-c-EC) at the original operating flow rate (13.3 LPM) and 75% of that inlet flow rate
(9.9 LPM; 25% reduction). The lower flow rate reduces NT losses by 6.9% (absolute
difference) and total losses by 7.8%. While the total system and ET losses at 9.9 LPM is
16.3%, experimental results are expected to be even lower based on the validation case
study.
6.5

Discussion
This study met its objective by presenting three MP design concepts that provide

CFD-predicted total deposition losses of less than 15%, with the best case being the REd+RA-a-EC design that showed a total DF on the device outlet, patient interface, and MT
region of 5.1%. Combining these CFD-predicted interface and ET losses with the
approximate 10% device loss from Farkas et al. (2019) suggests the possibility of a
pediatric lung dose greater than 85% of the loaded dose. The NC design concepts did
not perform as well as the MP designs with respect to increasing lung dose, as changes
to the flow pathway had little effect on reducing NT losses. The combination of the REd+RA-a-EC design concept with a reduced operating flow rate of 9.9 LPM (25% decrease)
gave a CFD-predicted total DF of 16.3%. Previous work showed that device losses are
strongly associated with flow rate through the pediatric air-jet DPI (Bass, Farkas, et al.,
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2019); hence operation of the delivery system at a lower flow rate, to reduce NT losses,
may lead to increased device losses. However, experimental results of the device (Case
1.60/2.39) that had a 25% reduction in flow rate from the Bass et al. study (2019) gave
negligible change in MMAD (1.69 µm vs. 1.71µm) and a 2.5% increase (absolute
difference) in device losses . Therefore, overall system losses may be improved when
administering the aerosol via N2L delivery at a reduced flow rate. Adding this loss to the
experimentally determined DPI loss (Farkas et al., 2019) suggests a lung dose that is
approximately 74% of the loaded dose. This is slightly outside the performance targets
laid out in the objective (lung dose >75%), but the validation cases showed that the CFD
models over-predict deposition in the NC and NT, so there is a possibility that
experimentally determined losses may be less than those suggested by these CFDpredictions.
The CFD-predicted patient interface and ET losses, and associated lung dose, for
these candidate design concepts must be experimentally tested, which will be the focus
of a future study related to the development of this system for administration of tobramycin
to pediatric patients with CF. The candidate design concepts also met the sizing and
construction considerations that were stated in the objective. The total length to the MP
and NC designs is less than 75 mm and no wider than 40 mm, which allows for a compact
and portable device. The best performing RE-d+RA-a-EC design concept also requires
relatively few rods in the rod array, with a total of seven compared to other concepts that
required more than 50, which allows for simplified construction of the patient interfaces.
Considering volume, the MP and NC interfaces that employ the RE-d geometry had total
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internal volumes of 31 and 21 cm3, respectively, which can easily be cleared with device
actuation volumes on the order of 100s of mL.
In addition to the primary objective, this study presents correlations that predict
deposition in the MT and cannula bifurcation regions based on the maximum inlet velocity
to each of these regions, with the same volumetric flow rate. The results show that
imposing different velocity profiles with varying peak velocities can cause the CFDpredicted deposition to range from 3.8% to 8.8% in the MT region and from 0.9% to 7.2%
in the cannula bifurcation. Using these predictive correlations reduced the turnaround
time for analyzing numerous design candidates as only the flow pathway for each patient
interface was required for each CFD model. The reduction in processing time using this
method was especially important in this study as the oscillatory nature of the high-velocity
inlet jet required a transient solution of the transport equations.
The deposition correlation results also show that the impaction deposition in the
chosen region is dependent on the inlet velocity profile and not simply the inlet volumetric
flow rate. Each of the four velocity profiles in Figure 6.5a have the same flow rate, which
was 13.3 LPM to be consistent with the chosen DPI, but each resulted in considerably
different particle deposition results. A common method of predicting ET losses is to utilize
the impaction parameter (𝑑𝑎2 𝑄) where particle size (𝑑𝑎 ) and flow rate (𝑄) are used to
estimate transmission through the MT or NT region (Golshahi et al., 2011; Javaheri et al.,
2013; Storey-Bishoff et al., 2008; Tavernini et al., 2018). Studies that use the impaction
parameter typically describe a large amount of variability, with Golshahi et al. (2011),
Storey-Bishoff et al. (2008), and Tavernini et al. (2018) providing correlations that reduce
this variability for children, infants, and neonates, respectively. The results in Figure 6.8a
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and b show that for a constant flow rate the deposition results increased substantially with
respect to peak inlet velocity, which suggests that peak inlet velocity is also a significant
indicator of ET deposition. As such, the variability in predicting ET losses with the
impaction parameter may be reduced further if aspects of the inlet profile were taken into
consideration. For example, operating conditions that result in a turbulent flow regime
may have a lower peak velocity, due to the blunt turbluent velocity profile, which may
result in lower deposition than even laminar flow if turbulent particle dipersion is low.
Similarly, if the flow does not reach a fully-developed state before entering the
experimental model, the inlet velocity could be very different from either a laminar
(parabolic) or turbulent (blunt) profile, which could influence the development of
extratoracic deposition correlations.
As mentioned previously, particle deposition was higher in the NT models
compared to the MT, which resulted in lower expected lung doses with nasal
administration. This apparent disadvantage of the NC designs can be leveraged as a
benefit for the treatment of bacterial infections in the nasal cavity. There is evidence in
the literature that the nasal cavity and sinuses can harbor bacterial colonies that
repeatedly lead to lung infections in patients with CF (S. K. Hansen et al., 2012; Linnane
et al., 2015; Moller et al., 2017) despite elimination of bacteria in the lower airways.
Therefore, treatment methods may attempt to eradicate infections by administering
tobramycin in the nasal cavity and sinuses. This would mean that nasal administration
with the NC designs in the current study would be a preferred method, as a portion of the
delivered dose is deposited in the NT region. If treatment of bacterial infections in the
nasal cavity is not deemed necessary by clinicians and a high lung dose is required, then
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oral administration methods with the MP designs presented here would be the preferred
method. Beyond discussions of targeting deposition in the various regions of the airways
for uniform dosing, there are also practical aspects of oral and nasal administration that
should be taken into consideration. The proposed system aims to deliver the lung
inhalation volume to the subject during actuation, as well as the tobramycin dose, which
requires an air-tight seal between the device and patient.
Limitations of this study primarily include the assumptions and approximations
made by the CFD models. Hygroscopic growth is known to increase particle size as the
aerosol travels through the humid airways. This phenomenon was neglected from the
CFD model as the increase in ET deposition from hygroscopic growth is expected to be
small, with Walenga et al. (2014) reporting an approximate 0.1% increase in adult nasal
airways. The same negligible impact on ET deposition in infant and pediatric airways can
also be assumed in the present study. The rod array was added to the patient interface
in an effort to diffuse the high-velocity inlet jet, but rod arrays have also previously been
utilized to increase secondary particle breakup and reduce aerosol size (Behara, Longest,
et al., 2014a, 2014b; Longest et al., 2015; Longest, Son, et al., 2013). This secondary
breakup mechanism was not included in the CFD models due to the associated increase
in complexity and processing times. The deaggregation from passing the aerosol through
the rod array decreases the particle size, which would be expected to decrease interface
and ET losses and lead to further improvements in lung dose. These potential
improvements to the delivery system performance that were not captured by the CFD
models will be experimentally tested in a future study. The disadvantage of including a
rod array in the patient interface design is that placing obstacles in the flow would lead to

263

an increase in impaction deposition. However, the CFD models assumed the stainlesssteel rods did not trap any particles that contact the surface (i.e. a reflection boundary
condition was applied). Our previous work with rod arrays has shown the losses on the
stainless-steel cylindrical surfaces are small and matched in vitro validation data (Longest
et al., 2015; Longest, Son, et al., 2013), but this assumption must also be tested
experimentally.
In conclusion, candidate MP design concepts were developed that provide total
CFD-predicted losses of approximately 5%, and expected lung doses of approximately
85% (when coupled with the best-case DPI from Farkas et al. (2019)). Candidate NC
design concepts performed slightly worse than their MP counterparts, but operating the
DPI with a 25% reduction in flow rate lead to an expected lung dose of approximately
74%. Development of deposition correlations showed that losses were strongly related to
peak velocity on the outlet plane of the interface flow pathway, while the flow rate through
the device was maintained at 13.3 LPM. Findings from this study and our previous
publications on the subject will be used in the continuing development of a tobramycin
delivery system for treating CF lung infections in pediatric patients.
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6.6

Figures

Figure 6.1:

Overview of delivery system and extrathoracic models for (a) oral

administration via a mouth-piece (MP) through the mouth-throat (MT), (b) nasal
administration via a nasal cannula (NC) through the nose-throat (NT), and (c) location of
positive-pressure air source (ventilation bag). As noted in the figure, the air-jet DPI was
previously evaluated by Bass et al. (2019).
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Figure 6.2:

Overview of patient interface design concepts for (a) Screening Iteration 1,

(b) Screening Iteration 2, and (c) Screening Iteration 3.
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Figure 6.3:

Process flow chart to evaluate design concepts with the objective of

minimizing losses in the patient interface.
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Figure 6.4:

Overview of model geometry showing (a) mouthpiece flow pathway, (b)

mouth-throat only model (c) nasal cannula flow pathway, and (d) nose-throat and cannula
prongs model for evaluation of deposition metrics.
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Figure 6.5:

Boundary conditions used to establish extrathoracic deposition metrics in

the mouth-throat models showing (a) velocity profiles applied at the inlet boundary and
(b) spatial distribution of initial particle locations (nose-throat models used similar
boundary conditions).
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Figure 6.6:

Validation of CFD-predicted deposition with experimental data for (a) the

mouthpiece and mouth-throat models and (b) the nasal cannula and nose-throat model.
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Figure 6.7:

Plots showing the correlation between time-average peak velocity at the

patient interface outlet (umax) and the deposition efficiency (DE) up to the first impaction
point, which is (a) the back of the throat for the mouthpiece and mouth-throat model, and
(b) the bifurcation point for the nasal cannula and nose-throat model.
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Figure 6.8:

Particle deposition patterns in the (a) mouth-throat (MT) region with the jet

inlet velocity profile, (b) MT region with the turbulent inlet velocity profile, (c) nose-throat
(NT) and bifurcation (Bif) region with the jet inlet velocity profile, and (d) NT and Bif region
with the turbulent inlet velocity profile.
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Figure 6.9:

Example of jet diffusion by 3D rod array in the RE-d+RA-a mouth-piece

compared to the high velocity inlet jet in the RE-a design. Contours depict nodal values
of velocity magnitude (Vel. Mag.) on an axial slice though the mid-plane of the patient
interface.
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Figure 6.10: Deposition patterns in full mouthpiece & mouth-throat model for the (a) REa, (b) RE-d+RA-a, (c) RE-d+RA-g, and (d) RE-d+RA-c-EC design concepts (see Figure
6.2 for a description of the naming convention).
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Figure 6.11: Deposition patterns in full nasal cannula & nose-throat model for the (a) REa, (b) RE-d+RA-a, (c) RE-d+RA-g, and (d) RE-d+RA-c-EC design concepts (see Figure
6.2 for a description of the naming convention).
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Figure 6.12: Comparison of CFD-predicted deposition for the RE-d+RA-c-EC nasal
cannula design operated at (a) 13.3 LPM and (b) 9.9 LPM (25% reduction).
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6.7

Tables

Table 6.1:

Summary of experimentally determined patient interface and extrathoracic

deposition efficiencies and fractions (based on air-jet DPI emitted dose) from Farkas et
al. (2019) for the best-case mouthpiece and nasal cannula devices. Experimental values
are given as means with standard deviations shown in parenthesis [n=3].
Region

Mouthpiece
[%]
Interface DE
6.1 (0.7)
ET DE
9.4 (1.6)
Total DF
14.9 (2.1)
DE: Deposition efficiency
DF: Deposition fraction
ET:
Extrathoracic
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Nasal Cannula
[%]
7.1 (1.7)
11.4 (3.5)
17.8 (4.9)

Table 6.2:

Comparison of peak velocity (Peak Vel.), predicted regional deposition

efficiencies (DE) in the device (Dev), mouthpiece (MP), and mouth-throat (MT), and
predicted total deposition fraction (DF Tot) between the original mouthpiece and Design
Screen 1.
Case

Peak Vel.
[m/s]
10.5

DEDev
[%]
2.4

DEMP
[%]
6.4

DEMT
[%]
8.8a

DFTot
[%]
16.7

Original MP
Design Screen 1
GE-a
4.1
NAb
34.4
5.6
38.1
b
GE-b
4.7
NA
17.0
6.0
21.9
RE-ac
5.0
4.4
1.8
6.1
11.8
RE-b
3.9
14.0
15.9
5.5
31.7
RA-ad
2.7
27.7
7.7
4.9
36.5
RA-b
19.3
50.5
1.0
13.6
57.6
TD-a
3.7
0.8
57.0
5.4
59.7
TD-b
2.6
0.6
54.7
4.8
57.1
a:
Deposition efficiency for the Original MP case is from CFD-predicted particle
trajectories, whereas deposition efficiency for all other designs is predicted
from peak velocity at the mouthpiece outlet
b:
The gradual expansion cases go straight from the device outlet capillary to the
mouthpiece, hence there is no device loss
c:
The RE-a case gave the best reduction in device and MP losses from Design
Screen 1
d:
The RA-a case gave the best reduction in MT losses from Design Screen 1
GE:
RE:
RA:
TD:

Gradual Expansion
Rapid Expansion
Rod Array
Tear Drop
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Table 6.3:

Comparison of peak velocity (Peak Vel.), predicted regional deposition

efficiencies (DE) in the device (Dev), mouthpiece (MP), and mouth-throat (MT), and
predicted total deposition fraction (DF Tot) among the original mouthpiece, the best cases
from Design Screen 1, and Design Screen 2.
Case

Peak Vel.
DEDev
DEMP
DEMT
DFTot
[m/s]
[%]
[%]
[%]
[%]
Original MP
10.5
2.4
6.4
8.8
16.7
Design Screen 1 Best Cases
RE-a
5.0
4.4
1.8
6.1
11.8
RA-a
2.7
27.7
7.7
4.9
36.5
Design Screen 2
RE-a+RA-aa
2.1
6.0
4.9
4.6
14.6
RE-a+RA-c
2.6
1.9
13.2
4.9
19.0
RE-c+RA-a
3.9
22.5
10.6
5.5
34.5
CE+RA-aa
2.0
6.8
4.4
4.5
14.9
CE+RA-d
3.3
6.6
3.3
5.2
14.4
CE+RA-ea
1.8
1.9
7.4
4.4
13.1
CE+RA-f
1.7
0.8
9.5
4.4
14.1
a:
These cases demonstrated a marked improvement in predicted total deposition
fraction over the rod array cases from Design Screen 1, when combined with
the rapid expansion or cylindrical geometry, but further improvements are
possible
RE:
RA:
CE:

Rapid Expansion
Rod Array
Cylindrical Expansion
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Table 6.4:

Comparison of peak velocity (Peak Vel.), predicted regional deposition

efficiencies (DE) in the device (Dev), mouthpiece (MP), and mouth-throat (MT), and
predicted total deposition fraction (DFTot) among the original mouthpiece, the best cases
from Design Screens 1 and 2, and Design Screen 3.
Case

Peak Vel.
DEDev
DEMP
DEMT
DFTot
[m/s]
[%]
[%]
[%]
[%]
Original MP
10.5
2.4
6.4
8.8
16.7
Design Screen 1 and 2 Best Cases
RE-ab
5.0
4.4
1.8
6.1
11.8
RE-a+RA-a
2.1
6.0
4.9
4.6
14.6
CE+RA-a
3.3
6.6
3.3
5.2
14.4
CE+RA-e
1.8
1.9
7.4
4.4
13.1
Design Screen 3
RE-d+RA-aa,b
2.3
2.1
2.2
4.7
8.7
RE-d+RA-ea
2.4
0.6
2.0
4.8
7.2
a,b
RE-d+RA-g
2.7
0.9
1.7
4.9
7.4
RE-d+RA-a-434
3.9
2.9
1.4
5.5
9.6
a,b
RE-d+RA-c-EC
2.7
0.7
3.0
4.9
8.4
a:
These cases demonstrate a dramatic improvement in predicted total deposition
fraction (<9% combined MP and MT losses) compared to previous design
screens
b:
Candidate design concepts selected for evaluation with full mouthpiece and
mouth-throat CFD model
RE:
RA:
CE:
434:
EC:

Rapid Expansion
Rod Array
Cylindrical Expansion
4-3-4 rod array configuration (as opposed to 3-4-3)
Extended capillary from device outlet (inlet to MP)
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Chapter 7: Develop CFD Models of Upper Airway Geometries for
Pediatric Patients and Evaluate Delivery Efficiency and Aerosol
Growth with Comparisons to In Vitro Experiments
7.1

Objective
The objective of this study was to develop experimentally validated computational

fluid dynamics (CFD) models of the upper airways and growth chambers for 2-3-, 5-6-,
and 9-10-year-old patients with Cystic Fibrosis (CF), with a focus on using a nasal cannula
for nose-to-lung (N2L) administration. The 5-6-year-old model was experimentally tested
and provided in vitro data for validation of the CFD model. Results aim to establish
whether the hygroscopic properties of the powder formulation and expected residence
times through the model are capable of targeting the lower airways beyond Bifurcation 4
(B4+) and maximizing lung retention of the delivered dose.
7.2

Introduction
The primary symptom of CF in the respiratory airways is the dehydration and

thickening of mucus due to poor ion transport (Matsui et al., 1998; Tarran et al., 2001).
Due to poor mucociliary clearance of this thick mucus (Stoltz et al., 2015), it persists in
the patient’s airways and provides an ideal habitat for bacterial infections (Boucher,
2007). The most predominant bacteria found in the airways of CF patients is
Pseudomonas aeruginosa (Pa) (Elborn, 2016), which can be treated with inhalation of the
antibiotic tobramycin (Ramsey et al., 1999; A. L. Smith, 2002). The bacterial infections
cause various forms of damage to the respiratory airways and surfaces, such as
inflammation (narrowing of the airways), bronchiectasis (widening of the airways), and
mucus plugging (obstructions in the airways) (de Jong et al., 2004). Signs of such damage
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are apparent in computed tomography (CT) scans of patients diagnosed with CF at very
early stages in their life (Tiddens, Donaldson, Rosenfeld, & Pare, 2010), hence the need
for treatment of bacterial infections in pediatric subjects. Our group has recently
developed an optimized delivery system for oral and nasal administration of tobramycin
to pediatric patients, which consists of a ventilation bag to provide inhalation air, an inline
air-jet DPI for efficient aerosolization of the powder, and patient interface (mouthpiece or
nasal cannula) for high-efficiency extrathoracic (ET) transmission to the lungs (Bass,
Farkas, et al., 2019; Bass & Longest, 2020; Farkas, Bonasera, Bass, Hindle, & Longest,
2020; Farkas et al., 2019).
As a next step in the device development process, the current study explores
particle transport through the diseased airways to establish whether the pediatric air-jet
DPI system provides effective delivery of the pharmaceutical aerosol through the nose to
the lungs. The treatment of all infections with antibiotics requires eradication of the
bacterial colonies, otherwise mutated strains of the bacteria may develop that are drug
resistant. To ensure eradication of Pa with tobramycin, the amount of antibiotic delivered
to the airway surface liquid (ASL) must be above the minimum inhibitory concentration
(MIC) of 512 mg/L (Bos et al., 2017). Our proposed approach to tobramycin administration
in CF-diseased airways is to utilize excipient enhanced growth (EEG) powder
formulations to provide uniform dosing and maximize lung retention. EEG aerosols have
a small particle size when dry, which is characterized by mass-median aerodynamic
diameter (MMAD), that provides highly-efficient penetration into the lower airways.
Therefore, the advantage of using EEG aerosols for tobramycin administration is the
ability to target deposition in the lower airways where bacterial infection is more
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predominant (Tiddens et al., 2010). The hygroscopic excipient in the powder formulation
absorbs moisture from the humid respiratory airways, and the dry particles grow to form
larger droplets. The larger aerosol size in the lower airways improves lung delivery via an
increase in impaction during inhalation and exhalation, as well as increased
sedimentation during a breath hold.
The concept of an upper airway and growth chamber model to evaluate EEG
aerosol deposition and growth has previously been reported for oral (Longest, Tian, Li, et
al., 2012) and nasal (Longest et al., 2015) aerosol administration in adults. An
anatomically accurate model of the upper airways, from the ET region to Bifurcation 3
(B3), is used to model aerosol transmission to the lower airways. Thereafter, a cylindrical
growth chamber is used to model the aerosol growth as a representation of the humid
respiratory airways, with its dimensions selected to give a droplet residence time
consistent with the lungs. Previous studies using growth chamber models have shown
that they are an effective method for evaluating EEG aerosol growth via a concurrent
numerical and experimental approach, with good validation between CFD and in vitro
deposition and particle size data (Longest et al., 2015; Longest, Tian, Li, et al., 2012).
The present study developed new growth chamber models, which included the nosethroat (NT) region through the upper airways (up to B3), to evaluate EEG aerosol
deposition and growth in CF-diseased airways of patients aged 2-3, 5-6, and 9-10 years
old.
7.3

Methods
Three models were developed to evaluate aerosol transport and growth in a 2-3-,

5-6-, and 9-10-year-old patient. An in vitro growth chamber model for a 5-6-year-old
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patient (see Figure 7.1) was prototyped and tested with the best-case DPI and nasal
cannula from Farkas et al. (2020) (see Figure 7.2) to provide experimental data for CFD
model validation. Thereafter, numerical models for all three age groups were developed
to evaluate particle deposition and growth in the representative geometries. The
geometries used in the in vitro and numerical models consists of an upper airway (NT to
B3) extracted from CT scans and a growth chamber that was designed to provide an
aerosol residence time of approximately two seconds throughout the entire model (see
Figure 7.1). Characteristic airway dimensions for the three upper airway models are
provided in Table 7.1. Characteristic length scales in the NT region are consistent with
nasal deposition studies by Storey-Bishoff et al. (2008) and Golshahi et al. (2011), and
dimensions from the trachea were measured directly from CT scans. Measurements
beyond the trachea are not reported as the diseased state of the CF airways may not
provide a clear comparison between age groups. As expected, characteristic dimensions
for older patients are generally larger than the younger patients, which will likely influence
aerosol deposition in the upper airways.
Upper Airway and Growth Chamber Geometries
The NT region of the upper airway models were developed by segmentation of CT
scans with the Mimics software suite (Materialise, Leuven, Belgium) from patients with
healthy airways, as no nasal scans were available for patients diagnosed with CF. This
approach was deemed acceptable as the lung disease attributed to CF and Pa infections
predominantly affects the lower airways (Tiddens et al., 2010). Scans for the NT region
of the 2-3-, 5-6-, and 9-10-year-old upper airway models were selected from our database
of medically necessary CT scans, which were reviewed for quality and completeness
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under an Institutional Review Board protocol. When selecting scans for the study,
preference was given to scans that had a slice resolution of 1.0 mm or less and of patients
that had heights consistent with average values for the chosen age ranges. For the 2-3-,
5-6-, and 9-10-year-old models, the patient heights were 90 cm, 114 cm, and 144 cm
respectively, which are within the 20 th and 80th percentiles based on the WHO growth
charts (WHO, 2006). The segmentation and CAD model development generally followed
the same method as outlined by Bass et al. (2019), with the exception that the latest
automated skin surfacing capabilities in SpaceClaim v19.3 were utilized, which reduces
the manual effort required to convert STL surfaces to CAD data.
The tracheobronchial (TB) regions of the upper airway model (trachea to B3) were
also developed by segmentation of CT scans with Mimics, but the chosen scans were
from patients with moderate CF lung damage as scored by the PRAGMA-CF system
(Rosenow et al., 2015). The CF CT scans for all three age groups were provided and
evaluated for PRAGMA-CF score by Erasmus University Medical Center. For the 2-3-, 56-, and 9-10-year-old model, the patient heights were 100 cm, 122 cm, and 131 cm
respectively, which are also within the 20th and 80th percentiles based on the WHO growth
charts (WHO, 2006) and consistent with the NT scans. After segmentation and CAD
model development of the diseased TB regions, the airway was coupled to the NT region
of the healthy patient to form the upper airway geometry (NT-B3). The two regions were
coupled along the trachea at a point where there was less than a 1.0 mm deviation
between the cross-section profiles of the NT and TB regions and preserved the expected
tracheal length. A 10 mm coupling region along the length of the trachea (5 mm either
side of the coupling point) was then created to define the transition between the NT and
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TB regions. Due to the selection of a coupling point where there is minimal difference
between two regions and a relatively short coupling section, the effect of artificially joining
the healthy NT and diseased TB regions was assumed to be negligible. This assumption
will be tested by identifying any abnormal deposition patterns in the coupling region from
the CFD results.
The cylindrical growth chamber was designed with insight from preliminary CFD
work to provide minimal aerosol loss (<5% deposition) and a residence time of
approximately two seconds, which is consistent with the typical particle transport through
the lungs. The resulting chamber size for all age groups was a diameter of 101.6 mm (4”)
and length of 155.0 mm. For the in vitro model, the chamber was constructed from a
section of clear cast acrylic pipe, sourced from ePlastics (San Diego, CA), and a
prototyped lid, base, and outlet pipe.
Experimental Materials and Powder Formulation
Albuterol sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena,
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France).
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ).
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis,
MO).
Multiple batches of a spray-dried AS EEG powder formulation were produced
based on the optimized method described by Son et al. (Son, Longest, & Hindle, 2013;
Son, Longest, Tian, et al., 2013) using a Büchi Nano spray dryer B-90 (Büchi LaboratoryTechniques, Flawil, Switzerland). The AS EEG powder formulation contained a
30:48:20:2% w/w ratio of AS, mannitol, L-leucine, and Poloxamer 188. The AS EEG
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powder was used as a surrogate test aerosol in place of tobramycin. It is expected that
tobramycin powder formulations with the same hygroscopic properties as AS EEG will
perform comparably in regard to targeted lung delivery.
Experimental Methods
The in vitro tests of the 5-6-year-old model were conducted under room (22.0°C
and 33.5% RH) and humid airway (37.0°C and 99.0% RH) conditions, with the humid
conditions controlled in an environment cabinet. In addition, for the humid airway
conditions, the model walls were pre-wetted by running humid air (40.0°C and 99.0% RH)
through the model before actuating the device in the humid airway experiments. Cooling
of the 40°C saturated air in contact with the interior model walls resulted in water vapor
condensing onto the walls forming a thin liquid layer. All experimental model components
were developed by utilizing the CAD modelling capabilities in SolidWorks 2019 (Dassault
Systèmes, Paris, France) and most parts were then rapid prototyped. The exceptions to
prototyped parts were the acrylic growth chamber cylinder, as mentioned previously, and
the face of the NT region, which was made from cast silicone to create a soft nose. The
soft nose was required to accommodate the existing cannula design (which was
developed to fit a different NT model) and to provide an air-tight seal around the cannula
prongs. The material from which the soft nose is made is also more consistent with the
flexible soft tissue of the human nose than rigid 3D printer plastic. The casting process
used to make the soft nose was relatively simple, with the cast components developed in
SolidWorks 2019 such that the void represents the anterior region of the NT model. The
cast was then filled with Dragon SkinTM 20 silicone (Smooth-On, Lower Macungie, PA),
left to cure following the product instructions, removed from the cast, and then fixed into

287

the NT model with epoxy. As an additional precaution against air leaks in the model, all
connections between model components included O-rings to ensure air-tight sealing.
The delivery system chosen for experimental testing was the best-case device and
nasal cannula combination from Farkas et al. (2020). Details of the pediatric air-jet DPI
(see Figure 7.2a) and patient interfaces (see Figure 7.2b) have been discussed
extensively in our previous publications related to the development of this delivery system
(Bass, Farkas, et al., 2019; Bass & Longest, 2020; Farkas et al., 2020; Farkas et al.,
2019). The chosen air-jet DPI operates at an approximate flow rate of 10 LPM (from a
positive pressure gas source) and actuation time of 4.5 s (for an inhalation volume of 750
mL for a 5-6-year-old) with inlet and outlet airflow passage (i.e. capillary) diameters of
1.40 mm and 2.39 mm, respectively. The design parameters and operating conditions for
the air-jet DPI have previously been shown to give the best aerosolization performance
and high-efficiency N2L aerosol transmission (Farkas et al., 2020). The chosen nasal
cannula utilizes a 3D rod array to attenuate the high-velocity, highly turbulent air jet that
leaves the DPI outlet orifice, which has previously been shown to reduce interface and
NT losses (Bass & Longest, 2020).
The device actuation and experimental testing in the present study generally
follows the methods presented by our previous in vitro development performance
evaluation of the pediatric air-jet DPI and patient interfaces (Bass, Farkas, et al., 2019;
Farkas et al., 2020). Briefly, the aerosolization chamber is loaded with 10 mg of AS EEG
powder and actuated with a 6 kPa positive-pressure air source, using a compressed air
line and solenoid valve device, which efficiently aerosolizes the powder. Characterization
of the aerosol that leaves the growth chamber was performed using a Next-Generation
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Impactor (NGI) and AS drug masses were assayed with high-performance liquid
chromatography (HPLC). Preliminary experimental tests of the growth chamber model
showed that device actuation time was not sufficient to clear all the aerosol from the
growth chamber to the NGI, which lead to low recovered doses as powder remained
dispersed in the cylinder and was not assayed. Therefore, a second solenoid valve was
utilized that switched between pulling air from the chamber to ambient air, which was
controlled by a separate timer from the device actuation and ran for 8 s longer than device
actuation. In summary, the testing process was as follows: (i) switch the device solenoid
valve to deliver compressed air to the DPI at 10 LPM (see Label 1 in Figure 7.1) and at
the same time switch the NGI solenoid valve to pull air through the growth chamber at 45
LPM (see Label 2 in Figure 7.1) allowing make-up air at 35 LPM to be drawn through the
top of the growth chamber via one-way valves (see Label 3 in Figure 7.1); (ii) after 4.5 s,
the device solenoid valve closes and device actuation stops while the NGI solenoid valve
stays open for a total of 12 s, drawing all the aerosol from the chamber and delivering it
to the NGI. Using this approach, all recovered doses from experimental runs were greater
than 90% (average of 96.5%). The device emitted dose (ED) was defined as the
difference between the loaded AS dose and the mass of AS retained in the DPI after
actuation, divided by the loaded dose, and expressed as a percentage. The delivery
system ED was defined with a similar method, with the combined mass of AS retained in
the device and nasal cannula divided by loaded dose. The aerosol MMAD was identified
with linear interpolation of a cumulative percentage drug mass vs. cut-off diameter plot
from the NGI. The cut-off diameters of each NGI stage were calculated using the formula
specified in USP 35 (Chapter 601, Apparatus 5) for the operating flow rate of 45 LPM.
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CFD Models
Computational Domain and Spatial Discretization
The computational domain for the 5-6-year-old upper airway and growth chamber
replicates the experimental model as closely as possible, with numerical extensions
added as needed to ensure fully-developed flow enters the model inlets. As the CFD
model in this study neglects the device and patient interface, the inlet to the computational
domain begins 5 mm downstream of the nostrils, which is consistent with insertion of the
cannula prongs into the soft nose of the in vitro model. The inlet boundary is the elliptical
cross-section of the cannula prongs, with the surface between the nostrils and prongs
defined as walls to represent the air-tight seal between the cannula and soft nose. All
other inlet, outlet, and fluid-side wall boundaries are consistent between the
computational domain and in vitro model. The CFD model geometry was generated by
combining the flow path in the upper airway with the internal volume of the growth
chamber, and the solid parts of the TB region were subtracted from the air-side volume
to include the thickness of the model components in the chamber region. For CFD
evaluation of all three age groups, a similar approach was used to generate the 2-3- and
9-10-year-old models, using the same size growth chambers, with all geometries created
in SpaceClaim v19.3. Figure 7.3a shows the full geometry, including the upper airway
and growth chamber, for the 5-6-year-old CFD model, with Figure 7.3b-d showing only
the upper airway geometry for the 2-3-, 5-6-, and 9-10-year-old CFD models, respectively.
The cannula prong inlets on all three models were dimensioned to have similar areas,
and hence provide similar inlet velocities given a flow rate of 5 LPM, but the major and
minor radii of the elliptical prongs differed slightly to accommodate the different nostril
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shapes. For the 2-3- and 9-10-year old models, the major and minor radii were 2.5 and
4.5 mm respectively, which gave an average inlet velocity of approximately 2.36 m/s. For
the 5-6-year-old model, the major and minor radii were 2.25 and 5.25 mm respectively,
which gave an average inlet velocity of 2.25 m/s. As there is only a 0.1 m/s absolute
difference in inlet velocity between the models (5.0% relative difference) the effect of
changing cannula prongs on NT deposition is expected to be negligible and is a necessary
modification to accommodate differing nostril dimensions. Also note that the angular
rotation of prongs was different among all three models to fit the specific characteristics
of each patient. The effect of these alterations to the cannula design on patient interface
deposition is not known at this time.
Spatial discretization of the computational domain was performed by utilizing the
meshing capabilities available in FLUENT v19.3 (ANSYS Inc., Canonsburg, PA). An
unstructured mesh approach, as opposed to structured hexahedral cells, was used to
accurately resolve the complexity of the nasal passage surfaces and the transition from
the upper airway to growth chamber regions. Instead of traditional tetrahedral-type cells,
polyhedral cells were used to discretize the computational domain, which our group has
previously shown to be more computationally efficient and equally as accurate for
modeling particle transport through the upper airways (Bass, Boc, et al., 2019). Our
previous model development work has also identified that the near-wall (NW) mesh
resolution is critical to obtaining a successful experimental validation of the CFD model
(Bass & Longest, 2018b). The CFD models in the present study follow our current best
practices for polyhedral meshes of the respiratory airways (Bass, Boc, et al., 2019; Bass
& Longest, 2018b) with a wall y+ value of approximately one, five prismatic NW cell layers,
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and a layer-to-layer growth ratio of 1.2. As a final step, cell nodes were smoothed in
FLUENT v19.3 until the orthogonal quality metric was greater than 0.15, which ensures
a high-quality spatial discretization of the computational domain.
Mesh independence of the 5-6-year-old CFD model was established using the
Roache method for mesh refinement studies (Roache, 1994) by comparing the volumeaverage velocity magnitude (𝑣𝑚𝑎𝑔 ) and turbulent kinetic energy (𝑘) between three meshes
with increasingly higher degrees of spatial resolution. The three meshes had total cell
counts of 1.17, 1.98, and 4.06 million cells, which resulted in normalized grid spacing
ratios of 1.51, 1.27, and 1.00 respectively. Comparing the 1.98 and 4.06 million cell
meshes, the grid convergence index was less than 1% for both volume-average 𝑣𝑚𝑎𝑔 and
𝑘. Using Richardson Extrapolation (Richardson & Gaunt, 1927) to estimate the exact
solution of the field quantities and comparing these values to the 1.98 million cell case,
the relative error in 𝑣𝑚𝑎𝑔 and 𝑘 was 0.07% and 0.45%. Therefore, the 1.98 million cell
case was chosen for evaluation of the 5-6-year-old model, and its degree of spatial
discretization was subsequently applied to the 2-3- and 9-10-year old models.
Furthermore, the 1.98 million cell count is consistent with the previous growth chamber
study by Longest et al. (2012) which used a total of 1.49 million cells.
Numerical Models and Solver Settings
The Reynolds number at each nostril inlet, given a flow rate of 5 LPM and hydraulic
diameter of 6.1 mm (from the elliptical inlet boundary), was approximately 1,000, which
suggests laminar flow conditions. However, changes in cross-section throughout the
entire domain are known to change local flow conditions and induce turbulence in the
respiratory airways (Bass, Boc, et al., 2019). As such, the low-Reynolds number (LRN)
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k-ω turbulence model was implemented to model the transitional-to-turbulent flow regime.
The LRN k-ω model includes an eddy viscosity damping coefficient that allows it to
provide an accurate representation of the flow field in regions of both low and high levels
of turbulence. As this study evaluated EEG aerosol growth, both water vapor and air are
modeled as components of the continuous phase in the computational domain to account
for varying degrees of relative humidity, which required the addition of multi-species and
energy transport equations to the standard mass, turbulence, and continuity equations.
As the gas phase is composed of both air and water vapor, and temperature is not a
constant variable, the incompressible ideal gas law was used to model the fluid density.
Preliminary work on model development showed a jet formed as the flow passed
through the constriction of the glottis in the larynx (laryngeal jet), and this jet exhibits
transient behavior by oscillating back and forth through the trachea. The laryngeal jet
phenomenon is consistent with previous observations by Xi et al. (2008) and has a
significant effect on aerosol transport and deposition in the TB region. To capture this
phenomenon accurately and achieve a converged solution, a transient formulation of the
flow and turbulence transport equations was implemented in the CFD models. A time step
of 0.005 s was sufficient to reach convergence within at most 100 iteration per time step
and accurately modelled the oscillatory behavior of the laryngeal jet. A negligible
difference in flow field and particle deposition results was also observed when decreasing
the time step to 0.002 and 0.001 s, so using a time step of 0.005 s was deemed sufficient
for all CFD models. The flow field was initialized with quiescent conditions and a water
vapor mass fraction that was consistent with either room or humid airway conditions.
Monitoring plots of volume-average 𝑣𝑚𝑎𝑔 and 𝑘 against flow time showed that the
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transient start-up plateaued after approximately 0.5 s, so a total simulation time of 1.0 s
was used for all CFD models. As an alternative and more computationally efficient method
of tracking particles simultaneously with the flow field solution, particle trajectories were
calculated at a single representative time step, as opposed to tracking particles
throughout the full simulation duration. To ensure particle deposition and residence time
was not vastly different between time steps, trajectories were calculated in the 5-6-yearold model every 0.25 s, with the maximum absolute deviation from the mean deposition
fraction (DF) being 0.4% and the maximum absolute deviation from the mean residence
time being 0.3 s.
FLUENT v19.3 (ANSYS Inc., Canonsburg, PA) was used to obtain solutions for all
flow and turbulence equations, and all settings for modeling particle transport in the
respiratory airways followed our previously defined best practices (Bass, Boc, et al., 2019;
Bass & Longest, 2018b). The spatial discretization of the flow and turbulence transport
equations were second-order accurate, the gradient discretization used the Green-Gauss
Node-based method, and the SIMPLEC pressure-velocity coupling scheme was used.
Further details on the mass, momentum, and turbulence transport equations are available
in our previous publications (Longest et al., 2007; Longest et al., 2006). All inlet
boundaries used mass flow inlet conditions, with the nostril inlets (see Label 1 in Figure
7.1) each assigned a mass flow that gave a volumetric flow rate of 5 LPM (based on the
10 LPM device flow rate). The two one-way valve inlets (see Label 2 in Figure 7.1) were
each assigned a mass flow rate that gave a volumetric flow rate of 17.5 LPM, which
totaled a flow rate of 45 LPM through the model outlet to match the NGI operating
conditions (see Label 3 in Figure 7.1). Considering the water vapor entering the domain
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under humid airway conditions, the water vapor mass fraction at the one-way valve inlets
was consistent with the 99% RH at 37°C in the environmental chamber. As the device
was actuated with compressed air from a wall outlet, the water vapor mass fraction at the
nostril inlets was consistent with the 10% RH that is expected from dry wall air. All wall
boundaries in the CFD model use the no slip shear condition, the effects of surface
roughness on the flow field and particle trajectories were neglected, and the deposit-ontouch particle boundary condition was used to model deposition. As the walls of the in
vitro model were pre-wetted to be representative of upper airway conditions, the water
vapor mass fraction on all model walls was 99% RH at a wall temperature of 37°C.
Particle Transport and Growth
The discrete phase model (DPM) available in FLUENT v19.3 was used to calculate
the particle trajectories and deposition through the domain, with the Runge-Kutta scheme
selected to integrate the particle equations of motion. All DPM settings followed our
previously defined best practices and modeling recommendations (Bass, Boc, et al.,
2019; Bass & Longest, 2018b; Longest & Xi, 2007; Walenga & Longest, 2016), which
have been validated against experimental deposition data in the upper airways. NW
corrections, implemented via FLUENT user-defined functions (UDFs), were applied to
correct the over-prediction of micro-particle deposition that is often observed with the LRN
k-ω model. These NW corrections have been discussed in detail in our previous studies
(Bass, Boc, et al., 2019; Bass & Longest, 2018b; Longest & Xi, 2007) and provide an
accurate match between CFD and experimental deposition data. The effect of two-way
coupling between the flow field and particles, which is where the particle trajectories and
growth influence the continuous phase and vice versa, was evaluated as a possible
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improvement to matching numerical and experimental growth results. This is in contrast
to one-way coupling where only the flow field influences the particle trajectories and
growth. For two-way coupling, changes to water vapor mass fractions in the continuous
phase, based on mass transfer in and out of the discrete phase, is implemented via a
UDF and was previously described by Longest and Hindle (2011). Preliminary work
showed that a monodisperse aerosol, as opposed to using a polydisperse size
distribution, was capable of providing the expected aerosol growth and minimized
computational expense. When evaluating two-way particle tracking, reducing processing
times is an important consideration due to the additional computational requirements. The
initial particle diameter entering the nostrils is based on the 1.53 µm MMAD for the bestcase device and nasal cannula combination from Farkas et al. (2020). To ensure particle
convergence, a total of 10,000 particles were introduced to the domain, with 5,000
particles at each nostril inlet.
The current study implemented an enhancement to the NW correction UDFs
regarding the threshold, below which, the damping of the wall-normal velocity is applied
to model particle-wall hydrodynamic interactions. Previous versions of the NW correction
UDFs used a critical wall-normal distance between the particle and wall (called the NW
limit), and the wall-normal velocity was damped in the region below this value, with CFD
models using a typical NW limit value of 1-2 µm (Bass, Boc, et al., 2019; Bass & Longest,
2018b). A drawback to this approach in the current study is that there is a vast difference
between the average velocity in the upper airways and growth chamber, so a single NW
limit value was not able to achieve adequate model validation for both regions. Therefore,
a local Stokes number was implemented to define the criterion for damping the wall-
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normal velocity as a non-dimensionalized approach. The local Stokes number (Stk 𝑙 ) was
defined as:
𝑣𝑝 𝜌𝑝 𝑑𝑝2 𝐶𝑐
Stk 𝑙 =
18𝜇𝑓 ℎ𝑝

(7.3.1)

where: 𝑣𝑝 is the particle velocity magnitude, 𝜌𝑝 is the particle density, 𝑑𝑝 is the particle
diameter, 𝐶𝑐 is the Cunningham slip correction factor, 𝜇𝑓 is the fluid viscosity, and ℎ𝑝 is
the wall-normal distance between the particle and wall. With this implementation of the
NW correction UDFs, a critical Stk 𝑙 of 15 was used to determine whether the wall-normal
velocity is damped (as opposed to the NW limit), which gave the best validation with
experimental deposition data throughout the model geometry.
As a dry particle absorbs water from the humid airways it becomes a droplet, with
this condensation (as well as evaporation) of water implemented in FLUENT v19.3 via a
UDF. Longest and Xi (2008) originally reported the heat and mass transfer model for
multicomponent hygroscopic aerosols in the respiratory airways that was used in the
current study. These aerosol growth UDFs have been successfully validated against
experimental data in a simplified coiled tube geometry (Longest & Hindle, 2012), adult
growth chamber models (Longest et al., 2015; Longest, Tian, Li, et al., 2012), and for
noninvasive ventilation high flow therapy (Golshahi et al., 2013). The mass flux between
the droplet and humid ambient air is dependent on the mass fraction of water vapor on
the surface of the droplet (𝑌𝑣,𝑠 ), which is given as:
𝑌𝑣,𝑠 =

𝑃𝑣,𝑠 𝑆
𝜌𝑓 𝑅𝑣 𝑇𝑑

(7.3.2)

where: 𝑆 is the water activity coefficient, 𝑃𝑣,𝑠 is the water vapor saturation pressure, 𝜌𝑓 is
the fluid density, 𝑅𝑣 is water vapor gas constant, and 𝑇𝑑 is the droplet temperature. In
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Equation (7.3.2), the water vapor saturation pressure (𝑃𝑣,𝑠 ) is a function of the droplet
temperature, which is calculated in the growth UDFs with the Antoine equation and
includes the influence of the Kelvin effect, as follows:
𝑃𝑣,𝑠 = exp (

23.196 − 3816.44
4𝜎𝑑
) × exp (
)
𝑇𝑑 − 46.13
𝑑𝑑 𝜌𝑑 𝑅𝑣 𝑇𝑑

(7.3.3)

where: 𝜎𝑑 is the droplet surface tension, 𝑑𝑑 is the droplet diameter, and 𝜌𝑑 is the droplet
density. In Equation (7.3.3), the droplet surface tension is a function of the droplet
temperature, which is given by:
𝜎𝑑 = 0.0761 − 1.55𝐸-4(𝑇𝑑 − 273)

(7.3.4)

In Equation (7.3.2), the water activity coefficient (𝑆) is given by:
𝑖AS 𝜒AS + 𝑖MN 𝜒MN + 𝑖L 𝜒L −1
𝑆 = (1 +
)
𝜒𝑤

(7.3.5)

where: 𝑖 represents the component van’t Hoff factors, 𝜒 represents the component mole
fraction, and the subscripts 𝐴𝑆, 𝑀𝑁, and 𝐿 are the Albuterol Sulfate, Mannitol, and lLeucine formulation components, respectively. The growth UDFs calculate the mass flux
(Δ𝑚𝑤 ) to or from the droplet from condensation and evaporation as:
Δ𝑚𝑤 = 𝜌𝑓 ℎ𝑚 (𝑌𝑣,𝑠 − 𝑌𝑣,𝑓 )

(7.3.6)

where: ℎ𝑚 is the mass transfer coefficient and 𝑌𝑣,𝑓 is the mass fraction of water vapor in
the ambient air. In Equation (7.3.6), the mass transfer coefficient (ℎ𝑚 ) is given as:
ℎ𝑚 = Sh

𝐷
𝑑𝑑

(7.3.7)

where: Sh is the Sherwood number and 𝐷 is the mass diffusivity. Further details on the
specifics of the particle growth UDFs with regard to growth chamber models were
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described by Longest et al. (2012), and the material and hygroscopic properties for the
drug and the excipients were presented by Longest and Hindle (2011).
7.4

Results

Experimental Aerosol Deposition and Growth
Table 7.2 summarizes the aerosol deposition and growth results from experimental
testing of the 5-6-year-old model under room (22.0°C and 33.5% RH) and airway (37.0°C
and 99.0% RH) conditions. The mean (standard deviation (SD)) delivery system ED
(exiting the cannula and based on the device loaded dose) was 80.1% (3.6%) and 79.4%
(2.8%) for room and airway conditions respectively, which is consistent with the previous
experimental testing of the same device and nasal cannula combination by Farkas et al.
(2020) (reported as 79.5% (2.6%)). N2L aerosol transmission was very good and
provided high-efficiency delivery to the lower airways (B4+), with mean (SD) NT-B3
deposition losses of 4.2% (0.9%) and 5.3% (2.3) for room and airway conditions,
respectively. Comparing upper airway losses between the room and airway results shows
EEG aerosol growth in the humid conditions does not affect impaction deposition in the
NT and TB regions, and is hence capable of targeting the lower airways, as there is no
statistical significance between the room and airway NT-B3 DFs (p-value = 0.25). In vitro
losses in the growth chamber were below the acceptable limit (<5%) under both the room
and airway conditions with mean (SD) DFs of 3.7% (2.1%) and 0.9% (0.6%), respectively.
There was a significant increase in growth chamber losses under room conditions
compared to the humid experimental test (p-value = 0.03), which may be attributed to
increased static charge on the cast acrylic cylinder when humidity is relatively low.
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The aerosol MMAD at the growth chamber outlet under room conditions is
significantly larger (p-value = 0.002) than the aerosol size at the cannula prong outlet
reported by Farkas et al. (2020), with mean (SD) MMADs of 1.70 (0.05) µm and 1.53
(0.03) µm respectively. This result is consistent with observations from the growth
chamber study from Longest et al. (2012). At this time, it is unclear whether a small
amount of hygroscopic growth occurs in the in vitro model under room conditions, or
whether deposition associated with Brownian diffusion and turbulent dispersion increases
the aerosol MMAD at the growth chamber outlet. Comparing aerosol growth between the
room and airway conditions, the MMAD increased from 1.70 µm to 3.49 µm (with an
absolute difference of 1.49 µm MMAD or growth ratio of 1.9) due to humidity in the
respiratory airways, which is expected to provide targeted drug delivery to the lower
airways.
CFD Model Validation
The validation of CFD-predicted aerosol deposition and growth with experimental
data is illustrated in Figure 7.4. Figure 7.4a shows deposition results in the computational
domain under room conditions, with DFs based on the ED from the delivery system (as
opposed to loaded dose), due to the fact that the CFD model does not include the device
or patient interface. Numerical deposition predictions in the NT-B3 model and growth
chamber regions match the in vitro data well and are within the experimental SD, which
indicates successful validation of the particle tracking models. CFD predictions of
depositional losses in the growth chamber are somewhat lower than the experimental
results, but as mentioned previously, it is suspected that static charge on the acrylic
cylinder walls increased losses in this region. The CFD models do not include the effect
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of static charge on wall boundaries, and hence this behavior was not accounted for in the
numerical deposition results. As stated in the Methods, a 10 mm coupling region between
the healthy NT and CF-diseased TB regions was required in the model geometry.
Deposition patterns in the trachea, where the coupling region is located, do not show any
signs of abnormal deposition, which suggests the steps taken to connect the NT and TB
regions do not adversely affect interpretation of the results. Due to the relatively small
amount of hygroscopic particle growth that occurs under room conditions, aerosol
MMADs are not compared between experiments and CFD results in Figure 7.4a.
Figure 7.4b compares aerosol deposition and growth between experimental and
numerical data under humid airway conditions, with one-way coupling between the
continuous and discrete phase. As with the results from room conditions, CFD-prediction
of DFs in the NT-B3 model and growth chamber regions are well validated against in vitro
data and fall within the experimental SDs. A small decrease in airway model deposition
fraction was observed for humid airway conditions, which is surprising considering that
aerosol size increase should increase deposition by impaction. However, this small
decrease can be attributed to the random nature of both the turbulent dispersion model
and anisotropic NW turbulence corrections, and may also stem from small variations in
the flow fields for each case. That said, both CFD models are well validated and fall within
the experimental SDs for aerosol deposition, so the CFD predictions are considered an
accurate representation of particle transport. There was also no statistical significance
between NT-B3 losses when comparing experimental results under room and airway
conditions, so the DF increase that was observed during in vitro testing cannot be
attributed only to the presence of humidity. Looking at losses in the growth chamber, static
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charge on the cylinder walls is expected to be lower under humid conditions, and this
supports the decrease in deposition losses in this region that is seen in Figure 7.4b. The
CFD-predicted deposition on the growth chamber walls also shows a closer match to
experimental results in Figure 7.4b, which reinforces the suggestion that growth chamber
losses under room conditions were due to static charge on the cylinder walls. The CFDpredicted MMAD at the growth chamber outlet compares well to the in vitro data, which
indicates successful validation of the one-way coupled particle transport models and
evaporation/condensation UDFs.
Comparisons between the one-way and two-way coupled particle tracking
methods for aerosol deposition and growth are provided in Table 7.3. This shows there
is little difference between the two methods in the current study, with a maximum absolute
difference between two-way and one-way particle tracking for NT-B3 DF, Chamber DF,
and outlet MMAD of 0.1%, 0.7%, and 0.06 µm respectively. For two-way coupling, results
are presented for both 10 and 20 coupled cycles between the continuous and discrete
phase, which shows that doubling the number of coupled cycles does not influence
aerosol deposition and growth. Two-way coupled particle tracking consumes water vapor
(and reduces the RH) from the continuous phase as the particles grow under humid
conditions, but the relatively large volume of the growth chamber region means a large
amount of humid air is available, which is the most likely reason why there is little apparent
difference between one-way and two-way coupled particle tracking in the current study.
When considering particle paths through narrow airway bifurcations with less volume, the
effect of using with one-way or two-coupled particle tracking may be more pronounced.
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As the CFD model is well validated against experimental results using one-way particle
tracking (see Figure 7.4), this method is used throughout the remainder of this study.
Flow Field Characteristics
Figure 7.5 shows plots of velocity magnitude and relative humidity to illustrate the
flow field characteristics in the computational domain. Figure 7.5a presents a contour plot
of velocity magnitude on a plane that cuts through the left nostril, nasal passage, trachea,
and growth chamber. The figure demonstrates the wide range of velocity magnitudes in
the CFD model; for example, the velocity magnitudes at Point A and B were 8.55 m/s and
0.16 m/s respectively. This justifies the implementation of a local Stokes number to
determine the upper limit of the NW region, below which, wall-normal velocity is damped
to model particle-wall hydrodynamic interactions. The inset in Figure 7.5a shows a closeup view of flow through the larynx and clearly illustrates the laryngeal jet phenomena.
Similarly, Figure 7.5c shows the three-dimensional nature of the laryngeal jet with an isosurface of 7.0 m/s velocity magnitude through the trachea.
Figure 7.5b shows contours of relative humidity on the same plane as Figure 7.5a,
with the inset providing a close-up view of the nostrils and anterior nose. This illustrates
the introduction of the dry actuation air (at 10% RH) to the computational domain, which
is delivered from the cannula prong outlets in the experimental model. By the time the
flow reaches the nasopharynx region, observations from the CFD model show the dry air
has mixed with the humid air and RH values are greater than approximately 90%.
Conditions in the growth chamber are close to 99% RH, which facilitates aerosol growth
and provides an accurate representation of the respiratory airways. Figure 7.5d shows an
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iso-surface of 80% RH in the nasal passage and further illustrates mixing of dry and humid
air in the anterior region of the nose.
Residence Time and Maximum Particle Growth
Figure 7.6 plots the particle diameter (as MMAD) vs. residence time for the 5-6year-old CFD model. The points represent the diameter and time for each individual
particle that was tracked through the domain, at the time that they either deposited or
exited the mixing chamber, up to a maximum time of 5.0 s. The red dotted line shows a
logistic best-fit curve that represents the average particle diameter vs. residence time
profile, which is given by:
𝑑𝑝 =

2.67
0.75 + exp(−4.5𝑡)

(7.4.1)

where: 𝑑𝑝 is the particle diameter and 𝑡 is the particle residence time. This shows that the
MMAD begins to plateau around 1.2 s and levels off completely by a residence time of
2.0 s. As 𝑡 → ∞ in Equation (7.4.1), the particle diameter (𝑑𝑝 ) approaches an MMAD of
3.56 µm. From this, the 𝑡90 is defined as the residence time used in Equation (7.4.1) that
gives an MMAD that is 90% of 3.56 µm, which for this case is 0.55 s. Therefore, a
residence time of approximately 2.0 s is more than sufficient to maximize aerosol growth
and target drug delivery in the lower airways.
Comparison of Deposition and Growth between Age Groups
CFD predicted particle trajectories (colored by MMAD) and regional DFs are
presented in Figure 7.7. All three models show that the particle MMADs were less than
approximately 2.5 µm when the aerosol leaves the upper airways (NT-B3) and enters the
growth chamber. This suggests the hygroscopic properties of the powder formulation are
capable of targeting drug delivery to the lower airways (B4+). This claim was further
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supported with CFD predictions of relatively low aerosol deposition in the NT-B3 region
for all age groups. The MMADs at the outlet of the growth chamber for the 2-3- (Figure
7.7a) and 9-10-year-old (Figure 7.7c) models were 3.40 µm and 3.47 µm respectively,
which is consistent with the 3.38 µm MMAD from the 5-6-year-old model (Figure 7.4b and
Figure 7.7b). As stated above, a residence time of approximately 0.55 s was required to
reach 90% of the average final particle size for the 5-6-year-old model. Similar
expectations can be applied to the 2-3- and 9-10-year-old age groups, based on the
consistency in CFD predictions of aerosol growth between all three models. The relatively
large increase in aerosol size (absolute increase of 1.49 µm MMAD or a growth ratio of
1.9) suggests the EEG powder formulation is capable of targeting the lower airways. The
larger particle diameters in the lower airways are expected to reduce exhalation losses
with an increase in particle momentum and impaction, and improve lung retention with an
increase in sedimentation deposition (if a breath hold maneuver is employed).
As mentioned previously, the delivery system and powder formulation provide
high-efficiency N2L transmission in the 5-6-year-old model with a NT-B3 DF of 4.8%, as
shown by both Figure 7.4b and Figure 7.7b. For the 2-3-year-old model in Figure 7.7a,
the NT-B3 losses are higher than the 5-6-year-old with a CFD-predicted DF of 10.9%.
This increase in upper airway losses can be attributed to the smaller airway dimensions
in the younger patient (see Table 7.1), which leads to an increase in impaction deposition.
For the 9-10-year-old model in Figure 7.7c, the NT-B3 losses are also higher than the 56-year-old with a CFD-predicted DF of 7.0%. In this case, the increased losses are most
likely due to the increase in length of the upper airways, which leads to longer residence
times and more hygroscopic growth in the NT-B3 region. Looking at the particle
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trajectories in Figure 7.7c, the MMADs in the 9-10-year-old model are approximately 2.5
µm around the glottis, whereas the MMADs in a similar region for the 2-3- and 5-6-yearold models is less than approximately 1.75 µm. The increased particle size in the upper
airways for the 9-10-year-old caused more impaction losses and accounts for the small
increase in NT-B3 DFs. Despite the 2-3- and 9-10-year-old models having slightly higher
deposition in the NT-B3 region than the 5-6-year-old model, upper airway losses were
relatively low for all three cases and expected drug delivery to the lower airways (B4+)
was high. Upper airway losses may be improved by designing air-jet DPIs specifically for
the 2-3 and 9-10-year-old age groups.
7.5

Discussion
This study meets the objective by using a concurrent numerical and experimental

approach to demonstrate EEG powder formulations are capable of targeting the lower
airways (B4+) with N2L transmission through the diseased airways of pediatric patients
with CF. Upper airway losses (NT-B3) for the 2-3-, 5-6-, and 9-10-year-old age groups
were 10.9%, 4.8%, and 7.0%, respectively. Furthermore, the experimental results in
Table 7.2 show upper airway penetration fractions of approximately 70%, which is a vast
improvement to lung doses in pediatric patients compared to commercial devices. For
example, Below et al. (2013) reported that the Novolizer and Easyhaler provide a lung
dose (with respect to nominal dose) of 5% and 22%, respectively, on the tracheal filter of
a 4-5-year-old in vitro model. For the Cyclohaler, HandiHaler, and Spinhaler, Linder et al.
(2014) reported lung delivery efficiencies of 9% to 11%. The validated CFD models
showed the aerosol MMAD is expected to grow to at least 3.3 µm in the lower airways
after a residence time of approximately two seconds. As aerosol MMADs greater than 2.5
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µm are expected to be retained in the lungs (Longest et al., 2015), this demonstrates EEG
powder formulations are capable of maximizing lung dose in the diseased airways. Both
N2L transmission and lung retention may be improved further by designing devices and
powder formulations that are specific to each age group. Results in Figure 7.7 showed
differences in NT-B3 losses between the three models, which are attributed to differences
in airway dimensions between patients at different ages (see Table 7.1).
As a secondary outcome of this study, a locally-defined Stokes number (see
Equation (2.3.1)) was implemented for the first time to define the NW region where wallnormal velocities are damped to model particle-wall hydrodynamic interactions. This
approach led to successful validation of the CFD model by matching experimental particle
deposition data in both the upper airways and growth chamber regions. The
implementation of particle condensation and growth, as described by Equations (7.3.2)
to (7.3.7), was also successfully validated by matching the experimental characterization
of the aerosol MMAD at the growth chamber outlet.
A primary limitation of the current study for evaluating tobramycin delivery to CFdiseased airways is the use of AS EEG powder as a surrogate test aerosol. At this time,
the hygroscopic properties of tobramycin, particularly the van’t Hoff factor, have not been
experimentally determined, and as such tobramycin EEG powder formulations cannot be
evaluated with CFD models. Despite this limitation to the current study, inferences on the
ability for the delivery system to provide highly-efficient N2L transmission are still valid,
providing future tobramycin EEG powder formulation have similar hygroscopic
capabilities as the AS EEG aerosol. Other limitations include the use of a growth chamber
as a representation of particle growth in the lung pathways, modifications to the cannula
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prongs specific to each patient, and a lack of evaluation regarding interpatient variability.
The growth chamber was designed to provide a residence time of two seconds, which is
consistent with transport through the airways, but particle trajectories through lung
bifurcations are vastly different and may have an influence on aerosol growth. As such,
evaluation of EEG aerosol transport and growth through complete airways of CFdiseased lungs is required, which may be modelled using the stochastic individual
pathway methodology (Longest et al., 2015; Longest & Hindle, 2009a; Longest et al.,
2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Longest
& Vinchurkar, 2007b; Tian et al., 2011; Walenga & Longest, 2016). Modifying the cannula
prong dimensions and angular rotation for the 2-3- and 9-10-year-old age groups may
influence upstream losses in the patient interface. If device development of age-specific
devices is conducted, the effect of modifying the cannula design can be tested at the
same time. Finally, the current study evaluated a single upper airway model for each of
the three age groups, but interpatient variability is known to be significant for nasal
deposition of aerosols (Garcia, Tewksbury, Wong, & Kimbell, 2009; Golshahi, Noga, &
Finlay, 2012; Golshahi et al., 2011; Storey-Bishoff et al., 2008) and should be taken into
consideration.
Future work should intend to address the limitations of the current study that are
outlined above, including the evaluation of cannula modifications and expectations for
interpatient variability. The most important consideration for future work is to identify the
hygroscopic properties of tobramycin and conduct CFD-based evaluation of tobramycin
EEG aerosol transport through complete airway models. Identification of optimal powder
formulations is required to maximize lung delivery and retention, which can be tested by
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changing the fractions and types of hygroscopic excipients. Two-way coupled particle
tracking should also be reconsidered in complete airway models, as the reduced volume
of airway bifurcations compared to the growth chamber may cause a greater decrease in
RH values in the continuous phase as the particles absorb moisture. Also, the effect of
two-way coupled particle tracking is expected increase in significance as the aerosol
grows beyond 3 µm (Longest & Hindle, 2010, 2012), which is true for the current powder
formulation. Beyond numerical and in vitro testing of the air-jet DPI and 3D rod array
interface, in vivo evaluation of tobramycin delivery to the lower airways is required.
Additional validation of the locally-defined Stokes number and its implementation in the
NW correction UDFs is required to determine whether it is a worthwhile enhancement for
a variety of geometries and applications. Finally, future experimental work that uses
growth chamber models should endeavor to minimize static charge on the cast acrylic
cylinder to reduce chamber losses and provide better comparisons between the in vitro
and CFD results.
In conclusion, three growth chamber models were developed that represent the
diseased upper airways of pediatric patients diagnosed with CF in the age ranges of 2-3,
5-6, and 9-10 years old. The CFD models successfully validated aerosol deposition and
growth through the computational domain against experimental data via the
implementation of NW corrections and aerosol condensation and growth models. Results
show that the chosen air-jet DPI and nasal cannula delivery system was capable of
providing highly-efficient N2L aerosol delivery to the lower airways (B4+), with NT-B3
losses of 10.9%, 4.8%, and 7.0% for the 2-3-, 5-6-, and 9-10-year-old models
respectively. Lung retention of the delivered aerosol is also expected to be high, as the

309

aerosol grows to an MMAD of approximately 3.4 µm in all three cases after a residence
time of approximately two seconds.
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7.6

Figures

Figure 7.1:

Schematic of the experimental model showing the device (Air-jet DPI),

patient interface (Nasal Cannula), in vitro model (Upper Airway), and two-second
residence time chamber (Growth Chamber). Air flow in and out of the model is labelled
(1) 10 LPM actuation air into the device, (2) 35 LPM make-up air through two one-way
valves on the top of the chamber, and (3) 45 LPM to the NGI.
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Figure 7.2:

Overview of flow pathways for the best-case nose-to-lung delivery system

from Farkas et al. (2020) showing (a) the air-jet dry powder inhaler with inlet and outlet
flow passages and powder aerosolization chamber and (b) the 3D rod array nasal
cannula. Note that the air-jet DPI and cannula interface are included in the in vitro portion
of the study but not in the CFD models.
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Figure 7.3:

Summary of computational domains showing (a) the full CFD model of the

nose-throat, tracheobronchial region, and growth chamber for the 5-6-year-old child, (b)
the nose-throat to B3 (NT-B3) for the 2-3-year-old child, (c) the NT-B3 for the 5-6-yearold child, and (d) the NT-B3 for the 9-10-year-old child.
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Figure 7.4:

Validation of the numerical models showing (a) comparison of deposition

fractions (DF) in the airway and chamber regions between the CFD and in vitro
experimental (Exp.) results under room (i.e. no particle growth) conditions (22.0 °C and
33.5% RH) and (b) comparison of regional DF and particle mass-median aerodynamic
diameter (MMAD) at the model outlet between the CFD and experimental results under
upper airway conditions (37°C and 99%RH). Note that DFs here are given based on
system emitted dose, instead of loaded dose, as the CFD models do not include the
delivery system.
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Figure 7.5:

Summary of flow field characteristics in the 5-6-year-old model showing (a)

contours of velocity magnitude (Vel. Mag.) with a close-up view of the laryngeal jet, (b)
contours of relative humidity (RH) with a close-up view of the dry wall air (used to actuate
the device) entering the in vitro model, (c) iso-surface of 7 m/s velocity magnitude
depicting the 3D nature of the laryngeal jet, and (d) iso-surface of 80% RH in the nasal
cavity.
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Figure 7.6:

Plot of particle diameter vs. residence time, with each individual point

representing the values for a single particle at the time it deposited or exited the
computational domain. The red dashed line shows the best-fit curve and the dotted line
marks the average chamber residence time, which shows a two-second residence time
is sufficient to maximize particle growth.
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Figure 7.7:

Examples of CFD-predicted particle trajectories and growth through the

domain for the (a) 2-3-year-old, (b) 5-6-year-old, and (c) 9-10-year-old models, with
annotations of nose-throat to Bifurcation 3 deposition fraction (DF NT-B3), growth chamber
deposition fraction (DFGC), and outlet mass-median aerodynamic diameter (MMADOut).
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7.7

Tables

Table 7.1:

Characteristic dimensions for the 2-3-, 5-6-, and 9-10-year-old upper airway

models.
Dimension
2-3-year-old
5-6-year-old
3
𝑉 [mm ]
18,411
24,186
2
𝐴𝑠 [mm ]
13,742
16,202
𝑉/𝐴𝑠 [mm]
1.34
1.49
𝐿𝐶𝑃 [mm]
124.4
126.4
12.2
13.8
√𝑉/𝐿𝐶𝑃 [mm]
𝐷ℎ,𝐺 [mm]
5.7
6.7
𝐿 𝑇 [mm]
64.6
75.3
𝑉:
NT-B3 volume
𝐴𝑠 :
NT-B3 surface area
𝐿𝐶𝑃 : Central path length from nostrils to glottis
𝐷ℎ,𝐺 : Hydraulic diameter of the glottis
𝐿𝑇:
Length of trachea from glottis to carinal ridge

318

9-10-year-old
41,323
23,060
1.79
128.5
17.9
6.8
97.7

Table 7.2:

Summary of aerosol deposition and growth from experimental testing under

room and humid airway conditions. Deposition fractions are defined based on device
loaded dose. Experimental values are given as means with standard deviations shown in
parenthesis [n=3].
Room Conditions
(22.0°C and 33.5% RH)
Aerosol Deposition
Device DF [%]
13.3 (2.1)
Cannula DF [%]
6.6 (1.5)
System ED [%]
80.1 (3.6)
NT-B3 DF [%]
4.2 (0.9)
Chamber DF [%]
3.7 (2.1)
Model PF [%]
70.6 (5.0)
Aerosol Growth
MMAD [µm]
1.70 (0.05)
RH:
Relative humidity
DF:
Deposition fraction
ED:
Emitted dose
NT-B3: Nose-throat to Bifurcation 3
PF:
Penetration fraction
MMAD: Mass-median aerodynamic diameter
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Airway Conditions
(37.0°C and 99.0% RH)
13.8 (3.1)
6.9 (0.5)
79.4 (2.8)
5.3 (2.3)
0.9 (0.6)
70.1 (1.4)
3.19 (0.30)

Table 7.3:

Comparison of aerosol deposition and growth between the one-way and

two-way coupled particle tracking methods. Deposition fractions are based on delivery
system emitted dose.
One-way Coupling

Two-way Coupling
10 Cycles

Aerosol Deposition
NT-B3 DF [%]
4.8
4.7
Chamber DF [%]
1.7
1.2
Aerosol Growth
MMAD [µm]
3.38
3.39
NT-B3:
Nose-throat to Bifurcation 3
DF:
Deposition fraction
MMAD:
Mass-median aerodynamic diameter
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Two-way Coupling
20 Cycles
4.8
1.0
3.32

Chapter 8: Extend and Develop CFD Lung Models to Predict Regional
Lung Deposition and Tobramycin ASL Concentrations in Healthy
and CF Complete-airway Lung Models
8.1

Objective
The objective of this study was to develop a high-efficiency aerosol delivery

strategy for nose-to-lung (N2L) administration of tobramycin antibiotics to children with
Cystic Fibrosis (CF) using a complete-airway computational fluid dynamics (CFD) model.
The basis of the strategy is excipient enhanced growth (EEG) delivery where a small
particle aerosol is initially formed and increases in size through the respiratory airways.
Ideal conditions for antibiotic aerosol delivery included: (i) airway surface liquid (ASL)
concentrations of tobramycin greater than the minimum inhibitory concentration (MIC) of
512 mg/L; (ii) uniform drug delivery throughout the tracheobronchial (TB) airways; and
(iii) high concentrations of tobramycin in the small TB airways (which often have
occlusions and trapped air). Specifically, this study aimed to: (i) determine tobramycin
concentration in the ASL for N2L aerosol delivery in a 5-6-year-old complete airway model
for static and EEG aerosol administration; (ii) determine the effect of CF-diseased airways
on aerosol delivery for static and EEG aerosols; and (iii) determine the extent to which
EEG powder formulations can overcome the challenges associated with the delivery of
aerosols to partially occluded airways.
8.2

Introduction
Bacterial lung infections in patients that are diagnosed with CF can be treated by

oral prophylactic antibiotics (Elborn, 2016; Hoiby, 2011), but administration of inhaled
tobramycin is the preferred method as it treats Pseudomonas aeruginosa (Pa) infections
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directly in the airways (Proesmans, Vermeulen, Boulanger, Verhaegen, & De Boeck,
2013; Ratjen, Munck, Kho, Angyalosi, & Grp, 2010; Taccetti et al., 2012). Pa is the most
predominant bacteria found in the lungs of CF patients (Elborn, 2016), and early treatment
in pediatric patients can prevent the development of chronic infections during childhood
(Hoiby, 2011). In a series of publications, our group has developed a high-efficiency
delivery system (Bass, Farkas, et al., 2019; Bass & Longest, 2020; Farkas et al., 2020;
Farkas et al., 2019) for N2L administration of tobramycin EEG powder formulations to
children. Most recently, the best-case air-jet dry powder inhaler (DPI) and nasal cannula
system from Farkas et al. (2020) demonstrated excellent aerosolization and delivery
performance, with a 1.53 µm mass-median aerodynamic diameter (MMAD) and 79.5%
emitted dose (ED) from the cannula prong outlets. This delivery system is operated at a
flow rate of approximately 10 LPM, which combined with an inhalation volume of 750 mL,
gives an actuation time of approximately 4.5 s. The small aerosol size and hygroscopic
growth of the powder formulation is expected to maximize nasal transmission and target
delivery to the lower airways. Concurrent numerical and experimental evaluation in a
growth chamber model of a 5-6-year-old CF patient (Chapter 7) showed low upper airway
losses (6.6%) and an outlet MMAD of 3.19 µm after a residence time of approximately
2.0 s.
This study builds upon the previous work in this series by evaluating EEG aerosol
transport and delivery in an anatomically-accurate, complete-airway, CFD model. The
growth chamber model provides a good representation of typical aerosol residence times
through the lungs, but particle trajectories through airway bifurcations are expected to be
very different. Our group has developed and used stochastic individual pathway (SIP)
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models for a number of studies on pharmaceutical aerosol delivery in the complete-airway
CFD models. This method has been successfully validated against both in vitro (Longest,
Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 2011) and
in vivo (Longest et al., 2015; Tian et al., 2015; Walenga & Longest, 2016) data sets. The
current study advances SIP modeling capabilities by applying the method to pediatric
patients and including the effects of CF-related airway disease on airway anatomy.
Previous work has also used albuterol sulphate (AS) EEG powder formulations as
a surrogate test aerosol, as the hygroscopic properties of tobramycin were not
established. The water activity characteristics for tobramycin were identified by
supplemental work for this study, following a similar method as Longest and Hindle
(2011), which allowed for CFD-based evaluation of tobramycin EEG powder formulations
through complete-airway models. The EEG method uses an initially small aerosol size,
with the particles growing in size and becoming droplets due to hygroscopic excipients
that absorb moisture from the humid airways. The chosen hygroscopic excipient in this
case was mannitol, which has the added benefit of improving transport though the ASL
(Geller & Rubin, 2009). This study provides a proof of concept for the administration of
tobramycin EEG aerosol to the diseased airways of pediatric CF patients. EEG delivery
strategies are capable of navigating the natural filtration of the extrathoracic (ET) region
and targeting delivery to specific airways. Lung retention can also be improved, with the
larger final particle size increasing sedimentation (breath-hold) and impaction (exhalation)
deposition in the lower airways. These advantages are well suited to the challenges
associated with treating bacterial infection in diseased airways, as antibiotics require
uniform dosing and high drug concentrations at the site of infection.
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8.3

Methods

SIP Airways
The SIP methodology for complete airway modeling has been utilized in numerous
studies by our group and has shown successful validation against both in vitro (Longest,
Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 2011) and
in vivo (Longest et al., 2015; Walenga & Longest, 2016) data. The current study follows
the most recent methodology and best practices for SIP models from Tian et al. (2015)
who validated pharmaceutical aerosol deposition against in vivo, 2D gamma scintigraphy
results. Briefly, the airways of the lungs are split into three regions that are modeled
individually with CFD: (i) the upper airways consisting of the nose-throat to Bifurcation 3
(NT-B3); (ii) the middle airways (B4-B7); and (iii) the lower airways (B8-B15). Alveolar
models are also available for evaluation of aerosol transport beyond B15 (KhajehHosseini-Dalasm & Longest, 2015). Separating the airways into distinct regions allows
for the application of the required CFD models to account for differences in flow conditions
throughout the lungs. The upper airway geometry is extracted from computed tomography
(CT) scans to ensure that it is anatomically accurate and specific to the chosen patient
population (e.g. adults, pediatrics, and disease states). The small diameters of the middle
and lower airways make it difficult to extract them from CT scans, so idealized, physically
realistic bifurcation units are used for the geometry from B4-B15 (Heistracher & Hofmann,
1995). Previous work has shown that following pathways through the lower-left lobe
provides a representative average of deposition in the entire lung (Longest, Tian,
Delvadia, et al., 2012), so the same approach is applied in the current study as a basis
for comparison between aerosol delivery strategies. However, future studies are planned
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that intend to compare lobar differences between healthy and CF-diseased airways. The
current study assumes a breath-hold maneuver is performed by the patient after aerosol
administration, and as such all particles that leave B15 are assumed to deposit in the
alveoli by sedimentation deposition. Therefore, a numerical alveolar-level aerosol
transport and deposition model was not required.
The SIP models in previous work have focused on aerosol transport through adult
airways. As the current study is specific to healthy and CF-diseased pediatric airways,
modifications to the models must be made to account for the differences in airway
dimensions and disease characteristics. For the upper airways, the NT-B3 region is
extracted from CT scans of a healthy and a CF-diagnosed 5-6-year-old child. For the B4B7 and B8-B15 regions, the SIP geometries must first be scaled to appropriate
dimensions. The scale factor was selected such that the B4 inlet diameter matched the
hydraulic diameter of the B3 outlets into the lower-left lobe from the upper airway CT
scans. A hydraulic diameter was used as the CT scan geometry had non-circular outlets.
For the healthy and CF-diseased airways the measured diameters were 4.4 mm and 3.8
mm, respectively, which is consistent with the 4.4 mm diameter from the ICRP model
(1994) and the 4.6 mm diameter (standard error of 0.37 mm) from Phalen et al. (1985) of
an average 5-year-old. It is also expected that the diseased airways would generally have
smaller diameters due to mucus accumulation and inflammation (de Jong et al., 2004),
as well as CF patients generally being underdeveloped compared to their peers (Stalvey
et al., 2017). This approach to scaling the SIP geometries was previously validated
against well-known algebraic and empirical correlations for an infant complete airway
model (Bass & Longest, 2018a). Due to the absence of relevant in vitro and in vivo data,
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the current study also validates the 5-6-year-old SIP models against the ICRP (1994),
Rudolf (1990), and Finlay (2001) algebraic correlations of deposition fraction. Specifically,
the Finlay correlation combines an analytical approximation for sedimentation (Heyder &
Gebhart, 1977) and an empirical impaction probability (Chan & Lippmann, 1980). To
account for hygroscopic growth in the correlations, the particle size in distal regions of
each model is taken as the average particle size from upstream outlets of the CFD results.
For example, the particle size entering the B4 region in the correlations is taken as the
average MMAD of the aerosol that leaves the upper airway CFD model (NT-B3).
As a disease and in combination with bacterial infections, CF is associated with
several types of damage to the airways, including inflammation (airway narrowing),
bronchiectasis (airway widening), and mucus accumulation (airway obstructions) (de
Jong et al., 2004). Instances of these forms of airway damage were observed in CFdiagnosed patients at very early ages (Tiddens et al., 2010), with examples from CT scans
of a 5-6-year-old patient shown in Figure 8.1a. Label A in Figure 8.1a shows an example
of axisymmetric mucus plugging on a daughter branch of a bifurcation, Label B shows an
example of asymmetric mucus accumulation in the bifurcation, and Label C shows an
example of bronchiectasis. To provide an accurate representation of the diseased
airways, modifications were added to the B4-B7 and B8-15 SIP regions to account for
CF-related airway damage. Figure 8.1b shows axisymmetric mucus plugging on the
daughter branch of B4, Figure 8.1c shows asymmetric mucus accumulation in the
bifurcation region of B5, Figure 8.1d shows axisymmetric bronchiectasis on the daughter
branch of B6, and Figure 8.1e shows asymmetric mucus accumulation on the daughter
branch of B7 (not shown in CT scan example). These four forms of lung damage were
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selected as they were both representative of observations in CF-diseased airways and
could be added to the structured block meshing of the SIP models. More complex forms
of airway damage would require an unstructured meshing approach for the SIP
bifurcations, which has not currently been validated. Measurements from CT scans of a
patient with moderate CF disease, as scored by PRAGMA-CF (Rosenow et al., 2015),
showed an average 30% change in cross section (narrowing or widening) in areas of
airway damage, up to an approximate maximum of 60% to 70%. As such, these same
localized percent reductions or increases in airway dimensions were included in the
diseased SIP models (as shown in Figure 8.1b-e) to be consistent with observations from
the CT scans.
In summary, four SIP models were evaluated in the current study as a basis for
comparison between healthy patients and varying degrees of CF disease states, namely:
the (i) Healthy; (ii) CF Scaled; (iii) CF Moderate; and (iv) CF Severe models. For the
Healthy model, the upper airways (NT-B3) were extracted from separate head and chest
CT scans taken from a single patient on the same day. The CT scans were medically
necessary, yet unrelated to airway disease, and confirmed to be free of airway
abnormalities by a pediatric otolaryngologist. The B4-B7 and B8-B15 regions of the
Healthy model were scaled versions (to a B4 inlet diameter of 4.4 mm) of the adult SIP
geometries through the lower-left lobe, as described above. For the three CF models, the
upper airways used the same nose-throat (NT) region as the Healthy model, as CT scans
of the nasal cavity for CF patients are typically not conducted to minimize radiation
exposure. The trachea to B3 region was extracted from CT scans of a patient with
moderate CF disease, which were provided by Erasmus Medical Centre (Dr. Harm
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Tiddens), and coupled to the healthy NT region. This CF upper airway geometry is the
same as the 5-6-year-old model used in the growth chamber study (Chapter 7). For the
B4-B7 and B8-B15 regions, three examples of each region were developed to account
for varying degrees of disease state. The CF Scaled model uses scaled versions (to a B4
inlet diameter of 3.8 mm) of the adult SIP geometries through the lower-left lobe. The CF
Moderate model starts with the CF Scaled geometry and adds one form of airway damage
(from Figure 8.1b-e) to each bifurcation with a 30% change in cross section. Forms of
airway damage added to each bifurcation were randomly selected. Similarly, the CF
Severe model also starts with the CF Scaled geometry, but adds one instance of
axisymmetric mucus plugging (Figure 8.1b), asymmetric mucus accumulation (Figure
8.1c), and axisymmetric bronchiectasis (Figure 8.1d) to each bifurcation (resulting in three
forms of damage per bifurcation) with a 60% change in cross section. Comparisons
between the Healthy and CF models are given in Figure 8.2, with Figure 8.2a showing
the NT-B3, B4-B7, and B8-B15 regions for the Healthy model, and Figure 8.2b showing
the same three regions for the CF Moderate model. Comparing between the three CF
models, Figure 8.3a and b show the B4-B7 and B8-B15 regions for the CF Scaled model,
Figure 8.3c and d show the same two regions of the CF Moderate model, and Figure 8.3e
and f show the extreme case in the CF Severe model.
One final consideration for applying SIP models to CF-diseased pediatric airways
is lobar ventilation and its influence on flow distribution at each of the outlets in the upper
airway CFD models. For the original SIP models, lobar ventilation fractions were sourced
from Horsfield et al. (1971), Asgharian and Price (2006), and Yin et al. (2010), which were
measured from healthy adults. However, lobar differences in disease severity is known
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to exist in the lungs of CF patients (Bos et al., 2017; Bos et al., 2015), which affects lobar
ventilation fractions. In the current study, lobar ventilation fractions were measured
directly from inhalation and exhalation CT scans of a 5-6-year-old with moderate CF
disease (the same patient as the upper airway models). Lung lobes were semiautomatically segmented from the inhalation and exhalation scans using the Chest
Imaging Platform module (Estepar et al., 2015) available in the open-source 3D Slicer CT
segmentation software (Kikinis, Pieper, & Vosburgh, 2014). The ratio of inhalation to
exhalation volume for each lobe was then used to determine the lobar ventilation fractions
specific to the selected patient. Figure 2.1 shows the segmentation of each lung lobe at
inhalation and exhalation, and Table 7.1 summarizes the ventilation fractions for the
healthy (based on the adult SIP models) and diseased models.
CFD Models
Computational Domain and Spatial Discretization
The geometry for the computational domain of both the Healthy and CF upper
airway models was generated with a similar method to the growth chamber study
(Chapter 7). Briefly, CT scans of the nasal cavity and tracheobronchial airways were
segmented with the Mimics software suite (Materialise, Leuven, Belgium). The triangular
STL surfaces of the NT-B3 regions were then converted to CAD surfaces by utilizing the
automated skin surfacing capabilities in SpaceClaim v19.3 (ANSYS Inc., Canonsburg,
PA), and prepared for mesh generation. Spatial discretization of the computational
domain was performed with the polyhedral meshing capabilities available in FLUENT
v19.3 (ANSYS Inc., Canonsburg, PA) to accurately resolve the complexity of the nasal
cavity geometry. The spatial resolution of the mesh matched the grid independent,
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validated results from the growth chamber study (Chapter 7). The near-wall mesh
resolution follows our best practices of five prismatic layers and an area-averaged wall y+
value of approximately one (Bass, Boc, et al., 2019; Bass & Longest, 2018b). Numerical
extensions were added to each of the upper airway B3 outlets to prevent reversed flow
and aid in convergence of the transport equations. As the physically realistic bifurcations
of the B4-B7 and B8-B15 regions lend themselves to blocked topologies, a structured
hexahedral mesh can be applied to resolve the spatial discretization, which improves
solution convergence, model accuracy, and computation times. The spatial resolution of
the B4-B7 and B8-B15 regions matches the models used in the in vivo validations
described by Tian et al. (2015). When adding examples of airway damage to the middle
and lower airways for the CF Moderate and CF Severe models, care was taken to
maintain the blocking structure and spatial resolution of the SIP models.
Numerical Models and Solver Settings
The numerical models and solver settings for the upper airway flow fields generally
followed the SIP best practices outlined by Tian et al. (2015). Despite an inlet Reynolds
number of approximately 1,000 (flow rate of 5 LPM and hydraulic diameter of 6.1 mm),
low-Reynolds number (LRN) k-ω turbulence was used to model the transitional-toturbulent flow regime, as the glottis in the laryngeal region is known to induce turbulence
(Bass, Boc, et al., 2019; Xi et al., 2008; J. X. Xi et al., 2012). A transient form of the
transport equations was also employed to model the oscillatory behavior of the laryngeal
jet (Xi et al., 2008), which is also consistent with the SIP modeling recommendations
presented by Tian et al. (2015). Plots of deposition fraction vs. flow time were monitored
and aerosol deposition was observed to plateau at approximately 0.5 s, so flow solutions
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were terminated after 1.0 s flow time instead of modeling the full 4.5 s actuation time. In
contrast to the upper airways, the CFD set-up for the middle and lower airways employs
laminar flow models and a steady-state formulation of the transport equations.
Observations from CFD models have previously shown that turbulent flow can extend
from the laryngeal jet through B4 (Xi et al., 2008), but validation work in the SIP models
have shown the best match to in vivo data with laminar conditions in the B4-B7 and B8B15 regions (Longest et al., 2015; Tian et al., 2015; Walenga & Longest, 2016). For
context, in the Healthy model, the Reynolds number is approximately 500 at the B4 inlet
and approximately 100 at the B8 inlet.
Beyond considerations specific to SIP models, the remaining solver settings
followed our previously defined best practices for respiratory aerosol transport (Bass,
Boc, et al., 2019; Bass & Longest, 2018b). FLUENT v19.3 (ANSYS Inc., Canonsburg,
PA) was used to obtain solutions for all flow and turbulence equation. The spatial
discretization of the flow and turbulence transport equations were second-order accurate,
the gradient discretization used the Green-Gauss Node-based method, and the SIMPLEC
pressure-velocity coupling scheme was used. As the current study evaluates hygroscopic
aerosol growth, the continuous phase in the flow field was composed of air and water
vapor to model the relative humidity (RH) of the fluid. The multi-species and energy
models were activated, and the incompressible ideal gas law was used to model fluid
density.
In this study, the pediatric air-jet DPI was operated in nose-to-lung aerosol delivery
mode, in which the nasal cannula interface is inserted into the nostrils forming an airtight
seal. The simulation began at the nostril interface. As the device was operated at a flow
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rate of 10 LPM, the mass flow inlet boundary condition was applied at the nostrils with a
mass flow rate selected that provided a volumetric flow rate of 5 LPM through each nostril.
The water vapor mass fraction at the nostril inlets was consistent with the 10% RH that is
expected from dry wall air, which is passed through the air-jet DPI and nasal cannula,
and the temperature was set to ambient conditions (20°C). The outlet boundaries in the
upper airway models were set to the outflow condition at approximately the lobar bronchi,
where a fraction of the total outlet mass flow rate is applied to each boundary, with the
fractions defined for the Healthy and CF models as shown in Table 7.1. Downstream of
the upper airways, in the B4-B7 and B8-B15 regions, the inlet boundaries used velocity
inlet boundary conditions with a parabolic spatial profile (due to laminar flow) that matched
the volume flow rate from the upstream bifurcation outlet. The water vapor mass fractions
at the inlet to the middle and lower airways were taken as the area-weighted average
value from the upstream outlet, which was close to 99% RH in all cases as the dry wall
air had completely mixed with the humid airway by the end of the upper airways. Outlet
boundaries used outflow fractions that assume 50% of the flow goes through each
bifurcation outlet, which is consistent with the assumptions from Tian et al. (2015). The
wall boundaries in all models used the no-slip shear condition, and effects of surface
roughness were neglected as airway surfaces are expected to be smooth at the
microscopic level. In addition, the water vapor mass fraction on all wall boundaries was
set to 99% RH as the airway surfaces are expected to be moist.
Particle Transport and Growth
The discrete phase model (DPM) available in FLUENT v19.3 was used to calculate
the particle trajectories and deposition through the domain, with all DPM settings following
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our previously defined best practices and modeling recommendations (Bass, Boc, et al.,
2019; Bass & Longest, 2018b). In the upper airways, where the k-ω turbulence model is
applied, near-wall corrections were implemented (Longest & Xi, 2007) to account for the
over-prediction of aerosol deposition associated with the k-ω model. As the middle and
lower airways were modeled with laminar flow conditions the near-wall corrections were
not applicable and not required. At the inlet to the upper airway models, particles were
introduced in to the domain with a monodisperse size distribution, which is an acceptable
assumption based on findings from Tian et al. (2015). Using a polydisperse size
distribution would provide a more accurate representation of the aerosol, but would be
more computationally expensive in the transient model. In the B4-B7 and B8-B15 regions,
the particles were introduced with a polydisperse distribution that matched the aerosol
size at the upstream outlet and accounted for variability in particle growth through the
upper airways. To ensure particle convergence, a total of 90,000 particles were
introduced into each SIP region, which is consistent with the recommendations from Tian
et al. (2015).
The growth of the EEG aerosol is implemented in the CFD models with the
evaporation and condensation UDF that was described in Chapter 7 and originally
presented by Longest and Xi (2008). Previous work has utilized AS EEG powder
formulation as a surrogate test aerosol for tobramycin, as the hygroscopic properties for
tobramycin were not available. In the current study, the hygroscopic properties for
tobramycin were established by the VCU School of Pharmacy, which allowed for
tobramycin EEG formulations and its growth characteristics to be modeled with CFD for
the first time. The material and hydroscopic properties for tobramycin used in this study
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were a molecular weight of 467.5 g/mol, density of 990.0 kg/m3, saturated mole fraction
of 0.037, and van’t Hoff factor of 2.46. The true density was measured by gas pycnometer
AccuPyc II 1340 (Micromeritics) and the water activity (saturated mole fraction and van’t
Hoff factor) was measured with a method consistent with Longest and Hindle (2011). The
chosen tobramycin EEG powder formulation in this study contained a 60:20:20% w/w
ratio of tobramycin, mannitol, and L-leucine, which resulted in a particle density of 1117.2
kg/m3.
In summary, four initial aerosol cases were modeled to demonstrate a comparison
between delivery strategies and provide a proof of concept for tobramycin EEG aerosol
administration to CF-diseased airways, namely: (i) Base EEG; (ii) Min Static; (iii) Max
Static; and (iv) Optimal EEG. The Base EEG case includes aerosol growth based on the
tobramycin EEG powder formulation stated above, and an initial monodisperse geometric
particle diameter of 1.45 µm, which is consistent with the 1.53 µm aerosol MMAD from
the chosen delivery system (Farkas et al., 2020). The Min Static case does not include
aerosol growth and uses an initial geometric particle diameter of 1.45 µm (ρ = 1117.2
kg/m3) to evaluate how hygroscopic growth influences drug delivery by drawing
comparisons with the Base EEG case. Similarly, the Max Static case also does not
include hygroscopic growth, but uses an initial geometric particle diameter of 3.31 µm
(3.50 µm MMAD) to evaluate how a small or large aerosol size penetrates the upper
airways. The three initial aerosol cases stated above all assumed a nominal value of 75
mg of tobramycin entered the upper airways, which was used to determine ASL
concentrations throughout the airways. Based on the current fraction of tobramycin
loaded into EEG particles, this would require a 125 mg mass of delivered powder. In
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contrast, the Optimal EEG case uses a monodisperse aerosol with a geometric particle
diameter of 1.45 µm that represents 50 mg of tobramycin, and a second monodisperse
aerosol with a geometric particle diameter of 1.80 µm (aerodynamic diameter of 1.91 µm)
that represents 25 mg of tobramycin, which both included hygroscopic growth. This case
demonstrates how delivery strategies can be optimized to achieve regional deposition
targets, such as the uniform distribution and lower thresholds associated with inhaled
antibiotics. If a polydisperse aerosol were employed, the Optimal EEG case could be
described as a bi-modal distribution, with the first peak (smaller aerosol) used to target
distal airways and the second peak (larger aerosol) used to target intermediate regions.
The selection of the Optimal EEG tobramycin mass distribution and particle sizes was
based on analysis of the CFD results, but is included here for clarity in the Methods
section.
ASL Volumes
To determine whether the delivered tobramycin provided uniform concentrations
and was above the MIC, regional ASL volumes in the lung bifurcations and alveoli were
required. The airway surface area was measured from the SIP models and combined with
estimations of ASL thickness to determine the regional ASL volume, which can be used
with the deposited mass and bifurcation counts to establish regional tobramycin
concentrations (mg/L). The method for calculating regional tobramycin concentration in
the ASL is given as:
∑𝑁
𝑖=1 DF𝑖 𝑚𝑖𝑛
𝑐𝑅 =
∑𝑁
𝑖=1 𝑉𝑖

(8.3.1)

where: 𝑐𝑅 is the concentration in region R, DF𝑖 is the CFD-predicted DF in the bifurcation,
𝑚𝑖𝑛 is the mass that enters region R, and 𝑉𝑖 is the ASL volume in the bifurcation. Previous
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studies of aerosol delivery to CF-diseased airways have assumed a uniform ASL
thickness throughout the airways (Bos et al., 2017; Bos et al., 2015), with minimum
(Tarran et al., 2005) and maximum (Tarran, Button, & Boucher, 2006) thicknesses of 3
µm and 7 µm, and also evaluated an average thickness of 5 µm. These uniform ASL
thicknesses were specific to CF-disease lungs, but the literature shows that ASL
thickness varies between bifurcation levels (Hasan & Lange, 2007; ICRP, 1994; Patton,
1996).
In the extrathoracic (ET), bronchial (BB), and bronchiolar (bb) regions, the ICRP
model (1994) reports the thickness of the mucus and cilia layers (which combined give
the ASL thickness) as 15 µm, 11 µm, and 6 µm, respectively. More recently, Hasan and
Lange (2007) presented a mass conservation model for estimating ASL thickness (ℎ𝐴𝑆𝐿,𝑘 )
based on mucus production and clearance rates:

ℎ𝑀,𝑘

= 𝑟𝑘 − √𝑟𝑘2 −

𝑟𝑘 =

∑𝑁
𝑖=𝑘 𝑝𝑖
2𝑘 𝜋𝑣𝑘

𝑑𝑘
− ℎ𝐶,𝑘
2

ℎ𝐴𝑆𝐿,𝑘 = ℎ𝐶,𝑘 + ℎ𝑀,𝑘

(8.3.2)

(8.3.3)
(8.3.4)

where: 𝑘 is the generation number, ℎ𝑀 is the mucus layer thickness, 𝑟𝑘 is the radius of
the airway up to the mucus layer, 𝑝𝑖 is the mucus production rate, 𝑣𝑘 is the mucus
clearance rate, 𝑑𝑘 is the generation diameter, and ℎ𝐶,𝑘 is the height of the cilia layer. The
cilia height was determined from experimental measurements by Serafini and Michaelson
(1977) and the bifurcation-level mucus production distribution was sourced from material
measured from rhesus monkeys by Plopper et al. (1989). Mucus clearance rates are
known to have both interpatient and intrapatient (from day-to-day) variability (Hasan &
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Lange, 2007; Lange, Hancock, Samuel, & Finlay, 2001). Typical fast and slow clearance
rates in the trachea for healthy nonsmoking adults (Wanner, Salathe, & O'Riordan, 1996)
are 15 mm/min and 5 mm/min, respectively, with Yeates et al. (1976) reporting no
difference in clearance rates for CF-diseased lungs. Clearance rates in distal lung regions
are scaled from the tracheal value and data sourced from Stahlhofen (1980). For mucus
production, Finlay et al. (2000) reported a pediatric (4-years-old) rate of 2.8 mL/day based
on body-weight scaling from adult values, with Oberwaldner et al. (Oberwaldner, Evans,
& Zach, 1986; Oberwaldner, Theissl, Rucker, & Zach, 1991) reporting that production
rates can be up to four times higher in CF-diseased airways. In the alveolar-interstitial
region (AI), the ASL is predominantly surfactant with Weibel (1963) and Macklin (1955)
reporting thicknesses of 0.068 µm and 0.2 µm, respectively. This was combined with the
AI surface area from the ICRP model (1994), scaled to pediatric dimensions, and gave
the ASL volume distal to B15.
In summary, three ASL volume cases were evaluated in the current study to
provide a range of tobramycin concentration predictions, namely: the (i) ICRP ASL, (ii)
Min ASL, and (iii) Max ASL volumes. In the ET, BB, and bb regions, the ICRP ASL volume
is simply based on the regional thicknesses reported by the ICRP model (1994). The Min
ASL volume in the NT-B15 regions is based on the mass conservation model (Hasan &
Lange, 2007) and uses fast clearance (trachea: 15 mm/min) and low mucus production
(2.8 mL/day for a healthy pediatric) as input to the model, which provides the minimum
estimation of ASL volume. Similarly, the Max ASL volume also uses the mass
conservation model, but uses slow clearance (trachea: 5 mm/min) and increased mucus
production (11.2 mL/day, or four times higher than a healthy pediatric), which provides
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the maximum estimation of ASL volume. In the upper airway CFD models, distinctions
are not made between bifurcation levels, so an area-average ASL thickness from B1-B3
is combined with its surface area to determine the ASL volume in this region. As the mass
conservation model only includes bifurcation-level mucus production distribution from B1
through B14, the ASL thickness for B15 was assumed to be the same as B14. The results
present regional tobramycin concentrations as an ensemble of multiple bifurcations, so
the effect of this assumption is assumed to be negligible. Similarly, the mass conservation
model does not include the ET region, so the thickness for the Min and Mas ASL cases
were scaled from the ICRP model based on total ASL volumes. In the AI region, the Min
ASL volume uses the 0.068 µm thickness from Weibel (1963), the Max ASL volume uses
the 0.2 µm thickness from Macklin (1955), and the ICRP ASL volume uses the average
of these two values (0.134 µm). For the three cases detailed above, Table 8.2
summarizes the bifurcation-level ASL thicknesses and volumes, and Table 8.3
summarizes the regional total ASL volumes used in calculation of tobramycin
concentrations.
8.4

Results

CFD Model Validation and Upper Airway Deposition
Figure 8.5 shows regional deposition fractions and patterns in the upper airways
(NT-B3) for the Healthy (Figure 8.5a) and CF Moderate (Figure 8.5b) models. The total
DF shown in Figure 8.5b is compared against the in vitro data from the 5-6-year-old
growth chamber model (Chapter 7). Note that both the CFD and experimental results in
Figure 8.5 use an AS EEG powder formulation, but validate aerosol deposition, not
growth. The initial AS EEG aerosol size from the growth chamber study was a geometric
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diameter of 1.29 µm (1.53 µm MMAD with ρ = 1399.7 kg/m3), which is consistent with the
MMAD of the tobramycin EEG aerosol that is evaluated in subsequent sections, and little
aerosol growth is expected in the ET region. This demonstrates validation of the upper
airway CFD model as the numerical prediction of aerosol deposition is within the standard
deviation of experimental replicates. Surprisingly, total and regional deposition fractions
in the Healthy model are higher than the CF Moderate model (absolute difference of
2.4%), though the difference between the two models is relatively small considering the
experimental standard deviation (2.6%). The variation in deposition between the two
models can be attributed to interpatient variability. Inspection of the TB anatomy in Figure
8.5 shows that the B1 branching angle is noticeably larger in the Healthy geometry, which
would suggest an increase in impaction deposition, and there is clearly more deposition
on the carinal ridge in the first bifurcation. CF-related airway damage would presumably
lead to increased deposition losses in the CF Moderate model, but disease is known to
be more predominant in the lower airways (Tiddens et al., 2010), so differences in the
upper airways are expected to be small.
Table 8.4 compares regional deposition in the bronchial (Trachea to B8) and
bronchiolar (B9-B15) regions between the Healthy SIP models and the ICRP (1994),
Rudolf (1990), and Finlay (2001) models. The aerosol size entering the bronchial region
(from the outlet of B3) was an MMAD of 1.67 µm, and the size entering the bronchiolar
region (from the outlet of B7) was an MMAD of 2.23 µm. The CFD results compare well
with the ICRP and Rudolf correlations, with the algebraic Finlay model suggesting slightly
higher deposition in these regions. These results are consistent with conclusions from
Bass and Longest (2018a), which used a similar method for validating the numerical SIP
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model results. It is noted that aerosol growth was accounted for in the correlations by
using the average aerosol size in distal regions from upstream regions. This validation of
the SIP models ensures that CFD-predictions of deposited drug mass provide accurate
regional ASL concentrations.
Particle Trajectories and Aerosol Growth
Figure 8.6 illustrates particle trajectories and growth through the three regions of
the Healthy (Figure 8.6a) and CF Moderate (Figure 8.6b) models for the Base EEG
aerosol case. Note that particle trajectories extend beyond the computation domain due
to the addition of numerical extensions. In both models, the particle MMAD leaving the
upper airways is less than approximately 2.0 µm, which provides good N2L aerosol
transmission. In distal regions (B4-B15) of the healthy and CF-diseased lungs, the
tobramycin EEG powder formulation grows larger than 2.5 µm due to hygroscopic
absorption of moisture from the humid airways. This aerosol size increase would lead to
increased sedimentation deposition (with a breath hold) and impaction deposition (upon
exhalation), and helps to target lung regions where CF-related bacterial infections are
more predominant. The growth characteristics of the tobramycin EEG powder formulation
in the current study (60:20:20% w/w ratio of tobramycin:mannitol:L-leucine) is consistent
with the AS EEG powder that has been used as a surrogate test aerosol in Chapter 7 and
previous publications (Bass, Farkas, et al., 2019; Bass & Longest, 2020; Farkas et al.,
2020; Farkas et al., 2019).
Airway Surface Liquid Concentrations
Table 8.5 summarizes CFD-predicted regional deposition fractions (similar to
Figure 8.5), which were combined with the assumed 75 mg of tobramycin (leaving the
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nasal cannula) and ASL volumes (see Table 8.2) to determine regional drug
concentrations. Figure 8.7 plots the tobramycin concentrations in the ASL for all four SIP
models and the ICRP (Figure 8.7a), Min (Figure 8.7b), and Max (Figure 8.7c) ASL
volumes for the Base EEG aerosol. The solid and dashed lines on these plots indicate
the MIC (512 mg/L) and double the MIC for reference. Table 8.6 summarizes regional
tobramycin concentrations relative to the MIC for the Base EEG aerosol and compares
between all SIP models and ASL volumes. This shows that the Base EEG delivery
strategy, with 75 mg of tobramycin emitted from the delivery system, is consistently
capable of delivering tobramycin ASL concentrations that are well above the MIC for all
SIP models and ASL volumes considered. The worst-case regional delivery is the B4-B7
region of the Healthy SIP model with Max ASL volume that had a CFD-predicted
concentration of 2.5 x MIC. Recall that the dimensions of the Healthy SIP model were
larger than all CF-diseased models, due to different scaling factors, which decreases the
Stokes number and suggest less impaction deposition. This justifies the lower tobramycin
ASL concentrations that the CFD models predicted in the Healthy SIP model, as less drug
mass is deposited. In the CF SIP models, the worst-case regional delivery is the B4-B7
region of the CF Scaled model with Max ASL volumes that had a CFD-predicted
concentration of 2.9 X MIC. Interestingly, the models with increased states of disease
progression (CF Moderate and CF Severe) had higher concentrations, as the forms of
lung damage added to the geometry increased potential impaction deposition sites.
Though the minimum delivered concentrations are above the MIC targets of this study,
regional uniformity of tobramycin in the ASL can be improved with an optimal EEG
delivery strategy.
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Figure 8.8 and Table 8.7 present the tobramycin concentrations for all SIP models
and ASL volumes considered for the Min Static aerosol. As with the Base EEG case, the
small aerosol size of the Min Static aerosol is capable of penetrating the upper airways
beyond B3. However, as there is no hygroscopic growth, the aerosol is also able to
navigate the filtration of the lower airways and shows relatively low levels of deposition in
the B4-B7 and B8-B15 regions. Therefore, delivered tobramycin concentrations in the
ASL for the lower airways is low for all cases considered. Minimum concentrations were
predicted to be only just above the MIC for the B8-B15 region of the Healthy SIP model
with Max ASL volume (1.0 x MIC), with similar results for the B8-B15 regions of the CF
SIP models with Max ASL volume (1.2-1.6 x MIC). Figure 8.9 and Table 8.8 present the
tobramycin concentrations for all SIP models and ASL volumes considered for the Max
Static aerosol. In this case, concentrations are consistently high and well above the MIC
due to a large amount of deposited drug mass from the larger aerosol size (minimum
concentrations of 3.1 and 4.8 x MIC for the Healthy and CF SIP models, respectively).
However, as there is poor N2L transmission due to the increased particle size, CFD
predictions show up to a 10-fold difference in regional concentrations (4.8-45.9 x MIC in
the NT and B4-B7 regions of CF Scaled with Max ASL) and exhibit poor dose uniformity
throughout the airways.
Figure 8.10 and Table 8.9 present the tobramycin concentrations for all SIP models
and ASL volumes considered for the Optimal EEG aerosol. Recall that the Optimal EEG
aerosol used 50 mg of 1.45 µm and 25 mg of 1.80 µm particles (geometric particle
diameters). For the three CF SIP models, the Optimal EEG case reduced variability in
regional concentrations and is consistently well above the MIC (minimum of 5.8 x MIC in
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the B4-B7 region of CF Scaled with Max ASL). Table 8.10 compares the ratios of
maximum to minimum concentrations in all SIP models, ASL volumes, and aerosol cases.
For the CF-diseased models with EEG aerosols, variability (expressed as the ratio of
maximum to minimum ASL concentration) is reduced from a range of 2.4- to 5.2-fold
(Base EEG) to a range of 1.7- to 4.3-fold (Optimal EEG). For the Healthy SIP model,
variability in tobramycin concentration is also reduced with the Optimal EEG aerosol, but
it is not as low as the CF-diseased models. As the delivery system is intended to
administer antibiotics to pediatric patients with CF, the variability in the Healthy model is
not considered a negative outcome. However, this does raise questions on interpatient
variability and its influence on establishing an optimal delivery strategy.
8.5

Discussion
This study meets the objective by providing a proof of concept for tobramycin EEG

aerosol administration to treat bacterial lung infections in pediatric patients diagnosed
with CF. Validated CFD predictions demonstrated that the EEG delivery strategy was
consistently capable of delivering tobramycin to the ASL that was above the MIC for all
cases considered, with the minimum CF-diseased concentration being 2.8 and 5.8 x MIC
for the Base and Optimal EEG aerosol, respectively. The Optimal EEG aerosol was
capable of reducing regional concentration variability to an approximate four-fold
difference between maximum and minimum CFD-predicted values. Furthermore, the
validated numerical models predicted high tobramycin ASL concentrations in the lower
airways (B8-B15), where bacterial infections are more predominant (Tiddens et al., 2010),
with a minimum concentration of 7.5 x MIC in the CF Moderate SIP model with Max ASL
volume. This study assumed a nominal value of 75 mg of tobramycin entering the upper
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airways from the delivery system, which combined with the 79.5% device ED (Farkas et
al., 2020) and 60% mass fraction in the EEG formulation, suggests a loaded dose of
approximately 160 mg of powder. This is high considering the device is designed to hold
100 mg of powder (Farkas et al., 2020), but the high-efficiency delivery of tobramycin to
the ASL means that less powder would still ensure concentrations above the MIC. For
example, a loaded dose of 100 mg of powder (60 mg of the drug) leads to 47.7 mg of
tobramycin entering the upper airway, which gives a worst-case ASL concentration of 3.7
x MIC for the Optimal EEG aerosol. Alternatively, different EEG powder formulations that
increase the mass fraction of drug relative to excipients may be considered, as the water
activity characteristics show that tobramycin has good hygroscopic properties.
As a secondary outcome, this study directly compared a range of static and EEG
aerosol delivery strategies and demonstrates the advantages of powder formulations that
utilize hygroscopic growth. The Min Static aerosol was capable of navigating the filtration
of the ET region, but the small aerosol size in the lower airways lead to low tobramycin
ASL concentrations. This becomes more of an issue when considering drug delivery and
lung retention during a breath-hold or upon patient exhalation. The Max Static aerosol
provided high regional ASL concentrations, but variability between regions was poor due
to increased upper airway losses. Only the EEG aerosol cases were able to provide good
N2L transmission, and meet the MIC and regional variability targets that are associated
with the administration of inhaled antibiotics. This study also compared the delivery of
inhaled tobramycin between healthy patients and varying degrees of CF disease states.
The smaller dimensions of the CF-diseased airways and addition of various forms of lung
damage increase the likelihood of impaction deposition throughout the SIP models, which
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leads to an increase in predictions of tobramycin concentrations from the numerical
models. This is promising for treatment methods with inhaled antibiotics, as the regions
with increased lung damage are also likely to have the most bacterial infections, which is
where the drug is required. The increase in CFD-predicted tobramycin delivery in the CF
models is most apparent in the middle airways (B4-B7) due to the increased flow
velocities in this region compared to the lower airways (B8-B15).
Interpatient variability in delivered tobramycin concentrations was apparent when
drawing comparisons between the Healthy and CF models. Differences in upper airway
anatomy lead to differences in CFD-predicted losses in the NT-B3 region, which in turn
affected the amount of drug that was delivered to the middle and lower airways.
Interpatient variability has been well established for infant, pediatric, and adult populations
in the ET region (Garcia et al., 2009; Golshahi et al., 2012; Golshahi et al., 2011; StoreyBishoff et al., 2008), and it is reasonable to expect the same in regard to deposition in
distal diseased (Bos et al., 2015) airways. Establishing an ideal EEG delivery strategy
that is applicable to the entire patient population is difficult, as an optimal aerosol for one
patient may not meet delivery targets for others. One approach may be to define low,
medium and high deposition models for the ET region and distal airways that are
representative of the chosen patient population, which is similar to the method described
by Rani et al. (2020). Predictions of delivered tobramycin concentrations are also
inherently dependent on the estimations of regional ASL volumes, which also exhibit
interpatient and intrapatient variability (Hasan & Lange, 2007; Lange et al., 2001).
Regarding MIC targets, results should focus on predicted aerosol delivery to ASL
thicknesses that provide estimations of maximum ASL volumes, as the concentration
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exhibits the worst-case scenario. The mass conservation model (Hasan & Lange, 2007)
gives increased fidelity over the ICRP model (ICRP, 1994) as it provides bifurcation-level
estimations of ASL thickness in the airways. However, as with all models, it is only as
accurate as the assumptions and inputs allow. The cilia thickness was estimated from
data measured from adults (Serafini & Michaelson, 1977) and the bifurcation-level mucus
production distribution from rhesus monkeys (Plopper et al., 1989), both of which may
need to be redefined for pediatric patients with CF. Furthermore, lobar and regional
variability in mucus production, especially for diseased airways, has a direct effect on
CFD predictions of regional variability in delivered tobramycin concentrations. Finally, the
ASL volumes in this study do not account for the mucus accumulation and plugging that
is typically observed in CF-diseased airways. Measurements from CT scans showed up
a to 70% reduction in airway cross sections, equating to mucus accumulations that are
approximately 1 mm thick, which is three orders of magnitude larger than the calculated
ASL thicknesses. The sites of mucus accumulations are expected to be highly infected
with bacteria, so adequate delivery of tobramycin is important in these regions.
Beyond the variability in deposition predictions and ASL volumes, limitations in the
current study primarily include assumptions made in the numerical models and validation
of the CFD predictions. In the middle and lower airway SIP geometries, a parabolic
velocity profile was applied at the inlet that matched the upstream outlet volumetric flow
rate. This assumption was made as the non-circular shape and polyhedral mesh topology
in the upper airways does not permit one-to-one matching of cell centroids and velocities
between regions, which is recommended by the in vivo validation of Tian et al. (2015).
The parabolic profile assumption is reasonable, given the laminar flow conditions, but the
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curvature of airway bifurcations is known to skew the velocity profile at the outlet (Longest
& Oldham, 2008). An improved approach would be to map the non-circular spatial
distribution to the circular SIP model inlet and use inverse-distance weighted interpolation
between the velocities at the polyhedral and hexahedral face centroids. The CFD models
also assumed that the MMAD of the tobramycin EEG aerosol that is emitted from the
delivery system was the same as the experimental data from Farkas et al. (2020), which
used an AS EEG powder formulation as a surrogate test aerosol. As the particle density
differs between the tobramycin and AS EEG powder formulations (1117.2 kg/m3 and
1339.72 kg/m3, respectively), it is reasonable to expect different MMADs for the same
device, if the physical particle diameter is the same between the two from the spray drying
process. The differences in powder dispersion characteristics between tobramycin and
AS EEG formulations are also not established, which may also affect the aerosol size
leaving the DPI. Finally, the outlet ventilation fractions in the upper airway models were
based on lobar volumes extracted from inhalation and exhalation CT scans, and assumed
that all lobes inflated at the same rate. However, in CF-diseased lungs, it is known that
that the inflation of each lobe is time dependent (L. J. Smith et al., 2018). That is, the
inflation of a particular lobe may be delayed in relation to the onset of inhalation, and the
rate of inflation for each lobe varies. This can influence how much tobramycin is delivered
to each lung lobe based on the timing of inflation and aerosol delivery. For example, for
a 4.5 s device actuation time, aerosol may hypothetically only be emitted from the delivery
system for approximately 2.0 s. If one of the lung lobes only begins inflating after a 1.0 s
delay, it would receive much less of the inhaled antibiotic than the other four lobes.
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With regard to CFD model validation, the current study matched deposition in the
upper airway CF model with the experimental data (both with the same AS powder
formulation) from the growth chamber study (Chapter 7). The healthy B4-B7 and B8-B15
SIP models were validated against algebraic and empirical correlations (W. H. Finlay,
2001; ICRP, 1994; Rudolf et al., 1990). Ideally, the predictions of aerosol deposition in all
CFD models would be validated directly against in vitro or in vivo data. Ethical concerns
limit the availability of in vivo datasets for pediatric patients with CF, especially with radiolabelling, due to the amount of medically necessary CT scans that CF patients may
require during their life. SIP models have been validated against in vitro data by a number
of previous studies (Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al.,
2012; Tian et al., 2011), and similar methods could be applied to the CF SIP models that
were developed by the current study. The difficulty with experimental testing of diseased
pediatric models is whether current 3D printing capabilities can accurately produce
physical models with small airway dimensions. Similarly, the current study does not
directly validate the CFD-predicted growth of the tobramycin EEG powder formation
against experimental data. Previous work (Chapter 7) successfully validated the particle
condensation and evaporation models for AS EEG powder formulations, and the
tobramycin hygroscopic properties were experimentally determined based on the same
methods (Longest & Hindle, 2011), so the numerical results are expected to be accurate.
However, the CFD models for tobramycin EEG growth should also be validated against
in vitro data from a growth chamber model to increase confidence in the numerical
predictions.
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As this is the first study of its kind to evaluate tobramycin EEG powder formulations
in SIP models of CF-diseased airways, the scope for future work is extensive. As
mentioned in the Methods section, the current study followed pathways through the lowerleft lobe as this has previously been shown to be representative of the ensemble average
deposition in the entire lung (Longest, Tian, Delvadia, et al., 2012). Future studies are
planned that will compare lobar and regional variability in aerosol deposition, which is
known to be an issue in CF-diseased lungs (Bos et al., 2017; Bos et al., 2015), as some
lobes are generally more damaged than others. Future work also intends to expand the
range of pediatric populations considered by evaluating both a 2-3- and 9-10-year-old
model. Establishing whether the CF-diseased SIP models provide an accurate
representation of aerosol transport and deposition in the diseased airways is also
required. One approach may be to extract anatomically accurate, diseased bifurcations
from CT scans and compare them to the CF Moderate and Severe bifurcations.
Adjustments can then be made to the SIP models to improve the match to diseased
airway results. Previous work (Bos et al., 2017; Bos et al., 2015) has shown that CF
diseased airways can be extracted from CT scans up to approximately B6, so
assumptions would still need to be made about the lower airways. This approach would
also need to establish how unstructured meshes, required for modeling the complex
geometry of diseased airways from CT scans, compare with structured hexahedral
meshes in airway bifurcations.
Beyond expanding and improving the computational domain, the detail and
potential accuracy of the numerical models can also be explored in future work. The use
of polydisperse aerosols, as opposed to the monodisperse aerosol in this study, provides
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a more realistic representation of the aerosol that enters the domain and may influence
drug delivery to the lower airways. Two-way coupling between the continuous (fluid) and
discrete (particles) phase is also a more accurate, yet computationally expensive, method
of modeling aerosol growth, which has previously provided a better match to experimental
data (Longest & Hindle, 2012). Laminar flow was assumed in the middle and lower
airways based on the in vivo SIP model validation by Tian et al. (2015), but the k-ω model
may be considered in future work as constrictions in the diseased airway may induce
turbulence. In stenosed tubes, which are similar to the CF-diseased airway constrictions,
previous work has shown that a 50-75% area reduction at Reynolds numbers of 4001100 can induce turbulent flow (Ahmed & Giddens, 1983a, 1983b; Ghalichi et al., 1998).
Alveolar models (Khajeh-Hosseini-Dalasm & Longest, 2015) may also be used to
establish the breath-hold duration required to maximize sedimentation deposition. The
current delivery system requires an actuation time of approximately 4.5 s, so an extended
breath-hold period may not be feasible, but if the powder empties early in the delivery
cycle, it also may not be necessary. Related to actuation time, device flow rates may be
considered as part of delivery strategy optimization, in addition to bi-modal size
distributions, to target regions of the lungs and reduce regional variability. However,
compromises will need to be made, as the aerosolization performance of the air-jet DPI
is also influenced by the flow rate through the device (Bass, Farkas, et al., 2019).
In conclusion, this study provides a proof of concept for high-efficiency EEG
aerosol administration to treat bacterial infection in CF-diseased airways and meet the
dosing requirements of inhaled tobramycin antibiotics. This is the first such study to apply
numerical models for the evaluation of tobramycin EEG powder formulations in complete-
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airway, diseased, pediatric SIP models. An optimal EEG aerosol was identified that met
the delivery targets associated with tobramycin administration, with ASL concentrations
above the MIC, minimal regional variability, and high concentrations in the lower airways.
Comparisons were made between static and EEG particles that demonstrated the
advantages of administering aerosols that utilize hygroscopic growth. Furthermore,
comparisons were made between models that represent healthy patients and varying
degrees of CF disease states. Future work is planned that intends to expand upon this
initial study and further evaluate the use of EEG aerosols in pediatric CF patients.

351

8.6

Figures

Figure 8.1:

Examples of CF-related lung damage in (a) CT scans, with Label A showing

axisymmetric mucus plugging on a daughter branch, Label B showing asymmetric mucus
plugging in the bifurcation region, and Label C showing localized widening of a daughter
branch (bronchiectasis); and examples of lung damage implemented in the SIP geometry
with (b) axisymmetric mucus plugging, (c) asymmetric mucus accumulation in the
bifurcation region, (d) axisymmetric bronchiectasis, and (d) asymmetric mucus
accumulation in the daughter branch (not shown in CT scan).
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Figure 8.2:

Overview of CFD SIP model geometries showing the (a) Healthy and (b) CF

Moderate 5-6-year-old models.
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Figure 8.3:

Overview of the lower airway SIP geometries for the three CF-diseased

models showing the (a) CF Scaled B4-B7, (b) CF Scaled B8-B15, (c) CF Moderate B4B7 (d) CF Moderate B8-B15, (e) CF Severe B4-B7, and (f) CF Severe B8-B15 SIP
models.
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Figure 8.4:

Comparison of extracted lobes from CT scans at (a) inhalation and (b)

exhalation. Lobes are colored as: green – left upper; blue – left lower; red – right upper;
orange – right middle; and yellow – right lower.
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Figure 8.5:

Deposition patterns in the NT-B3 region for the (a) Healthy and (b) CF

Moderate models. Note that validation of the CF-diseased model is compared against the
experimental deposition data from the 5-6-year-old CF growth chamber model in Chapter
7.

356

Figure 8.6:

Particle trajectories and growth through the CFD regions, with the Base

EEG aerosol, for the (a) Healthy and (b) CF Moderate SIP models.

357

Figure 8.7:

Regional tobramycin concentrations in the airway surface liquid (ASL)

between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the Base EEG
aerosol, with respect to the (a) ICRP, (b) Min, and (c) Max ASL volumes.
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Figure 8.8:

Regional tobramycin concentrations in the airway surface liquid (ASL)

between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the Min Static
aerosol, with respect to the (a) ICRP, (b) Min, and (c) Max ASL volumes.
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Figure 8.9:

Regional tobramycin concentrations in the airway surface liquid (ASL)

between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the Max Static
aerosol, with respect to the (a) ICRP, (b) Min, and (c) Max ASL volumes.
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Figure 8.10: Regional tobramycin concentrations in the airway surface liquid
(ASL) between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the
Optimal EEG aerosol, with respect to the (a) ICRP, (b) Min, and (c) Max ASL volumes.
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8.7

Tables

Table 8.1:

Comparison of lobar ventilation fractions between healthy and CF-diseased

lungs.
Lobe
Healthya
CF Diseased
Left Upper
14%
16%
Left Lower
7%
7%
Right Upper
33%
28%
Right Middle
15%
21%
Right Lower
31%
28%
a:
Ventilation fractions consistent with the
Adult SIP model (Tian et al., 2015)
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Table 8.2:

Summary of bifurcation-level surface area, airway surface liquid thickness,

and volume for the ICRP, Min, and Max ASL volumes. Values are given for a single
bifurcation, that is, not summed over the number of a given bifurcation found in the lungs.
ICRP
As
h
V
[cm2]
[µm]
[µL]
1.47
11.00
1.62
1.43
11.00
1.57
0.99
11.00
1.09
0.81
11.00
0.90
0.47
11.00
0.51
0.42
6.00
0.25
0.23
6.00
0.14
0.20
6.00
0.12
0.15
6.00
0.092
0.040
6.00
0.024
0.025
6.00
0.015
0.016
6.00
0.010
Surface area
Airway surface liquid thickness
Airway surface liquid volume
Bifurcation number X

Region
B4
B5
B6
B7
B8
B9
B10
B11
B12
B13
B14
B15
As:
h:
V:
BX:

Min
h
[µm]
10.19
9.60
8.20
6.74
5.85
5.31
4.95
4.67
4.39
4.23
3.44
3.44
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Max
V
[µL]
1.50
1.37
0.82
0.55
0.27
0.22
0.11
0.10
0.067
0.017
0.0083
0.0053

h
[µm]
76.67
72.80
58.42
42.84
33.82
28.94
26.15
24.05
21.74
20.66
10.13
10.13

V
[µL]
11.27
10.40
5.81
3.49
1.58
1.22
0.59
0.49
0.33
0.084
0.025
0.016

Table 8.3:

Summary of regional airway surface liquid volumes for the ICRP, Min, and

Max ASL volumes. Values for each region include summation over the number of a given
bifurcation found in the lungs.
VICRP
VMin
[mL]
[mL]
NT
0.19
0.10
B1-B3
0.03
0.04
B4-B7
0.13
0.10
B8-B15
0.89
0.61
Alv
6.41
3.25
Total
7.65
4.09
VICRP: ICRP ASL Volume
VMin: Min ASL Volume
VMax: Max ASL Volume
NT: Nose-throat region
BX: Bifurcation number X
Alv: Alveolar region
Region
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VMax
[mL]
0.29
0.27
0.67
2.81
9.56
13.60

Table 8.4:

Comparison of regional deposition in the Healthy SIP model to algebraic

and empirical correlations.
Region
CFD SIP
MMAD [µm]
BB (T-B8)
2.25%
1.67
Bb (B9-B15)
4.74%
2.23
a:
Sourced from (ICRP, 1994)
b:
Sourced from (Rudolf et al., 1990)
c:
Sourced from (W. H. Finlay, 2001)
BB:
bb:

ICRPa
2.17%
3.56%

Bronchial region
Bronchiolar region
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Rudolfb
1.58%
5.91%

Finlayc
5.12%
10.86%

Table 8.5:

Summary of regional deposition fractions (DF) for all SIP models and all

aerosol cases.
Region
Base EEG
NT
1-3
4-7
8-15
Min Static
NT
1-3
4-7
8-15
Max Static
NT
1-3
4-7
8-15
Optimal EEG
NT
1-3
4-7
8-15

Healthy
DF [%]

CF Scaled
DF [%]

CF Moderate
DF [%]

CF Severe
DF [%]

4.6
2.7
1.2
6.6

3.8
1.5
1.4
13.4

3.8
1.5
3.3
9.6

3.8
1.5
4.6
12.4

4.6
2.6
0.9
2.2

3.9
1.4
1.1
3.3

3.9
1.4
2.7
2.4

3.9
1.4
3.7
3.1

8.6
5.2
1.7
9.8

9.1
2.4
2.5
11.8

9.1
2.4
5.8
12.6

9.1
2.4
7.1
13.7

5.0
3.1
1.4
12.1

4.0
1.5
2.8
18.3

4.0
1.5
3.4
15.7

4.0
1.5
4.1
17.6
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Table 8.6:

Summary of regional tobramycin concentrations in the airway surface liquid

(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all
ASL volumes, and the Base EEG case.
Healthy
[x MIC mg/L]
ICRP ASL Volume
NT
35.5
1-3
131.7
4-7
12.8
8-15
9.9
Alveolar
19.5
Min ASL Volume
NT
67.5
1-3
98.8
4-7
16.6
8-15
14.4
Alveolar
38.5
Max ASL Volume
NT
23.3
1-3
14.6
4-7
2.5
8-15
3.1
Alveolar
13.1
Region

CF Scaled
[x MIC mg/L]

CF Moderate
[x MIC mg/L]

CF Severe
[x MIC mg/L]

29.2
74.4
14.7
20.6
18.5

29.2
74.4
35.0
14.4
18.9

29.2
74.4
49.5
18.4
18.1

55.5
55.8
19.1
30.1
36.5

55.5
55.8
45.5
21.0
37.3

55.5
55.8
64.4
26.8
35.7

19.1
8.3
2.9
6.5
12.4

19.1
8.3
6.8
4.6
12.7

19.1
8.3
9.6
5.8
12.1
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Table 8.7:

Summary of regional tobramycin concentrations in the airway surface liquid

(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all
ASL volumes, and the Min Static case.
Healthy
[x MIC mg/L]
ICRP ASL Volume
NT
35.7
1-3
129.0
4-7
9.9
8-15
3.3
Alveolar
20.5
Min ASL Volume
NT
67.8
1-3
96.8
4-7
12.9
8-15
4.8
Alveolar
40.4
Max ASL Volume
NT
23.4
1-3
14.3
4-7
1.9
8-15
1.0
Alveolar
13.7
Region

CF Scaled
[x MIC mg/L]

CF Moderate
[x MIC mg/L]

CF Severe
[x MIC mg/L]

30.4
70.6
11.2
5.1
20.7

30.4
70.6
28.7
3.7
20.5

30.4
70.6
39.2
4.7
20.2

57.8
53.0
14.6
7.4
40.8

57.8
53.0
37.3
5.4
40.4

57.8
53.0
51.0
6.9
39.8

19.9
7.8
2.2
1.6
13.9

19.9
7.8
5.6
1.2
13.7

19.9
7.8
7.6
1.5
13.5
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Table 8.8:

Summary of regional tobramycin concentrations in the airway surface liquid

(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all
ASL volumes, and the Max Static case.
Healthy
[x MIC mg/L]
ICRP ASL Volume
NT
66.6
1-3
255.4
4-7
16.1
8-15
13.6
Alveolar
17.4
Min ASL Volume
NT
126.5
1-3
191.6
4-7
20.9
8-15
19.8
Alveolar
34.3
Max ASL Volume
NT
43.6
1-3
28.4
4-7
3.1
8-15
4.3
Alveolar
11.7
Region

CF Scaled
[x MIC mg/L]

CF Moderate
[x MIC mg/L]

CF Severe
[x MIC mg/L]

70.0
115.6
24.6
16.8
17.4

70.0
115.6
57.4
17.3
16.7

70.0
115.6
71.2
18.5
16.2

133.0
86.7
32.0
24.5
34.3

133.0
86.7
74.6
25.2
32.9

133.0
86.7
92.6
27.0
32.0

45.9
12.8
4.8
5.3
11.7

45.9
12.8
11.1
5.5
11.2

45.9
12.8
13.8
5.9
10.9
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Table 8.9:

Summary of regional tobramycin concentrations in the airway surface liquid

(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all
ASL volumes, and the Optimal EEG case.
Healthy
[x MIC mg/L]
ICRP ASL Volume
NT
38.3
1-3
152.8
4-7
14.2
8-15
18.0
Alveolar
18.2
Min ASL Volume
NT
72.8
1-3
114.6
4-7
18.5
8-15
26.3
Alveolar
35.9
Max ASL Volume
NT
25.1
1-3
17.0
4-7
2.8
8-15
5.7
Alveolar
12.2
Region

CF Scaled
[x MIC mg/L]

CF Moderate
[x MIC mg/L]

CF Severe
[x MIC mg/L]

30.6
74.0
30.0
27.6
17.1

30.6
74.0
36.1
23.6
17.6

30.6
74.0
43.2
26.3
17.1

58.1
55.5
39.0
40.3
33.7

58.1
55.5
46.9
34.4
34.7

58.1
55.5
56.2
38.4
33.7

20.0
8.2
5.8
8.7
11.5

20.0
8.2
7.0
7.5
11.8

20.0
8.2
8.4
8.3
11.5
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Table 8.10: Ratios of maximum to minimum regional concentration, demonstrating
deposition variability, for all SIP models, all ASL volumes, and all initial aerosol cases.
Region
Healthy
ICRP ASL Volume
Min ASL Volume
Max ASL Volume
CF Scaled
ICRP ASL Volume
Min ASL Volume
Max ASL Volume
CF Moderate
ICRP ASL Volume
Min ASL Volume
Max ASL Volume
CF Severe
ICRP ASL Volume
Min ASL Volume
Max ASL Volume

Base
EEG

Min
Static

Max
Static

Optimal
EEG

13.3
6.8
9.4

39.1
20.1
22.4

18.8
9.7
14.0

10.8
6.2
9.1

5.1
2.9
6.7

13.8
7.8
12.3

6.9
5.4
9.6

4.3
1.7
3.4

5.2
2.7
4.2

19.1
10.7
17.0

6.9
5.3
8.4

4.2
1.7
2.9

4.1
2.4
3.3

15.0
8.4
13.4

7.1
4.9
7.8

4.3
1.7
2.4
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Chapter 9: Conclusions and Future Work
9.1

Objective 1: Accurate CFD Simulations of Aerosol Delivery in Infants and
Children
The packed bed lung model study (Chapter 2) sought a complete-airway in vitro

model with aerosol deposition characteristics similar to in vivo conditions in an infant,
which meets the requirements of Task 1.1. This study concluded that in vitro packed bed
lung models are capable of matching total aerosol deposition in the lungs of an infant.
However, comparisons between sphere layers and bifurcation regions of a CFD SIP
model showed a marked difference in regional deposition patterns and particle residence
times. This means that packed bed models are not well suited for comparisons with
regional in vivo data, where gamma scintigraphy characterizes deposition in central and
peripheral regions. The fundamental issue was that the geometry of the voids in a packed
bed model are too far removed from lung bifurcations, such that particle trajectories and
deposition patterns were very different. The positive outcome from this study was that the
CFD-based infant SIP model matched algebraic and empirical correlations with regard to
deposition profiles across the micro-particle size range.
The 90° bend study (Chapter 3) established recommended meshing and solution
guidelines for modeling aerosol transport and deposition with the LRN k-ω model, which
meets the requirements of Task 1.2. This study demonstrated the successful validation
of the numerical models against experimental data across a range of Reynolds numbers
and micro-particle sizes. The primary benefit of these recommendations is an increase in
model accuracy and consistency, as well as streamlining the CFD mesh and model
development process. Furthermore, the results from the two-equation k-ω model, with
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near-wall corrections, provided comparable accuracy to the more complex LES model.
LES models are more computationally expensive, so utilizing the more efficient k-ω model
has benefits when running transient studies or more advance particle tracking methods.
The 6-month-old nose-to-lung study (Chapter 4) validated the CFD meshing and
solution guidelines in a nasal cavity model, which meets the requirements of Task 1.3.
The nasal cavity model had more complex geometry features and flow field conditions
than the characteristic 90° bend, which extended the applicability of the aforementioned
CFD recommendations. Numerical results compared well with experimental data for nasal
administration of EEG aerosols to infants. As a secondary outcome, this study also
demonstrated the capabilities of EEG aerosols for navigating the natural filtration of the
extrathoracic airways in infant patients, which maximizes available lung dose.
Furthermore, evaluation of the CFD results identified deposition hotspots in the nasal
cannula and nostril regions, which should be the focus of further effort to reduce
depositional losses. A final outcome of this study was an anatomically-accurate infant
nose-to-lung model, extracted from CT scans, which will be useful for future studies on
pharmaceutical aerosol delivery to infants.
9.2

Objective 2: Quantitative Analysis and Design of High Efficiency Pediatric
DPIs
The tobramycin DPI study (Chapter 5) detailed the optimization process for

improving the aerosolization performance of a positive-pressure pediatric DPI, which
meets the requirements of Task 2.1. This study developed dispersion parameters and
correlations that were predictive of the aerosol MMAD and emitted dose from the DPI
outlets. A priori validation of the best-case design candidates was successful, whereby
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experimental results confirmed the performance improvements from CFD predictions,
with no subsequent changes to the numerical models. Furthermore, results showed how
changes to design parameters affected turbulent kinetic energy and flow rate (by changes
to flow resistance), which were key factors in the dispersion parameter correlations. The
best-case design candidates improved aerosolization performance over the initial device
by reducing aerosol MMAD from 1.69 µm to 1.55 µm and increasing emitted dose from
86.0% to 92.3%, while maintaining a constant pressure drop across the device.
The patient interface study (Chapter 6) presented design improvements to
pediatric mouthpieces and nasal cannulas that minimized delivery system and
extrathoracic losses, thus maximizing available lung dose, which meets the requirements
of Task 2.2. The aerosolization performance of the air-jet DPI (from Task 2.1) requires
small diameter capillaries, which lead to a highly-turbulent, high velocity jet entering the
patient interface and extrathoracic region. This jet increases aerosol loss in these regions
through turbulent dispersion and inertial impaction, so a design was sought that was
capable of effectively diffusing the air jet. This study followed several design iterations,
which concluded that the addition of a 3D rod array and widening the geometry near the
device outlet capillary gave the best reduction in losses. Three mouthpiece design
concepts were presented with CFD predictions of a three-fold reduction in total interface
and extrathoracic loss over the original design (from 16.7% to 5.1%). The nasal cannula
design concepts were not as efficient, as the design concepts were not as effective at
reducing losses in the nose-throat region. However, a 25% reduction in device flow rate
(from 13.3 to 9.9 LPM) reduced delivery system and extrathoracic losses from 24.1% to
16.3%. This reduction in device flow rate is not expected to have a negative impaction on
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the DPI aerosolization performance (Bass, Farkas, et al., 2019). Furthermore, this study
presented correlations that were predictive of extrathoracic deposition based on the
maximum value of the velocity profile that leaves the patient interface. This showed that
for a constant flow rate, the downstream deposition was vastly different if the velocity had
a high peak velocity (jet-like profile) compared with a low peak velocity (blunt turbulent
profile). This has implications for extrathoracic loss correlations that utilize the impaction
parameter (𝑄𝑑𝑎 ), as this traditional metric does not capture the characteristics of the
velocity profile that enters the mouth-throat or nose-throat regions.
9.3

Objective 3: CFD Predictions of EEG Aerosol Antibiotic Delivery to Children
with Cystic Fibrosis
The growth chamber study (Chapter 7) developed three experimental and CFD

models (2-3-, 5-6-, and 9-10-year-olds) for evaluating upper airway deposition and EEG
aerosol size increase through the lungs of CF pediatric patients, which meets the
requirements of Task 3.1 and 3.2. This study demonstrated concurrent numerical and
experimental analysis of EEG aerosol delivery, with good validation of the CFD results
against in vitro deposition and growth data. Results showed administration of EEG
aerosols with the best-case delivery system gave low upper airway losses, with
approximately 11%, 5%, and 7% deposition for the 2-3-, 5-6-, and 9-10-year-old models,
respectively, at a constant device actuation flow rate of 10 LPM. This is a marked
improvement over evaluation of commercial devices and delivery strategies in the
literature, with the best available case being 22% lung dose (78% loss) from the Easyhaler
(Below et al., 2013). The growth chamber was designed to provide a particle residence
time of approximately 2.0 s, which is consistent with typical particle trajectories through
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the lungs, resulting in final aerosol MMAD of approximately 3.3 µm due to hygroscopic
growth. The larger aerosol size in distal regions of the lungs is expected to maximize lung
retention of the delivered drug via increased sedimentation (during a breath-hold
maneuver) and impaction (upon exhalation) deposition. This study also presented an
enhancement to the near-wall corrections by implementing a local particle Stokes number
to determine when particle-wall hydrodynamic interactions are modeled. The new method
provided a non-dimensional approach and allowed the near-wall corrections to work
independently of local flow conditions.
The CF SIP study (Chapter 8) developed complete-airway CFD models of
diseased pediatric patients to predict regional tobramycin concentrations delivered to the
airway surface liquid, which meets the requirements of Task 3.3. This study provided a
proof of concept for EEG aerosol administration to treat bacterial infections in the
diseased airways of CF patients. Treatment of infection with antibiotics requires the drug
dose to be above a minimum lower threshold and a uniform distribution through all lung
regions. For both EEG aerosol cases considered, the delivered tobramycin concentration
within the airway surface liquid was consistently above the minimum inhibitory
concentration (MIC), which is 512 mg/L, within all lung regions. For the CF-diseased
models, the minimum predicted concentration in all lung regions was 2.9 x MIC for the
base EEG aerosol and 5.8 x MIC for the optimal case. The optimal case also reduced
regional variability to an approximate four-fold difference between maximum and
minimum concentrations. Furthermore, the CFD models predicted high tobramycin
concentrations in the lower airways, where CF-related airway damage is most
predominant, with a minimum value of 7.5 x MIC in the B8-B15 region. As a secondary
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outcome, this study also compared the advantages of EEG powder formulations
compared to static aerosols (no hygroscopic growth) in regard to nasal transmission and
targeted drug delivery. Finally, this study evaluated delivery to airways with varying
degrees of disease state and considered the influence of interpatient variability on optimal
delivery strategies.
9.4

Contributions to Science
From the studies detailed in this dissertation, the contributions to the fields of CFD

methods development, respiratory device design, and aerosol delivery strategy
development are summarized below.
Task 1.1: Evaluate Deposition Realism of In Vitro Packed-Bed Breathing Infant
Lung Model (BIL)
•

Thorough assessment of packed bed lung models and their use for in vitro
evaluation of pharmaceutical aerosol delivery, showing they are representative
of total, but not regional, deposition fractions

•

Complete-airway CFD SIP model of microparticle particle tracking and
deposition in a neonate

Task 1.2: Recommendations for Simulation of Microparticle Transport and
Deposition Using Two-Equation Turbulence Models
•

A set of CFD meshing and solution guidelines for modeling microparticle
trajectories through respiratory airways, which were validated against
experimental data in a characteristic 90° bend geometry

•

Enhancement to near-wall corrections that interpolate flow quantities at the
particle location, from nodal values, with an inverse-distance weighted method
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•

Established that the k-ω turbulence model, with near-wall corrections, is
capable of matching in vitro data with comparable accuracy to the more
computationally-expensive LES model

Task 1.3: Validating CFD Predictions of N2L Aerosol Delivery in a 6-Month-Old
Infant Airway Model
•

Experimental and CFD models for nasal administration of pharmaceutical
aerosols to a 6-month-old infant

•

Further validation of k-ω turbulence and the aforementioned guidelines in the
complex flow field of the nasal cavity

Task 2.1: CFD Optimization of an Inline DPI for EEG Tobramycin Formulations
•

Pediatric air-jet DPI designs that maximize aerosolization performance by
optimization of inlet and outlet capillary diameters

•

Dispersion parameters that are predictive of the device aerosol size and
emitted dose from CFD flow field quantities

Task 2.2: Develop DPI Patient Interfaces for Improved Aerosol Delivery to
Children
•

Patient interface design concepts that minimize delivery system and
extrathoracic losses by utilizing a 3D rod array for flow intensity attenuation

•

Deposition correlations that are predictive of extrathoracic losses from
characteristics of the flow field at the interface outlet
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Task 3.1: Develop In Vitro Upper Airway Geometries of CF Patients in Age Ranges
of 2-3, 5-6, And 9-10 Years
•

Three rapid-prototyped growth chamber models for the given age ranges and
moderate disease state that will be utilized in future tobramycin EEG aerosol
studies

Task 3.2: Develop CFD Models of Upper Airway Geometries for Pediatric Patients
and Evaluate Delivery Efficiency and Aerosol Growth with Comparisons to In
Vitro Experiments
•

Concurrent numerical and experimental evaluation of hygroscopic aerosol
growth through CF-diseased pediatric upper airways

•

Enhancement to near-wall corrections that implement a localized particle
Stokes number as a non-dimensional method of identifying when particle-wall
hydrodynamic interactions take effect

Task 3.3: Extend and Develop CFD Lung Models to Predict Regional Lung
Deposition and Tobramycin ASL Concentrations in Healthy and CF CompleteAirway Lung Models
•

Proof of concept for administration of tobramycin EEG aerosols to treat
bacterial infections in pediatric CF patients

•

Development of complete-airway pediatric SIP models that include forms of
airway damage that are associated with CF and bacterial infection

9.5

Future Work
Considering CFD methods development for respiratory drug delivery, future work

should focus on exploring new meshing technologies and modeling capabilities as they
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become available in commercial software. Polyhedral cell topologies are a relatively
recent advancement in volume discretization methods, which have been shown to provide
computationally-efficient, accurate, and validated results (Bass, Boc, et al., 2019; Bass &
Longest, 2020). Unstructured meshing approaches, such as polyhedral cells, are
invaluable when developing the computational domain for complex geometries, as the
surface and volume discretization can conform to irregular surfaces. Considering
diseased airways where structured meshes may not be feasible, polyhedral cells will be
useful for resolving flow fields and particle trajectories in the complex domain.
Commercial CFD software is also regularly updated, and advancements in modeling and
solver capabilities may be implemented to reduce the computational overhead and
increase the solution and post-processing detail. For example, physical details of the
secondary breakup mechanism in air-jet DPIs and through 3D rod arrays is not well
understood at this time. Discrete element methods or other advanced Lagrangian tracking
models may be able to provide more insight into this phenomenon. For diseased airways,
the complete-airway SIP models can be developed further to provide a more realistic and
validated representation of aerosol transport in the airways of pediatric CF patients.
Further enhancements can also be made to the near-wall corrections to make them
suitable to a wider range of applications and reduce the amount of parameter tuning that
is required to match in vitro and in vivo data sets.
For delivery system improvements, future work should explore the influence of
more design factors on DPI aerosolization performance. This dissertation evaluated
changes to the inlet and outlet capillary diameters, but the size and shape of the
aerosolization chamber can be optimized, as well as flow orifice positioning and actuation
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flow rates. Similar optimization studies can be conducted on the 3D rod array patient
interfaces that explore the effects of rod array configuration and placement on delivery
system and extrathoracic losses. Other design changes may be required to maximize
system performance in different pediatric age ranges, such as younger (2-3-year-old) and
older (9-10-year-old) patients. Furthermore, it would be interesting to test the aerosol
dispersion parameters and extrathoracic loss correlations on a wider range of air-jet DPI
design concepts and different patient populations. Finally, as mentioned above, greater
insight in to the secondary break-up mechanisms, as the powder is aerosolized and
passes through the rod array, is required.
Regarding delivery strategy development, future work should expand the
assessment of EEG aerosols in complete-airway CFD models by evaluating lobar
variability in delivered tobramycin and consider the 2-3- and 9-10-year-old age groups.
Interpatient variability and its effect on establishing optimized delivery strategies should
be considered, as well as the use of different cannula sizes (to meet the needs of the
entire patient population) and how they influence delivery system and extrathoracic
losses. Direct validation of the numerical models for aerosol deposition and growth of
tobramycin EEG powder formulations is required. In addition, the optimal EEG delivery
strategy can be explored further by testing the influence of powder formulation (mass
fractions of drug and excipients), bi-modal aerosol size distributions, and delivery flow
rates. Finally, advanced CFD modeling capabilities can be implemented, such as
polydisperse aerosols and two-way coupled tracking, to improve the accuracy and detail
in results obtained from numerical models.
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